Rank,NCT_Number,Title,Recruitment,Study Results,Conditions,Interventions,Sponsor_Collaborators,Gender,Age Groups,Phases,Enrollment,Funded Bys,Study Types,Study Designs,Other IDs,First Received,Start Date,Completion Date,Last Updated,Last Verified,Results First Received,Acronym,Primary Completion Date,Outcome Measures,URL
1,NCT02752334,Magnesium Sulphate in the Ultrasound-guided Supraclavicular Brachial Plexus Block,Recruiting,No Results Available,Pain,Drug: Magnesium Sulphate,Magrabi Eye & Ear Hospital,Both,Adult,Phase 2,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Outcomes Assessor)",MEEC-IRB-2016-1,"March 3, 2016",Sep-15,May-16,"April 21, 2016",Mar-16,No Study Results Posted,Mg,Apr-16,The sensory block duration (the time interval between the end of local anesthetic administration and restoration of normal sensation) were evaluated as primary endpoint|the postoperative analgesic effects (the time interval between the end of local anesthetic administration and the first analgesia given) as a secondary endpoint.,https://ClinicalTrials.gov/show/NCT02752334
2,NCT02752282,"Anticipatory Counseling on LNG-IUS Continuation, Utilization and Satisfaction: A Pilot Study",Recruiting,No Results Available,Vaginal Bleeding|Uterine Cramping,Other: Anticipatory Counseling|Other: Cancer Screening Guidelines,University of Washington|Bayer|John H. Stroger Hospital,Female,Adult,,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject),49648-EA,"April 15, 2016",Mar-16,Aug-17,"April 21, 2016",Apr-16,No Study Results Posted,ACCCUSS,Dec-16,"Change in LNG-IUS knowledge, satisfaction and continuation from baseline|Percent of subjects in Phase II who complete all 3 surveys on-time over 6 months compared by recruitment method and site|Number of subjects reporting LNG-IUS discontinuation during the study time frame (6 months) by reason for LNG-IUS removal|LNG-IUS user self-reported satisfaction with video counseling|LNG-IUS user self-reported LNG-IUS healthcare utilization during study period",https://ClinicalTrials.gov/show/NCT02752282
3,NCT02752269,Early Detection of Pulmonary- and Pulmonary Vascular Disease in SjÌ¦gren Syndrome,Recruiting,No Results Available,SjÌ¦gren Syndrome|Pulmonary Hypertension,,Medical University of Graz,Both,Adult|Senior,,100,Other,Observational,Time Perspective: Cross-Sectional,26-446 ex 13/14,"November 24, 2015",Oct-14,Oct-16,"April 22, 2016",Apr-16,No Study Results Posted,null,Oct-16,prevalence of pulmonary hypertension in SjÌ¦gren syndrome|forced vital capacity|systolic pulmonary arterial pressure at 50 Watts,https://ClinicalTrials.gov/show/NCT02752269
4,NCT02752256,Thrombolytic Care During Inter-hospital Transfer,Recruiting,No Results Available,Stroke,Drug: Tissue Plasminogen Activator,University of Iowa,Both,Adult|Senior,,70,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB:201507803,"April 18, 2016",Oct-15,Oct-16,"April 22, 2016",Apr-16,No Study Results Posted,null,Oct-16,Percentage of participants with a rtPA protocol violation,https://ClinicalTrials.gov/show/NCT02752256
5,NCT02752243,CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.,Recruiting,No Results Available,Myelodysplastic Syndromes|Acute Leukemia,Drug: CIK-Cells,Peter Bader|Johann Wolfgang Goethe University Hospitals,Both,Child|Adult|Senior,Phase 1|Phase 2,40,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,FFM-CIK-Cell Study 01|2013-005446-11,"March 31, 2016",Mar-16,Mar-20,"April 22, 2016",Apr-16,No Study Results Posted,null,Mar-20,The occurrence of grade three or four acute Graft versus Host Disease (aGvHD)|Extensive chronic Graft versus Host Disease (cGvHD)|Efficacy of CIK-Cells analyzed by progression free survival|Overall survival,https://ClinicalTrials.gov/show/NCT02752243
6,NCT02752217,Effectiveness of Inspiratory Muscle Training With Slow Breathing in Elderly With ISH,Recruiting,No Results Available,Hypertension,Other: Inspiratory Muscle Training|Other: Control,Khon Kaen University,Both,Adult|Senior,,32,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),HE 581469,"April 7, 2016",Mar-16,Sep-18,"April 25, 2016",Apr-16,No Study Results Posted,null,Jul-18,Change from baseline in Maximal inspiratory pressure (MIP)|Lung capacity|Exercise capacity|Chest wall expansion and abdominal expansion|Blood pressure (BP),https://ClinicalTrials.gov/show/NCT02752217
7,NCT02752204,An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma,Recruiting,No Results Available,Diffuse Large B-Cell Lymphoma,Drug: AZD 2014|Drug: Rituximab,University of Birmingham|Bloodwise|AstraZeneca|Cancer Research UK,Both,Adult|Senior,Phase 2,36,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,RG_14-212,"April 18, 2016",Oct-15,Nov-18,"April 22, 2016",Apr-16,No Study Results Posted,TORCH,Nov-17,"Best overall response rate (PR plus CR) (using the Revised Response Criteria for Malignant Lymphoma ) during the first 6 cycles|Tolerability rate (based on toxicity assessments using CTCAE v 4.0 criteria) of single agent AZD2014|Tolerability rate of additional toxicities when rituximab is combined with AZD2014 at its standard dose (stage 2 only)|Best overall response rate post 6 cycles until the end of the trial, assessed using Revised Response Criteria|Overall survival (OS) at 1 year|Progression free survival (PFS) at 1 year|Duration of response|Maximum % decrease in the radiological sum of the product of the diameters (SPD) from baseline by CT NCAP",https://ClinicalTrials.gov/show/NCT02752204
8,NCT02752191,Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease,Recruiting,No Results Available,Pediatric Congenital Heart Disease,Drug: ferumoxytol|Drug: gadofosveset,"Paul Finn|University of California, Los Angeles",Both,Child,Phase 4,120,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,16-00016,"April 15, 2016",Apr-16,null,"April 22, 2016",Apr-16,No Study Results Posted,null,Apr-21,Composite image quality score among 7 anatomical structures.|Image quality score at individual anatomical sites.|Incidence of adverse events,https://ClinicalTrials.gov/show/NCT02752191
9,NCT02752178,Peripheral Immunomarker Validation in Treatment-resistant Depression,Recruiting,No Results Available,"Depressive Disorder, Major",Other: MA|Other: DEP,"University of Cambridge|University of Oxford|University of Glasgow|University of Sussex|King's College London|Janssen, LP|H. Lundbeck A/S|GlaxoSmithKline",Both,Adult,,250,Other|Industry,Observational,Observational Model: Case Control|Time Perspective: Prospective,15/EE/0092,"March 16, 2016",Jun-15,Dec-17,"April 22, 2016",Apr-16,No Study Results Posted,BIODEP,Jun-17,"C-reactive protein (CRP) levels (mg/l)|Flow cytometric immunophenotype|Structural parameters of the brain|Response to stimulus|Microglial activation in the brain|Pro-inflammatory (M1-like) phenotype-producing cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-ë± circulating in cerebrospinal fluid",https://ClinicalTrials.gov/show/NCT02752178
10,NCT02752152,Counseling for HIV and STIs Screening,Recruiting,No Results Available,"HIV, Hepatitis B, Hepatitis C and Syphilis Infections",Behavioral: Computer-assisted counseling|Behavioral: On-demand counseling|Behavioral: Standard counseling,Institut de Recherche pour le Developpement|Chiang Mai University|Expertise France,Both,Adult|Senior,,1600,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,Lightning,"April 22, 2016",Dec-15,Feb-19,"April 22, 2016",Apr-16,No Study Results Posted,Lightning,Jan-19,Proportion of participants in at-risk populations coming for a HIV re-test,https://ClinicalTrials.gov/show/NCT02752152
11,NCT02752113,Effects of Empagliflozin Plus Linagliptin vs Metformin Plus Insulin Glargin on Renal and Vascular Changes in Type 2 Diabetes,Recruiting,No Results Available,Diabetes Mellitus Type 2,Drug: Empagliflozin and Linagliptin|Drug: Metformin and Insulin sc,Institut fÌ_r Pharmakologie und PrÌ_ventive Medizin|University of Erlangen-NÌ_rnberg Medical School,Both,Adult|Senior,Phase 3,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IPPMed-2016-01-ELMI|2016-000242-57,"April 19, 2016",Apr-16,Jun-18,"April 21, 2016",Apr-16,No Study Results Posted,ELMI,Jun-17,"Effect of empagliflozin plus linagliptin vs metformin plus insulin glargin on basal NO activity of renal vasculature (response of RPF (renal plasma flow) to L-NMMA (NG-monomethyl-L-arginine) infusion)|Changes in oxidative stress level of renal vasculature (response of RPF to vitamin C infusion)|changes in intraglomerular resistances (Ra and Re) and Pglom|changes in albuminuria (urinary albumin to creatinine ratio [UACR]), assessed in the 24-hour urine",https://ClinicalTrials.gov/show/NCT02752113
12,NCT02752100,A Study on the Effects of Interventional Therapy in Patients With Lower Extremity Arterial Occlusive Disease and Its Risk Factors(EILRF),Recruiting,No Results Available,PAD,Procedure: Percutaneous transluminal angioplasty,Third Military Medical University,Both,Adult|Senior,,200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,EILRF,"March 17, 2016",Mar-16,May-20,"April 21, 2016",Apr-16,No Study Results Posted,null,Feb-20,Ankle-brachial index|Mortality(%)|Incidence of amputation(%)|Incidence of major adverse cardiac events (MACE)(%)|High-sensitive C reactive protein(mg/L)|Fasting plasma glucose(mmol/L)|Blood pressure(mmHg)|HbA1c(%)|triglyceride(mmol/L)|total cholesterol(mmol/L)|LDL-c(mmol/L)|HDL-c(mmol/L)|The lower limb transcutaneous oxygen pressure(mmHg),https://ClinicalTrials.gov/show/NCT02752100
13,NCT02751866,Early Intervention in Cognitive Aging,Recruiting,No Results Available,"Overweight, Obesity and Other Hyperalimentation (E65-E68)",Dietary Supplement: Either berry fruit supplement OR nutritional ketosis|Dietary Supplement: Placebo powder OR higher carbohydrate diet,University of Cincinnati,Both,Adult,,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,2015-1256,"April 21, 2016",Jan-16,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Jan-20,Insulin resistance|Cognitive function|Long term glucose concentration,https://ClinicalTrials.gov/show/NCT02751866
14,NCT02751827,Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer,Recruiting,No Results Available,Cancer,Other: Blood sample,Institut BergoniÌ©|Agence Nationale de sÌ©curitÌ© du MÌ©dicament,Both,Senior,,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IB 2015-02,"April 25, 2016",Feb-16,Feb-19,"April 25, 2016",Apr-16,No Study Results Posted,PreToxE,Feb-19,Toxicity|Non-progression|Progression-free survival (PFS),https://ClinicalTrials.gov/show/NCT02751827
15,NCT02751788,Physical Activity and Screen-Time Regulations in Childcare Centers - Aim 1,Recruiting,No Results Available,Childhood Obesity,,Pennington Biomedical Research Center|National Institute on Minority Health and Health Disparities (NIMHD),Both,Child,,10,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PBRC 2015-044|U54MD008602-P02UAB,"April 19, 2016",Apr-16,Sep-17,"April 21, 2016",Apr-16,No Study Results Posted,Pause and Play,Jul-17,Change in EPAO score and EPAO subscales.|Changes in practice-based survey items based on childcare director responses.,https://ClinicalTrials.gov/show/NCT02751788
16,NCT02751723,Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease,Recruiting,No Results Available,"Cancer Disease, Palliative Therapy",Other: validated questionnaires,"Florian Lordick, MD|University of Leipzig",Both,Adult|Senior,,500,Other,Observational,Time Perspective: Prospective,APM Project|DRKS00007536,"April 14, 2016",Sep-14,Sep-17,"April 21, 2016",Apr-16,No Study Results Posted,APM-Project,Sep-17,Change from Baseline Patientå«s answers regarding symptom burden at 12 months|Change from Baseline physicianå«s report at 12 months|Change from Baseline Patientå«s answers regarding symptom burden at 6 months|Change from Baseline physicianå«s report at 6 months|Change from Baseline Patientå«s answers regarding symptom burden at 3 months|Change from Baseline physicianå«s report at 3 months,https://ClinicalTrials.gov/show/NCT02751723
17,NCT02751606,Nano MRI on 7 Tesla in Rectal and Breast Cancer,Recruiting,No Results Available,Rectal Neoplasms|Breast Neoplasms,Drug: ferumoxtran-10|Device: 7 Tesla MRI|Device: 3 Tesla MRI,Radboud University,Both,Adult|Senior,Phase 3,30,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,7TNANO1,"November 28, 2014",Jun-15,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Sep-16,Sensitivity and specificity of 7 Tesla MRI in combination with ferumoxtran-10 on nodal level.|Comparison of 7 Tesla and 3 Tesla MRI,https://ClinicalTrials.gov/show/NCT02751606
18,NCT02751580,Telehealth in Improving Quality of Life in Patients During Post Radiation Therapy Visits,Recruiting,No Results Available,Malignant Neoplasm,Other: Telemedicine|Other: Questionnaire Administration,Thomas Jefferson University,Both,Adult|Senior,,65,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research|Masking: Open Label,15D.580,"April 11, 2016",Mar-16,null,"April 25, 2016",Apr-16,No Study Results Posted,null,Aug-21,"Feasibility of conducting a future randomized clinical trial comparing telehealth and in person visits (i.e., rate of accrual)|Patient satisfaction with telehealth visits as measured by the Patients Satisfaction with Cancer Care score|Patient assessment of physician communication during telehealth visit as measured by the Communication assessment tool|Patient distrust in the healthcare system as measured by the health care system distrust scale|Physicians ability to evaluate a patient during a telehealth visit as measured by the physician questionnaire|Physician satisfaction with post-treatment telehealth visit as measured by the modified physician satisfaction scale|Patient costs for telehealth visit based on questionnaire response|Clinic savings derived from telehealth visits",https://ClinicalTrials.gov/show/NCT02751580
19,NCT02751554,PET Imaging of Patients With Cancer Using 124I-PU-AD,Recruiting,No Results Available,Solid Malignancy|Lymphoma|Multiple Myeloma,Drug: 124I-PU-AD|Device: PET Scan|Other: Blood draws,Memorial Sloan Kettering Cancer Center,Both,Adult|Senior,,10,Other,Interventional,Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,16-004,"April 19, 2016",Apr-16,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Apr-18,the plasma time activity concentration curves,https://ClinicalTrials.gov/show/NCT02751554
20,NCT02751450,The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity(DH),Recruiting,No Results Available,Dentin Sensitivity,Device: Stannous Fluoride dentifice|Other: Sodium Monofluorophosphate dentifrice,GlaxoSmithKline,Both,Adult,,230,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),205084,"April 21, 2016",Feb-16,May-16,"April 21, 2016",Apr-16,No Study Results Posted,null,May-16,Change from baseline in Schiff sensitivity score after 3 days use|Change from baseline in tactile threshold after 3 days use|Change from baseline in Schiff sensitivity score after a single 60 second direct application|Change from baseline in tactile threshold after a single 60 second direct application,https://ClinicalTrials.gov/show/NCT02751450
21,NCT02751411,Effectiveness & Safety of Natural Microenemas Against Oral Macrogol 4000 in Chronic Constipation in Children 6-24 Months,Recruiting,No Results Available,Functional Constipation,Device: micro-enema with Promelaxin|Drug: Macrogol 4000,Aboca Spa Societa' Agricola,Both,Child,Phase 4,120,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,ABO-MELI-15,"April 22, 2016",Apr-16,Aug-17,"April 22, 2016",Apr-16,No Study Results Posted,null,Jun-17,"Improvement of constipation evaluated as a reduction of the typical symptoms of chronic functional constipation|score of the quality of life of parents calculated on day 21 and 56|score of the quality of life of children calculated on day 21 and 56|Gastrointestinal symptoms in infants on days 14, 21 and 56|changes in the intestinal microbioma on day 21 and 56|Evaluation of the normalization of intestinal activity measured by recording frequency of evacuations and stool consistency on day 14, 21 and 56|Product safety in terms of adverse events reported by parents/legal representative of the subject.",https://ClinicalTrials.gov/show/NCT02751411
22,NCT02751333,Esophageal Stent Migration With Endoscopic Suture Fixation Compared to Standard Deployment,Recruiting,No Results Available,Esophageal Strictures|Esophageal Leak|Esophageal Perforation|Esophageal Fistula|Endostitch|Esophageal Stent,Procedure: FCSEMS with Endostitch (ES)|Procedure: FCSEMS with No Suturing (NS)|Device: Fully Covered Self-Expanding Metal Stents (FCSEMS)|Device: EndoStitch (ES) with the OverStitchTM system,Johns Hopkins University,Both,Adult|Senior,Phase 2,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),IRB00091684,"April 18, 2016",Mar-16,Mar-18,"April 21, 2016",Apr-16,No Study Results Posted,null,Mar-18,Number of participants with Stent Migration as assessed by Symptoms suggestive of stent migration or objective evidence of migration on radiological imaging or endoscopy.|Clinical success of stent deployment as assessed by the relief of the pre-stent dysphagia|Procedure time|Stent insertion complication rate|Quality of life,https://ClinicalTrials.gov/show/NCT02751333
23,NCT02751320,Efficacy of Three Toothpastes Using an in Situ Caries Model,Recruiting,No Results Available,Dental Caries,"Drug: 0.425 % w/w phytate,1150ppm F|Drug: 0.85 % w/w phytate,1150ppm F|Drug: 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Other: 0 ppm F|Drug: 1150ppm F|Drug: 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F",GlaxoSmithKline,Both,Adult|Senior,,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Single Blind (Outcomes Assessor),202301,"April 21, 2016",Feb-16,Aug-16,"April 21, 2016",Apr-16,No Study Results Posted,null,Jul-16,"Percentage Surface Microhardness Recovery (SMHR) of phyte (0% 0.425% and 0.85%) at 2 weeks|Transverse Microradiography (TMR) net remineralization change (ëÓM) value of of phytate (0% 0.452% and 0.85%) at 4 weeks|Enamel Fluoride Uptake (EFU) of phytate (0%, 0.452% and 0.85%) at 4 weeks|Percentage Surface Microhardness Recovery (SMHR) of 0.85% phytate compared to 0% phytate in presence of 1150ppm F and 0.3% zinc chloride (ZnCl2) at 2 weeks|TMR ëÓm Value of 0.85% Phytate Compared to 0% Phytate in the presence of 1150ppm F and 0.3% ZnCl2 at 4 Weeks|Percentage Surface Microhardness Recovery (SMHR) of 0.3% ZnCl2 compared to 0% ZnCl2 in the presence of 1150ppm F at 2 weeks|TMR ëÓm Value of Of 0.3% ZnCl2 Compared to 0% Zncl2 in the presence of 1150ppm F at 4 Weeks|Percentage Surface Microhardness Recovery (SMHR) of 0.3% ZnCl2 to 0% ZnCl2 in the presence of 1150ppm F and 0.85% phytate at 2 weeks|TMR ëÓm Value of 0.3% ZnCl2 to 0% ZnCl2 in the presence of 1150ppm F and 0.85% phytate at 4 Weeks|Enamel Fluoride Uptake (EFU) of the study formulation variables",https://ClinicalTrials.gov/show/NCT02751320
24,NCT02751177,"Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer",Recruiting,No Results Available,Colorectal Cancer Metastatic,"Genetic: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA",Institut de CancÌ©rologie de Lorraine,Both,Adult|Senior,,236,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,2015-A01272-47,"March 3, 2016",Mar-16,Dec-16,"April 21, 2016",Apr-16,No Study Results Posted,ColoBEAM,Oct-16,"KRAS, NRAS et BRAF mutational status",https://ClinicalTrials.gov/show/NCT02751177
25,NCT02751151,Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients,Recruiting,No Results Available,Nonmelanoma Skin Cancers,Other: have Levulan Kerastick (aminolevulinic acid) solution,"Inova Health Care Services|DUSA Pharmaceuticals, Inc.",Both,Adult|Senior,Phase 2,20,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,15-1845,"March 21, 2016",Feb-16,null,"April 21, 2016",Apr-16,No Study Results Posted,PDT,Feb-20,Number of non melanoma skin cancers in organ transplant recipients|Reduction of actinic keratosis damage/epidermal dysplasia in organ transplant recipients as assessed by physician and graded per actinic damage scale,https://ClinicalTrials.gov/show/NCT02751151
26,NCT02751138,Determination of Immune Phenotype in Glioblastoma Patients,Recruiting,No Results Available,Glioblastoma Multiforme,Procedure: Surgery,University of Ulm,Both,Adult|Senior,,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,University Hospital Ulm,"April 19, 2016",Mar-16,Mar-18,"April 25, 2016",Apr-16,No Study Results Posted,null,Mar-18,Overall survival|Progression free survival|Quality of life|Karnofsky performance score,https://ClinicalTrials.gov/show/NCT02751138
27,NCT02751125,Reconstruction of Jaw Bone Using Mesenchymal Stem Cells,Recruiting,No Results Available,Bone Atrophy,Drug: BCP with autologous mesenchymal stem cells (MSC).,University of Bergen|University of Ulm|Haukeland University Hospital|UniversitÌ© de Nantes,Both,Adult|Senior,Phase 1,13,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,2012-003139-50,"March 22, 2016",Jun-14,Dec-19,"April 25, 2016",Apr-16,No Study Results Posted,null,Dec-17,Amount of newly formed bone induced by MSCs and the bone substitute. These measurements are based on radiological assessments.|Implant stability|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],https://ClinicalTrials.gov/show/NCT02751125
28,NCT02751112,Evaluation of a Kit for the Prediction of the Risk of Graft Versus Host Disease,Recruiting,No Results Available,Hemopathy,Biological: Predictor' kit,Imagine Institute,Both,Adult,,122,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,IMIS2014-03,"April 13, 2016",Nov-15,May-18,"April 25, 2016",Mar-16,No Study Results Posted,Predictor007,May-18,Assessment of the diagnosis test performance|Assessment of the reproductibility of the test,https://ClinicalTrials.gov/show/NCT02751112
29,NCT02751099,Bone and Cardiovascular Disease After Kidney Transplant,Recruiting,No Results Available,Chronic Renal Insufficiency|Disorder Related to Renal Transplantation|Metabolic Bone Diseases|Vascular Disease,Other: transplanted patients,Centro Hospitalar de Lisboa Central,Both,Adult|Senior,,80,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHLC.CI363.2016,"April 21, 2016",Nov-15,Dec-18,"April 21, 2016",Apr-16,No Study Results Posted,null,Jan-18,Metabolic Bone Diseases|Cardiovascular disease|Bone fracture|vascular calcification,https://ClinicalTrials.gov/show/NCT02751099
30,NCT02751086,"Robotic, Laparoscopic and Open Gastrectomy Compared on Short and Long Term Outcomes",Recruiting,No Results Available,Gastric Cancer,Procedure: Robotic Gastrectomy|Procedure: Laparoscopic Gastrectomy,International Study Group on Minimally Invasive Surgery for Gastric Cancer,Both,Adult|Senior,,5000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2,"April 10, 2016",Apr-16,Dec-24,"April 21, 2016",Apr-16,No Study Results Posted,IMIGASTRICII,May-19,Rate of patients with intraoperative adverse events|Mean of retrieved lymph nodes|Rate of patients alive|Mean post-operative hospital stay|Rate of complications after discharge,https://ClinicalTrials.gov/show/NCT02751086
31,NCT02751073,Evaluation of the Relationship Between Vaginal and Lower Urinary Tract Microbiomes and Infection After Hysterectomy,Recruiting,No Results Available,Pelvic Organ Prolapse|Hysterectomy|Urinary Tract Infection,,Mayo Clinic,Female,Adult|Senior,,20,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,15-006300,"February 22, 2016",Feb-16,Jun-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Jun-17,Identification of baseline vaginal microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of baseline urinary tract microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of pre-operative vaginal microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of pre-operative urinary tract microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of the immediate postoperative vaginal microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of the immediate postoperative urinary tract microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of the postoperative vaginal microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of the postoperative urinary tract microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of vaginal microbiome in the setting of postoperative urinary tract infection through DNA extraction and 16S rRNA gene sequencing|Identification of urinary tract microbiome in the setting of postoperative urinary tract infection through DNA extraction and 16S rRNA gene sequencing|Identification of key biomarkers associated with risk of postoperative urinary tract infection through proteomic mass spectrometry analysis of vaginal swab collected in the setting of postoperative urinary tract infection|Identification of the vaginal microbiome at least 6 weeks following surgery through DNA extraction and 16S rRNA gene sequencing|Identification of the postoperative urinary tract microbiome at least 6 weeks following surgery through DNA extraction and 16S rRNA gene sequencing,https://ClinicalTrials.gov/show/NCT02751073
32,NCT02750891,A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas,Recruiting,No Results Available,Glioblastoma|Diffuse Intrinsic Pontine Glioma,Drug: DSP-7888,"Sumitomo Dainippon Pharma Co., Ltd.",Both,Child|Adult,Phase 1|Phase 2,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,DB601001,"April 13, 2016",Apr-16,Apr-19,"April 25, 2016",Apr-16,No Study Results Posted,null,Jan-18,DLT (dose-limiting toxicity)|Overall Survival •_öOS•_ä|Overall Response Rate•_öORR•_ä|Progression-free survival (PFS)|adverse events (AEs)|serious adverse events (SAEs)|DTH •_ödelayed-type hypersensitivity•_ä|WT1 peptide-specific CTL-induction activity|expression of WT1 in biopsy tissues|expression of HLA in biopsy tissues|expression of PD-L1 in biopsy tissues,https://ClinicalTrials.gov/show/NCT02750891
33,NCT02750878,Surgical Consent Process for Trans-obturator Tape Slings.,Recruiting,No Results Available,"Urinary Incontinence, Stress",Other: Informational Handout,Boston Urogynecology Associates,Female,Adult|Senior,,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,034-2015,"April 14, 2016",Nov-15,Jul-18,"April 21, 2016",Apr-16,No Study Results Posted,null,Jul-18,A knowledge questionnaire at the pre-operative holding area to measure the patients' knowledge regarding their Trans Obturator Tape surgery. The percentage of correct answers will be reported and analyzed.,https://ClinicalTrials.gov/show/NCT02750878
34,NCT02750800,"Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary",Recruiting,No Results Available,Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis|Psoriasis|Crohn's Disease|Ulcerative Colitis,,AbbVie|AdWare Research Kft.,Both,Adult|Senior,,387,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,P15-673,"April 13, 2016",Apr-16,Oct-17,"April 21, 2016",Apr-16,No Study Results Posted,VALUE,Oct-17,"Change from baseline (month 0) in 36-Item Short Form Health Survey, Version 2.0 (SF-36 V2) Physical Component Score (PCS)|Change from baseline (month 0) in EuroQol five-dimension scale (EQ-5D-5L) quality of life score|Change from baseline (month 0) in total Treatment Satisfaction Questionnaire for Medication (TSQM)-1.4 score|Change from baseline (month 0) in total Satisfaction with Information About Medicines Scale (SIMS) score|Change from baseline (month 0) in total Morisky Medication Adherence Scale, 4 questions (MMAS-4) score|Changes from baseline (month 0) in Work Productivity and Activity Impairment (WPAI) Specific Health Problem (SHP) score",https://ClinicalTrials.gov/show/NCT02750800
35,NCT02750774,An Early-customized Low Glycaemic-index (GI) Diet Prevents LGA Babies in Overweight/Obese Pregnant Women,Recruiting,No Results Available,"Maternal Obesity Complicating Pregnancy, Birth,or Puerperium|Gestational Diabetes Mellitus|Birthweight|Large for Gestational Age (LGA)|Caloric Restriction|Lifestyle Intervention",Behavioral: Low-glycemic index group|Other: Standard Care Group,University of Modena and Reggio Emilia|Dr. Elisabetta Petrella,Female,Adult,,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,Pratica CE 136/15,"April 14, 2016",Dec-15,Dec-16,"April 20, 2016",Apr-16,No Study Results Posted,null,Jul-16,Large-for-gestational-age (LGA) occurrence|Gestational Diabetes Mellitus (GDM) occurrence|Gestational Weight Gain (GWG)|Pre-term Birth (PTB)|Neonatal hypoglycemia|Neonatal Intensive Care Unit (NICU) admission,https://ClinicalTrials.gov/show/NCT02750774
36,NCT02750657,Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection,Recruiting,No Results Available,"Carcinoma, Pancreatic Ductal",Genetic: Molecular Profiling,"University Health Network, Toronto",Both,Adult|Senior,,180,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,COMPASS-001,"January 19, 2016",Feb-16,Dec-21,"April 20, 2016",Apr-16,No Study Results Posted,COMPASS,Feb-21,"The feasibility of prospectively identifying subgroups of patients with advanced PDAC who have distinct genomic characteristics for better treatment selection while undergoing 1st-line chemotherapy using next generation sequencing.|Disease control rate achieved by m-FOLFIRINOX|Disease control rate achieved by nab-paclitaxel|Duration of response defined as the interval between the first date of complete response or partial response and the earliest date of disease progression or death due to any cause to m-FOLFIRINOX|Duration of response defined as the interval between the first date of complete response or partial response and the earliest date of disease progression or death due to any cause to nab-paclitaxel.|Progression free survival defined as the interval between the date of registration and the earliest date of disease progression or death due to any cause of patients treated with m-FOLFIRINOX.|Progression free survival defined as the interval between the date of registration and the earliest date of disease progression or death due to any cause of patients treated with nab-paclitaxel.|Overall survival defined as the interval between the date of registration and the date of death of patients treated with m-FOLFIRINOX|Overall survival defined as the interval between the date of registration and the date of death of patients treated with nab-paclitaxel.|Correlation between tumor genomic characteristics and m-FOLFIRINOX response using next generation sequencing.|Correlation between tumor genomic characteristics and nab-paclitaxel response using the next generation sequencing.|Percentage of patients with germline BRCA, PALB2 and ATM mutations who might benefit from a personalized treatment strategy such as combination of cisplatin and a PARP inhibition.|Percentage of patients with somatic DSBR deficiency who might benefit from a personalized treatment strategy such as combination of cisplatin and a PARP inhibitor.|Percentage of patients who might benefit from immunotherapy (patients with smoking genomic signatures, patients with a hypermutated phenotype, patients with mismatch repair deficiency and patients with tumor neo-antigen expression).|Percentage of patients with rare but targetable somatic mutations.|Difference in disease control rate between patients with tumor smoking signature and those without.|Difference in overall survival between patients with tumor smoking signature and those without.|Correlation with tumor molecular characteristics and toxicities to treatment using next generation sequencing.",https://ClinicalTrials.gov/show/NCT02750657
37,NCT02750631,"Out-patient Wake Therapy, Light Therapy and Sleep Phase Advance for Depression",Recruiting,No Results Available,Unipolar Depression,Device: Triple Therapy,New York State Psychiatric Institute,Both,Adult,Phase 2,30,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,6938,"April 20, 2016",Apr-14,Jul-17,"April 22, 2016",Apr-16,No Study Results Posted,WakeTherapy,Feb-17,17-item Hamilton Rating Scale for Depression,https://ClinicalTrials.gov/show/NCT02750631
38,NCT02750605,DEB ( Drug Eluting Balloon) in Crural Arteries and Critical Limb Ischemia,Recruiting,No Results Available,Peripheral Vascular Diseases,Device: DEB|Device: POBA,Skane University Hospital,Both,Adult|Senior,,70,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,TF3,"January 19, 2016",Feb-16,Jun-18,"April 22, 2016",Apr-16,No Study Results Posted,null,Jun-18,Primary patency of treated crural vessels|Clinical driven target lesion revascularization (TLR),https://ClinicalTrials.gov/show/NCT02750605
39,NCT02750592,Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis,Recruiting,No Results Available,Ankylosing Spondylitis,Drug: secukinumab 150mg,Novartis Pharmaceuticals|Novartis,Both,Adult|Senior,Phase 3,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,CAIN457H1301,"April 4, 2016",Mar-16,May-18,"April 20, 2016",Apr-16,No Study Results Posted,null,May-18,"Assessment of SpondyloArthritis International Society criteria (ASAS) 20 response|ASAS 40 response|Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50|high sensitivity C-Reactive Protein (hsCRP)|ASAS 5/6 response criteria|BASDAI|Short Form Health Survey Physical Component Summary ( SF-36 PCS)|Ankylosing Spondylitis Quality of Life (ASQoL)|ASAS partial remission|Serum concentration of secukinumab|Concentration of anti-secukinumab antibodies|Vital sign, clinical laboratory values and adverse event",https://ClinicalTrials.gov/show/NCT02750592
40,NCT02750579,Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?,Recruiting,No Results Available,Acute Coronary Syndrome,Procedure: Percutaneous coronary intervention for revascularization,Assistance Publique Hopitaux De Marseille,Both,Adult|Senior,,740,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2016-A00379-42,"April 21, 2016",Apr-16,Oct-19,"April 21, 2016",Apr-16,No Study Results Posted,null,Apr-19,recurent ischemic events|cardiovascular death,https://ClinicalTrials.gov/show/NCT02750579
41,NCT02750566,Comparing the Effect of Osteopathic Manipulative Medicine (OMM) Versus Counseling in the Treatment of Concussion,Recruiting,No Results Available,Post-Concussion Symptoms|Distorted; Balance,Procedure: Osteopathic Manipulative Treatment|Other: Counseling,New York Institute of Technology,Both,Adult,,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),BHS-1139,"December 4, 2015",Nov-15,Dec-17,"April 20, 2016",Apr-16,No Study Results Posted,null,Dec-17,SMART Balance Master balance scores pre and post intervention arm|Post-concussion symptoms as measured by ImPACT|Post-concussion symptoms as measured by King-Devick|Post-concussion symptoms as measured by SCAT-3,https://ClinicalTrials.gov/show/NCT02750566
42,NCT02750436,A Comparison of Ultrasound Versus Fluoroscopic Guidance for Sacral Lateral Branch Blocks,Recruiting,No Results Available,Back Pain,Device: Ultrasound guided|Device: Fluoroscopy guided,Montreal General Hospital,Both,Adult|Senior,,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,15-544MUHC,"April 17, 2016",Apr-16,Dec-16,"April 22, 2016",Apr-16,No Study Results Posted,USGSLBB,Dec-16,Performance time|Change in pain numerical rating score from baseline,https://ClinicalTrials.gov/show/NCT02750436
43,NCT02750423,Neurologic Injury Following Aortic Arch Replacement,Recruiting,No Results Available,Aortic Arch Replacement|Hemi Arch Replacement,Procedure: DHCA+RCP|Procedure: MHCA + SACP,Emory University,Both,Adult|Senior,Phase 1,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IRB00087270,"April 21, 2016",Apr-16,Dec-18,"April 21, 2016",Apr-16,No Study Results Posted,null,Jun-17,Incidence of Stroke|Incidence of Transient Ischemic Attack (TIA)|Rate of Neurologic Injury assessed by Magnetic Resonance Imaging (MRI)|Change in Verbal Memory Test Score|Change in Visual Memory Test Score|Change in Finger Tapping Test Score|Change in Symbol Digit Coding Score|Change in Stroop Test Score|Change in Shifting Attention Test Score|Change in Continuous Performance Test Score|Incidence of Temporary Neurologic Deficit (TND)|Change in Serum S-100 Levels,https://ClinicalTrials.gov/show/NCT02750423
44,NCT02750319,Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery,Recruiting,No Results Available,Thoracic Surgery|Atrial Fibrillation in High Risk Patients,Drug: Amiodarone|Drug: N-Acetylcysteine|Drug: Placebo,Memorial Sloan Kettering Cancer Center|Washington University School of Medicine|The Cleveland Clinic|Vanderbilt University School of Medicine,Both,Adult|Senior,Phase 3,244,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",16-307,"April 21, 2016",Apr-16,null,"April 22, 2016",Apr-16,No Study Results Posted,null,Apr-18,rate of sustained (lasting >30 seconds) or clinically significant post-operative atrial fibrillation (POAF),https://ClinicalTrials.gov/show/NCT02750319
45,NCT02750293,The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors,Recruiting,No Results Available,Vitamin D Deficiency,Drug: Cholecalciferol|Drug: Placebo,University of Tromso,Both,Adult|Senior,Phase 3,600,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",TromsÌüEndo-2013-1|2013-003514-40,"April 12, 2016",Jun-15,Sep-17,"April 20, 2016",Apr-16,No Study Results Posted,D-COR,Aug-17,"Change from baseline in systolic and diastolic blood pressure|Change from baseline in hand-grip, quadriceps and biceps muscle strength measured by hand held dynamometry .|Change from baseline in score on Becks Depression Inventory|Change from baseline in cognitive function evaluated with The Twelve Word Memory Test|Change from baseline in cognitive function evaluated with The Digit Symbol Coding Test|Change from baseline in cognitive function evaluated with The Tapping Test|Change from baseline in arterial stiffness and endothelial function evaluated with pulse wave velocity|Change from baseline in arterial stiffness and endothelial function evaluated with augmentation index (AIX)|Change from baseline in arterial stiffness and endothelial function evaluated with the subendocardial viability ratio (SEVR)|Change from baseline in number of subjects with nasal staphylococcus aureus colonization|Change from baseline in bone mass density measured with dual energy x-ray absorptiometry (DEXA) at the lumbar spine and hip|Change from baseline in the bone turnover marker serum type 1 procollagen (P1NP)|Change from baseline in the bone turnover marker serum collagen type 1 cross-linked C-telopeptide (CTX-1)|Change from baseline in serum marker of interferon-ë_ mediated macrophage activation|Change from baseline in serum vitamin B6 status.|Change from baseline in the glycosylation marker HbA1c|Change from baseline in the glycosylation marker the receptor for advanced glycosylation end products (s-RAGE)|Change from baseline in the glycosylation marker carboxy-methyllysine|Change from baseline in psoriasis Activity in subjects with psoriasis evaluated with the Self-Administered Psoriasis Area Severity Index (SAPASI)|Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Dermatological Life Quality Index (DLQI)|Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Psoriasis Area Severity Index (PASI)|Change from baseline in transcriptomic profile (mRNA) in adipose tissue biopsies|Change from baseline in number of subjects with nocturnal legg cramps|Change from baseline in sleep pattern evaluated with the TromsÌü Study 7th Survey sleep pattern questionnaire|Change from baseline in the serum total cholesterol|Change from baseline in the serum HDL-cholesterol|Change from baseline in the serum LDL-cholesterol|Change from baseline in the serum triglycerides|Change from baseline in the serum Apolipoprotein A1|Change from baseline in the serum Apolipoprotein B,|Change from baseline in insulin resistance evaluated with the homeostasis model assessment (HOMA) index based on fasting serum glucose and serum insulin|Change from baseline in proteomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)|Change from baseline in metabolomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)",https://ClinicalTrials.gov/show/NCT02750293
46,NCT02750241,Pink Warrior‰ÛÓSupport Group Toolkit for Breast Cancer Survivors,Recruiting,No Results Available,Breast Cancer|Physical Activity,Behavioral: Active video game-based intervention|Behavioral: Pedometer,"The University of Texas Medical Branch, Galveston|The President's Cabinet Award at The University of Texas Medical Branch",Female,Adult|Senior,,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor),16-0040,"April 18, 2016",Apr-16,Dec-18,"April 20, 2016",Apr-16,No Study Results Posted,null,Sep-18,Change in physical activity steps per day as measured by an Actigraph wGT3X-BT monitor|Change in physical activity minutes as measured by an Actigraph wGT3X-BT monitor|Change in physical function as measured by the Short Physical Performance Battery|Change in dietary pattern as measured by the Dietary Screener Questionnaire|Change in quality of life as measured by the Functional Assessment of Cancer Therapy-Breast measure|Change in hand grip strength as measured by hand dynamometer,https://ClinicalTrials.gov/show/NCT02750241
47,NCT02750189,The Economic Burden of Chronic Obstructive Pulmonary Disease(COPD) in South Korea,Recruiting,No Results Available,COPD|Chronic Obstructive Pulmonary Disease,Other: Direct cost|Other: Indirect cost,Konkuk University Medical Center|GlaxoSmithKline,Both,Adult|Senior,,400,Other|Industry,Observational,Time Perspective: Retrospective,KUH1010636,"March 28, 2016",Jun-15,Dec-16,"April 22, 2016",Apr-16,No Study Results Posted,BOC,Jun-16,Total cost of COPD|The number of acute exacerbations|The cost of alternative medication use|Cost of productivity lost|EuroQol five dimension(EQ-5D)|The total number of visits|Nursing cost,https://ClinicalTrials.gov/show/NCT02750189
48,NCT02750176,Rehabilitation: Closed-Chain Exercises for Rotator Cuff Tears,Recruiting,No Results Available,Full Thickness Rotator Cuff Tear,Other: Closed chain exercises,University of Southern California,Both,Adult|Senior,Phase 0,30,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,HS-15-00771,"April 18, 2016",Apr-16,Apr-18,"April 20, 2016",Apr-16,No Study Results Posted,CERCT,Apr-18,Feasibility - recruitment|Patient Specific Functional Scale (PSFS)|Penn Shoulder Score (Penn)|Feasibility - retention|Quick Disabilities of the Arm Shoulder Hand (QDASH) scale|Global Rating of Change (GRoC) scale|Numeric Pain Rating Scale (NPRS)|American Shoulder and Elbow Surgeon Patient-report (ASES) scale|Shoulder pain-free active elevation range of motion|Shoulder elevation strength|Shoulder external rotation strength|Patient Acceptable Symptom State (PASS) score,https://ClinicalTrials.gov/show/NCT02750176
49,NCT02750059,Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis,Recruiting,No Results Available,Acute HIV Infection|HIV CNS Involvement,Drug: TDF/3TC/EFV + Telmisartan|Drug: TDF/3TC/EFV only,South East Asia Research Collaboration with Hawaii|National Institute of Neurological Disorders and Stroke (NINDS),Both,Adult|Senior,Phase 2,21,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,SEARCH 018|1R01NS084911-01,"May 30, 2015",Jan-15,May-18,"April 25, 2016",Apr-16,No Study Results Posted,null,Feb-18,"Difference between study arms at weeks 48 and 72 in CSF neopterin|Difference between study arms in lymphoid tissue fibrosis at week 48|Difference between study arms at weeks 48 and 72 in brain inflammation by magnetic resonance spectroscopy (MRS)|Difference between study arms at weeks 48 and 72 in CSF HIV RNA by single copy assay|Difference between study arms at weeks 48 and 72 in aggregate neuropsychological testing performance score (NPZ-4) on Grooved Pegboard, Color Trails 1, Color Trails 2 and Trail Making A|Difference between study arms at weeks 48 and 72 in CSF monocyte chemoattractant protein-1 (MCP-1) levels|Difference between study arms at weeks 48 and 72 in CSF interferon-gamma-inducible protein-10 (IP-10) levels|Difference between study arms at weeks 48 and 72 in plasma neopterin levels|Difference between study arms at weeks 48 and 72 in plasma soluable CD14 (sCD14) levels|Difference between study arms at weeks 48 and 72 in plasma interleukin-6 (IL-6) levels|Difference between study arms at weeks 48 and 72 in plasma D-dimer levels|Difference between study arms at weeks 48 and 72 in plasma soluable CD163 (sCD163) levels",https://ClinicalTrials.gov/show/NCT02750059
50,NCT02750020,Policy-related Survey on Tobacco Control,Recruiting,No Results Available,Smoking,Other: Questionnaire,The University of Hong Kong,Both,Child|Adult|Senior,,5000,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2016 Policy Survey,"April 13, 2016",Feb-16,Feb-17,"April 22, 2016",Apr-16,No Study Results Posted,null,Jul-16,Attitudes to tobacco control policies,https://ClinicalTrials.gov/show/NCT02750020
51,NCT02750007,Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: HS-20004,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",Both,Adult,Phase 1,12,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,HS-20004-Id,"April 11, 2016",Dec-15,null,"April 22, 2016",Apr-16,No Study Results Posted,null,Jan-17,Number of Treatment Emergent Adverse Events(TEAEs)|Number of Nausea and vomiting during titration|Mean Change From Baseline in Body Weight at different dose steps|Change in plasma concentration of HS-20004 from baseline at different dose steps|Change in plasma concentration of glucose from baseline at different dose steps|Change in plasma concentration of insulin from baseline at different dose steps|Change in plasma concentration of glucagon from baseline at different dose steps|The minimum dose of HS-20004 that could keep plasma glucose under 6.1 mmol/L in Type 2 Diabetic Patients,https://ClinicalTrials.gov/show/NCT02750007
52,NCT02749994,A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study),Recruiting,No Results Available,Hypercholesterolemia,Drug: Rosuvastatin|Drug: Ezetimibe,IlDong Pharmaceutical Co Ltd,Both,Adult|Senior,Phase 3,354,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",ID-ROEZ-302,"April 19, 2016",Apr-16,null,"April 20, 2016",Mar-16,No Study Results Posted,I-ROSETTE,Jan-17,Percent change from baseline to 8 week in LDL-Cholesterol|Percent change from baseline to 4 and 8 week in Total Cholesterol|Percent change from baseline to 4 and 8 week in Triglyceride|Percent change from baseline to 4 and 8 week in HDL-Cholesterol|Percent change from baseline to 4 and 8 week in non-HDL-Cholesterol|Percent change from baseline to 4 and 8 week in Apolipoprotein B|Percent change from baseline to 4 and 8 week in Apolipoprotein A1|Percent change from baseline to 4 week in LDL-Cholesterol|Percent change from baseline to 4 and 8 week in hs-CRP(high-sensitivity C-reactive protein)|The change of LDL-Cholesterol/HDL-Cholesterol ratio|The change of Total Cholesterol/HDL-Cholesterol ratio|The change of non-HDL-Cholesterol/HDL-Cholesterol ratio|The change of Apolipoprotein B/Apolipoprotein A1 ratio|The ratio of subjects who reach the goal of LDL-Cholesterol according to NCEP(National Cholesterol Education Program Adult Treatment Panel) III Guideline,https://ClinicalTrials.gov/show/NCT02749994
53,NCT02749955,Partner Services Pre-exposure Prophylaxis (PS-PrEP),Recruiting,No Results Available,"HIV Transmission, Transtheoretical Model of Change",Behavioral: PS-PrEP Intervention Group|Behavioral: PrEPLine Control Group,University of Chicago,Male,Adult,,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,IRB14-1087,"February 23, 2016",Nov-15,Dec-19,"April 20, 2016",Apr-16,No Study Results Posted,PS-PrEP,Dec-17,Surveying the uptake of PrEP care after randomized behavioral intervention or routine linkage|Timing of linkage to care after behavioral intervention,https://ClinicalTrials.gov/show/NCT02749955
54,NCT02749864,Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP),Recruiting,No Results Available,Hepatitis C|Hepatitis B,,Instituto de InvestigaciÌ_n MarquÌ©s de Valdecilla,Both,Adult|Senior,,16000,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,JCG-PREVHEP-2015-01,"April 16, 2016",Jun-15,Dec-16,"April 22, 2016",Apr-16,No Study Results Posted,PREVHEP,Dec-16,Serum Anti-HCV|HCV RNA viral load|Serum HBsAg|Serum anti-HIV 1 and 2|Birth date|Sex|Nationality|Residence time in Spain|Educational level|Activity and professional qualifications|Lifestyle habit/risk factor score|Nosocomial risk score|History of previous check of HCV/HBV exposure|Sexual behaviour|Number of sexual partners|Weight (kg)|Height (cm)|BMI|Abdominal perimeter (cm)|Waist perimeter (cm)|Blood pressure (mmHg)|ALT|AST|Alkaline Phosphatase (AP)|GGT (Gammaglutamyl transferase)|Bilirubin|Serum Albumin|Total Cholesterol|LDL Cholesterol|HDL Cholesterol|Triglycerides|White blood cell count (WBC or leukocyte count)|Hemoglobin|Platelets|INR|kPa in Fibroscan,https://ClinicalTrials.gov/show/NCT02749864
55,NCT02749851,Placenta Imaging Project,Recruiting,No Results Available,High Risk Pregnancy,Device: MRI,Oregon Health and Science University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Female,Adult,Phase 1|Phase 2,300,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,OHSU IRB 15196|U01HD087182,"February 8, 2016",Mar-16,Jan-18,"April 22, 2016",Apr-16,No Study Results Posted,PIP,Jan-18,Placental perfusion (Units of measure: ml/min) measured at 3 time points across gestation.|Optimal cutoff values of placental MRI for placenta mediated adverse outcomes using receiver operating characteristics (ROC)|Composite of placenta-mediated adverse pregnancy outcomes|Composite of Placenta histologic outcomes|Diagnosis of preeclampsia using standard clinical criteria|Small for gestational age fetus at 3% and 5%|Gestational age at delivery prior to 37 weeks gestation.,https://ClinicalTrials.gov/show/NCT02749851
56,NCT02749799,Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis,Recruiting,No Results Available,Plaque Psoriasis,Drug: DFD-01,"Promius Pharma, LLC",Both,Adult|Senior,Phase 3,45,Industry,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,DFD-01-CD-014,"April 13, 2016",Feb-16,Jul-16,"April 20, 2016",Apr-16,No Study Results Posted,null,May-16,Change in Total Sign Score from baseline to Day 14.|Treatment Satisfaction Questionnaire for Medication - version II will be administered at Day 14|Change in Clinical response in Investigator's Global Assessment from baseline to Day 14.|Change in % of body surface area from baseline to Day 14.|Change in Dermatology Life Quality from baseline to Day 14.,https://ClinicalTrials.gov/show/NCT02749799
57,NCT02749786,Genetic Basis of Rosacea Study (Control),Recruiting,No Results Available,Rosacea,Genetic: Skin Biopsy,Stanford University,Both,Adult|Senior,,10,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,22419,"April 18, 2016",Oct-15,Oct-16,"April 20, 2016",Apr-16,No Study Results Posted,null,Oct-16,Gene expression profile of papulopustular rosacea compared to normal skin and skin from individuals without rosacea.,https://ClinicalTrials.gov/show/NCT02749786
58,NCT02749747,Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric,Recruiting,No Results Available,Menopausal Syndrome|Hot Flashes,Drug: Sulpiride use|Drug: Placebo,Hospital de Clinicas de Porto Alegre,Female,Child|Adult|Senior,Phase 3,2,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)",14-0038,"April 13, 2016",Jun-14,Feb-17,"April 22, 2016",Apr-16,No Study Results Posted,null,Oct-16,Number of hot flashes per week based on a diary of Hot flashes applied for 12 Weeks,https://ClinicalTrials.gov/show/NCT02749747
59,NCT02749734,Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases,Recruiting,No Results Available,Macular Degeneration|Stargardt's Macular Dystrophy,Procedure: Subretinal transplantation,"Southwest Hospital, China",Both,Adult|Senior,Phase 1,15,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,2013CB967002,"January 7, 2016",May-15,Dec-17,"April 20, 2016",Apr-16,No Study Results Posted,null,Dec-16,Number of participants with Treatment-Related Adverse Events [Safety and Tolerability]|Number of Early Treatment Diabetic Retinopathy (ETDR ) letters participants can recognize|Visual Field as examined by Static perimetry|Flash Electroretinogram (FERG)|Amplitude and Latency of Flash Visual Evoked Potentials (FVEP)|Multifocal Electroretinogram (MFERG),https://ClinicalTrials.gov/show/NCT02749734
60,NCT02749669,Health Care Courses of Elderly Hospitalized Patients for Inappropriate Reasons: Qualitative and Economic Analyzes,Recruiting,No Results Available,Cognitive Impairment,Other: Qualitative research,RÌ©gis AUBRY|Centre Hospitalier Universitaire de Besancon,Both,Senior,,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,PAGE,"April 7, 2016",Mar-16,Jun-16,"April 20, 2016",Apr-16,No Study Results Posted,PAGE,Jun-16,90 semi-structured interviews|Demographic and socio-economic questionnaires of 15 patients|Caregiver Reaction Assessment (CRA) scale,https://ClinicalTrials.gov/show/NCT02749669
61,NCT02749643,Functional Outcome Measures With Vibrotactile Feedback to Prostheses,Recruiting,No Results Available,Unilateral Transradial Amputation,Device: Vibrotactile feedback system,Hadassah Medical Organization|Tel Aviv University,Both,Adult|Senior,,15,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,VTF- HMO-CTIL,"April 13, 2016",Apr-16,Jun-17,"April 22, 2016",Apr-16,No Study Results Posted,null,Apr-17,Orthotics and Prosthetics User Survey-Upper Extremity Functional Status|Modified Box & Blocks test|Time to complete dual tasking test|Activity,https://ClinicalTrials.gov/show/NCT02749643
62,NCT02749630,A Safety Study of Intraveniously Administered UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis.,Recruiting,No Results Available,"Healthy Volunteer, Ulcerative Colitis",Drug: Placebo (IV escalating doses)|Drug: UTTR1147A,"Genentech, Inc.",Both,Adult|Senior,Phase 1,45,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",GA29469|2015-002512-32,"April 12, 2016",Mar-16,Oct-17,"April 20, 2016",Apr-16,No Study Results Posted,null,Oct-17,"Incidence, nature and severity of adverse events during and following administration of UTTR1147A|Changes in vital signs, physical exam findings, and laboratory abnormalities during and following administration of UTTR1147A|Pharmacokinetics: Maximum serum concentrations (Cmax) of UTTR1147A in healthy volunteers and UC subjects|Pharmacokinetics: Minimum (through) serum concentrations (Cthrough) of UTTR1147A in healthy volunteers and UC subjects|Pharmacokinetics: Total serum clearance(CL) of UTTR1147A in healthy volunteers and UC subjects|Pharmacokinetics: Volume of distribution (V) of UTTR1147A in healthy volunteers and UC subjects|Pharmacokinetics: Area under the Curve (AUC) Dosing Interval of UTTR1147A in healthy volunteers and UC subjects|Pharmacokinetics: Elimination half-life (t1/2) of UTTR1147A in healthy volunteers and UC subjects|Immunogenicity: Incidence of Anti-Therapeutic Antibodies (ATAs) in serum",https://ClinicalTrials.gov/show/NCT02749630
63,NCT02749604,Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the Prostate,Recruiting,No Results Available,Prostatic Hyperplasia,Procedure: Non-ejaculatory sparring PVP|Procedure: Ejaculatory sparring PVP,Mansoura University,Male,Adult|Senior,Phase 4,40,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",Mans 4-5-2016,"April 20, 2016",Mar-16,Mar-18,"April 20, 2016",Apr-16,No Study Results Posted,null,Sep-17,ejaculatory function|Bladder outlet obstruction index|International index of erectile function-15,https://ClinicalTrials.gov/show/NCT02749604
64,NCT02749565,The Role of Endothelium A and EGFR Receptor in Fibrocytes From Asthma With Obstructive Sleep Apnea,Recruiting,No Results Available,Asthma|OSA,Device: continuous positive airway pressure (CPAP),"Chang Gung Memorial Hospital|Ministry of Science and Technology, Taiwan",Both,Adult|Senior,,60,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,102-5744A3,"April 7, 2016",Jan-15,Apr-19,"April 22, 2016",Apr-16,No Study Results Posted,null,Apr-17,circulating fibrocyte proportion between asthmatic patient with OSA and without OSA|the change of circulating fibrocyte proportion in asthmatic patients with OSA,https://ClinicalTrials.gov/show/NCT02749565
65,NCT02749526,Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial,Recruiting,No Results Available,Esophageal,"Drug: ""Endostar""|Drug: Liposo|Drug: cisplatin|Drug: Gimeracil and Oteracil Potassium •_öTegafur•_ä",The First Affiliated Hospital with Nanjing Medical University,Both,Adult|Senior,Phase 2,70,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,JS-ENDO-003,"March 28, 2016",Apr-16,Dec-16,"April 22, 2016",Apr-16,No Study Results Posted,null,Dec-16,R0 Resection rate|pCR rate,https://ClinicalTrials.gov/show/NCT02749526
66,NCT02749513,Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients,Recruiting,No Results Available,Esophageal Cancer,Drug: Itraconazole,Dallas VA Medical Center,Both,Adult|Senior,Phase 0,10,U.S. Fed,Interventional,Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label,15-084,"April 14, 2016",Jan-16,null,"April 20, 2016",Apr-16,No Study Results Posted,null,Dec-18,Inhibition of Hedgehog pathway signaling as measured by real-time PCR.|Inhibition of VEGFR2 pathway signaling as measured by Western blot,https://ClinicalTrials.gov/show/NCT02749513
67,NCT02749487,Neutrophil Lymphocyte Ratio as a Predictor of Systemic Inflammation in Critically Ill Patients,Recruiting,No Results Available,Critical Care,Other: Neutrophil Lymphocyte Ratio,Assiut University,Both,Adult|Senior,,80,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,IRB00009905,"April 21, 2016",Jun-15,null,"April 22, 2016",Apr-16,No Study Results Posted,null,May-16,short term survival,https://ClinicalTrials.gov/show/NCT02749487
68,NCT02749474,"Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes",Recruiting,No Results Available,"Pregnancy,Neoplastic Complications",,The Cooper Health System,Female,Child|Adult|Senior,,400,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Cooper 15-028,"April 13, 2016",Jul-03,Jul-23,"April 20, 2016",Apr-16,No Study Results Posted,CANCRPREGREG,Jul-23,Neonatal Developmental Quotient|Congenital Malformations,https://ClinicalTrials.gov/show/NCT02749474
69,NCT02749461,Validation of the Bernese Pain Scale for Neonates,Recruiting,No Results Available,Pain Assessment,Procedure: heel stick,"Bern University of Applied Sciences|University Hospital Inselspital, Berne|University of Zurich|University Children's Hospital Basel|University of Toronto",Both,Child,,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SNF 320030_159573,"April 12, 2016",Nov-15,Dec-16,"April 22, 2016",Apr-16,No Study Results Posted,BERN-PAIN,Dec-16,Change in pain response across time|Influence of individual contextual factors on pain response across time|Psychometric testing of the BPSN,https://ClinicalTrials.gov/show/NCT02749461
70,NCT02749331,Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy,Recruiting,No Results Available,Neuroendocrine Tumors,Drug: AdVince,Uppsala University,Both,Adult|Senior,Phase 1|Phase 2,35,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,VIRUSNET201401|2014-000614-64,"March 11, 2016",Mar-16,Dec-18,"April 19, 2016",Apr-16,No Study Results Posted,RADNET,Aug-18,Number of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03|Change in tumor size|Change in tumor metabolic activity|Progression-free survival (PFS)|Change in replication profile of AdVince|Change in the humoral immune response to AdVince|Change in the cytokine-mediated immune response,https://ClinicalTrials.gov/show/NCT02749331
71,NCT02749305,Comparative Effectiveness of Bariatric Surgery With PROMs,Recruiting,No Results Available,Bariatric Surgery|Metabolic Surgery|Weight Reduction,Other: Focus groups,Massachusetts General Hospital,Both,Adult|Senior,,79,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,2016P000346|CER-1503-29209,"March 25, 2016",Mar-16,null,"April 19, 2016",Apr-16,No Study Results Posted,LOBSTER PROMs,Jun-19,Changes in bariatric related quality of life will be measured using validated patient reported outcome measures,https://ClinicalTrials.gov/show/NCT02749305
72,NCT02749214,Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes,Recruiting,No Results Available,Parkinson's Disease,Other: Blood Sample Collection|Other: Breath Sample Collection,Emory University|Michael J. Fox Foundation for Parkinson's Research,Both,Adult|Senior,,100,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,IRB00086732,"April 20, 2016",Feb-16,Feb-18,"April 20, 2016",Apr-16,No Study Results Posted,null,Feb-18,Unified Parkinson's Disease Rating Scale Subscale II Score|Unified Parkinson's Disease Rating Scale Subscale III Score|Modified Hoehn and Yahr Scale Score|Overnight Questionnaire Score|Beck's Depression Scale Score|Montreal Cognitive Assessment (MOCA) Score,https://ClinicalTrials.gov/show/NCT02749214
73,NCT02749201,Transmitted Light Tissue Thickness Analysis (TiLTT),Recruiting,No Results Available,Morbid Obesity,Device: Gastrisail,Maimonides Medical Center|Medtronic,Both,Adult|Senior,,10,Other|Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,2015-06-15-MMC,"April 20, 2016",Apr-16,Apr-17,"April 21, 2016",Apr-16,No Study Results Posted,TiLLT,Apr-17,Correlation (Correlation of transmitted light intensity to gastric wall thickness),https://ClinicalTrials.gov/show/NCT02749201
74,NCT02749188,Evaluation of Bladder Stimulation as a Noninvasive Technique of Urine Collection in Infant Who Have Not Acquired Walking,Recruiting,No Results Available,Urinary Retention,Other: Bladder stimulation,Fondation Lenval,Both,Child,Phase 3,300,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,14-HPNCL-07,"April 20, 2016",Oct-14,Oct-17,"April 20, 2016",Apr-16,No Study Results Posted,StiVeN,Oct-17,Evaluation of bladder stimulation as a noninvasive technique of urine collection in infants who have not acquired walking|evaluation period of urine collection|Evaluation of the tolerance of the infant|alternative of the urine sample,https://ClinicalTrials.gov/show/NCT02749188
75,NCT02749162,Perineural Dexamethasone in Femural Nerve Block After Ligament Reconstruction,Recruiting,No Results Available,Postoperative Pain,Drug: Dexamethasone phosphate|Drug: Paracetamol|Drug: Morphine|Drug: Lidocaine|Drug: Ropivacaine,Foisor Orthopedics Clinical Hospital,Both,Adult,Phase 3,90,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",ID AN-001-14,"February 22, 2016",Nov-15,May-16,"April 21, 2016",Feb-16,No Study Results Posted,null,Apr-16,the total amount of morphine|the patient satisfaction|the number of patients with neurological motility side effects|duration of analgesia|the number of patients with neurological sensibility side effects,https://ClinicalTrials.gov/show/NCT02749162
76,NCT02749123,Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis,Recruiting,No Results Available,Back Pain|Arthritis,"Drug: lidocaine 5% patch|Drug: lidocaine 3.6%, menthol 1.25%|Drug: Placebo",J.A.R. Laboratories,Both,Adult|Senior,,100,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",527-03,"April 18, 2016",Apr-16,May-16,"April 19, 2016",Apr-16,No Study Results Posted,null,May-16,"Efficacy comparison of lidocaine 5% and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale|Quality of life comparison of placebo and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale|Efficacy comparison of placebo and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale|Side effect comparison of placebo and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale|Side effect comparison of lidocaine 5% and lidocaine 3.6%, menthol 1.25% as measured by VAS numeric 0-10 pain scale",https://ClinicalTrials.gov/show/NCT02749123
77,NCT02749019,Dual Integrin ë±vë_3 and GRPR Targeting PET Imaging in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer,Drug: 68Ga-NOTA-BBN-RGD,Peking Union Medical College Hospital|National Institute for Biomedical Imaging and Bioengineering (NIBIB),Female,Adult|Senior,Phase 1,40,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,PUMCHNM012|ZIAEB000073,"April 20, 2016",Jul-15,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Jul-18,Standardized uptake value of 68Ga-NOTA-BBN-RGD in breast cancer,https://ClinicalTrials.gov/show/NCT02749019
78,NCT02748993,A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Pediatric Atopic Dermatitis,Recruiting,No Results Available,Atopic Dermatitis,Drug: PAC-14028 Cream 0.1%|Drug: PAC-14028 Cream 0.3%|Drug: PAC-14028 Cream 1.0%|Drug: PAC-14028 Cream Vehicle,Amorepacific Corporation,Both,Child,Phase 1|Phase 2,56,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",AP-TRPV1_PII-05,"April 20, 2016",Mar-16,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Dec-16,Success rate of Investigator's Global Assessment (IGA)|Blood concentrations of PAC-14028|Change of IGA (Investigator's Global Assessment)|Change of SCORAD (Severity Scoring of Atopic Dermatitis)|% Change of EASI (Eczema Area and Severity Index)|Patient satisfaction measurement,https://ClinicalTrials.gov/show/NCT02748993
79,NCT02748980,Clinical Observation of Coronary Arterial Microcirculation Dysfunction in Diabetic Patients With Non- Obstructive Coronary Artery Disease,Recruiting,No Results Available,Complications of Diabetes Mellitus|Coronary Artery Disease,,Shaanxi Provincial People's Hospital,Both,Adult|Senior,,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,LHJJ20159029,"April 17, 2016",Mar-16,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Mar-19,The coronary microcirculation dysfunction is measured by index of microcirculatory resistance,https://ClinicalTrials.gov/show/NCT02748980
80,NCT02748915,Electrophysiological-based Estimation of Cochlear Implant Fitting,Recruiting,No Results Available,Cochlear Implants,Other: Electrophysiological and psychoacoustic tests,Hospices Civils de Lyon,Both,Adult|Senior,,120,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,69HCL15_0309,"April 14, 2016",Jan-16,Jul-20,"April 19, 2016",Apr-16,No Study Results Posted,ENPICME,Jul-20,ECAP threshold|ECAP maximal amplitude|ECAP latency|ECAP AGF slope|EABR wave V maximal amplitude|EABR wave V latency|EABR wave V threshold|EABR wave V AGF slope|EABR binaural interaction component (BIC)|Most Comfort Level (MCL)|Speech recognition score,https://ClinicalTrials.gov/show/NCT02748915
81,NCT02748902,Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.,Recruiting,No Results Available,Verruca Vulgaris|Common Warts,Drug: ingenol mebutate 0.05% gel,"Neal D. Bhatia, MD|LEO Pharma|TCR Medical Corporation",Both,Adult|Senior,Phase 1,16,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,TCR-202i-03-16,"April 20, 2016",Apr-16,Oct-16,"April 21, 2016",Apr-16,No Study Results Posted,null,Oct-16,Efficacy assessed by verruca vulgaris lesion counts (total number of lesions present)|Safety assessed by number and severity of adverse events reported|Safety assessed by application site reactions on a 5 point scale (0/clear - 4/severe),https://ClinicalTrials.gov/show/NCT02748902
82,NCT02748889,Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,Recruiting,No Results Available,Small Cell Lung Cancer ( SCLC ),Drug: Carboplatin|Drug: Etoposide|Biological: MPDL3280A,Giuseppe Giaccone|Vanderbilt University|Memorial Sloan Kettering Cancer Center|Georgetown University,Both,Adult|Senior,Phase 1|Phase 2,178,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2015-1380,"February 2, 2016",Mar-16,Feb-19,"April 19, 2016",Apr-16,No Study Results Posted,null,Feb-18,"Incidence of adverse events by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0) grade and associated dose of MPDL3280A, carboplatin and etoposide given in combination|Incidence of dose-limiting toxicities (DLTs) by NCI CTCAE v4.0 grade and associated dose of MPDL3280A, carboplatin and etoposide given in combination|Incidence of Grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of MPDL3280A, carboplatin and etoposide given in combination|Hazard ratio (HR) for PFS according to modified RECIST v1.1 in patients receiving first-line carboplatin, etoposide and MPDL3280A for ED-SCLC compared with patients receiving carboplatin and etoposide alone|2.2.1 To evaluate PFS with carboplatin, etoposide and MPDL3280A compared to chemotherapy alone according to RECIST v1.1|To evaluate the complete response rate with carboplatin, etoposide and MPDL3280A compared to chemotherapy alone according to RECIST v1.1|To evaluate ORR with carboplatin, etoposide and MPDL3280A compared to chemotherapy alone according to RECIST v1.1|To evaluate the HR for OS in patients receiving first-line carboplatin, etoposide and MPDL3280A for ED-SCLC compared with patients receiving carboplatin and etoposide alone",https://ClinicalTrials.gov/show/NCT02748889
83,NCT02748850,Evaluation of the Effectiveness of an Aldehyde Inhibitor Dehydrogenases (DIMATE) on the Cell Population Leukemic or Normal Stem,Recruiting,No Results Available,Leukemia,Biological: blood sample|Biological: Stem cell donation,Assistance Publique Hopitaux De Marseille,Both,Adult|Senior,,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,2014-42|2015-A00043-46|RCAPHM15_0066,"April 13, 2016",Apr-16,Apr-20,"April 19, 2016",Apr-16,No Study Results Posted,DIMATE,Apr-20,Number of cell in apoptose|Number of cells which shows a rate the ALDH,https://ClinicalTrials.gov/show/NCT02748850
84,NCT02748811,Effect of Geriatric Intervention in Frail Elderly Patients Receiving Chemotherapy for Colorectal Cancer,Recruiting,No Results Available,Colorectal Neoplasms,Other: Intervention group,University of Copenhagen|Danish Cancer Society,Both,Senior,,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,GERICO,"March 31, 2016",May-15,Dec-18,"April 21, 2016",Apr-16,No Study Results Posted,GERICO,Dec-17,Number of patients completing planned treatment without dose reductions|Occurrence of dose reductions|delay of treatment|toxicity|time to recurrence|Survival|Cancer specific mortality|Quality of Life prior,https://ClinicalTrials.gov/show/NCT02748811
85,NCT02748785,MTX Discontinuation and Vaccine Response,Recruiting,No Results Available,"Arthritis, Rheumatoid",Drug: Methotrexate|Biological: Seasonal Influenza vaccine,Seoul National University Hospital,Both,Adult|Senior,Phase 4,600,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,SNUH-IMJ-001,"September 8, 2015",Sep-15,null,"April 19, 2016",Apr-16,No Study Results Posted,null,Aug-16,Proportion of seroresponse|Proportion of seroprotection|Change from baseline in antibody titer|Change from baseline in Disease Activity Score (DAS) 28-(CRP),https://ClinicalTrials.gov/show/NCT02748785
86,NCT02748772,Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical,Recruiting,No Results Available,Colorectal Neoplasms,Drug: Two Anti-angiogenesis Drugs•_öEndostar and Thalidomide•_ä|Drug: Pure chemotherapy•_öXelox•_ä,"The First People's Hospital of Hefei|Anhui Cancer Hospital|Anhui Jimin Cancer Hospital|Simcere Pharmaceutical Co., Ltd",Both,Adult|Senior,Phase 3,148,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),FirstPeoplesHHeFei,"April 20, 2016",Jan-16,Dec-18,"April 21, 2016",Apr-16,No Study Results Posted,null,Dec-17,PFS|RR,https://ClinicalTrials.gov/show/NCT02748772
87,NCT02748733,Proof of Concept of Adapted PD in Children (PC-AAPD),Recruiting,No Results Available,Primary Study Outcome: Dialytic Sodium Removal|Solute Removal|Ultrafiltration,Other: Adapted double mini PET|Other: Standard double min PET,"Heidelberg University|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Great Ormond Street Hospital for Children NHS Foundation Trust|HÌ«pital de Hautepierre",Both,Child|Adult,,15,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),S-545/2015,"April 13, 2016",Apr-16,Sep-17,"April 19, 2016",Apr-16,No Study Results Posted,PC-AAPD,Mar-17,"Dialytic sodium removal, i.e. the amount of sodium (mmol) per double mini PET (via ultrafiltration and diffusive sodium transport)|dialytic water and solute removal, i.e. ultrafiltrate per double mini PET (ml/gram intraperitoneal glucose exposure), phosphate removal per dmPET (mmol); Kt/V, clearance of creatinine (ml/min*1.73må_), intraperitoneal pressure (cm water)",https://ClinicalTrials.gov/show/NCT02748733
88,NCT02748707,Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study,Recruiting,No Results Available,Oral Squamous Cell Carcinoma|Carcinoma of Buccal Mucosa|Tongue Cancers|Head and Neck Cancers,Drug: Celecoxib|Drug: Erlotinib|Drug: Celecoxib + Erlotinib,Tata Memorial Hospital,Both,Adult|Senior,Phase 2,64,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Open Label,830,"April 20, 2016",Aug-15,null,"April 20, 2016",Apr-16,No Study Results Posted,ERLO-XIB,Aug-18,"Change in expression of selected biomarkers in tissue samples, assessed by immunohistochemistry (IHC) and PCR|Clinical and radiological Change in tumor size and appearance",https://ClinicalTrials.gov/show/NCT02748707
89,NCT02748681,Telemedicine Monitoring of Sleep Apnea in Stroke,Recruiting,No Results Available,Stroke|Sleep Apnea,Device: Auto CPAP AirSense‰ã¢ 10(Resmed),Neurologisches Rehabiliationszentrum RosenhÌ_gel,Both,Adult|Senior,Phase 4,55,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),HOPESV3,"April 14, 2016",Apr-16,Sep-18,"April 21, 2016",Apr-16,No Study Results Posted,HOPES,May-18,CPAP adherence in minutes used per night|systolic BP,https://ClinicalTrials.gov/show/NCT02748681
90,NCT02748668,Extracorporeal Membrane Oxygenation: Blood Cells,Recruiting,No Results Available,Extracorporeal Membrane Oxygenation,Other: Blood specimen collection,Spectrum Health Hospitals|Van Andel Research Institute,Both,Adult|Senior,,600,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,ECMO: Blood Cells,"April 19, 2016",Mar-15,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Mar-24,All cause mortality,https://ClinicalTrials.gov/show/NCT02748668
91,NCT02748655,Alkaline Ionized Water: Sports Recovery and Inflammation Management,Recruiting,No Results Available,Sports Recovery,Other: Alkaline ionized water|Other: Tap water,Natural Immune Systems Inc,Male,Adult,Phase 1|Phase 2,12,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label,NIS119004,"March 11, 2016",Mar-16,Jun-16,"April 21, 2016",Apr-16,No Study Results Posted,null,May-16,Plasma lactate levels|Complete Blood Count,https://ClinicalTrials.gov/show/NCT02748655
92,NCT02748629,ProGrip Mesh Repair vs Lichtenstein Operation,Recruiting,No Results Available,Inguinal Hernia,Device: Covidien Parietex ProGrip Self-Fixating Mesh|Device: Lightweight Polypropylene Mesh (<38g/m2 after absorption),"Regional Health Center in Kartuzy, Poland|Medical University of Gdansk",Both,Adult|Senior,,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),NKBNN/258/2015,"April 12, 2016",Mar-15,Oct-16,"April 21, 2016",Apr-16,No Study Results Posted,null,Jun-16,Incidence of post-operative pain and its intensity using VAS Scale|Rate of foreign body sensation - Subjective feeling of discomfort in the groin|Hernia recurrence rate|Post-operative complications|Duration of surgery|Incidence of Treatment-Emergent Adverse Events [Safety],https://ClinicalTrials.gov/show/NCT02748629
93,NCT02748603,Appropriateness of Coronary Angioplasty in PAtients With isCHEmic Heart Disease,Recruiting,No Results Available,Non ST Elevation Acute Coronary Syndromes|Stable Coronary Syndromes|NSTEMI|Unstable Angina,,Italian Society of Invasive Cardiology|IRCCS Policlinico S. Matteo,Both,Child|Adult|Senior,,400,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20140003325,"April 11, 2016",Oct-14,Jul-16,"April 19, 2016",Apr-16,No Study Results Posted,APACHE,May-16,"Proportion of patients with stable Coronary Artery Disease (CAD) whose clinical indication was appropriate for the treatment with Percutaneous Coronary Intervention (PCI).|Proportion of patients with complex lesions (left main, proximal LAD, three-vessel disease) treated ad hoc without documentation of Heart Team discussion in the medical records with stable CAD.|Proportion of patients receiving incomplete revascularization (i.e. residual SYNTAX > 8)Heart Team or in patients without documented ischemia with stable CAD.|Proportion of patients receiving guideline-recommended medical therapy at the time of PCI with stable CAD.|Incidence of FFR-guided PCI for stenosis of uncertain significance according to the Central Heart Team or in patients without documented ischemia with stable CAD.|Proportion of patients who received PCI but with an indication for CABG according to guidelines and no Heart team discussion in the medical record with stable CAD.|Proportion of patients treated with PCI whose clinical indication appears appropriate defined by a final score of ‰ä´ 7 of the Heart Team according to appropriate use criteria for Non ST elevation ACS (nSTE-ACS).|Proportion of PCI procedures performed within 24 hours of admission in patients with nSTEACS with GRACE> 140 for nSTE-ACS.|Proportion of patients with nSTEACS who are stabilized (no recurrent ischemic symptoms) who have multivessel disease and a high SYNTAX score (>22), without documentation of Heart Team discussion in the medical records for nSTE-ACS.",https://ClinicalTrials.gov/show/NCT02748603
94,NCT02748577,Pain Processing in Adults With Migraines,Recruiting,No Results Available,Migraines,Other: Psychological Measures|Other: Quantitative Sensory Testing (QST) Pain Measurements,Wake Forest School of Medicine,Both,Adult|Senior,,98,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,IRB00027845,"April 11, 2016",Jan-16,Jul-20,"April 19, 2016",Apr-16,No Study Results Posted,null,Jul-20,Heat Pain Intensity coefficient and intercept from stimulus response curve|Heat Pain Unpleasantness coefficient and intercept from stimulus response curve|Pain Catastophizing score|Difficulty in Emotions Regulation score,https://ClinicalTrials.gov/show/NCT02748577
95,NCT02748551,A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer,Recruiting,No Results Available,Gastric Cancer,Procedure: Laparoscopic procedures|Procedure: Open Surgery,Moscow Clinical Scientific Center,Both,Adult|Senior,Phase 3,800,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,MKNC 01/2016,"April 10, 2016",Apr-16,Apr-22,"April 19, 2016",Apr-16,No Study Results Posted,null,Apr-18,"""Major"" Surgical Morbidity|3-year progression-free survival|3-year overall survival|5-year overall survival rate|Surgical Mortality|Peri-operative blood loss|Postoperative recovery index|Pain scores|Postoperative quality of life|long-term surgical morbidity|Extent of lymph node dissection",https://ClinicalTrials.gov/show/NCT02748551
96,NCT02748525,Evaluation of Gallbladder Contractility Using Both CCK and Milk Consecutively,Recruiting,No Results Available,Abdominal Pain,Other: Milk|Biological: CCK,"The University of Texas Health Science Center, Houston",Both,Adult|Senior,,50,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,HSC-MS-16-0015,"April 4, 2016",Apr-16,Sep-17,"April 19, 2016",Apr-16,No Study Results Posted,Milk,Apr-17,Change in ejection fraction from original|Number of participants who reported abdominal pain at 6 months|Number of patients who received cholecystectomy,https://ClinicalTrials.gov/show/NCT02748525
97,NCT02748512,"A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye",Recruiting,No Results Available,Posterior Uveitis|Intermediate Uveitis|Panuveitis,Drug: FAI insert,pSivida Corp.,Both,Adult|Senior,Phase 3,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,PSV-FAI-006,"April 19, 2016",Feb-16,Jun-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Oct-16,Investigator reported ease of intravitreal administration,https://ClinicalTrials.gov/show/NCT02748512
98,NCT02748460,"Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting",Recruiting,No Results Available,Uterine Fibroids,,PregLem SA,Female,Adult|Senior,,1500,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PGL14-001 (PREMIUM),"April 19, 2016",Dec-15,Dec-22,"April 19, 2016",Apr-16,No Study Results Posted,Premium,Dec-22,"Occurrence of gynaecological AEs, SAEs, non-serious ADRs, AEs leading to ESMYA treatment discontinuation",https://ClinicalTrials.gov/show/NCT02748460
99,NCT02748408,The Medacta International SMS Post-Marketing Surveillance Study,Recruiting,No Results Available,Arthrosis|Traumatic Arthritis|Rheumatoid Polyarthritis|Congenital Hip Dysplasia|Avascular Necrosis of the Femoral Head,Device: SMS femoral stem,Medacta International SA,Both,Adult|Senior,,550,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,P01.019.01,"April 11, 2016",Jul-15,Jul-28,"April 21, 2016",Apr-16,No Study Results Posted,null,Jul-28,survivorship of the Medacta SMS femoral stem|clinical performance|radiographic performance|satisfaction|quality of life|pattern of bone remodeling|stem migration|Adverse events,https://ClinicalTrials.gov/show/NCT02748408
100,NCT02748356,Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB,Recruiting,No Results Available,Lower Urinary Tract Symptoms,Drug: Lactobacillus,Medstar Research Institute|Patient-Centered Outcomes Research Institute|Children's Research Institute|Georgetown University,Both,Child|Adult|Senior,Phase 2,25,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,5753,"January 29, 2016",Jan-16,Sep-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Sep-17,Urinary Symptom Questionnaire|Urine Acquisition|Health History Questionnaire|Patient Satisfaction|Urinalysis|Urine Culture|Microbiome SMRT Sequencing,https://ClinicalTrials.gov/show/NCT02748356
101,NCT02748343,The Clinical Therapeutic Effects and Safety of Tissue-engineered Bone,Recruiting,No Results Available,Bone Defect|Bone Nonunion,Device: allograft bone|Device: tissue-engineered bone,Xijing Hospital,Both,Child|Adult,Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),bilong11,"March 9, 2016",Nov-14,Dec-16,"April 19, 2016",Mar-16,No Study Results Posted,null,Sep-16,The scores of bone healing|the adverse event incidence using tissue-engineered bone and allograft bone|The scores of blood routine test|The scores of erythrocyte sedimentation rate(ESR)|The scores of C-reactive protein|The scores of the ratio of complement C3 to complement C4|The scores of immunoglobulin assay|The scores of duration of hospital stay|the scores of time of weight loading after operation|The scores of tumorigenesis|The scores of treatment course|The scores of number of operations|The scores of pain|The scores of wound healing of soft tissue,https://ClinicalTrials.gov/show/NCT02748343
102,NCT02748317,Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB,Recruiting,No Results Available,Lower Urinary Tract Symptoms,Drug: Lactobacillus rhamnosus GG,Medstar Research Institute|Patient-Centered Outcomes Research Institute|Georgetown University|Children's Research Institute,Both,Adult|Senior,Phase 2,25,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,2014-211,"January 29, 2016",Jan-16,Sep-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Sep-17,Urine Symptom Questionnaire|Health History Questionnaire|Patient satisfaction|Urine Acquisition|Urinalysis|Urine Culture|Microbiome SMRT Sequencing,https://ClinicalTrials.gov/show/NCT02748317
103,NCT02748265,A Study of Nebulized Epoprostenol (FLOLAN) and Phenylephrine on Arterial Oxygenation During One Lung Ventilation (OLV),Recruiting,No Results Available,Oxygenation During One Lung Ventilation,Drug: Inhaled Epoprostenol and phenylephrine|Drug: Sevoflurane|Drug: Propofol,"University Health Network, Toronto",Both,Adult|Senior,Phase 4,10,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,14-7520,"March 23, 2016",Mar-16,May-17,"April 21, 2016",Mar-16,No Study Results Posted,FLOLAN,Mar-17,"Increase of arterial oxygen tension in mmHg, during one-lung ventilation surgery, in response to combined nebulized epoprostenol/phenylephrine treatment|Changes in base status in pH|Differences between anesthetic technique -volatile vs. intravenous- in increase of arterial oxygen tension in mmHg, during one-lung ventilation surgery, in response to combined nebulized epoprostenol/phenylephrine treatment|Changes in mean arterial blood pressure in mmHg|Changes in platelet function count|Changes in acid status in pH",https://ClinicalTrials.gov/show/NCT02748265
104,NCT02748252,Prognosis of a First-Ever Stroke in Persons Living With HIV,Recruiting,No Results Available,"Cerebrovascular Accident, Acute|HIV",Other: stroke center referral,Fondation Ophtalmologique Adolphe de Rothschild,Both,Adult|Senior,,180,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AMR_2014-3,"April 18, 2016",Dec-15,null,"April 19, 2016",Apr-16,No Study Results Posted,PROFES,Jul-18,degree of disability measured with the modified Rankin Scale,https://ClinicalTrials.gov/show/NCT02748252
105,NCT02748226,Korean Vascular Intervention Society Multicenter Registry Study on Outcomes of Endovascular Therapy in Lower Limb Artery Diseases: (A Retrospective & Prospective Observational Study),Recruiting,No Results Available,Peripheral Arterial Disease(PAD),Procedure: endovascular treatment,Yonsei University,Both,Adult|Senior,,7000,Other,Observational,Observational Model: Cohort,4-2013-0463,"April 5, 2016",Aug-13,Jul-18,"April 19, 2016",Apr-16,No Study Results Posted,null,Jul-18,Primary patency|Target lesion revascularization (TLR),https://ClinicalTrials.gov/show/NCT02748226
106,NCT02748200,External Beam Radiotherapy for Muscle Invasive Bladder Cancer,Recruiting,No Results Available,Toxicity,Radiation: external beam radiotherapy (EBRT),"University Hospital, Ghent",Both,Adult|Senior,Phase 1,9,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2015/0169,"March 18, 2015",Mar-15,May-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Mar-17,Number of participants with treatment-related adverse events as assessed by Radiation Therapy Oncology Group toxicity scale|Number of participants free from local relapse assessed on cystoscopy and Magnetic Resonance Imaging,https://ClinicalTrials.gov/show/NCT02748200
107,NCT02748187,Attachment Style and Reflective Functioning in CBASP,Recruiting,No Results Available,Depression,Other: Cognitive Behavioural Analysis System of Psychotherapy,University of Edinburgh,Both,Adult,,20,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,15/SS/0232,"March 27, 2016",Jan-16,Oct-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Oct-17,Psychological distress on the Clinical Outcome in Routine Evaluation Measure (CORE)|Depressive symptomology on the Patient Health Questionnaire (PHQ-9)|Therapeutic relationship on the Working Alliance Inventory (WAI),https://ClinicalTrials.gov/show/NCT02748187
108,NCT02748174,Protective HA Factors,Recruiting,No Results Available,Post Concussive Headache,Behavioral: Audio Files,New York University School of Medicine,Both,Adult,,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,15-01055,"April 19, 2016",Mar-16,Mar-18,"April 21, 2016",Apr-16,No Study Results Posted,null,Mar-18,Number of completers (assessment of adherence)|Number of days with migraine and other headache|Number of migraine headaches|Number of significant trigger/warning sign - migraine attack associations,https://ClinicalTrials.gov/show/NCT02748174
109,NCT02748148,Implementation Study of Enhanced Medication Therapy Management in Primary Care Practice,Recruiting,No Results Available,Medication Therapy Management|Pharmacogenomics,Other: Medication therapy management,Tabula Rasa HealthCare,Both,Adult|Senior,,50,Industry,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research|Masking: Open Label,MTM-309,"April 1, 2016",Apr-16,Jun-16,"April 19, 2016",Apr-16,No Study Results Posted,EMTM,Jun-16,Qualitative description of process-related challenges and successes as assessed by observation and survey|Quantitative description of bidirectional communication as assessed by turn-around times from pharmacist's recommendations delivered to prescriber's responses received|Qualitative description of incorporation of pharmacogenomic testing into workflow and receptiveness as assessed by observation and survey|Qualitative description of prescriber satisfaction with enhanced medication therapy management services as assessed by survey|Qualitative and quantitative description of potential impact of enhanced medication therapy management services on drug regimens as assessed by before-and-after observations,https://ClinicalTrials.gov/show/NCT02748148
110,NCT02748122,CSII Pilot in Adolescents With Type 2 Diabetes,Recruiting,No Results Available,Diabetes,Device: MMT 723,New York University School of Medicine,Both,Child|Adult,,150,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,15-00313,"April 19, 2016",Oct-15,Oct-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Oct-17,Change in score on Quality of Life questionnaire,https://ClinicalTrials.gov/show/NCT02748122
111,NCT02748109,Assessment and Rehabilitation of Central Sensory Impairments for Balance in mTBI,Recruiting,No Results Available,Brain Injury,Behavioral: Vestibular Rehabilitation + audio biofeedback|Behavioral: Vestibular Rehabilitation,Oregon Health and Science University|Portland VA Medical Center,Both,Adult,,130,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,15010|CDMRP-MR141257,"March 29, 2016",Apr-16,Sep-19,"April 19, 2016",Apr-16,No Study Results Posted,null,Sep-19,Change in gait activity in the home as measured using an inertial sensor continuously in the home for a week before and after intervention.|Change in Sensory Orientation Test (SOT) Composite Score|Change in Modified Balance Error Scoring System (mBESS) instrumented and non-instrumented scores|Change in dynamic gait coordination|Change in Sport Concussion Assessment Tool - 3rd edition (SCAT-3) symptoms questionnaire|Automated Neuropsychological Assessment Metrics (ANAM)|Dizziness Handicap Index (DHI)|PTSD Checklist|Pain Location Inventory|SIQR symptom Questionnaire|Sports Concussion Assessment Tool - 3 (SCAT-3) symptom questionnaire|Becks Depression Inventory (BDI)|Short Form - 36|Neurobehavioral Symptom Inventory|Change in Central Sensorimotor Integration (CSMI) Weighting Scores; vision|Change in Central Sensorimotor Integration (CSMI) Weighting Scores; vestibular|Change in Central Sensorimotor Integration (CSMI) Weighting Scores; proprioception,https://ClinicalTrials.gov/show/NCT02748109
112,NCT02748083,Transcranial Direct Current Stimulation (tDCS) as a Treatment for Cognitive Deficits in Schizophrenic,Recruiting,No Results Available,Schizophrenia,Device: tDCS|Device: Sham tDCS,Shanghai Mental Health Center|Nathan Kline Institute for Psychiatric Research,Both,Adult,,40,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",2015-09,"January 15, 2016",Dec-15,Dec-16,"April 19, 2016",Jan-16,No Study Results Posted,null,Dec-16,The MATRICS Consensus Cognitive Battery (MCCB)|Neuroimage changes in Magnetic Resonance Imaging (MRI)|The CogState: Working memory and attention|The Positive and Negative Syndrome Scale (PANSS)|Side-effects of tDCS,https://ClinicalTrials.gov/show/NCT02748083
113,NCT02748070,Perioperative Oral Steroids for Chronic Rhinosinusitis Without Polyps (CRSsNP),Recruiting,No Results Available,Chronic Rhinosinusitis|Endoscopic Sinus Surgery|Chronic Rhinosinusitis Without Polyps|Oral Steroids,Drug: Prednisone|Drug: Flonase,Stanford University,Both,Adult|Senior,,76,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",33096,"April 15, 2016",Aug-15,null,"April 19, 2016",Apr-16,No Study Results Posted,null,Aug-17,Sino-nasal Outcome Test (SNOT 22)|Lund-Kennedy score|Steroid Side Effect Questionnaire,https://ClinicalTrials.gov/show/NCT02748070
114,NCT02747940,Neurologic Signatures of Chronic Pain Disorders,Recruiting,No Results Available,Chronic Pain|Chronic Migraine|Fibromyalgia,Drug: flunarizine and/or pregabalin,"Taipei Veterans General Hospital, Taiwan|Ministry of Science and Technology, R.O.C.",Both,Adult|Senior,Phase 4,200,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,2015-10-001BC2015-11-001AC002B,"April 1, 2016",Dec-15,null,"April 19, 2016",Mar-16,No Study Results Posted,null,Dec-19,"clinical improvement after treatment (1) headache/pain intensity [NRS, numeric rating scale]|clinical improvement after treatment (2) headache/pain frequency [attacks per month]|clinical improvement after treatment (3) headache/pain duration [hours per day]|EEG change after treatment|sensory and pain threshold change after treatment|Autonomic function change after treatment",https://ClinicalTrials.gov/show/NCT02747940
115,NCT02747901,Comparison Between Kinesiotaping and Cold Therapy After Total Knee Arthroplasty,Recruiting,No Results Available,Surgery,Other: KINESIOTAPING|Other: COLD THERAPY,Dokuz Eylul University,Both,Adult|Senior,,111,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Supportive Care|Masking: Open Label,1886-GOA,"March 27, 2016",Jan-15,Apr-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Jun-16,"The maximum isometric muscle strength of Quadriceps and hamstring muscles of all the patients will be measured using Hand Held Dynamometer (Lafayette Instrument Company, Lafayette, Ind., USA).|Pain intensity of the knees will be measured by a numerical rating scale.|The active knee range of motion will be measured using a full circle manual goniometer.",https://ClinicalTrials.gov/show/NCT02747901
116,NCT02747888,Hereditary Risk Factors for Thyroid Cancer,Recruiting,No Results Available,Thyroid Cancer,"Other: Collection of family and medical history, and blood or saliva sample for genetic studies",Dana-Farber Cancer Institute,Both,Child|Adult|Senior,,165,Other,Observational,Time Perspective: Prospective,15-159,"March 31, 2016",Mar-16,Mar-21,"April 19, 2016",Mar-16,No Study Results Posted,null,Mar-19,Number of participants who have childhood or suspected familial thyroid nodules/cancer|Number of germline mutations identified associated with thyroid cancer predisposition|Prevalence of suspected familial thyroid cancer among those with childhood thyroid nodules/cancer,https://ClinicalTrials.gov/show/NCT02747888
117,NCT02747862,Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program,Recruiting,No Results Available,Attenuated Familial Adenomatous Polyposis|Deleterious Familial Adenomatous Polyposis,Other: Chart Review,M.D. Anderson Cancer Center,Both,Child|Adult|Senior,,1500,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,DR08-0006,"April 14, 2016",Feb-08,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Feb-20,Chart Review of Outcomes of Participants with Attenuated Familial Adenomatous Polyposis (AFAP) and Deleterious Familial Adenomatous Polyposis (FAP) Undergoing Endoscopic Surveillance,https://ClinicalTrials.gov/show/NCT02747862
118,NCT02747849,Hand & Foot TENS Study,Recruiting,No Results Available,Bedwetting,Device: TENS,Children's Hospital of Pittsburgh|Society of Urodynamics and Female Urology The Coulter Foundation,Both,Child|Adult,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,Pro15120157,"April 5, 2016",Apr-16,Jul-18,"April 19, 2016",Apr-16,No Study Results Posted,null,Apr-18,Questionnaire|Night Time Log,https://ClinicalTrials.gov/show/NCT02747849
119,NCT02747745,Theoretical Based Case Management Intervention for Dementia Family Caregivers,Recruiting,No Results Available,Dementia,Behavioral: Four risk areas reflecting the great needs of FCGs of PWDs,Chang Gung University|Chang Gung Memorial Hospital,Both,Adult|Senior,,152,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Subject),CMRPD1F0051,"April 10, 2016",Jan-16,Dec-18,"April 19, 2016",Apr-16,No Study Results Posted,null,Dec-18,The Change of FCG Quality of Life|Yielding to FCG role (the PWD status),https://ClinicalTrials.gov/show/NCT02747745
120,NCT02747719,Effects of Light and Exercise on Human Circadian Rhythms and Performance,Recruiting,No Results Available,Circadian Rhythm,Behavioral: Light and exercise,Brigham and Women's Hospital|NSBRI,Both,Adult,,18,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,HFP02802,"April 18, 2016",Apr-16,May-17,"April 19, 2016",Apr-16,No Study Results Posted,null,May-17,Circadian Phase|Subjective alertness,https://ClinicalTrials.gov/show/NCT02747719
121,NCT02747706,Childhood Asthma Mentoring Program for Parents,Recruiting,No Results Available,Asthma,Behavioral: Parent-to-parent mentoring,"InquisitHealth, Inc.|National Institutes of Health (NIH)|Montefiore Medical Center|University of North Carolina, Chapel Hill|Washington University School of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",Both,Child,,240,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,Asthma23|4R44HD081830,"April 18, 2016",Apr-16,Mar-18,"April 19, 2016",Apr-16,No Study Results Posted,CAMPP,Sep-17,Number of hospital admissions|Number of emergency department visits,https://ClinicalTrials.gov/show/NCT02747706
122,NCT02747680,Cerebral Responses to Insulin Induced Hypoglycemia,Recruiting,No Results Available,Type 1 Diabetes|Healthy|Hypoglycemia Unawareness,Other: hypoglycemia (low blood sugar) in MRI,University of Minnesota - Clinical and Translational Science Institute,Both,Adult,,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,0301M40641,"April 11, 2016",Jan-03,Jul-18,"April 21, 2016",Apr-16,No Study Results Posted,1018,Feb-18,Brain activation during euglycemia (normal blood sugar) using functional MRI|Brain activation during hypoglycemia (low blood sugar) using functional MRI,https://ClinicalTrials.gov/show/NCT02747680
123,NCT02747654,Isoniazid Dosage Prediction Model Development,Recruiting,No Results Available,NAT2 Genotype,Genetic: genotype,Samsung Medical Center,Both,Child|Adult|Senior,,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,SMC-2013-07-155-002,"April 19, 2016",Jun-14,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Dec-16,Serum concentrations of INH,https://ClinicalTrials.gov/show/NCT02747654
124,NCT02747589,Feasibility of Stimulating the Visual Cortex in Blind,Recruiting,No Results Available,"Blindness,Acquired",Procedure: Surgical device implant in brain,"University of California, Los Angeles",Both,Adult|Senior,,5,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,BlindStim,"April 14, 2016",Apr-16,Dec-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Dec-16,Stimulation level required to elicit visual phosphene|Characterization of stimulation-induced visions|Spatial localization of stimulation to produce visual phenomena with direct cortical stimulation.,https://ClinicalTrials.gov/show/NCT02747589
125,NCT02747576,Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma,Recruiting,No Results Available,Medulloblastoma,,St. Jude Children's Research Hospital|St. Baldrick's Foundation,Both,Child|Adult,,120,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,FACES,"April 13, 2016",Apr-16,Jan-19,"April 21, 2016",Apr-16,No Study Results Posted,null,Jun-18,"Performance on standardized measures of facial affect recognition (NEPSY-II; Advanced Clinical Solutions Social Cognition)|Performance on tests of visual spatial processing and executive functioning using standardized neurocognitive assessment measures|Activation of the core face perception network (lateral fusiform gyrus, inferior occipital gyri, superior temporal sulcus) using fMRI analysis|White matter integrity between the nodes of the core face perception network (lateral fusiform gyrus, inferior occipital gyri, superior temporal sulcus) using DTI analysis",https://ClinicalTrials.gov/show/NCT02747576
126,NCT02747498,Comparison of Circumferential Pulmonary Vein Isolation and Complex Pulmonary Vein Isolation Additional Linear Ablation for Recurred Atrial Fibrillation After Previous Catheter Ablation: Prospective Randomized Trial (CALRA-AF),Recruiting,No Results Available,Recurred Atrial Fibrillation,Procedure: Procedure with circumferential pulmonary vein isolation|Procedure: Procedure with linear ablation in addiction to pulmonary vein isolation,Yonsei University,Both,Adult|Senior,,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,4-2015-1057,"April 19, 2016",Jan-16,Dec-19,"April 20, 2016",Apr-16,No Study Results Posted,null,Dec-19,Clinical recurrence of atrial fibrillation after catheter ablation|procedure time|procedure related complication rate|rate of hospitalization,https://ClinicalTrials.gov/show/NCT02747498
127,NCT02747472,GIP Receptor Antagonist Studies in Humans,Recruiting,No Results Available,Glucose Metabolism,Drug: GIP-A|Drug: GIP(1-42)|Other: Saline,"University Hospital, Gentofte, Copenhagen|University of Copenhagen",Male,Adult,,10,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",UHG-CFD-GIPANTA-1,"April 19, 2016",Apr-16,null,"April 19, 2016",Apr-16,No Study Results Posted,GA-1,Jun-16,Insulin levels,https://ClinicalTrials.gov/show/NCT02747472
128,NCT02747394,Cognitive Training for Fragile X Syndrome,Recruiting,No Results Available,Fragile X Syndrome,Other: Working Memory Training,"University of California, Davis",Both,Child|Adult,,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",MerckCogmed,"April 5, 2016",Jan-13,null,"April 18, 2016",Apr-16,No Study Results Posted,null,Apr-16,"Composite of Stanford Binet, Fifth Edition Block Span and Leiter-R Spatial Working Memory|Wechsler Intelligence Scale for Children-IV Digit Span|Kiddie Test of Attentional Performance (KiTAP)|Behavior Rating Inventory Rating of Executive Function (BRIEF; Teacher and Caregiver Reports)|Swanson, Nolan and Pelham (SNAP-IV)",https://ClinicalTrials.gov/show/NCT02747394
129,NCT02747316,Iron Absorption and Transfer to the Fetus During Pregnancy in Normal Weight and Overweight/Obese Women and the Effects on Infants Iron Status,Recruiting,No Results Available,Overweight|Obesity|Pregnancy,Other: Stable iron isotope 57 (57Fe) labeled iron solution|Other: Stable iron isotope 58 (58Fe) labeled iron solution,Swiss Federal Institute of Technology,Female,Adult,,70,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,PIANO,"January 8, 2016",Jan-16,Mar-17,"April 18, 2016",Apr-16,No Study Results Posted,PIANO,Mar-17,Fractional iron absorption|iron transfer from the mother to the fetus in cord blood|Plasma ferriting|Hepcidin|Transferrin receptor|Hemoglobin|c-reactive protein|interleukin-6|alpha-1-acid glycoprotein|retinol binding protein|riboflavin,https://ClinicalTrials.gov/show/NCT02747316
130,NCT02747290,68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer Patients,Recruiting,No Results Available,Prostate Cancer,Drug: 68Ga-NOTA-BBN-RGD,Peking Union Medical College Hospital|National Institute for Biomedical Imaging and Bioengineering (NIBIB),Male,Adult|Senior,Phase 0,30,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,PUMCHNM011|ZIAEB000073,"April 19, 2016",Jul-14,null,"April 19, 2016",Mar-16,No Study Results Posted,null,Jul-17,Standardized uptake value of 68Ga-NOTA-BBN-RGD in prostate cancer|Adverse events collection,https://ClinicalTrials.gov/show/NCT02747290
131,NCT02747173,"Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques",Recruiting,No Results Available,Renal Cell Carcinoma,,Spanish Oncology Genito-Urinary Group|Pfizer,Both,Adult|Senior,,60,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,SOG-ANG-2014-01,"April 23, 2015",Oct-15,Sep-18,"April 18, 2016",Apr-16,No Study Results Posted,METHEOS,Jun-18,Assess bone biomarkers in response to TKI|Progression free survival|Objective response rate|Measurements in time of bone metastases in RCC using whole body magnetic resonance and bone scintigraphy|Change and correlation of magnetic resonance and CT results in the assessment of global disease response to TKI. Using RECIST and MASS criteria|Quality of life of patients with RCC and bone metastases throughout the study period using the FSI-15|Quality of life of patients with RCC and bone metastases throughout the study period using FACT-BP|Efficacy of TKI in the improvement of pain produced by bone metastases throughout the study period|Efficacy of TKI in the improvement of pain produced by bone metastases throughout the study period using the NPR scale|Assessment osteonecrosis of the jaw with use of biphosphonates or denosumab throughout the study period,https://ClinicalTrials.gov/show/NCT02747173
132,NCT02747160,Anxiety With Cancer in the Elderly (ACE): A Cognitive-behavioral Intervention,Recruiting,No Results Available,Anxiety|Depression|Quality of Life,Behavioral: Managing Anxiety from Cancer (MAC),Weill Medical College of Cornell University,Both,Adult|Senior,,30,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label,1510016676,"April 12, 2016",Apr-16,Apr-17,"April 18, 2016",Apr-16,No Study Results Posted,null,Apr-17,Intervention feasibility|Intervention acceptability|Patient/caregiver adherence|Change in anxiety from baseline to post-intervention|Change in distress from baseline to post-intervention|Emotional health-related quality of life|Change in depression from baseline to post-intervention,https://ClinicalTrials.gov/show/NCT02747160
133,NCT02747108,ForgIng New Paths to Prevent DIabeTes (FINDIT),Recruiting,No Results Available,Prediabetes,Behavioral: Blood Test Group Intervention|Behavioral: Brochure Group Intervention,VA Office of Research and Development,Both,Adult|Senior,Phase 3,315,U.S. Fed,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,CDX 15-001|CDA 13-267,"April 18, 2016",Dec-15,Mar-20,"April 18, 2016",Apr-16,No Study Results Posted,FINDIT,Jun-17,Weight change from baseline to 12 months|Change in use of medication for T2DM prevention|Changes in participation in a weight management program|Changes in perception for risk for T2DM|Changes in knowledge of strategies to prevent T2DM|Changes in motivation to prevent T2DM|Changes in self-efficacy to engage in behaviors to prevent T2DM|Change in physical activity|Change in mental health,https://ClinicalTrials.gov/show/NCT02747108
134,NCT02746991,Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis,Recruiting,No Results Available,Posterior Uveitis|Intermediate Uveitis|Panuveitis,Drug: Sham Injection|Drug: FAI Insert,pSivida Corp.,Both,Adult|Senior,Phase 3,150,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",PSV-FAI-005,"April 19, 2016",Jun-15,Sep-19,"April 20, 2016",Apr-16,No Study Results Posted,null,Mar-17,Recurrence of uveitis in study eye,https://ClinicalTrials.gov/show/NCT02746991
135,NCT02746965,Magnetic Seizure Therapy for Schizophrenia,Recruiting,No Results Available,Schizophrenia,Procedure: magnetic seizure therapy|Procedure: electroconvulsive therapy,Shanghai Mental Health Center,Both,Adult,,180,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",SHDC12014111,"January 15, 2016",Apr-16,Mar-18,"April 18, 2016",Apr-16,No Study Results Posted,null,Sep-17,changes of The Positive and Negative Syndrome Scale (PANSS)|changes of The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|changes of Clinical Global Impressions (CGI)|changes of Motor Evoked Potentials (MEP)|changes of Magnetic Resonance Spectroscopy (MRS)|changes of Magnetic Resonance Imaging (MRI)|changes of Treatment Emergent Symptom Scale (TESS),https://ClinicalTrials.gov/show/NCT02746965
136,NCT02746913,Ambulatory Pessary Trial,Recruiting,No Results Available,Urinary Incontinence,Device: Urodynamics|Device: Pessary,New York University School of Medicine,Female,Adult|Senior,,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,15-00598,"April 18, 2016",Nov-15,Aug-17,"April 18, 2016",Mar-16,No Study Results Posted,null,Aug-17,"Medical, Epidemiological, and social Aspects of Aging (MESA) questionnaire|Overactive bladder quality of life (QAB-Q)- short term questionnaire",https://ClinicalTrials.gov/show/NCT02746913
137,NCT02746900,Cervical Cerclage for Preventing Spontaneous Preterm Birth in Singleton Pregnancies Without Prior Spontaneous Preterm Birth and With Short Transvaginal Ultrasound Cervical Length,Recruiting,No Results Available,Preterm Birth,Procedure: Cervical cerclage,Federico II University,Female,Adult,Phase 4,587,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,100/16,"April 8, 2016",Apr-16,Apr-19,"April 18, 2016",Apr-16,No Study Results Posted,null,Apr-18,Spontaneous preterm birth (SPTB)|Gestational age at delivery|Latency|chorioamnionitis|Birth weight|Admission to neonatal intensive care unit|respiratory distress syndrome|low birth weight|intraventricular hemorrhage|neonatal mortality,https://ClinicalTrials.gov/show/NCT02746900
138,NCT02746887,Risk Factors Related to Metabolic Syndrome in School-aged Children Who Were Born Preterm,Recruiting,No Results Available,Metabolic Syndrome,Other: Preterm/term cohort,Seoul National University Hospital,Both,Child,,120,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,1509-030-702,"December 9, 2015",Dec-15,null,"April 18, 2016",Apr-16,No Study Results Posted,null,Nov-16,number of participants with abnormal laboratory values and/or abnormal physical status|The number of participants with catch-up growth failure|The number of participants with hypertension,https://ClinicalTrials.gov/show/NCT02746887
139,NCT02746874,Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes,Recruiting,No Results Available,Total Knee Replacement,Procedure: Radiofrequency Ablation (RFA)|Procedure: Simulated Radiofrequency Ablation (RFA),Northwestern University|Halyard Health,Both,Adult|Senior,Phase 4,60,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",STU00200439,"April 18, 2016",Dec-15,null,"April 18, 2016",Apr-16,No Study Results Posted,null,Dec-17,Opioid consumption after surgery|Pain Score,https://ClinicalTrials.gov/show/NCT02746874
140,NCT02746861,Peer-Supported Diabetes Self-Management Support,Recruiting,No Results Available,Diabetes,Behavioral: Peer-Supported DSMS,"InquisitHealth, Inc.|National Institutes of Health (NIH)|National Institute on Minority Health and Health Disparities (NIMHD)",Both,Adult|Senior,,96,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,DSMS24|5R43MD009555,"April 19, 2016",Apr-16,Jun-17,"April 19, 2016",Apr-16,No Study Results Posted,DSMS,Mar-17,Average reduction in HbA1c from baseline,https://ClinicalTrials.gov/show/NCT02746861
141,NCT02746822,Thrombus Aspiration in Acute ST-elevation Myocardial Infarction,Recruiting,No Results Available,Acute ST-elevation Myocardial Infarction,,Oslo University Hospital,Both,Adult|Senior,,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2015/169,"April 8, 2016",Apr-15,Dec-20,"April 18, 2016",Apr-16,No Study Results Posted,TASTI,Dec-17,Cell composition of the intracoronary thrombus related to symptom length,https://ClinicalTrials.gov/show/NCT02746822
142,NCT02746796,Study of ONO-4538 in Gastric Cancer,Recruiting,No Results Available,Gastric Cancer,Drug: ONO-4538|Drug: Oxaliplatin|Drug: Tegafur- Gimeracil-Oteracil potassium|Drug: Capecitabine,Ono Pharmaceutical Co. Ltd,Both,Adult|Senior,Phase 2,268,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,ONO-4538-37,"March 29, 2016",Mar-16,null,"April 18, 2016",Feb-16,No Study Results Posted,null,Feb-18,"Objective response rate (only Part 2)|Overall survival (only Part 2)|Progression-free survival (only Part 2)|Duration of response (only Part 2)|Disease control rate (only Part 2)|Time to response (only Part 2)|Best overall response (only Part 2)|Percent change in the sum of diameters of target lesions (only Part 2)|Safety will be analyzed through the incidence of adverse events, serious adverse events|Safety will be analyzed through the incidence of laboratory abnormalities",https://ClinicalTrials.gov/show/NCT02746796
143,NCT02746757,Glucagon Like Peptide-1 in Remote Ischemic Conditioning,Recruiting,No Results Available,Healthy Volunteers,Other: Remote conditioning|Drug: Exendin 9-39,Karolinska Institutet,Male,Adult,,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label,RIPC GLP-1,"April 18, 2016",May-15,null,"April 18, 2016",Apr-16,No Study Results Posted,null,Apr-16,Change in endothelium dependent vasodilatation,https://ClinicalTrials.gov/show/NCT02746757
144,NCT02746718,Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness,Recruiting,No Results Available,Pompe Disease,Other: Blood sample,Centre Hospitalier Universitaire de Nice,Both,Adult|Senior,,500,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,14-PP-13,"April 12, 2016",Dec-15,Dec-17,"April 18, 2016",Apr-16,No Study Results Posted,POPS3,Dec-15,Number of new cases of Pompe disease diagnosed by a positive DBS|Number of new cases and etiologies of neuromuscular diseases diagnosed in patients with unexplained restriction of lung volumes|Frequency and description of neurological symptoms associated with neuromuscular diseases to respiratory revelation,https://ClinicalTrials.gov/show/NCT02746718
145,NCT02746705,National Multiple Sclerosis Society (NMSS) Pilot Study of Transcranial Direct Current Stimulation (tDCS),Recruiting,No Results Available,Multiple Sclerosis,Device: Transcranial Direct Current Stimulation (tDCS)|Device: Sham Transcranial Direct Current Stimulation|Behavioral: Cognitive Training Program,New York University School of Medicine|Stony Brook University,Both,Adult|Senior,Phase 3,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver)",15-01189,"April 4, 2016",Apr-16,Sep-17,"April 20, 2016",Apr-16,No Study Results Posted,null,Sep-17,The number of participants completing at least 80% of the targeted sections|Total score of the Brief International Assessment of Cognition in MS (BICAMS)|Comparisons between the active and sham conditions on Fatigue Impact Scale|comparisons between the active and sham conditions on measure Cognitive State Brief Battery Score,https://ClinicalTrials.gov/show/NCT02746705
146,NCT02746653,Effectiveness and Safety of Gordian Surgical's TroClose1200‰ã¢,Recruiting,No Results Available,Hernia,Device: TroClose1200(TM),Gordian Surgical,Both,Adult,,50,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,GOR-CLN-01,"April 12, 2016",Apr-16,Aug-18,"April 20, 2016",Apr-16,No Study Results Posted,GOR-CLN-01,Aug-16,"Primary Outcome is the proportion of successfully created ports and their closure by the TRoClosed|Secondary efficacy outcome assessed by hernia signs at 6,12,and 24 months|Secondary Safety Outcome assessed by surgical complications",https://ClinicalTrials.gov/show/NCT02746653
147,NCT02746601,My Health eSnapshot - A Preconception Health Research Study,Recruiting,No Results Available,Preconception Care|Health Information Technology|Primary Health Care|Risk Assessment,"Behavioral: Risk Assessment, Counselling & Resources",Wellington-Dufferin-Guelph Public Health|University of Guelph|Boston Medical Center|East Wellington Family Health Team|Minto-Mapleton Family Health Team|Upper Grand Family Health Team|Norfolk Family Medical,Female,Child|Adult,,720,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Screening|Masking: Open Label,2016-1,"April 10, 2016",Feb-16,Jun-17,"April 20, 2016",Apr-16,No Study Results Posted,null,Feb-17,"Patient-reported risk factors as assessed by Risk Assessment Tool|Patient-reported feedback on Risk Assessment, Counselling, and Resources as assessed by a One-Week Survey|Patient-reported health behaviour change and motivation for health behaviour change as assessed by a two-month survey",https://ClinicalTrials.gov/show/NCT02746601
148,NCT02746588,Description of the Uterine Cavity in Patients With Recurrent Miscarriages,Recruiting,No Results Available,Recurrent Miscarriages|Habitual Abortions,Other: Office hysteroscopy,Hvidovre University Hospital|University Hospital Copenhagen,Female,Adult,,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,H-15011157,"April 18, 2016",Feb-16,Jun-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Jun-17,Description of the Uterine Cavity in Patients With Recurrent Miscarriages,https://ClinicalTrials.gov/show/NCT02746588
149,NCT02746575,Pilot - Peri-operative Beta Blockade,Recruiting,No Results Available,"Adrenergic Beta-Receptor Blockader|Troponin Levels|Cardiomyopathy, Post-surgical",Drug: metoprolol,Washington University School of Medicine,Both,Adult|Senior,Phase 4,20,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,201507010,"April 14, 2016",Nov-15,Dec-16,"April 18, 2016",Apr-16,No Study Results Posted,null,May-16,Myocardial ischemia|Myocardial injury|Clinically relevant hypotension|AE monitoring,https://ClinicalTrials.gov/show/NCT02746575
150,NCT02746549,Accuracy of 1.5 T Versus 3 T Magnetic Resonance Arterial Spin Labeling to Measure Renal Blood Flow,Recruiting,No Results Available,Hypertension|Chronic Kidney Disease,Other: renal perfusion,University of Erlangen-NÌ_rnberg Medical School,Both,Adult|Senior,,20,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Caregiver, Investigator)",MRT2014,"October 8, 2015",May-14,Mar-17,"April 18, 2016",Apr-16,No Study Results Posted,null,Jan-17,Accuracy of 1.5 T versus 3 T magnetic resonance arterial spin labeling to measure renal perfusion (ml/min),https://ClinicalTrials.gov/show/NCT02746549
151,NCT02746536,Slow Chest Compression on Dynamic Hyperinflation and Dyspnea in COPD Patients,Recruiting,No Results Available,Chronic Obstructive Pulmonary Disease,Other: Slow chest compression|Other: No slow chest compression,University of the State of Santa Catarina,Both,Adult|Senior,,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single Blind (Investigator),SCC2016,"April 8, 2016",Aug-15,May-17,"April 18, 2016",Mar-16,No Study Results Posted,null,Dec-16,Patients with COPD will perform the inspiratory capacity (IC) by the slow vital capacity (SVC) maneuver in order to measure dynamic hyperinflation (DH).|Patients with COPD will answer dyspnea score by modified Borg scale,https://ClinicalTrials.gov/show/NCT02746536
152,NCT02746523,Effects of Multiple Concussions in Retired NHL Players,Recruiting,No Results Available,Cognitive Deficits|Proprioceptive Disorders,Other: Sensory Organization Test|Genetic: Biomarkers|Other: Conners' Adult ADHD Rating Scale (CAARS)|Other: Depression Scale|Other: Cognitive Assessment,New York Institute of Technology,Male,Adult|Senior,,20,Other,Observational,Observational Model: Case Control,BHS-1170,"April 8, 2016",Mar-16,Mar-18,"April 18, 2016",Apr-16,No Study Results Posted,NHL,Mar-17,Cognition assessed with the Montreal Cognitive Assessment Scale|Beck's Depression Inventory|Adult Attention Deficit assessed with the Connors' Adult Attention Deficit Disorder Rating Scale|Proprioception/Postural Stability assessed with the Sensory Organization Test|Human Interleukin-6 (IL-6)|Patient Health Questionnaire 9 (PHQ-9)|Interleukin 7 (IL-7)|Human 8-hydroxy-2' -deoxyguanosine (8-OHdG)|3-nitrotyrosine|8-iso-Prostaglandin F2a|Dityrosine|Apolipoprotein E-4|Complement Component 3 B (C3b)|MicroRNA miR132|MicroRNA miR183|S-100B Calcium binding protein|Brain derived neurotrophic factor (BDNF)|Amyloid beta 40|Total Tau Protein (tTAU)|Eco-Rna Species,https://ClinicalTrials.gov/show/NCT02746523
153,NCT02746471,Medtronic Reveal LINQ Insertable Cardiac Monitor Registry,Recruiting,No Results Available,"Arrhythmias, Cardiac",,Medtronic Cardiac Rhythm Disease Management,Both,Child|Adult|Senior,,2300,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,Reveal LINQ Registry,"February 29, 2016",Apr-14,Mar-21,"April 18, 2016",Apr-16,No Study Results Posted,null,Mar-21,Frequency of clinical actions initiated by Reveal LINQ arrhythmia detection feature|Procedure-related acute infection rate,https://ClinicalTrials.gov/show/NCT02746471
154,NCT02746432,Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial,Recruiting,No Results Available,Colon Cancer,Drug: Hyper insulinemic euglycemic clamp,King Saud University,Both,Adult|Senior,Phase 4,144,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",KSULDRCCRCMH001,"April 6, 2016",Mar-16,Mar-21,"April 21, 2016",Apr-16,No Study Results Posted,null,Mar-21,The anti-inflammatory effects of intraoperative hyper-insulinimic euglycemic therapy in patients undergoing colorectal cancer surgery.|The immunomodulatory effect of intraoperative hyper-insulinimic euglycemic infusion.,https://ClinicalTrials.gov/show/NCT02746432
155,NCT02746367,Bipolar Proteomic Assay Validation Study,Recruiting,No Results Available,"Major Depressive Disorder, Bipolar I and Bipolar II",Other: Diagnostic test (LDT),"Myriad Genetic Laboratories, Inc.|University of Minnesota - Clinical and Translational Science Institute",Both,Adult|Senior,,261,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EP-001,"April 12, 2016",Mar-16,null,"April 20, 2016",Apr-16,No Study Results Posted,null,Apr-18,"Agreement between the model derived diagnosis (based on panel of serum proteomic markers) and the clinical diagnosis (confirmed by the SCID DSM-5)|Self-report clinical rating scales (IDS-SR30, PHQ-9, MDQ, HCL-32 and TEMPS-A)|Changes in proteomic markers at Week 2 and Week 8",https://ClinicalTrials.gov/show/NCT02746367
156,NCT02746341,Natural History Study of Patients With MPS IIIA,Recruiting,No Results Available,Mucopolysaccharidosis IIIA,,LYSOGENE,Both,Child,,25,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,P3-LYS-SAF,"April 15, 2016",Apr-16,Mar-19,"April 18, 2016",Apr-16,No Study Results Posted,null,Dec-18,The change from baseline in cognitive function using the Bayley scales of infant and toddler development third edition|Change from baseline in the adaptive behavior composite standard score as measured by the Vineland Adaptive Behavior scale|Sleep disturbances measured by Actigraphy|Patient Quality of Life Questionnaires|Change from baseline in total cortical grey matter volume,https://ClinicalTrials.gov/show/NCT02746341
157,NCT02746276,Optimising Antibiotic Treatment for Sick Malnourished Children,Recruiting,No Results Available,Malnutrition,Drug: Ceftriaxone|Drug: Metronidazole,"University of Oxford|KEMRI Wellcome Trust Research Program, Kenya|Centre for Research in Therapeutic Sciences, Strathmore University, Nairobi Kenya|University College, London|Centre for Microbiology Research, Kenya Medical Research Institute|Centre for Clinical Research, Kenya Medical Research Institute",Both,Child,Phase 2,80,Other,Interventional,Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,OXTREC 47-15|KEMRI/SERU/CGMR-C/023/3161,"April 4, 2016",Apr-16,Sep-16,"April 25, 2016",Apr-16,No Study Results Posted,FLACSAM-PK,Sep-16,Area under the curve (AUC) of ceftriaxone|Trough level of metronidazole|Prevalence of faecal carriage of extended spectrum beta-lactamase (ESBL),https://ClinicalTrials.gov/show/NCT02746276
158,NCT02746263,Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain,Recruiting,No Results Available,"Acute Pain, Postoperative",Drug: IV acetaminophen|Drug: Oral acetaminophen|Drug: Morphine,Mallinckrodt,Both,Adult|Senior,Phase 4,130,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",MNK14504054,"March 18, 2016",Feb-16,Sep-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Jul-16,Pain intensity measured by a numerical pain scale (NPS) over an 18 hour duration,https://ClinicalTrials.gov/show/NCT02746263
159,NCT02746250,Muscle Soreness and Stiffness in Patients With Chronic or Frequent Episodic Tension Type Headache.,Recruiting,No Results Available,Tension-type Headache,Drug: Amitriptyline,Danish Headache Center,Both,Adult,,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,H-16000619,"April 13, 2016",Mar-16,Feb-17,"April 18, 2016",Apr-16,No Study Results Posted,null,Jan-17,Change in Total Tenderness Score|Change in muscle stiffness|Change in Local Tenderness Score,https://ClinicalTrials.gov/show/NCT02746250
160,NCT02746224,Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior Resection,Recruiting,No Results Available,Colorectal Cancer|Rectal Tumors,Procedure: Initially dissection of inferior mesenteric vein|Procedure: Initially dissection of inferior mesenteric artery|Procedure: Latero-terminal colorectal anastomosis|Procedure: Termino-terminal colorectal anastomosis,Institut d'InvestigaciÌ_ BiomÌ¬dica de Girona Dr. Josep Trueta,Both,Adult|Senior,,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),34502,"April 13, 2016",Apr-16,Sep-22,"April 18, 2016",Apr-16,No Study Results Posted,TAHR,Sep-19,Total number of resected lymph nodes|Anorectal functional outcome at 12 months assessed by COREFO questionnaire|Anorectal functional outcome at 12 months assessed by LARS scale|Intraoperative outcomes: duration of surgery|Intraoperative outcomes: surgical bleeding|Intraoperative outcomes: surgical conversion|Postoperative complications|Survival|Quality of life|Anorectal functional outcome assessed by COREFO questionnaire|Postoperative complications and anastomotic leakage|Anorectal functional outcome assessed by LARS scale|Distance to surgical margins,https://ClinicalTrials.gov/show/NCT02746224
161,NCT02746198,Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD),Recruiting,No Results Available,Antibiotic-associated Diarrhea,Other: probiotic dairy drink|Other: acidified milk,"Clinical Research Center Kiel GmbH|Yakult Honsha Co., LTD",Both,Adult|Senior,,124,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",14DE-KIEL-HPAAD1,"April 12, 2016",Jan-16,Dec-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Oct-16,Occurrence of antibiotic-associated diarrhea (AAD)|Cumulated duration of antibiotic-associated diarrhea (AAD)|Gastrointestinal Symptom Rating Scale|Cumulative sverity of antibiotic-associated diarrhea (AAD),https://ClinicalTrials.gov/show/NCT02746198
162,NCT02746172,Clinical Metrics for Assessing Cochlear Implant Recipient MAPs,Recruiting,No Results Available,Hearing Loss,Device: Cochlear implant with in-situ audiometry,The Hearing Cooperative Research Centre|Royal Victoria Eye and Ear Hospital|Cochlear,Both,Adult|Senior,,40,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CRC5628,"April 13, 2016",Nov-15,Nov-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Nov-16,"Sensitivity of percentage words/ phonemes correct, in detecting MAPs with inaccurate T and C levels in cochlear implant MAPs.|Sensitivity of speech reception threshold for numbers and sentences in noise, in detecting MAPs with inaccurate T and C levels in cochlear implant MAPs.|Sensitivity of aided hearing thresholds, in detecting MAPs with inaccurate T and C levels in cochlear implant MAPs.|Sensitivity of loudness ratings for narrow band noise presented at different frequencies and levels, in detecting MAPs with inaccurate T and C levels in cochlear implant MAPs.|Test-retest reliability of in-situ aided audiometry",https://ClinicalTrials.gov/show/NCT02746172
163,NCT02746107,"Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.",Recruiting,No Results Available,Atrial Fibrillation|Stroke,Other: decision aid,Cristian Baicus|Carol Davila University of Medicine and Pharmacy,Both,Adult|Senior,,958,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label,Studiul Cozia,"April 18, 2016",Mar-16,Oct-16,"April 20, 2016",Apr-16,No Study Results Posted,null,Jun-16,decision to prescribe/take the treatment,https://ClinicalTrials.gov/show/NCT02746107
164,NCT02746068,A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions,Recruiting,No Results Available,"Osteoarthritis, Knee",Drug: AXS-02|Drug: Placebo,"Axsome Therapeutics, Inc.",Both,Adult|Senior,Phase 3,346,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",AXS02-K301,"April 14, 2016",Mar-16,Sep-17,"April 18, 2016",Apr-16,No Study Results Posted,COAST-1,Sep-17,Change in patient reported pain intensity|Patient Global Impression of Change (PGI-C)|Clinical Global Impression of Change (CGI-C) scores|Change in WOMAC pain and stiffness subscales over time,https://ClinicalTrials.gov/show/NCT02746068
165,NCT02746042,Sinupret Extract Coated Tablets in Chronic Rhinosinusitis,Recruiting,No Results Available,Chronic Rhinosinusitis,Drug: Sinupret extract coated tablets|Drug: Placebo coated tablets,Bionorica SE,Both,Adult|Senior,Phase 3,514,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",CRS-03|2015-001952-31,"April 18, 2016",Apr-16,May-17,"April 25, 2016",Apr-16,No Study Results Posted,null,May-17,Major Symptom Score (MSS) assessed by the investigator at Visit 7 with Baseline as Covariate,https://ClinicalTrials.gov/show/NCT02746042
166,NCT02745977,Recruiting All Strictly Breast-fed Babies With Blood In Stool,Recruiting,No Results Available,Breast Milk Protein Intolerance,Other: Dairy Free Diet,Winthrop University Hospital,Female,Child|Adult|Senior,,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,14021,"April 18, 2016",Jun-14,Dec-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Jun-17,Presence of blood in the stool as evidenced by positive stool guaiac|guaiac negative on diary free diet,https://ClinicalTrials.gov/show/NCT02745977
167,NCT02745951,HELIox CardiOPlegia Trial During Cardiac surgERy,Recruiting,No Results Available,C.Surgical Procedure; Cardiac,Other: Heliox|Other: Standard of care,"David Mazer|St. Michael's Hospital, Toronto",Both,Adult|Senior,,24,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,15 - 311,"April 18, 2016",Apr-16,Jun-17,"April 18, 2016",Apr-16,No Study Results Posted,HELICOPTER-1,Dec-16,Feasibility of using Heliox to oxygenate the blood cardioplegia|New Myocardial Infarction,https://ClinicalTrials.gov/show/NCT02745951
168,NCT02745886,Metformin Induces a Dietary Restriction-like State in Human,Recruiting,No Results Available,Overweight Subjects|Metformin|Aging,Drug: metformin 0.85 twice daily for 6 months|Behavioral: Calorie restriction,Xiang Guang-da|Wuhan General Hospital of Guangzhou Military Command,Male,Adult,Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,Wze2016009,"April 1, 2016",Apr-16,Dec-16,"April 22, 2016",Apr-16,No Study Results Posted,null,Dec-16,The differences of gene expression profile among 3 groups.|The differences of insulin sensitivity in 3 groups,https://ClinicalTrials.gov/show/NCT02745886
169,NCT02745834,The Influence of Dual Task and Gait Speed on Gait Variability in Patients With Chronic Ankle Instability,Recruiting,No Results Available,Chronic Instability of Joint,Other: Gait analysis,"Medical Corps, Israel Defense Force|Ariel University",Both,Adult,,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,IDF-1482-2014,"March 15, 2016",Oct-15,Oct-16,"April 19, 2016",Jan-16,No Study Results Posted,null,May-16,Stride time variability|Stride length variability|Dual task general score,https://ClinicalTrials.gov/show/NCT02745834
170,NCT02745808,Injectable Collagen Scaffold‰ã¢ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes,Recruiting,No Results Available,Erectile Dysfunction|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Biological: HUC-MSCs|Biological: Injectable Collagen Scaffold + HUC-MSCs,Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Male,Adult,Phase 1,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),CAS-XDA-DEF/IGDB,"April 12, 2016",Sep-15,Apr-17,"April 18, 2016",Apr-16,No Study Results Posted,null,Dec-16,Safety and Tolerability assessed by Adverse Events|Improvement in IIEF-5 (International Index of Erectile Function)|Improvement in penile colour Doppler ultrasonography,https://ClinicalTrials.gov/show/NCT02745808
171,NCT02745782,A Study of the Trigeminal Cardio-Reflex in Endodontic and Other Dental Treatment,Recruiting,No Results Available,Pulpitis,Other: Observational Study,YI SHENG HUANG|Chung Shan Medical University,Both,Adult|Senior,,500,Other,Observational,Time Perspective: Prospective,CS 14112,"April 9, 2016",Oct-14,Oct-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Sep-17,Mean Arterial Blood Pressure(MABP) lower than 20%|Heart Rate (HR): lower than 60 beats/ minute,https://ClinicalTrials.gov/show/NCT02745782
172,NCT02745756,A Combined Cell Therapy Approach to the Treatment of Neuroblastoma,Recruiting,No Results Available,"Neuroblastoma|Neoplasms, Nerve Tissue",Procedure: Autologous Hematopoietic Progenitor Cell Transplant|Biological: KLH and Tumor Lysate Pulsed DC Vaccine,H. Lee Moffitt Cancer Center and Research Institute|All Children‰Ûªs Hospital Johns Hopkins Medicine,Both,Child|Adult,Phase 1,16,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,MCC-17181,"April 18, 2016",Apr-16,May-20,"April 18, 2016",Apr-16,No Study Results Posted,null,May-20,Occurrence of Sufficient Tumor Cell Lysate and Dendritic Cells|Occurrence of Dendritic Cell Related Adverse Events,https://ClinicalTrials.gov/show/NCT02745756
173,NCT02745730,RS-fMRI to Nutrient Shakes,Recruiting,No Results Available,Pleasure,Other: Glucose|Other: Fructose|Other: Sucralose|Other: Allulose,Unilever R&D|Leiden University Medical Center,Male,Adult,,20,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",REF-ICE-2421,"April 4, 2016",Mar-16,Oct-16,"April 21, 2016",Apr-16,No Study Results Posted,null,Jul-16,Change from baseline in the connectivity in the default mode and salience network: glucose and fructose vs. sucralose and allulose.|2. Change from baseline in the connectivity in the default mode and salience network: glucose vs. fructose.|3. Change from baseline in the connectivity in the default mode and salience network: allulose vs. sucralose.,https://ClinicalTrials.gov/show/NCT02745730
174,NCT02745717,The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia,Recruiting,No Results Available,Severe Aplastic Anemia,Procedure: IST|Biological: cord blood transfusion|Drug: Thymoglobulineå¨ and oral CSA,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai Tongji Hospital, Tongji University School of Medicine|Zhejiang Provincial Hospital of TCM",Both,Child|Adult,Phase 4,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,Shanghai1st-48,"April 7, 2016",Jan-16,Dec-18,"April 19, 2016",Mar-16,No Study Results Posted,null,Dec-18,neutrophil recovery day|response rate|disease free survival|overall survival,https://ClinicalTrials.gov/show/NCT02745717
175,NCT02745678,Localized Therapeutics for the Treatment of Gastrointestinal Disorders II,Recruiting,No Results Available,"Colitis, Ulcerative",Drug: Thermosensitive gel rectal formulation,Stanford University,Both,Child|Adult|Senior,Phase 1,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,IRB- 34970,"March 23, 2016",Jan-16,Dec-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Dec-16,Safety and efficacy of a new formulation in patients with mild-to-moderately-active Ulcerative Colitis using the Mayo Disease Activity Index (MMDAI),https://ClinicalTrials.gov/show/NCT02745678
176,NCT02745613,Type 2 Diabetes Affect Exercise Induced Improvement in Insulin Sensitivity,Recruiting,No Results Available,Insulin Sensitivity/Resistance,Other: 8 weeks of combined exercise intervention,"University of Texas, El Paso",Male,Adult,,24,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Double Blind (Caregiver, Outcomes Assessor)",755513-1,"April 18, 2016",Apr-16,Dec-17,"April 19, 2016",Apr-16,No Study Results Posted,HIT,Aug-17,Insulin sensitivity|Myokine concentrations,https://ClinicalTrials.gov/show/NCT02745613
177,NCT02745600,"Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment",Recruiting,No Results Available,Hepatocellular Carcinoma|Liver Metastases,Device: RFA therapy simulator,University of Leipzig|Medical University of Graz|University Medical Center Nijmegen|University of Turku,Both,Adult|Senior,,60,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,610886,"March 23, 2016",Feb-16,Mar-17,"April 21, 2016",Apr-16,No Study Results Posted,ClinicIMPPACT,Feb-17,"Comparison of the size and shape, using quantitative and semi-quantitative measures, of the real ablation zone one month after RFA treatment of liver tumors with the simulation results of the ClinicIMPPACT software.|Comparison of the spatial coordiantes of the real ablation zone one month after RFA treatment of liver tumors with the simulation results of the ClinicIMPPACT software.|Duration/Efficiency of workflow steps measured in minutes|Would the treatment protocol been influenced by the simulation results if it would have been known in advance by the treating doctor.|Does the follow - up (3, 6 ,12months) imaging support the assumptions regarding local tumor control",https://ClinicalTrials.gov/show/NCT02745600
178,NCT02745587,Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.,Recruiting,No Results Available,Prostate Cancer,Radiation: radiotherapy,"University Hospital, Ghent",Male,Adult|Senior,Phase 3,330,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2016/0246,"April 15, 2016",Apr-16,Apr-24,"April 20, 2016",Apr-16,No Study Results Posted,PROPER,Apr-21,Assessment of number of participants without clinical relapse|Assessment of number of participants experiencing Radiation Therapy Oncology Group toxicity|Assessment of number of participants with biochemical control,https://ClinicalTrials.gov/show/NCT02745587
179,NCT02745574,Randomized Controlled Trail for Post Laparoscopic Pain,Recruiting,No Results Available,Shoulder Pain,Procedure: Combined maneuver|Procedure: Intraperitoneal infusion,"Taipei Veterans General Hospital, Taiwan",Female,Adult|Senior,,360,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)",2013-04-038B,"September 1, 2014",Apr-13,Mar-17,"April 16, 2016",Apr-16,No Study Results Posted,null,Jan-17,"Change from baseline pain score of should and upper abdominal pain at 12 hours after surgery|Change from baseline pain score of should and upper abdominal pain at 24 hours after surgery|Change from baseline pain score of should and upper abdominal pain at 48 hours after surgery|Change from baseline of Nause, vomiting and abdominal distention rate at 48 hours after surgery",https://ClinicalTrials.gov/show/NCT02745574
180,NCT02745561,Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.,Recruiting,No Results Available,Esophageal Cancer|Endostatin,Drug: Endostatins|Drug: Oxaliplatin|Radiation: Radiotherapy,Hangzhou Cancer Hospital,Both,Adult|Senior,Phase 2,22,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,HangzhouCH05,"April 18, 2016",Jan-16,Dec-18,"April 19, 2016",Apr-16,No Study Results Posted,null,Dec-17,response rate|Acute and late toxicities assessed based on the common toxicity criteria for adverse events version 3.0 (CTCAEv3.0)|Progression-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT02745561
181,NCT02745535,"Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Subjects With Previous DAA Experience",Recruiting,No Results Available,Chronic Hepatitis C,Drug: Sofosbuvir/Velpatasvir/GS-9857,"University of Maryland|Unity Health Care, Inc.|Gilead Sciences",Both,Adult|Senior,Phase 2,120,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,HP-00067213,"April 11, 2016",Mar-16,null,"April 15, 2016",Apr-16,No Study Results Posted,RESOLVE,Dec-16,Incidence of grade 3 and 4 adverse events during treatment with and/or within 30 of completion of SOF/VEL/GS-9857 in HCV infected|Proportion of participants who achieve Sustained Virologic Response (SVR) 12 weeks after completion of therapy (SVR12)|Proportion of participants who achieve End of Treatment Virologic Response (ETR) at completion of therapy.|Proportion of participants who achieve Sustained Virologic Response (SVR) 4 weeks after completion of therapy.|Proportion of participants who achieve Sustained Virologic Response (SVR) 24 weeks after completion of therapy.,https://ClinicalTrials.gov/show/NCT02745535
182,NCT02745522,Can Oxytocin Enhance the Placebo Effect?,Recruiting,No Results Available,Oxytocin Effect on Memory Performance During Phase 1|Oxytocin Effect on Memory Performance During Phase 2|Oxytocin Effect on Memory Performance During Phase 3,Drug: Oxytocin|Drug: Placebo,University of Electronic Science and Technology of China,Male,Adult,Phase 1,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)",UESTC-neuSCAN-07,"March 11, 2016",Dec-15,Jan-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Dec-16,Memory performance in different phases,https://ClinicalTrials.gov/show/NCT02745522
183,NCT02745509,Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (EIPL),Recruiting,No Results Available,Gastric Cancer,Other: Extensive Intraoperative Peritoneal Lavage,"Sun Yat-sen University|Anhui Provincial Hospital|The First Affiliated Hospital of Anhui Medical University|Anqing Municipal Hospital|Yuebei People's Hospital|The First Affiliated Hospital of Guangdong Pharmaceutical University|Guangdong Provincial Hospital of Traditional Chinese Medicine|Jiangsu Cancer Institute & Hospital|Jiangxi Provincial Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|First Affiliated Hospital of Wannan Medical College|Lishui hospital of Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University",Both,Adult|Senior,Phase 3,530,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CGCG002,"March 28, 2016",Mar-16,Mar-20,"April 19, 2016",Apr-16,No Study Results Posted,EIPL,Mar-17,Overall survival|Disease-free survival|Peritoneal recurrence|Postoperative complications|Post-operative quality of life,https://ClinicalTrials.gov/show/NCT02745509
184,NCT02745496,Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Procedure: TRUS Biopsy|Procedure: TRUS/FUSION Biopsy,University of Dundee|NHS Tayside|Prostate Cancer UK|Tayside Clinical Trials Unit|Health Informatics Centre,Male,Adult|Senior,,600,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,MULTIPROS Study,"March 4, 2016",Dec-14,Dec-19,"April 15, 2016",Apr-16,No Study Results Posted,MULTIPROS,Jan-19,"Number of prostate cancers detected by MP-MRI when compared to gold standard prostatectomy|Number of clinically significant cancers detected by MP-MRI when compared to gold standard prostatectomy specimen|Number of cancer detected in each randomised group, namely intervention group (TRUS/FUSION biopsy) versus standard of care (TRUS biopsy)|Number of significant cancer detected in each randomised group, namely intervention group (TRUS/FUSION biopsy) versus standard of care (TRUS biopsy)|Number of patients with treatment related adverse events in each randomisation group|Number of patients which required repeated biopsies in each randomisation group|Number of patients with biopsy related side effects of pain and haematuria with recorded severity on 4 - point scale and with recorded duration of symptoms",https://ClinicalTrials.gov/show/NCT02745496
185,NCT02745470,Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain,Recruiting,No Results Available,Diabetes Mellitus,Drug: Lixisenatide|Other: Placebo,Seoul National University Hospital|Seoul National University,Both,Adult|Senior,,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Single Blind (Subject),H-1507-038-686,"April 17, 2016",Feb-16,Dec-16,"April 20, 2016",Feb-16,No Study Results Posted,null,Dec-16,Difference of BOLD (Blood oxygenation level-dependent) signal in hypothalamus|Whole brain connectivity|appetite change|mood change|intake of food in the buffet,https://ClinicalTrials.gov/show/NCT02745470
186,NCT02745457,Body Composition in Children With Inflammatory Bowel Disease,Recruiting,No Results Available,Crohn's Disease|Ulcerative Colitis,,"Schneider Children's Medical Center, Israel",Both,Child,,75,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,BodPod IBD,"April 13, 2016",Apr-16,Sep-18,"April 16, 2016",Apr-16,No Study Results Posted,null,Aug-18,To evaluate the change in body composition accorging to treatment treatment is children with IBD over the course of 2 years|To assess the accuracy of ADP in comparison to DEXA based measurement of body composition in children with IBD|To evaluate the correlation of body composition to skin fold and mid arm circumference measurements in children with IBD|To evaluate the correlation of body composition with BMI|To evaluate the correlation of body composition with disease activity|To evaluate the correlation of body composition with physical activity,https://ClinicalTrials.gov/show/NCT02745457
187,NCT02745444,Prevention of Acute Kidney Injury - Molecular Mechanisms of Dietary Pre-conditioning in Human,Recruiting,No Results Available,Chronic Kidney Disease,Dietary Supplement: low-calorie formula diet,University of Cologne,Both,Adult|Senior,,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,CR_LSP,"March 29, 2016",Apr-15,Dec-17,"April 15, 2016",Apr-16,No Study Results Posted,CR_LSP,Feb-17,Number of differentially regulated genes on a transcriptomic level|Number of differentially regulated genes on a lipidome level|Number of differentially regulated genes on a metabolome level|Number of differentially regulated genes on a epigenome level|Number of differentially regulated genes on a proteome level|Number of differentially regulated genes on a phosphoproteome level|Change of NGAL in urine|Cystatin C|Occurrence of acute kidney injury|Maximum postoperative serum creatinine,https://ClinicalTrials.gov/show/NCT02745444
188,NCT02745431,Oxytocin Effects on Likeability After Being Liked or Disliked,Recruiting,No Results Available,Likeability Ratings,Drug: Oxytocin|Drug: Placebo,University of Electronic Science and Technology of China,Male,Adult,,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)",UESTC-neuSCAN-06,"April 15, 2016",Jun-15,Apr-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Apr-16,Oxytocin effect on likeability after being liked or disliked,https://ClinicalTrials.gov/show/NCT02745431
189,NCT02745418,The Role of Filaggrin Mutations and Sensitization Pathways in Allergic Rhinitis and Peanut Allergy,Recruiting,No Results Available,Allergic Rhinitis|Peanut Allergies,,Queen's University,Both,Adult|Senior,,100,Other,Observational,Time Perspective: Cross-Sectional,FLG-AR-001,"March 2, 2016",Mar-16,Dec-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Aug-17,Peanut patch testing|Birch patch testing,https://ClinicalTrials.gov/show/NCT02745418
190,NCT02745379,Effect of Buccal Fat Pad Derived Stem Cells in Maxillary Sinus Augmentation,Recruiting,No Results Available,Alveolar Bone Loss,Procedure: BFPSCs+ DFDBA+ PRF|Procedure: DFDBA + PRF,Shahid Beheshti University of Medical Sciences,Both,Adult|Senior,Phase 1,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,sbmu9212,"April 18, 2016",Jan-16,Sep-16,"April 24, 2016",Apr-16,No Study Results Posted,null,Aug-16,amount of regenerated bone,https://ClinicalTrials.gov/show/NCT02745379
191,NCT02745366,Buccal Fat Pad Derived Stem Cells With Cortical Tenting in Posterior Mandible Reconstruction,Recruiting,No Results Available,Alveolar Bone Loss|Atrophy,Procedure: BFPSC+FDBA+PRF|Procedure: FDBA+PRF,Shahid Beheshti University of Medical Sciences,Both,Adult|Senior,Phase 1,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,sbmu9217,"April 18, 2016",Jan-16,Sep-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Aug-16,amount of regenerated bone,https://ClinicalTrials.gov/show/NCT02745366
192,NCT02745327,"Nutrition, Overgrowth, and Vaccine Efficacy in Low-income Settings",Recruiting,No Results Available,Small Intestine Bacterial Overgrowth,,"University of Virginia|Virginia Commonwealth University|International Centre for Diarrhoeal Disease Research, Bangladesh",Both,Child,,275,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PR14083,"April 15, 2016",Nov-14,Jul-18,"April 25, 2016",Apr-16,No Study Results Posted,NOVEL,Jul-18,Glucose-Hydrogen Breath Test|Fecal Regenerating Islet-Derived 1 Beta (Reg 1B)|Fecal Myeloperoxidase|Serum 25-OH vitamin D|Serum Zinc|Serum Retinol Binding Protein|Serum Cobalamin|Serum Albumin|Lactulose mannitol ratio|Serum Tetanus antibody titers|Serum Polio antibody titers to sabin strains|Oral fluid Tetanus antibody titers|Height|Weight|Head circumference,https://ClinicalTrials.gov/show/NCT02745327
193,NCT02745184,Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis,Recruiting,No Results Available,Idiopathic Pulmonary Fibrosis,Biological: Lung stem cells,Shanghai East Hospital|Regend Therapeutics,Both,Adult|Senior,Phase 1|Phase 2,20,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,201602101,"April 15, 2016",Apr-16,Dec-18,"April 15, 2016",Apr-16,No Study Results Posted,null,Jan-18,Changes in forced vital capacity (FVC)|Changes in Forced expiratory volume in one second (FEV1)|The differences of diffusing capacity of the lung for carbon monoxide (DLco)|Changes in 6 minute walk distance (6MWD)|Life quality: assessed by St. George respiratory questionnaire (SGRQ)|Dyspnea score according by Modified Medical Research Center(MMRC),https://ClinicalTrials.gov/show/NCT02745184
194,NCT02745171,Continuous Behavior Assessment of the Effects of a Physical Therapy Program for Patients With Parkinson's Disease,Recruiting,No Results Available,Parkinson's Disease,Other: physical therapy,Universidade Federal de Pernambuco,Both,Adult|Senior,,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),50967815.7.0000.5208,"March 30, 2016",Jan-16,Jun-16,"April 19, 2016",Apr-16,No Study Results Posted,null,Apr-16,change from quality of life,https://ClinicalTrials.gov/show/NCT02745171
195,NCT02745158,The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry,Recruiting,No Results Available,Fibrodysplasia Ossificans Progressiva (FOP),,The International FOP Association,Both,Child|Adult|Senior,,800,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IFOPA-REG-001,"March 6, 2016",Jul-15,Dec-25,"April 15, 2016",Mar-16,No Study Results Posted,null,Jul-25,Patient Reported Changes in New Bone Growth Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Episodic Flare-Ups Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Mobility Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Health Resource Utilization Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Signs Related to the Ear Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Signs Related to the Skin Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Signs Related to the Central Nervous System Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Signs Related to the Pulmonary System Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Signs Related to the Gastrointestinal System Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Signs Related to the Cardiovascular System Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Signs Related to the Renal System Using a Patient-Directed Survey Developed by the IFOPA|Patient Reported Changes in Signs Related to the Endocrine System Using a Patient-Directed Survey Developed by the IFOPA,https://ClinicalTrials.gov/show/NCT02745158
196,NCT02745106,Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary Thromboendarterectomy,Recruiting,No Results Available,Chronic Thromboembolic Pulmonary Hypertension,Procedure: Radiofrequency pulmonary artery denervation|Device: Ablation catheter|Device: Swan-Ganz catheter for right heart catheterization,Novosibirsk Scientific Research Institute for Circulatory Pathology,Both,Adult|Senior,,70,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,PADN1,"April 4, 2016",Aug-15,Dec-17,"April 24, 2016",Apr-16,No Study Results Posted,null,Dec-16,Pulmonary artery pressure|6-minute walking distance test|Echocardiographical sings of right ventricle function - 1|Echocardiographical sings of right ventricle function - 2|Pulmonary vascular resistance,https://ClinicalTrials.gov/show/NCT02745106
197,NCT02744976,Coronary Artery Disease Progression in Patients With Prediabetes,Recruiting,No Results Available,Coronary Artery Disease|Atherosclerosis|Prediabetic State,Drug: Metformin|Behavioral: Lifestyle recommendations,Pauls Stradins Clinical University Hospital,Both,Adult|Senior,Phase 4,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IVUS-0216,"April 15, 2016",Feb-16,null,"April 15, 2016",Apr-16,No Study Results Posted,null,Dec-18,"Percentage plaque volume change over 24 months|Culprit lesion in-stent restenosis|Plaque tissue component percentage change over 24 months|Correlation of glycemic parameters, c peptide, HOMA-IR index with plaque characteristics|Plaque volume change in metformin vs non-metformin treated patients over 24 months",https://ClinicalTrials.gov/show/NCT02744976
198,NCT02744872,Copenhagen Acute Renal Complications After Transplantations Study Group,Recruiting,No Results Available,Disorder Related to Lung Transplantation,Drug: Felodipine|Drug: Placebo,"Rigshospitalet, Denmark",Both,Adult|Senior,Phase 4,42,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)",2008-004771-22,"March 30, 2016",Sep-13,Jun-18,"April 19, 2016",Apr-16,No Study Results Posted,CARCATS,Dec-17,Change in glomerular filtration rate,https://ClinicalTrials.gov/show/NCT02744872
199,NCT02744755,Clinical Trial to Compare Treatment With GP2017 and Humiraå¨ in Patients With Rheumatoid Arthritis,Recruiting,No Results Available,Rheumatoid Arthritis,Biological: Adalimumab - GP2017|Biological: Adalimumab - US licensed Humira,Sandoz|Hexal AG|Sandoz Inc.,Both,Adult|Senior,Phase 3,308,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",GP17-302|2015-003433-10,"April 12, 2016",Mar-16,Oct-17,"April 15, 2016",Apr-16,No Study Results Posted,ADMYRA,Feb-17,Change in DAS28-CRP score,https://ClinicalTrials.gov/show/NCT02744755
200,NCT02744729,99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients,Recruiting,No Results Available,Esophageal Cancer,Drug: 99mTc-3PRGD2,First Affiliated Hospital of Fujian Medical University,Both,Adult|Senior,Phase 0,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,FirstAHFujian,"March 8, 2016",Oct-15,Jun-18,"April 16, 2016",Apr-16,No Study Results Posted,null,Feb-18,Visual Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan|Semiquantitative Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan|18F-FDG PET/CT Scan|Laboratory Values|Adverse events collection|Contrast-enhanced CT,https://ClinicalTrials.gov/show/NCT02744729
201,NCT02744690,Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia,Recruiting,No Results Available,Glaucoma,Drug: Mitomycin-C (MMC),Francis I. Proctor Foundation|Menelik II Hospital,Both,Adult|Senior,,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",15-16075-MMC,"February 11, 2016",Feb-16,Mar-17,"April 16, 2016",Apr-16,No Study Results Posted,null,Mar-17,"Cumulative incidence of complications|Reduction of intraocular pressure from baseline, mmHg",https://ClinicalTrials.gov/show/NCT02744690
202,NCT02744638,Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains on Bacterial Vaginosis,Recruiting,No Results Available,Bacterial Vaginosis,Other: probiotic yoghurt|Other: chemically acidified milk|Drug: Arilin,"Clinical Research Center Kiel GmbH|Dairyfem R&D GmbH|University of Natural Resources and Life Sciences, Vienna",Female,Adult|Senior,,216,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",DF-WCT-2014,"March 31, 2016",Feb-15,Jul-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Apr-16,Rate of BV-free woman|Alteration (G2 - G1) of Nugent Score,https://ClinicalTrials.gov/show/NCT02744638
203,NCT02744586,Zambia One Love Aim 3 Trial,Recruiting,No Results Available,HIV|Sexually Transmitted Diseases|Neglected Diseases|Non-communicable Diseases,Behavioral: Strengthening Our Vows (SOV)|Behavioral: Good Health Package Plus (GHPP),Emory University,Both,Adult,,3600,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label,IRB00083001,"April 15, 2016",Jan-16,null,"April 15, 2016",Apr-16,No Study Results Posted,null,Dec-16,HIV Incidence Rate|Syphilis Incidence Rate|Vaginal Trichomoniasis Incidence Rate|Number of Self-Reported Sexually Transmitted Infections (STIs)|Number of Reports of Sex without a Condom with Outside Partners|Number of Reported Outside Partners|Knowledge and use of hygiene and sanitation measures|Knowledge of hypertension and diabetes screening and management|Number of self-reports of accessing couples' testing (CVCT) with outside partners|Perceived Efficacy of Chlorine Use|Perceived Efficacy of Handwashing|Perceived Efficacy of Deworming|Perceived Efficacy of Management of Diabetes|Perceived Efficacy of Management of Hypertension|Change in Communication between Husband and Wife,https://ClinicalTrials.gov/show/NCT02744586
204,NCT02744560,Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C,Recruiting,No Results Available,Beta Thalassemia Major,Dietary Supplement: spirulina,Tanta University,Both,Child|Adult,Phase 4,30,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label,15/01/3026,"April 16, 2016",Mar-15,null,"April 16, 2016",Apr-16,No Study Results Posted,null,Dec-16,liver iron concentration using magnetic resonance imaging (T2* gradient echo pulse sequence in the axial plane),https://ClinicalTrials.gov/show/NCT02744560
205,NCT02744547,Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C,Recruiting,No Results Available,Beta Thalassemia Major,Dietary Supplement: Spirulina,Tanta University,Both,Child|Adult,Phase 4,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Caregiver, Outcomes Assessor)",14/11/2900,"April 16, 2016",Dec-15,null,"April 16, 2016",Apr-16,No Study Results Posted,null,Dec-16,serum hyaluronic acid levels|liver function tests|aspartate aminotransferase to platelet ratio index (APRI),https://ClinicalTrials.gov/show/NCT02744547
206,NCT02744534,Targeted Fusion Biopsy of the Prostate,Recruiting,No Results Available,Prostatic Neoplasms,Drug: FACBC PET-CT Scan|Procedure: Three-dimensional ultrasound-guided biopsy|Procedure: Standard transrectal ultrasound (TRUS) guided biopsy,Emory University,Male,Adult|Senior,Phase 2,36,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,IRB00080287,"April 15, 2016",Nov-15,Dec-18,"April 15, 2016",Apr-16,No Study Results Posted,null,Dec-18,Comparison of cancer detection between standard and targeted prostate biopsies,https://ClinicalTrials.gov/show/NCT02744534
207,NCT02744508,Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery,Recruiting,No Results Available,Orthopedic Surgery,Drug: palonosetron|Drug: palonosetron with dexamethasone,Yonsei University,Both,Adult,,202,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)",4-2015-0232,"April 18, 2016",Jul-15,May-16,"April 18, 2016",Apr-16,No Study Results Posted,null,May-16,incidence of clinically significant PONV with PONV impact scale,https://ClinicalTrials.gov/show/NCT02744508
208,NCT02744495,Prophylaxis of Postoperative Nausea and Vomiting After Cardiac Surgery,Recruiting,No Results Available,Postoperative Vomiting|Postoperative Nausea|Postoperative Emesis,Drug: prophylaxis of postoperative nausea and vomiting,HÌ«pital PrivÌ© de Parly II - Le Chesnay,Both,Adult|Senior,Phase 3,400,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,2015-A01440-49,"April 8, 2016",Feb-16,Feb-17,"April 19, 2016",Apr-16,No Study Results Posted,PONVACS,Jan-17,postoperative nausea and vomiting|number of postoperative nausea and vomiting|postoperative nausea and vomiting (VAS)|postoperative pain (VAS)|postoperative discomfort (VAS)|Antiemetics (treatment)|Analgesics|Side effects|QTc interval,https://ClinicalTrials.gov/show/NCT02744495
209,NCT02744456,N-of-1 Trials for Blood Pressure Medications in Adults,Recruiting,No Results Available,Hypertension|High Blood Pressure,Drug: Losartan|Drug: Amlodipine|Drug: Hydrochlorothiazide,Columbia University,Both,Adult|Senior,Phase 2,20,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,AAAN9419,"April 13, 2016",Aug-14,May-17,"April 18, 2016",Apr-16,No Study Results Posted,null,Nov-16,Participants satisfied with participating in N-of-1 trial|Participants satisfied with blood pressure regimen,https://ClinicalTrials.gov/show/NCT02744456
210,NCT02744404,Point of Care Early Infant Diagnosis Patient Impact Study,Recruiting,No Results Available,HIV,Device: POC EID,"Clinton Health Access Initiative Inc.|Ministry of Health, Malawi|UNICEF",Both,Child,,3000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Malawi POC EID,"April 15, 2016",Sep-15,May-16,"April 15, 2016",Apr-16,No Study Results Posted,null,May-16,ART initiation retention|Test turnaround time|Tests received,https://ClinicalTrials.gov/show/NCT02744404
211,NCT02744391,A Study of L-DOPA for Depression and Slowing in Older Adults,Recruiting,No Results Available,Major Depressive Disorder|Dysthymia|Depression Not Otherwise Specified|Decreased Processing Speed|Decreased Gait Speed,Drug: Levodopa,New York State Psychiatric Institute,Both,Adult|Senior,,60,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,7270,"April 13, 2016",Apr-16,null,"April 21, 2016",Apr-16,No Study Results Posted,null,Mar-21,"Hamilton Psychiatric Rating Scale for Depression|Pattern Comparison and Letter Comparison Tests|Single and dual task (ST, DT) using the GaitRite system|Digit Symbol test from the WAIS-III|CGI Severity and Improvement|Inventory of Depressive Symptoms - Self Report|fMRI scan|PET scan",https://ClinicalTrials.gov/show/NCT02744391
212,NCT02744365,"Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications",Recruiting,No Results Available,"Preeclampsia, Preterm Birth, Pregnancy Complications",Other: Observational,"Centre Hospitalier Universitaire de QuÌ©bec, CHU de QuÌ©bec",Female,Adult|Senior,,7725,Other,Observational,Time Perspective: Prospective,2015-2272,"April 15, 2016",Apr-15,Apr-20,"April 15, 2016",Apr-16,No Study Results Posted,null,Apr-18,early onset preeclampsia|Severe preeclampsia|Fetal growth restriction|spontaneous preterm birth|Fetal aneuploidies,https://ClinicalTrials.gov/show/NCT02744365
213,NCT02744352,Single Shot vs Catheter Infraclavicular Brachial Plexus Block After Distal Radius Fracture Repair,Recruiting,No Results Available,Distal Radius Fracture|Post Operative Pain Control,Drug: 20ml bolus of 0.5% ropivicaine|Drug: 0.2% of ropivacaine at 8 milliliter/hour,University of Pennsylvania,Both,Adult|Senior,,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,823323,"March 23, 2016",Oct-15,Nov-17,"April 15, 2016",Apr-16,No Study Results Posted,null,Oct-17,Pain Scores as measured by the Visual Analog Scale|Participants need for pain relief as measured by opiate consumption|Quality of recovery score|Number of subjects with insomnia as measured by Sleep questionnaire|Range of motion as measured by the Disability assessment of shoulder and hand questionnaire,https://ClinicalTrials.gov/show/NCT02744352
214,NCT02744339,Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction,Recruiting,No Results Available,"Hypertension, Pulmonary|Heart Failure With Normal Ejection Fraction",Drug: Riociguat|Drug: Placebo,Medical University of Vienna,Both,Adult|Senior,Phase 2,114,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",RIO-40400|2014-003055-60,"March 18, 2016",Mar-16,null,"April 15, 2016",Apr-16,No Study Results Posted,DYNAMIC,Feb-19,"Change from baseline of cardiac output at rest, measured by right heart catheterization|Change from baseline in cardiac magnetic resonance imaging parameters|Change from baseline in hemodynamic parameters other than cardiac output|Change from baseline in WHO functional class|Change from baseline in biomarker levels",https://ClinicalTrials.gov/show/NCT02744339
215,NCT02744313,MR Imaging of Fat Deposition in Adolescents With First Time Antipsychotic Use,Recruiting,No Results Available,Fat Deposition in Antipsychotic Naive,,Centre for Addiction and Mental Health|American Academy of Child Adolescent Psychiatry.,Both,Child|Adult,,12,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,060/2014,"April 6, 2016",Apr-16,Nov-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Oct-16,Change in hepatic and visceral adipose tissue from baseline to 3 months|Change in glucose tolerance from baseline to 3 months.|Change in insulin sensitivity from baseline to 3 months.,https://ClinicalTrials.gov/show/NCT02744313
216,NCT02744274,Efficacy of Acupuncture in Prevention of Chemotherapy Induced Peripheral Neuropathy - a Pilot Study,Recruiting,No Results Available,Colorectal Cancer,Other: Verum acupuncture,Tzu-Liang Chen|Research Center For Chinese Medicine and Acupuncture|China Medical University Hospital,Both,Adult|Senior,Phase 3,32,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Outcomes Assessor)",CMUH104-REC1-076,"April 13, 2016",Jan-16,Dec-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Dec-17,Change from Baseline in NCV at 48weeks.|Change from Baseline in Von frey filament test at 48weeks.|Change from Baseline in questionnaire - FACT/GOG-Ntx Subscale at 48weeks.|Change from Baseline in questionnaire - FACT-G at 48weeks.|Change from Baseline in questionnaire - Brief Pain Inventory Short Form at 48weeks.,https://ClinicalTrials.gov/show/NCT02744274
217,NCT02744248,"Evaluate MTD, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of IOP Injection in Healthy Subjects",Recruiting,No Results Available,Lymphatic Metastasis|Liver Cancer,Drug: IOP Injection|Drug: 0.9% normal saline,MegaPro Biomedical Co. Ltd.,Male,Adult,Phase 1,40,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Investigator)",CEECTTA20100721,"March 24, 2016",Feb-16,Dec-16,"April 20, 2016",Apr-16,No Study Results Posted,null,Dec-16,"Dose limiting toxicities (DLTs) of IOP|Maximum tolerated dose (MTD) of IOP|Pharmacokinetic parameters-Cmax|Pharmacokinetic parameters-Tmax|Pharmacokinetic parameters-AUC0-t|Pharmacokinetic parameters-AUC0-inf|Pharmacokinetic parameters-T1/2|Changes in laboratory safety tests (hematology, biochemistry, urinalysis, bleeding time) from baseline",https://ClinicalTrials.gov/show/NCT02744248
218,NCT02744235,Mainstream Sleep Tracking Devices vs Polysomnography,Recruiting,No Results Available,Severe Sleep Apnea|Severe Insomnia|Epileptiform Activity,Device: Polysomnography Data|Device: Jawbone UPå¨|Device: Fitbit Charge å¨,New York University School of Medicine,Both,Adult,,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,15-00071,"April 13, 2016",Mar-16,Mar-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Jun-16,Time it takes subject to fall asleep|Number of Minutes of Sleep|Number of Arousals,https://ClinicalTrials.gov/show/NCT02744235
219,NCT02744170,Effects of Supplemental Oxygen Delivery Via Demand Versus Continuous Flow in Hypoxemic COPD Patients,Recruiting,No Results Available,Chronic Obstructive Pulmonary Disease,Device: 1 continuous flow oxygen supplementation|Device: 2 demand delivery liquid oxygen supplementation|Device: 3 demand delivery oxygen supplementation via concentrator,Klinikum Berchtesgadener Land der SchÌ¦n-Kliniken,Both,Adult|Senior,,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",O2-Demand-Study,"March 8, 2016",Mar-16,Mar-19,"April 15, 2016",Apr-16,No Study Results Posted,null,Mar-19,"Oxygen saturation at isotime of the endurance shuttle walk test (ESWT), compared between CF (liquid oxygen) and DD (liquid oxygen)|Breathing frequency|Inspiratory capacity|Heart rate|Walking distance during ESWT|dyspnea|partial pressure of carbon dioxide",https://ClinicalTrials.gov/show/NCT02744170
220,NCT02744144,Wound Bacterial Microbiota and Their Antibiotic Resistance,Recruiting,No Results Available,"Wounds and Injuries|War-Related Injuries|Wound Infection|Wounds, Penetrating|Wounds, Gunshot|Arm Injuries|Leg Injuries|Soft Tissue Injuries",,"Karolinska Institutet|Medecins Sans Frontieres, Netherlands",Both,Child|Adult|Senior,,650,Other,Observational,Observational Model: Cohort,KISOS002,"April 13, 2016",Sep-14,Dec-16,"April 19, 2016",Apr-16,No Study Results Posted,null,Sep-16,Proportion of patients that develops infections after receiving surgical treatment|Frequency of different bacterial microbiota in wounds with clinical signs of infection|Frequency of microbiota with antibiotic resistance in wounds with clinical signs of infection|Length of stay,https://ClinicalTrials.gov/show/NCT02744144
221,NCT02744105,Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C,Recruiting,No Results Available,Beta Thalassemia Major,Dietary Supplement: Spirulina,Tanta University,Both,Child|Adult,Phase 4,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Caregiver, Outcomes Assessor)",14/11/2902,"April 16, 2016",Dec-15,null,"April 19, 2016",Apr-16,No Study Results Posted,null,Dec-16,liver stiffness measurement using transient elastography (Fibroscan)|liver function tests|aspartate aminotransferase to platelet ratio index (APRI),https://ClinicalTrials.gov/show/NCT02744105
222,NCT02744001,The Reinforcing Value of Added Sugars,Recruiting,No Results Available,Obesity,Other: Low Added Sugar Diet,USDA Grand Forks Human Nutrition Research Center,Both,Adult,,30,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,GFHNRC148,"April 15, 2016",Apr-16,Oct-18,"April 15, 2016",Apr-16,No Study Results Posted,null,Apr-18,Change in relative reinforcing value (RRV) of snacks as assessed by indicator,https://ClinicalTrials.gov/show/NCT02744001
223,NCT02743988,Influence of Oxygen Target Range on Intermittent Hypoxemia in Preterm Infants,Recruiting,No Results Available,Intermittent Hypoxemia|Apnea of Prematurity,Drug: Oxygen,University of Ulm,Both,Child,,36,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label,ULMNEONIRS05,"April 7, 2016",May-15,Sep-17,"April 14, 2016",Apr-16,No Study Results Posted,null,Apr-17,Duration SpO2 < 80%|Cerebral tissue oxygen saturation as measured by NIRS|Arterial SpO2 as measured by pulse oxymetry|Heart rate as measured by ECG|cerebral and visceral fractional oxygen extraction as measured by NIRS|Cardiac output as measured by Cardiovelocimetry|Number of hypoxemic and / or bradycardic events|Visceral tissue oxygen saturation as measured by NIRS,https://ClinicalTrials.gov/show/NCT02743988
224,NCT02743936,Mask Leak With Nasal Cannula in Noninvasive Positive Pressure Ventilation,Recruiting,No Results Available,Mechanical Ventilation Pressure High,Device: Nasal cannula|Device: Non-invasive positive pressure ventilation,Brooke Army Medical Center,Both,Adult|Senior,Phase 4,70,U.S. Fed,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),C.2016.030d,"April 15, 2016",Apr-16,May-16,"April 18, 2016",Apr-16,No Study Results Posted,null,May-16,Face Mask Leak measured in liters per minute by the noninvasive positive pressure ventilation machine|Patient discomfort (verbal numerical rating scale)|Non-invasive positive pressure ventilation tolerance (binary variable),https://ClinicalTrials.gov/show/NCT02743936
225,NCT02743858,Lymphedema Surveillance Study,Recruiting,No Results Available,Breast Cancer|Lymphedema,Other: Bilateral arm measurements|Other: Body mass index (BMI)|Behavioral: Quality of Life Questionnaire,Memorial Sloan Kettering Cancer Center,Female,Adult|Senior,,400,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,16-220,"April 8, 2016",Apr-16,null,"April 14, 2016",Apr-16,No Study Results Posted,null,Apr-18,number of incidences of lymphedema,https://ClinicalTrials.gov/show/NCT02743858
226,NCT02743845,"Gene Discovery Core, The Manton Center",Recruiting,No Results Available,Undiagnosed Conditions|Rare Disorders|Orphan Diseases,,Children's Hospital Boston,Both,Child|Adult|Senior,,10000,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,10-02-0053,"January 4, 2016",Feb-10,Dec-50,"April 14, 2016",Apr-16,No Study Results Posted,null,Dec-50,Identification of novel disease-causing genetic variants for a participant's disorder|Characterization of clinical features of novel and rare disorders using HPO terms,https://ClinicalTrials.gov/show/NCT02743845
227,NCT02743832,A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.,Recruiting,No Results Available,"Carcinoma, Squamous Cell",Procedure: Resection for primary lesion and cervical lymph node dissection|Procedure: Resection for primary lesion,"Jinsong Hou|First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital, Sun Yat-Sen University|Sun Yat-sen University",Both,Adult|Senior,,524,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,HouJ-2015018,"April 15, 2016",Jul-15,Jun-25,"April 20, 2016",Apr-16,No Study Results Posted,null,Jun-20,Five-year survival rate|Recurrence rate|Quality Of Life|Disease-free survival,https://ClinicalTrials.gov/show/NCT02743832
228,NCT02743780,A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma,Recruiting,No Results Available,Ocular Hypertension|Open-Angle Glaucoma,Drug: MGV354 ophthalmic suspension|Drug: MGV354 placebo,Alcon Research|Novartis Institute for BioMedical Research,Both,Adult|Senior,Phase 1|Phase 2,140,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)",MGV354-2201,"April 14, 2016",Mar-16,Aug-16,"April 14, 2016",Apr-16,No Study Results Posted,null,Aug-16,"Part 3: Change in diurnal IOP (averaged over 8 AM, 10 AM, noon, 4 PM, and 8 PM) from Baseline to Day 8|Part 3: Change in IOP from Baseline to Day 8 at 8 AM, 10 AM, noon, 4 PM, and 8 PM|Part 3: Change from baseline in IOP at 36 hours and 48 hours post Day 7 administration|Part 1: Maximum observed concentration [Cmax (ng/mL)]|Part 1: Time to reach maximum concentration [Tmax (h)]|Part 1: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUClast (ng*h/mL)]|Part 1: Area under the plasma concentration-time curve from time zero to 144 hours post dose [AUC0-144 (ng*h/mL)]|Part 1: Area under the concentration-time curve from 0 to infinity [AUC-inf (ng*h/mL)]|Part 1: Terminal elimination half-life [t1/2 (h)]|Part 2: Maximum observed concentration [Cmax (ng/mL)]|Part 2: Time to reach maximum concentration [Tmax (h)]|Part 2: Area under the concentration-time curve from 0 to the end of the dosing interval tau [AUCtau (ng*h/mL)]|Part 2: Accumulation Ratio (Racc)|Part 3: Observed concentration at 12 hours following drug administration [C12 (ng/mL)]",https://ClinicalTrials.gov/show/NCT02743780
229,NCT02743715,Transcranial Direct Current Stimulation (tDCS) for Treatment-Resistant Obsessive-Compulsive Disorder (FRONT),Recruiting,No Results Available,Obsessive-Compulsive Disorder,Device: Active tDCS (transcranial direct current stimulation)|Device: Sham tDCS,University of Sao Paulo|FundaÌ¤Ì£o de Amparo ÌÊ Pesquisa do Estado de SÌ£o Paulo,Both,Child|Adult,Phase 3,44,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",FRONT2016,"April 7, 2016",Apr-15,Dec-20,"April 18, 2016",Apr-16,No Study Results Posted,FRONT,Jul-20,"change in baseline Yale-Brown Obsessive Compulsive Scale score|Beck Depression Inventory symptoms,|Beck Anxiety Inventory|Hamilton Depression Scale|Hamilton Anxiety Scale|Global Clinical Impression Scale - improvement",https://ClinicalTrials.gov/show/NCT02743715
230,NCT02743689,Perioperative Risk Factors for Intensive Care Delirium After Cardiac Surgery,Recruiting,No Results Available,Delirium,,Vilnius University,Both,Adult|Senior,,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,DELI-1,"April 13, 2016",Mar-15,null,"April 19, 2016",Apr-16,No Study Results Posted,null,Jun-16,Incidence of early postoperative delirium in intensive care patients after cardiac surgery|Perioperative risk factors for delirium after cardiac surgery,https://ClinicalTrials.gov/show/NCT02743689
231,NCT02743663,The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children,Recruiting,No Results Available,Asthma|Wheeze|Obstructive Sleep Apnea|Food Allergy|Virus,Procedure: Bronchodilator response|Procedure: Allergy Skin Test|Procedure: Multiple-Breath Washout|Procedure: Forced Oscillation Technique|Procedure: Spirometry|Drug: salbutamol|Procedure: Nasal Brush|Procedure: Blood sample|Procedure: Basophil activation test|Procedure: Nasal swab,The Hospital for Sick Children|Dalhousie University,Both,Child,Phase 4,160,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1000041089,"January 13, 2016",Jun-14,Dec-16,"April 18, 2016",Apr-16,No Study Results Posted,Wheezy ER,Dec-16,Change in Lung Clearance Index (LCI) in wheezing subjects.|Obstructive Sleep Apnea (OSA)|Change in asthma symptoms|Change in Forced Oscillation Technique (FOT) values in wheezing subjects.|Change in spirometry values in wheezing subjects.|Comparison of LCI values between wheezy subjects and healthy controls.|Comparison of forced oscillation technique (FOT; lung impedence) values between wheezy subjects and healthy controls.|Comparison of spirometric values between wheezy subjects and healthy controls.|Change in nasal microbiome in wheezing subjects|Viral infections causing wheezing|Basophil activation test (BAT)|Lung epithelial cell immune response in wheezing subjects.,https://ClinicalTrials.gov/show/NCT02743663
232,NCT02743650,Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate,Recruiting,No Results Available,Chronic Kidney Disease,Dietary Supplement: Sodium bicarbonate,University of Utah|Robert Wood Johnson Foundation,Both,Adult|Senior,Phase 0,15,Other,Interventional,Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label,81006,"April 6, 2016",Feb-16,Feb-18,"April 13, 2016",Apr-16,No Study Results Posted,null,Feb-18,Change in serum bicarbonate concentration from baseline to 6 weeks|Change in serum bicarbonate concentration after 4 weeks of stopping sodium bicarbonate treatment,https://ClinicalTrials.gov/show/NCT02743650
233,NCT02743637,A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors,Recruiting,No Results Available,Advanced Malignancy|Advanced Solid Tumors|Neoplasm|Metastasis,Drug: SDX-7320,"SynDevRx, Inc.",Both,Adult|Senior,Phase 1,30,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,SDX-0101,"April 7, 2016",Feb-16,null,"April 14, 2016",Apr-16,No Study Results Posted,SDX-0101,Mar-17,Number of participants with adverse events as a measure of safety and tolerability of SDX-7320 to find the recommended Phase II dose|Anti-tumor activity,https://ClinicalTrials.gov/show/NCT02743637
234,NCT02743624,Criteria Analysis for Ventilatory Support Adjustment of Mechanical Ventilation,Recruiting,No Results Available,Acute Mechanical Ventilatory Failure,Procedure: Variation of the level of pressure support during the mechanical ventilation,University of Sao Paulo General Hospital,Both,Adult|Senior,,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,tematicomusculoUTI,"March 18, 2016",Feb-16,Aug-16,"April 13, 2016",Feb-16,No Study Results Posted,null,Mar-16,Measuring muscular force|Measuring inspiratory drive|Measuring endurance,https://ClinicalTrials.gov/show/NCT02743624
235,NCT02743572,Iron-fortified Parenteral Nutrition in the Prevention and Treatment of Anemia in Premature Infants,Recruiting,No Results Available,Premature Birth,Other: iron sucrose-1|Other: iron sucrose-2|Other: iron sucrose-3|Other: iron sucrose-4,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Both,Child,,150,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)",XH-16-002,"March 31, 2016",Sep-15,Aug-18,"April 14, 2016",Apr-16,No Study Results Posted,null,Aug-18,Changes of iron status index before and after iron-fortified parenteral nutrition support|Changes of iron storage index before and after iron-fortified parenteral nutrition support,https://ClinicalTrials.gov/show/NCT02743572
236,NCT02743533,Cardiovascular Diseases in the Silesian Region in Poland.,Recruiting,No Results Available,Cardiovascular Diseases,,Silesian Centre for Heart Diseases,Both,Adult|Senior,,10000000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SCD016,"April 4, 2016",Jan-06,Dec-20,"April 14, 2016",Apr-16,No Study Results Posted,SILICARD,Dec-20,Number of participants with reported deaths from any cause|Trends in the number of hospitalization due to cardiovascular diseases|Trends in the number of diagnostic and therapeutic procedures|Number of participants with reported rehospitalization,https://ClinicalTrials.gov/show/NCT02743533
237,NCT02743429,Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma,Recruiting,No Results Available,Neuroblastoma,Drug: dinutuximab beta,"University Medicine Greifswald|Children's Cancer Research Institute, Austria",Both,Child|Adult,Phase 2,40,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,APN311-304,"March 18, 2016",Mar-15,Jun-20,"April 13, 2016",Apr-16,No Study Results Posted,null,Dec-17,Anti-tumour activity of ch14.18/CHO continuous infusion|Progression-Free Survival|Safety and tolerability|Immunogenicity|Immunophenotyping|Antibody dependent cellular cytotoxicity (ADCC)|Complement dependent cytotoxicity (CDC)|Whole Blood Test (WBT)|Cytokines|Clearance (CL)|Volume distribution at steady state (Vdss)|mean residence time (MRT)|half-life time (t1/2)|Area Under the Curve (AUC)|Maximum Plasma Concentration (Cmax) and Minimum Plasma Concentration (Cmin),https://ClinicalTrials.gov/show/NCT02743429
238,NCT02743403,Effects of TENS in Pain During Application of Carboxytherapy in Patients With Gynoid Lipodystrophy,Recruiting,No Results Available,Pain,"Device: Neurodyn Portable activeTENS, IBRAMEDå¨|Device: Neurodyn Portable placeboTENS, IBRAMEDå¨|Device: Carboxyderm S20-1C",Universidade Cidade de Sao Paulo,Female,Adult,,81,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Open Label,"Carboxytherapy,TENS and pain","March 28, 2016",Jan-16,Jun-16,"April 13, 2016",Apr-16,No Study Results Posted,null,Apr-16,Mesure and denouement,https://ClinicalTrials.gov/show/NCT02743403
239,NCT02743390,Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension,Recruiting,No Results Available,Hypertension,Biological: Infliximab|Other: Saline,"University of Campinas, Brazil",Both,Adult,Phase 4,10,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",2015171517,"April 5, 2016",Mar-15,Jan-17,"April 18, 2016",Apr-16,No Study Results Posted,null,Nov-16,Mean blood pressure in mmHg|Cardiac hypertrophy in g/må_|Endothelial function in percentage|Arterial stiffness in m/s|Tumor necrosis factor-alpha in pg/mL|Interleukin-6|Interleukin-10,https://ClinicalTrials.gov/show/NCT02743390
240,NCT02743338,CompRest - a Comparison Between Sleep Compression and Sleep Restriction for Treating Insomnia,Recruiting,No Results Available,Insomnia,Behavioral: Sleep Restriction|Behavioral: Sleep Compression|Behavioral: Additional CBT-i components,Karolinska Institutet,Both,Adult|Senior,,180,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",2016/44-31/4,"April 12, 2016",Mar-16,Dec-17,"April 14, 2016",Apr-16,No Study Results Posted,CompRest,Dec-17,Insomnia Severity Index (ISI)|Sleep diary|Actigraphy|Adverse Events|Sleep Problems Acceptance Questionnaire,https://ClinicalTrials.gov/show/NCT02743338
241,NCT02743312,Long-Term Effects of Torso-Weighting,Recruiting,No Results Available,Multiple Sclerosis,Device: Balance-Based Torso-Weighting (WT)|Device: Sham Weights (SW)|Device: Fitbit Flex,San Francisco State University|Samuel Merritt University,Both,Adult|Senior,,5,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",X15-48a,"October 7, 2015",Nov-15,Jun-16,"April 18, 2016",Apr-16,No Study Results Posted,TWPS,Jun-16,"Steps per day|Sensory Organization Test|Gait Velocity|MAM-CAT (Movement Ability Measure, Computer Adaptive Test Version)|Activities-Specific Balance Confidence Scale|Multiple Sclerosis Impact Scale 29|Multiple Sclerosis Walking Scale 12|Six-Minute Walk Test|Stride Length|Percent of Gait Cycle in Single Limb Support|Step Width|Electromyography to assess muscle activation|Fall Frequency",https://ClinicalTrials.gov/show/NCT02743312
242,NCT02743286,Sedentary Behavior Interrupted - A Pilot Study of Acute Interventions on Prolonged Sitting,Recruiting,No Results Available,Sedentary Lifestyle,Behavioral: Frequent sit-to-stands|Behavioral: Walking breaks|Behavioral: Stand more,"University of California, San Diego",Female,Adult|Senior,,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label,150509,"March 30, 2016",Apr-16,Sep-16,"April 13, 2016",Mar-16,No Study Results Posted,null,Jun-16,Change in endothelial function|Change in glycemic regulation|Study feasibility|Change in mitochondrial metabolites,https://ClinicalTrials.gov/show/NCT02743286
243,NCT02743273,Identification of Prognostic Urinary Biomarker for Acute Kidney Injury in Preterm Infants by Proteomics,Recruiting,No Results Available,Acute Kidney Injury,,Seoul National University Hospital,Both,Child,,30,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,1507-028-686,"December 9, 2015",Oct-15,null,"April 18, 2016",Apr-16,No Study Results Posted,null,Aug-16,change the level of novel urinary biomarkers after ibuprofen administration|The level of novel urinary biomarkers in initial urine,https://ClinicalTrials.gov/show/NCT02743273
244,NCT02743260,Drug Transporter Interaction Study PHENTRA_2015_KPUK,Recruiting,No Results Available,Healthy,Drug: pitavastatin|Drug: Metformin|Drug: digoxin|Drug: Adefovir|Drug: sitagliptin,"University of Cologne|Umm Al-Qura University|Institute for Biomedical and Pharmaceutical Research (IBMP), NÌ_rnberg-Heroldsberg, Germany",Both,Adult|Senior,Phase 4,24,Other,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label,PHENTRA_2015_KPUK,"April 11, 2016",Apr-16,Dec-17,"April 13, 2016",Apr-16,No Study Results Posted,null,Jun-16,"organic anionic transporter polypeptide 1B1 (OATP1B1): Clearance over bioavialability (CL/F) of pitavastatin|organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and 2,kidney splice variant (MATE1/2K): Renal clearance (CLr) of metformin|intestinal p-glycoprotein (P-gp): Peak Plasma Concentration (Cmax) of digoxin|renal p-glycoprotein (P-gp): Renal clearance (CLr) of digoxin:|organic anion transporter 1 (OAT1): Renal clearance (CLr) of adefovir|organic anion transporter 3 (OAT3): Renal clearance (CLr) of sitagliptin",https://ClinicalTrials.gov/show/NCT02743260
245,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,Recruiting,No Results Available,Clostridium Difficile Infection,Other: Fecal microbiota transplantation|Drug: Fidaxomicin|Drug: Vancomycin,University of Aarhus,Both,Adult|Senior,Phase 3,64,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,FACIT,"April 8, 2016",Apr-16,Apr-19,"April 13, 2016",Apr-16,No Study Results Posted,FACIT,Aug-18,Microbiological response|Microbiological response week 1|Clinical response week 8|Microbiological response week 26|Clinical response week 26,https://ClinicalTrials.gov/show/NCT02743234
246,NCT02743195,Polyphenol/Prebiotic Blend Effects on GI Health and Microbial Composition,Recruiting,No Results Available,GI Health|Microbial Composition,Dietary Supplement: Polyphenol/prebiotic blend,Pharmanex|KGK Synergize Inc.,Both,Adult,,51,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,16-PHX-0001|16PMHN,"April 11, 2016",Mar-16,Sep-16,"April 14, 2016",Apr-16,No Study Results Posted,null,Aug-16,Change from baseline in microbial composition in the feces at day 57|Change from baseline in calprotectin in the feces at day 57|Change from baseline in IL-6 in the feces at day 57|Change from baseline in IL-8 in the feces at day 57|Change from baseline in IL-10 in the feces at day 57|Change from baseline in IL-1ë_ in the feces at day 57|Change from baseline in IL-12p70 in the feces at day 57|Change from baseline in TNFë± in the feces at day 57|Change from baseline in urine sugar test for gut permeability at day 57|Change from baseline in plasma zonulin at day 57|Change from baseline in Total Cholesterol at day 57|Change from baseline in HDL-C at day 57|Change from baseline in LDL-C at day 57|Change from baseline in Triglycerides at day 57|Change from baseline in weekly mean of daily Bristol Stool Scale (BSS) scores at day 57|Change from baseline in plasma endotoxin at day 57,https://ClinicalTrials.gov/show/NCT02743195
247,NCT02743156,Minimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute Nephropathy,Recruiting,No Results Available,Acute Kidney Injury|Acute Renal Failure|Acute Renal Injury,Procedure: IVUS-guided PCI|Procedure: Angiography-guided PCI,InCor Heart Institute,Both,Adult|Senior,Phase 4,300,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,Mozart II,"April 10, 2016",Apr-16,May-17,"April 24, 2016",Apr-16,No Study Results Posted,Mozart-II,Apr-17,Contrast-induced acute kidney injury|Major adverse cardiac events and components|Stent thrombosis|Serious acute kidney dysfunction|Procedure Time|Radiation exposure,https://ClinicalTrials.gov/show/NCT02743156
248,NCT02743143,Long-term Exercise Training Therapy in Patients With Schizophrenia,Recruiting,No Results Available,Schizophrenia,Behavioral: Exercise therapy|Other: Follow-up care as usual,St. Olavs Hospital|Trondheim Kommune|Norwegian University of Science and Technology,Both,Adult|Senior,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,2015/1611,"January 19, 2016",Dec-15,Aug-35,"April 13, 2016",Apr-16,No Study Results Posted,null,Aug-35,Change in peak oxygen uptake.|Change in physical activity.|Changes in walking economy.|Real world functional behavior|Functional competence|Hospital stays and contact with health care providers.|Balance|Sit-to-stand test|Walking performance|Stair performance|Clinical symptoms.|Global functioning|Quality of life.|Quality-adjusted life year|Morning fasting blood levels.|Tobacco|Alcohol and substance abuse|Motivation|Readiness/confidence to change|Client Satisfaction|Changes in maximal strength.,https://ClinicalTrials.gov/show/NCT02743143
249,NCT02743052,Anticoagulation in Cancer Related Stroke,Recruiting,No Results Available,Cancer|Stroke,Drug: Anticoagulation treatment.,Samsung Medical Center,Both,Adult|Senior,,400,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SMC 2016-02-104,"March 10, 2016",Oct-09,Dec-18,"April 18, 2016",Mar-16,No Study Results Posted,OASIS-CANCER,Dec-18,Recurrent stroke or systemic embolism|90-days modified Rankin Scale score|Effect of anticoagulation treatment|Symptomatic hemorrhagic transformation,https://ClinicalTrials.gov/show/NCT02743052
250,NCT02743026,HIV and Sexually Transmitted Infection Prevention Intervention in the Northwest Territories,Recruiting,No Results Available,HIV|Sexually Transmitted Diseases,Behavioral: FOXY,University of Toronto,Female,Child,,150,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,CIHR-CBR-0000303157,"April 11, 2016",Oct-15,Jun-17,"April 22, 2016",Apr-16,No Study Results Posted,null,Jun-17,HIV knowledge (Questionnaire)|Sexually Transmitted Infections knowledge (Questionnaire)|Self-esteem (scale)|safer sex self-efficacy (Scale)|cultural connectedness (Scale),https://ClinicalTrials.gov/show/NCT02743026
251,NCT02743013,Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers,Recruiting,No Results Available,COPD,"Drug: CHF 5993 100/6/12,5 pMDI|Drug: CHF 5993 100/6/12,5 DPI Test 1|Drug: CHF 5993 100/6/12,5 DPI Test 2|Drug: CHF 5993 100/6/12,5 pMDI replicate|Drug: CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber",Chiesi Farmaceutici S.p.A.,Both,Adult,Phase 1,50,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label,CCD-05993BA1-01|2015-005198-19,"March 31, 2016",Apr-16,Jul-16,"April 20, 2016",Apr-16,No Study Results Posted,null,Jul-16,"Evaluation of the area under the curve (AUC0-t) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.|Evaluation of the Area under the curve (AUC) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.|Evaluation of the Maximum Plasma Concentration (Cmax) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.|Evaluation of the Maximum Plasma Concentration (Cmax) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.|Evaluate the Area Under the Curve of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage|Evaluate the Maximum Plasma Concentration of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage|Evaluate the number of Adverse events and adverse drug reactions|Evaluation of Blood pressure|Evaluation of the heart rate",https://ClinicalTrials.gov/show/NCT02743013
252,NCT02743000,Food and the Brain,Recruiting,No Results Available,Binge Eating,,Stanford University,Female,Adult,,60,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,35204,"April 12, 2016",Jan-16,null,"April 13, 2016",Apr-16,No Study Results Posted,null,Aug-20,Brain activity during rest|Brain activity during emotion conflict|Brain activity during monetary wins and losses,https://ClinicalTrials.gov/show/NCT02743000
253,NCT02742974,Fluid Resuscitation Optimization in Surgical Trauma Patients (FROST),Recruiting,No Results Available,Critical Illness|Trauma,Device: FloTrac‰ã¢ and EV1000‰ã¢,CAMC Health System|Edwards Lifesciences,Both,Adult|Senior,,196,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,15-159,"February 10, 2016",Dec-15,Dec-19,"April 14, 2016",Apr-16,No Study Results Posted,FROST,Dec-18,Complications|Impact of Intervention|Lactic acid and Base deficit changes|APACHE II|SOFA scores|Changes in pre and post-operative lactic acid and base deficit|Changes in pre and post-operative APACHE II score,https://ClinicalTrials.gov/show/NCT02742974
254,NCT02742935,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects,Recruiting,No Results Available,Breast Cancer,Biological: SHR-1210,"Jiangsu HengRui Medicine Co., Ltd.",Both,Adult,Phase 1,36,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,SHR-1210-103,"April 14, 2016",Apr-16,Apr-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Dec-16,dose limited toxicity,https://ClinicalTrials.gov/show/NCT02742935
255,NCT02742922,Multicenter Study to Evaluate the Clinical and Cost-effectiveness of a Culturally Adapted Therapy (C-MAP),Recruiting,No Results Available,Self Harm,Behavioral: Culturally adapted therapy (C-MAP),"Pakistan Institute of Learning and Living|University of Manchester|Dow University of Health Sciences|Karachi Medical and Dental College|Services Hospital, Lahore|Peshawar Medical College",Both,Adult|Senior,Phase 1,700,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor),PILL-CMAP-001,"February 19, 2016",Feb-16,Dec-19,"April 25, 2016",Apr-16,No Study Results Posted,C-MAP,Dec-18,Suicide Attempt Self Injury Interview SASII|Beck Scale for Suicidal ideation (BSI).|Beck Hopelessness Scale|Beck Depression Inventory (BDI)|EuroQol-5 Dimensions (EQ5-D)|Coping Resource Inventory (CRI).|Client Satisfaction Questionnaire (CSQ).,https://ClinicalTrials.gov/show/NCT02742922
256,NCT02742909,Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease,Recruiting,No Results Available,Pulmonary Hypertension,Drug: rhBNP|Drug: placebo,LI ZHAO|Shengjing Hospital,Both,Adult|Senior,Phase 4,10,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",SJHX-001,"October 9, 2015",Dec-15,May-19,"April 24, 2016",Apr-16,No Study Results Posted,null,Dec-18,pulmonary artery systolic pressure (PASP) measured by Swan-Ganz catheter|pulmonary artery diastolic pressure(PADP) measured by Swan-Ganz catheter|mean pulmonary artery pressure(mPAP) measured by Swan-Ganz catheter|pulmonary vascular resistance(PVR) measured by Swan-Ganz catheter|cardiac output(CO) measured by Swan-Ganz catheter|heat rate (HR)|respiratory rate(RR)|blood pressure(BP)|blood oxygen saturation(SPO2)|Brog classification|Brain Natriuretic Peptide(BNP) in blood|N-terminal pro-Brain Natriuretic Peptide(NT-pro BNP) in blood|Potential of Hydrogen(PH) in artery blood gas analysis|arterial partial pressure of oxygen(PaO2)|arterial partial pressure of carbon dioxide (PaCO2)|oxygenation index in artery blood gas analysis|alveolar-arterial oxygen difference in artery blood gas analysis,https://ClinicalTrials.gov/show/NCT02742909
257,NCT02742896,Evaluation for Restoration of Erectile Dysfunction After Cardioversion Treatment Trial,Recruiting,No Results Available,Erectile Dysfunction,Other: Erectile dysfunction,Seoul St. Mary's Hospital,Both,Child|Adult|Senior,,358,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ERECT,"October 5, 2014",Dec-13,Nov-17,"April 13, 2016",Apr-16,No Study Results Posted,null,Sep-17,The changes of erectile function|The changes of cognitive function,https://ClinicalTrials.gov/show/NCT02742896
258,NCT02742883,"A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)",Recruiting,No Results Available,"Diffuse, Intrinsic Pontine Glioma",Drug: Antineoplaston therapy (Atengenal + Astugenal),Burzynski Research Institute,Both,Child|Adult|Senior,Phase 2,50,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,BRI-BT-55,"April 12, 2016",Apr-16,Feb-21,"April 14, 2016",Apr-16,No Study Results Posted,null,Mar-19,Efficacy Measured by Objective Response Rate|Efficacy Measured by Overall Survival,https://ClinicalTrials.gov/show/NCT02742883
259,NCT02742805,Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation,Recruiting,No Results Available,Urticaria,"Dietary Supplement: Vitamin D (4,000 IU/day)|Dietary Supplement: Vitamin D (400 IU/day)|Drug: Omalizumab","Selina Gierer, D.O.|University of Kansas Medical Center",Both,Adult|Senior,Phase 4,20,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",STUDY00002729,"April 14, 2016",Feb-16,Apr-17,"April 14, 2016",Apr-16,No Study Results Posted,null,Feb-17,Change in total Urticaria Severity Score (USS)|Number of subjects restarted on Omalizumab,https://ClinicalTrials.gov/show/NCT02742805
260,NCT02742779,"A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers",Recruiting,No Results Available,Healthy Volunteer,Drug: GDC-0310|Drug: GDC-0310 matching Placebo,"Genentech, Inc.",Both,Adult,Phase 1,316,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)",GN29829,"March 11, 2016",Sep-15,May-16,"April 14, 2016",Apr-16,No Study Results Posted,null,May-16,Number of participants with laboratory abnormalities|Number of participants with electrocardiogram (ECG) abnormalities|Number of participants with abnormalities in neurological examination|Incidence of adverse events|Number of participants with vital signs abnormalities|PK-dose proportionality as assessed with AUC of GDC-0310|Maximum plasma concentration (Cmax) of GDC-0310|Minimum plasma concentration (Cmin) of GDC-0310|Time to maximum plasma concentration (tmax) of GDC-0310|Area under the concentration-time curve (AUC) of GDC-0310|Apparent clearance (CL/F) of GDC-0310|Apparent terminal volume of distribution (Vz/F) of GDC-0310|Apparent terminal elimination rate constant (ke) of GDC-0310|Apparent terminal half-life (t1/2) of GDC-0310|Pharmacokinetics (PK) dose proportionality as assessed with Cmax of GDC-0310|Accumulation ratio for MD (calculated using AUC)|Accumulation ratio for MD (calculated using Cmax),https://ClinicalTrials.gov/show/NCT02742779
261,NCT02742766,"Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects",Recruiting,No Results Available,Healthy Subjects,Drug: GSK3008356|Drug: Placebo,"GlaxoSmithKline|Nucleus Network, Limited",Both,Adult,Phase 1,94,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",204856,"March 10, 2016",Mar-16,Nov-16,"April 14, 2016",Apr-16,No Study Results Posted,null,Nov-16,"Part 1: Number of subjects with clinically significant physical examination findings|Part 1: Number of subjects with clinically significant findings in vital signs|Part 1: Number of subjects with clinically significant 12-lead electrocardiograms (ECGs)|Part 1: Number of subjects with clinically significant findings during cardiac monitoring|Part 1: Number of subjects with clinically significant findings in laboratory parameters|Part 1: Number of subjects with adverse events and serious adverse events|Part 2: Number of subjects with clinically significant physical examination findings|Part 2: Number of subjects with clinically significant findings in vital signs|Part 2: Number of subjects with clinically significant 12-lead ECGs|Part 2: Number of subjects with clinically significant findings during cardiac monitoring|Part 2: Number of subjects with clinically significant findings in laboratory parameters|Part 2: Number of subjects with adverse events and serious adverse events|Part 3: Number of subjects with clinically significant physical examination findings|Part 3: Number of subjects with clinically significant findings in vital signs|Part 3: Number of subjects with clinically significant 12-lead ECGs|Part 3: Number of subjects with clinically significant findings during cardiac monitoring|Part 3: Number of subjects with clinically significant findings in laboratory parameters|Part 3: Number of subjects with adverse events and serious adverse events|Part 1: AUC(0-24), AUC(0-t) and AUC(0-inf) of GSK3008356 following a single dose in healthy subjects|Part 1: Maximum observed plasma concentration (Cmax) of GSK3008356 following a single dose in healthy subjects|Part 1: Time to maximum observed plasma concentration (tmax) and elimination half-life (t1/2) of GSK3008356 following a single dose in healthy subjects|Part 1: Cumulative amount of unchanged drug excreted into the urine (Ae) of GSK3008356 following a single dose in healthy subjects|Part 1: Renal clearance of drug from plasma (CLr) of GSK3008356 following a single dose in healthy subjects|Part 1: Dose proportionality of GSK3008356|Part 1: Postprandial triglyceride levels following a single dose of GSK3008356 in healthy subjects|Part 2: Area under the concentration-time curve from time zero (pre-dose) to the end of dosing interval (AUC[0-tau]) of GSK3008356 on Day 1 and Day 14|Part 2: Cmax of GSK3008356 on Day 1 and Day 14|Part 2: tmax of GSK3008356 on Day 1 and Day 14|Part 2: t1/2 of GSK3008356 on Day 14|Part 2: Ae of GSK3008356 on Day 14|Part 2: CLr of GSK3008356 on Day 14|Part 2: Dose proportionality of GSK3008356|Part 2: Observed accumulation ratio of GSK3008356|Part 2: Steady state assessment of GSK3008356 following 14-day repeat dosing|Part 2: Postprandial triglyceride levels following 14-day repeat dosing of GSK3008356 in healthy subjects|Part 3: AUC(0-tau) of GSK3008356 on Day 1 and Day 28|Part 3: Cmax of GSK3008356 on Day 1 and Day 28|Part 3: tmax of GSK3008356 on Day 1 and Day 28|Part 3: t1/2 of GSK3008356 on Day 28|Part 3: Ae of GSK3008356 on Day 28|Part 3: CLr of GSK3008356 on Day 28|Part 3: Dose proportionality of GSK3008356|Part 3: Observed accumulation ratio of GSK3008356|Part 3: Steady state assessment of GSK3008356 following 28-day repeat dosing|Part 3: Postprandial triglyceride levels following 28-day repeat dosing of GSK3008356 in obese subjects",https://ClinicalTrials.gov/show/NCT02742766
262,NCT02742727,CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma,Recruiting,No Results Available,"Acute Myeloid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-cell Prolymphocytic Leukemia|T-cell Large Granular Lymphocytic Leukemia|Peripheral T-cell Lymphoma, NOS|Angioimmunoblastic T-cell Lymphoma|Extranodal NK/T-cell Lymphoma, Nasal Type|Enteropathy-type Intestinal T-cell Lymphoma|Hepatosplenic T-cell Lymphoma",Biological: anti-CD7 CAR-pNK cells,"PersonGen Biomedicine (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei binhu hospital",Both,Adult|Senior,Phase 1|Phase 2,10,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,PG-107-002,"March 31, 2016",Mar-16,Mar-18,"April 13, 2016",Apr-16,No Study Results Posted,null,Mar-17,Adverse events attributed to the administration of the anti-CD7 CAR-pNK cells|Clinical response to CD7 CAR-pNK cell infusions|Determine the existence of CD7-CAR-pNK in vivo,https://ClinicalTrials.gov/show/NCT02742727
263,NCT02742675,Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery),Recruiting,No Results Available,Prostate Cancer,Drug: Bicalutamide|Drug: goserelin acetate|Drug: flutamide|Drug: leuprolide acetate|Drug: triptorelin|Procedure: Definitive Treatment,Fudan University,Male,Adult|Senior,Phase 2,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,FUSCC-OMPCa,"April 11, 2016",Mar-16,Mar-19,"April 14, 2016",Apr-16,No Study Results Posted,null,Mar-19,Progression-Free Survival|Overall survival|time of PSA progression|the quality of life,https://ClinicalTrials.gov/show/NCT02742675
264,NCT02742636,When is the Best Moment to Remove the Urinary Catheter After Laparoscopic Hysterectomy?,Recruiting,No Results Available,Urinary Tract Infection|Bladder Retention,Device: Foley catheter,Leiden University Medical Center|Bronovo Hospital|Haga Hospital|Alrijne Hospital|Reinier de Graaf Groep|Groene Hart Ziekenhuis|Medical Center Haaglanden,Female,Adult|Senior,,160,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,P15.382,"April 1, 2016",Apr-16,Aug-17,"April 13, 2016",Apr-16,No Study Results Posted,MUCH,Jun-17,Urinary retention (inability to void)|Rate of re-catheterisation|Urinary tract infection (by performing a urine dipstick test and based on clinical symptoms)|Patient satisfaction (self-administrated questionnaire)|Visual analogue scale score (VAS score),https://ClinicalTrials.gov/show/NCT02742636
265,NCT02742610,Smoking Cessation for Depressed Patients Following Psychiatric Hospitalization,Recruiting,No Results Available,Smoking Cessation,Behavioral: Mindfulness with Contingency Management,Fordham University|Albert Einstein College of Medicine of Yeshiva University|University of Texas at Austin|William Marsh Rice University,Both,Adult,Phase 1,10,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,1R34DA037364-01A1,"February 3, 2016",Nov-15,Jun-17,"April 14, 2016",Apr-16,No Study Results Posted,null,Apr-17,Smoking Status,https://ClinicalTrials.gov/show/NCT02742610
266,NCT02742597,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,Recruiting,No Results Available,Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV,Behavioral: TIP / IMPACT Plus Care Coordination,"Lawson Health Research Institute|Western University, Canada|UniversitÌ© de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Sunnybrook Health Sciences Centre|St. Michael's Hospital, Toronto|University Health Network, Toronto|Toronto East General Hospital|Providence HealthCare|Mount Sinai Hospital, Canada|Toronto Central Community Care Access Centre|Women's College Hospital, Toronto",Both,Adult|Senior,,1980,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label,104191,"March 21, 2016",Jan-16,Mar-19,"April 13, 2016",Mar-16,No Study Results Posted,PACEinMM-ON,Mar-18,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes|Evaluation of Intervention Effectiveness - Change in Transitions of Care|Evaluation of Intervention Effectiveness - Change in Self-Efficacy|Evaluation of Intervention Effectiveness - Change in Patient-Centredness|Evaluation of Intervention Effectiveness - Change in Chronic Diseases|Evaluation of Intervention Effectiveness - Change in Health Status|Evaluation of Intervention Effectiveness - Change in Quality of Life|Evaluation of Intervention Effectiveness - Change in Psychological Well-being|Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours|Evaluation of Intervention Effectiveness - Change in Equity|Evaluation of Intervention Effectiveness - Change in Demographics,https://ClinicalTrials.gov/show/NCT02742597
267,NCT02742506,Beneficial Effects of Music on Cognition and Consciousness Level,Recruiting,No Results Available,Coma,Other: Electroencephalography (EEG),Hospices Civils de Lyon,Both,Adult|Senior,,240,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,2012.75,"April 7, 2016",Jun-13,Jun-17,"April 13, 2016",Apr-16,No Study Results Posted,MUSICOREVEIL,Jun-16,P300 response in brain-damaged patients|P300 response in healthy volunteers|Medial prefrontal cortex activity level in healthy volunteers,https://ClinicalTrials.gov/show/NCT02742506
268,NCT02742493,RCT for the Effectiveness of 3 Orthodontic Retention Schemes on Post-treatment Stability and Gingival Recession,Recruiting,No Results Available,Relapse|Gingival Recession,Other: 0.028 bonded to canines|Other: 0.027 7-strand bonded to all 6|Other: removable Hawley-type,University of Athens,Both,Child,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,294,"April 14, 2016",Apr-16,Sep-21,"April 22, 2016",Apr-16,No Study Results Posted,OrthRe10tion,Sep-21,Changes in Little's Irregularity Index in the mandible (mm)|Changes in Intercanine width in the mandible (mm)|Changes in Interpremolar width in the mandible (mm)|Changes in Intermolar width in the mandible (mm)|Changes in Arch length in the mandible (mm)|Changes in Gingival Recessions on the lingual surfaces of the six lower anterior teeth|Changes in Intercanine width in the maxilla (mm)|Changes in Interpremolar width in the maxilla (mm)|Changes in Intermolar width in the maxilla (mm)|Changes in Arch length in the maxilla (mm)|Changes in Overbite and Overjet (mm)|Accidental bond failures of fixed retainers or breakages of removable ones|Leveling or torque related problems of the lower anterior teeth,https://ClinicalTrials.gov/show/NCT02742493
269,NCT02742402,DIAgnostic iMaging or Observation in Early Equivocal appeNDicitis,Recruiting,No Results Available,Appendicitis,Other: Diagnostic imaging|Other: Observation,Helsinki University Central Hospital,Both,Adult|Senior,,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,HUS/95/2016,"April 7, 2016",Apr-16,Apr-19,"April 20, 2016",Apr-16,No Study Results Posted,DIAMOND,Apr-18,Appendicitis requiring surgery or other intervention|Complicated appendicitis|Delayed appendicitis diagnosis|Number of diagnostic imaging studies needed|Negative appendectomy|Number of re-admissions to emergency unit|Number of other clinically relevant findings|Number of patients requiring of gynecological consultation|Time for decision,https://ClinicalTrials.gov/show/NCT02742402
270,NCT02742350,Effects of Muscle Trainins Inspiratory Linked to Cardiac Rehabilitation Post-operative of CABG Surgery,Recruiting,No Results Available,Cardiovascular Diseases,"Device: IMT - POWERbreathe Plus Light Resistanceå¨, SP, BR",Federal University of Health Science of Porto Alegre,Both,Adult|Senior,,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",IMT+exercise-CABG,"March 7, 2016",Sep-15,Mar-17,"April 13, 2016",Apr-16,No Study Results Posted,null,Dec-16,Six-minute walk test|30-s chair-stand|respiratory muscle strength test|Quality of life,https://ClinicalTrials.gov/show/NCT02742350
271,NCT02742337,Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease,Recruiting,No Results Available,"Arthritis, Rheumatoid",,Arthritis Northwest PLLC|Epigenesys LLC,Female,Adult|Senior,,30,Industry|Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,AE010831,"April 14, 2016",Oct-15,Sep-16,"April 14, 2016",Apr-16,No Study Results Posted,null,Sep-16,Counts of patients with epigenetic signatures.,https://ClinicalTrials.gov/show/NCT02742337
272,NCT02742324,Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg,Recruiting,No Results Available,Myelofibrosis,Drug: Ruxolotinib|Drug: peg-IFN alpha -2a,French Innovative Leukemia Organisation,Both,Adult|Senior,Phase 1|Phase 2,42,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,RUXOPeg,"March 8, 2016",Mar-16,Oct-18,"April 13, 2016",Apr-16,No Study Results Posted,RUXOPeg,Oct-17,study treatment efficacy/safety phase I|study treatment efficacy/safety phase II|molecular response,https://ClinicalTrials.gov/show/NCT02742324
273,NCT02742311,EuroPainClinicså¨ Study V (Prospective Observational Study),Recruiting,No Results Available,Back Pain|Intervertebral Disc Herniation,Procedure: Endoscopic disectomy,Europainclinics z.Ì¼.,Both,Adult|Senior,Phase 0,500,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,EK: 9N-2015,"April 10, 2016",Jan-16,Jan-19,"April 13, 2016",Apr-16,No Study Results Posted,EPCSV,Jan-17,1.Pain as assessed by the Visual analogue scale All acquired information will be noted in to the special anonymous protocol|2.Pain localization as assessed by note of radiating dermatome as neurologic examination|3.Pain progress as assessed by global pain scale|4. Changes in analgesics drugs consumption as assessed by equianalgesic dose ratios for opioids,https://ClinicalTrials.gov/show/NCT02742311
274,NCT02742272,Clinical Decision Rule for Pediatric Intracranial Pathology,Recruiting,No Results Available,Migraine Headache|Headache,,Children's Hospitals and Clinics of Minnesota,Both,Child|Adult,,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1506-076,"November 20, 2015",Sep-15,Jul-16,"April 13, 2016",Apr-16,No Study Results Posted,null,Jul-16,Intracranial pathology identified by imaging studies,https://ClinicalTrials.gov/show/NCT02742272
275,NCT02742220,Isometric Handgrip Training on Blood Pressure of Peripheral Artery Disease Patients,Recruiting,No Results Available,Peripheral Artery Disease,Other: Isometric Handgrip Training Group|Other: Control Group,University of Pernambuco|FundaÌ¤Ì£o de Amparo ÌÊ CiÌ»ncia e Tecnologia do Estado de Pernambuco,Both,Adult|Senior,,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",IHT PAD,"April 4, 2016",Mar-16,Dec-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Sep-16,Change from baseline in blood pressure at eight weeks|Change from baseline in autonomic cardiac modulation at eight weeks|Change from baseline in vasodilatory capacity at eight weeks|Change from baseline in arterial stiffness at eight weeks,https://ClinicalTrials.gov/show/NCT02742220
276,NCT02742194,Ginger Capsules for the Chronic Treatment of Obesity,Recruiting,No Results Available,Obesity,Dietary Supplement: Dry extract of ginger|Dietary Supplement: Placebo,Federal University of Minas Gerais|Conselho Nacional de Desenvolvimento CientÌ_fico e TecnolÌ_gico,Female,Adult,Phase 2,84,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",CAAE 30409114.8.0000.5149,"February 5, 2016",Aug-15,Nov-18,"April 13, 2016",Apr-16,No Study Results Posted,null,Nov-18,Change in basal metabolic rate.|Change in body fat percentage.|Changes in serum levels of inflammatory mediators|Change in depressive symptoms.|Change in anxiety symptoms.|Change in quality of life.|Change in perceived stress.|Change in quality of diet.|Changes in serum levels of neurotrophic factors,https://ClinicalTrials.gov/show/NCT02742194
277,NCT02742168,99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer,Radiation: 99mTc-3PRGD2,First Affiliated Hospital of Fujian Medical University,Both,Adult|Senior,Phase 0,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,FirstAHFujian2,"March 8, 2016",Jan-16,Mar-21,"April 13, 2016",Apr-16,No Study Results Posted,null,Dec-20,Visual Assessment of Breast Lesions in 99mTc-3PRGD2 SPECT/CT Scan|Semiquantitative Assessment of Breast Lesions in 99mTc-3PRGD2 SPECT/CT Scan|Adverse events collection|Mammography and/or ultrasound|18F-FDG PET/CT scan|carbohydrate antigen 153,https://ClinicalTrials.gov/show/NCT02742168
278,NCT02742077,Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease II,Recruiting,No Results Available,Peripheral Arterial Disease,Device: Robotic-assisted peripheral vascular intervention,Corindus Inc.,Both,Adult|Senior,,20,Industry,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,2016-01,"April 12, 2016",Mar-16,Aug-16,"April 18, 2016",Apr-16,No Study Results Posted,RAPID II,Jun-16,Clinical Success|Adverse Events|Operator Radiation Exposure Dose|Patient Radiation Exposure Dose,https://ClinicalTrials.gov/show/NCT02742077
279,NCT02742064,Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression,Recruiting,No Results Available,Depression|Bipolar Disorder,Other: Cogito Companion Mobile Phone Application,Cogito Health Inc|Massachusetts General Hospital|Partners HealthCare,Both,Adult|Senior,,1000,Industry|Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,1R44MH107065-01,"April 11, 2016",Apr-15,null,"April 13, 2016",Apr-16,No Study Results Posted,null,Apr-17,Severity of MDD symptoms as assessed by QIDS SR|Severity of Mania symptoms as assessed by ASRM,https://ClinicalTrials.gov/show/NCT02742064
280,NCT02742012,Validation of a Multimodal Indicator of Depth of Anesthesia,Recruiting,No Results Available,Anesthesia,Other: the study is observational,Technische UniversitÌ_t MÌ_nchen,Both,Adult|Senior,,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AMI-1250-KIE-0250-I,"June 25, 2015",Jun-15,Dec-16,"April 13, 2016",Apr-16,No Study Results Posted,null,Dec-16,"ability of the multimodal indicator of anesthetic depth to discriminate between consciousness and unconsciousness|the indicator's ability to discriminate between consciousness, surgical anesthesia and deep anesthesia",https://ClinicalTrials.gov/show/NCT02742012
281,NCT02741999,A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early,Recruiting,No Results Available,Plasma Cell Dyscrasia|Monoclonal Gammopathy,,Tufts Medical Center,Both,Child|Adult|Senior,,200,Other,Observational,Time Perspective: Prospective,12016,"April 11, 2016",Apr-16,Apr-23,"April 13, 2016",Apr-16,No Study Results Posted,SAVE,Apr-23,Observation of disease progression in participants with AL-associated VL germline genes,https://ClinicalTrials.gov/show/NCT02741999
282,NCT02741973,Yoga in School Sports - a Pilot Study in Germany,Recruiting,No Results Available,Yoga|Stress,Other: Yoga|Other: School sport,"Charite University, Berlin, Germany",Both,Child|Adult,,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,SchoolYoga,"March 23, 2016",Mar-16,Apr-18,"April 13, 2016",Apr-16,No Study Results Posted,null,Apr-17,"Cohen Perceived Stress Scale (CPS)|WHO-5 questionaire (quality of life)|Hospital Anxiety and Depression (HADS)|Profile of Mood States (POMS)|Visual analogue scales (VAS) for general pain, headache, shoulder and neck tension, fatigue, sleep quality|D2 Test of Attention|Yoga Self-Efficacy Scale|Overall assessment of efficacy and tolerability (Likert scales)",https://ClinicalTrials.gov/show/NCT02741973
283,NCT02741882,Zika and Microcephaly: Case-control Study,Recruiting,No Results Available,Microcephaly,Other: Questionary,LaboratÌ_rio Sabin,Female,Child|Adult|Senior,,90,Industry,Observational,Observational Model: Case Control|Time Perspective: Retrospective,Zika and microcephaly,"April 13, 2016",Feb-16,Aug-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Jun-16,Zika virus infection clinical outcomes during pregnancy|zika virus serology|Chikungunya virus serology|Dengue virus serology,https://ClinicalTrials.gov/show/NCT02741882
284,NCT02741791,A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder,Recruiting,No Results Available,Treatment Resistant Major Depressive Disorder,Drug: AXS-05|Drug: Bupropion,"Axsome Therapeutics, Inc.",Both,Adult,Phase 3,350,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",AXS-05-301,"April 5, 2016",Mar-16,null,"April 14, 2016",Apr-16,No Study Results Posted,STRIDE-1,Sep-17,Montgomery-ÌÉsberg Depression Rating Scale (MADRS) total score|Clinical Global Impressions-Severity (CGI-S)|Hamilton Depression Rating Scale - 17 items (HAMD-17),https://ClinicalTrials.gov/show/NCT02741791
285,NCT02741765,Exercise and Transcranial Magnetic Stimulation: Increasing Brain Plasticity in Parkinson's Disease,Recruiting,No Results Available,Parkinson Disease,Behavioral: Sham rTMS|Behavioral: Real rTMS|Behavioral: Supervised aerobic exercise,New York University School of Medicine,Both,Adult|Senior,,24,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Investigator)",15-00712,"March 31, 2016",Nov-15,Nov-16,"April 13, 2016",Apr-16,No Study Results Posted,null,Nov-16,Recruitment Enrollment Numbers|Number of enrolled subjects that remain in study|Plasticity measured by TMS-PAS25 (LTP-like plasticity biomarker)|Measurements of lymphocytes|Measurements of TrkB|Measurements of serum BDNF|Timed Up and Go Test|Freezing of Gait Questionnaire (FOG-Q)|Parkinson's Disease Quality of Life (PDQ-39)|Parkinson's Disease Sleep Scale (PDSS)|Frontal Function Assessment (FAB)|LASA Physical Activity Questionnaire (LAPAQ),https://ClinicalTrials.gov/show/NCT02741765
286,NCT02741739,Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects,Recruiting,No Results Available,Healthy,Drug: REGN1033,Regeneron Pharmaceuticals,Both,Adult,Phase 1,28,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,R1033-HV-1503,"April 13, 2016",Mar-16,Jun-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Jun-16,Serum REGN1033 concentration-time curve (AUC)|Peak REGN1033 concentration (Cmax)|Treatment-emergent adverse events (TEAEs) from baseline to the end of the study|Presence or absence of anti-drug antibody (ADA),https://ClinicalTrials.gov/show/NCT02741739
287,NCT02741661,Influence of Myocardial Shortening on Coronary Tortuosity,Recruiting,No Results Available,Coronary Artery Vessels|Coronary Artery Disease,Other: No intervention. Observational study,Oregon Health and Science University,Both,Adult|Senior,,100,Other,Observational,Observational Model: Case Control|Time Perspective: Retrospective,Coronary Tortuosity,"April 13, 2016",Jul-15,Aug-16,"April 16, 2016",Apr-16,No Study Results Posted,null,Aug-16,Degree of longitudinal shortening|LV mass,https://ClinicalTrials.gov/show/NCT02741661
288,NCT02741622,Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.,Recruiting,No Results Available,"Depressive Disorder|Depressive Disorder, Major",Behavioral: High aerobic intensity training (HIT)|Behavioral: Long slow distance training (LSD),St. Olavs Hospital|Norwegian University of Science and Technology,Both,Adult,,15,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,2015/2230,"March 15, 2016",Mar-16,Dec-17,"April 13, 2016",Apr-16,No Study Results Posted,null,Dec-16,Change in serum brain derived neurotropic factor (BDNF)|Change in affective symptoms|Change in state of anxiety.|Change in subjective exercise experience|Maximal oxygen uptake|Maximal Heart rate,https://ClinicalTrials.gov/show/NCT02741622
289,NCT02741544,Revlimidå¨ Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM]),Recruiting,No Results Available,Multiple Myeloma,,Celgene Corporation,Both,Adult|Senior,,450,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NIS-Celgene-JP-PMS-003,"April 5, 2016",Feb-16,Aug-21,"April 13, 2016",Apr-16,No Study Results Posted,null,Aug-21,Adverse Events (AEs),https://ClinicalTrials.gov/show/NCT02741544
290,NCT02741492,Transversus Abdominus Plane Catheters for Open Inguinal Hernia Repair,Recruiting,No Results Available,Post-Operative Pain,Procedure: Transversus Abdominis Plane Block|Procedure: Sham Block,Benaroya Research Institute,Both,Adult|Senior,,90,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)",Benaroya Research Institute,"April 12, 2016",Apr-16,Apr-19,"April 13, 2016",Apr-16,No Study Results Posted,null,Apr-18,Opioid Consumption (Intravenous Morphine Equivalents)|Pain (Numeric Rating)|Activity Assessment Score,https://ClinicalTrials.gov/show/NCT02741492
291,NCT02741362,"Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome",Recruiting,No Results Available,Systemic Lupus Erythematosus|Rheumatoid Arthritis|Sharp's Syndrome,Other: Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|Other: Lipoaspiration,Arkansas Heart Hospital,Both,Adult|Senior,Phase 1,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,ICMS-2015-51,"April 6, 2016",Dec-15,null,"April 18, 2016",Apr-16,No Study Results Posted,null,Dec-17,Frequency of Adverse Events (AE) and Serious Adverse Events (SAE) during a 6 month follow up period.|Quality of Life Questionnaires for SLE/ RA|Quality of Life Questionnaires for RA|Blood Flow Cytometry for CD4+CD25+Foxp3+ regulatory T cells|Blood Flow Cytometry for CD3+CD8-IL17A+TH17 cells|Serum C- reactive protein (CRP)|Erythrocyte Sedimentation Rate (ESR)|Serum Tumor Necrosis Factor- alpha (TNFa)|Serum Transforming Growth Factor- beta (TGFb)|Serum Interleukin- 6 (IL-6)|Serum Interleukin- 17 (IL-17),https://ClinicalTrials.gov/show/NCT02741362
292,NCT02741349,Thromboembolic and Bleeding Risk Stratification in Patients With Non-valvular Atrial Fibrillation,Recruiting,No Results Available,Atrial Fibrillation,,Saint Antoine University Hospital,Both,Adult|Senior,,825,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2014-A00280-47,"April 7, 2016",Jul-15,Jun-21,"April 12, 2016",Apr-16,No Study Results Posted,FASTRHAC,Dec-20,"composite endpoint of all-cause death, acute heart failure, stroke, acute coronary syndrome and major bleeding episode|incidence of all-cause death|incidence of cardiovascular death|incidence of acute heart failure|incidence of stroke|incidence of acute coronary syndrome|incidence of major bleeding episodes",https://ClinicalTrials.gov/show/NCT02741349
293,NCT02741336,Electrophysiologic Changes in Blacks Treated With CBT for Insomnia,Recruiting,No Results Available,Insomnia,Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral: Self-Monitoring,State University of New York - Downstate Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Female,Adult,,10,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,675013,"April 13, 2016",Nov-15,Nov-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Nov-16,Sleep Diary|QEEG tests of cognition,https://ClinicalTrials.gov/show/NCT02741336
294,NCT02741310,Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan,Recruiting,No Results Available,Healthy Subjects,Drug: Placebo|Drug: Sumatriptan|Drug: Placebo|Drug: Sumatriptan|Drug: AMG 334,Amgen,Both,Adult,Phase 1,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",20140255,"February 19, 2016",Feb-16,Jul-16,"April 13, 2016",Apr-16,No Study Results Posted,null,Apr-16,Change in individiual time-weighted averages of the mean arterial blood pressure in subjects.,https://ClinicalTrials.gov/show/NCT02741310
295,NCT02741297,VELOCITY: A Study to Characterize Real-World Outcomes of Spinal Cord Stimulation,Recruiting,No Results Available,Chronic Pain,Device: Spinal Cord Stimulation (SCS) System,Boston Scientific Corporation,Both,Adult|Senior,,60,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,91113648,"April 14, 2016",Apr-16,Dec-18,"April 19, 2016",Apr-16,No Study Results Posted,null,Jan-18,Change in proportion of low back pain responders,https://ClinicalTrials.gov/show/NCT02741297
296,NCT02741258,Mepitel Film Treatment for the Prevention and Cutaneous Toxicity Due to Radiotherapy,Recruiting,No Results Available,Post-surgery Radiotherapy,Device: Mepitel Film|Drug: skin cream,Dario Valcarenghi|Oncology Institute of Southern Switzerland,Female,Adult|Senior,Phase 3,164,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IOSI-INF-001,"March 15, 2016",Oct-15,Dec-18,"April 20, 2016",Apr-16,No Study Results Posted,null,Dec-18,Mepitel Film efficacy in treating skin toxicity evaluatet with Common Terminology Criteria for Adverse Events (CTCAE)|Time for the skin toxicity appearance and resolution|Severity of the chronic skin toxicity,https://ClinicalTrials.gov/show/NCT02741258
297,NCT02741232,Comparison of Perioperative Opioid Consumption Following Pectoral Nerve Block for Breast Cancer Surgery,Recruiting,No Results Available,Nerve Block|Mastectomy,Drug: Lidocaine 1% with epinephrine 1/400000|Other: sham block,Maisonneuve-Rosemont Hospital,Female,Adult|Senior,,50,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",15075,"April 13, 2016",Mar-16,Sep-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Sep-16,Intraoperative remifentanil consumption for the first 30 minutes of surgery|Total intraoperative remifentanil consumption|Total intraoperative sevoflurane consumption|Postoperative pain evaluation|Postoperative nausea and vomiting evaluation|Total time in the recovery room|Postoperative opioid consumption,https://ClinicalTrials.gov/show/NCT02741232
298,NCT02741219,A Multicenter Study: Dexmedetomidine Combined With Sufentanil for Patient Controlled Intravenous Analgesia After Caesarean Section,Recruiting,No Results Available,Postoperative Pain,Drug: Normal saline|Drug: Dexmedetomidine|Drug: Sufentanil|Drug: Sufentanil and dexmedetomidine,Obstetrics & Gynecology Hospital of Fudan University,Female,Adult,Phase 4,264,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)",OBGynFudanU,"March 11, 2016",Nov-15,Jul-16,"April 13, 2016",Apr-16,No Study Results Posted,null,Jul-16,Sufentanil consumption|Changes in pain score|Changes in Ramsay sedation score (RSS)|Changes in systolic blood pressure|Press times of analgesic pump|Changes in heart rate (HR)|Changes in saturation of blood oxygen (SpO2)|Changes in diastolic blood pressure|Changes in mean arterial blood,https://ClinicalTrials.gov/show/NCT02741219
299,NCT02741193,Presurgical Motor Mapping With Transcranial Magnetic Stimulation (TMS),Recruiting,No Results Available,Epilepsy,"Device: The Magstim Rapid2,",New York University School of Medicine,Both,Child|Adult,,14,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,15-00176,"April 8, 2016",Jun-15,Jun-17,"April 15, 2016",Mar-16,No Study Results Posted,null,Jun-17,"The primary outcome measure will be spatial correlation between topographic maps of hand motor representation obtained through nTMS compared to direct, extra-operative cortical stimulation performed as part of routine clinical care",https://ClinicalTrials.gov/show/NCT02741193
300,NCT02741180,Sparsity-based Magnetic Resonance Imaging of Cardiac Arrhythmias,Recruiting,No Results Available,Cardiac Arrythmias,Other: 3D Imaging|Other: Late Gadolinium Enhancement (LGE),New York University School of Medicine,Both,Child|Adult|Senior,,135,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,15-00116,"March 29, 2016",Nov-14,Nov-17,"April 13, 2016",Apr-16,No Study Results Posted,null,Nov-16,Paired-sample Wilcoxon signed rank test to evaluate measures on Likert scales|Paired-sample t tests for quantitative measures of intensity of image artifacts,https://ClinicalTrials.gov/show/NCT02741180
301,NCT02741167,Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy,Recruiting,No Results Available,Peritoneal Cancer,Procedure: CRS and HIPEC,University of Zurich,Both,Adult|Senior,,90,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HIPEC 2015-0529,"March 30, 2016",Jan-16,Dec-18,"April 12, 2016",Apr-16,No Study Results Posted,null,Dec-18,"C reactive protein (CRP) mg/l, receiver operating characteristic (ROC)",https://ClinicalTrials.gov/show/NCT02741167
302,NCT02741089,Bronchoscopy Registry,Recruiting,No Results Available,Indications for Flexible Bronchoscopy,Procedure: Indication for a flexible bronchoscopy,RWTH Aachen University,Both,Adult|Senior,,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,15-149,"February 17, 2016",Feb-16,Feb-17,"April 12, 2016",Apr-16,No Study Results Posted,BSK,Feb-17,"demographic data|indication for flexible bronchoscopy|smoking behaviour|relevant side diseases|lung function parameters|anesthetic risk (ASA-Score)|vital signs|detection of complications depending on the different analgosedations|duration of medical examination|medication (e.g. midazolam, fentanyl, propofol, lidocain)|general tolerance for the procedure and different symptoms like emesis, feeling of suffocation, cough and pain (0 = no stress, 100 = intolerable)|grade of amnesia|acceptance for later bronchoscopies|identification of prognostic factors related to complications",https://ClinicalTrials.gov/show/NCT02741089
303,NCT02740998,Long-Acting Progestin Contraception and the Vaginal Microbiome,Recruiting,No Results Available,Sexually Transmitted Infection,,Boston Medical Center,Female,Adult,,35,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,H-34707,"March 29, 2016",Mar-16,Apr-17,"April 12, 2016",Apr-16,No Study Results Posted,vMICROb,Apr-17,Biomarker discovery|Correlation of disease state and metadata factors with microbiome structure,https://ClinicalTrials.gov/show/NCT02740998
304,NCT02740959,Effects of PG2 on Fatigue-Related Symptom Clusters,Recruiting,No Results Available,Cancer-related Fatigue,Drug: Astragalus Polysaccharides 500 mg|Drug: Astragalus Polysaccharides 250 mg,Taipei Medical University,Both,Adult|Senior,,75,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",N201509006,"February 16, 2016",Mar-16,Dec-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Aug-16,Pittsburgh Sleep Quality Scale|Hospital Anxiety and Depression Scale|Actigraphy measuring circadian rhythm,https://ClinicalTrials.gov/show/NCT02740959
305,NCT02740881,Web-Based Contingency Management Training for Addictions,Recruiting,No Results Available,Substance Abuse Problem,Other: Counselor Training Methods,"Sheidow Consulting, Inc.|Oregon Social Learning Center",Both,Adult|Senior,,150,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Primary Purpose: Health Services Research|Masking: Open Label,R44DA033745,"November 25, 2015",Nov-15,Sep-17,"April 12, 2016",Apr-16,No Study Results Posted,CM-TSS,Sep-17,"Impact of training support on outpatient counselor fidelity to Contingency Management Substance Abuse Treatment Model measured using CM Therapist Adherence Measure (CM-TAM)|Impact of training support on outpatient counselor fidelity to Contingency Management Substance Abuse Treatment Model measured using session tape review and scoring|Impact of training support on outpatient counselor knowledge of, and fidelity to, the Contingency Management Substance Abuse Treatment Model measured using Contingency Management Knowledge Test (CM-KT)|Impact of training support on outpatient counselor fidelity to Contingency Management Substance Abuse Treatment Model measured using treatment outcomes.|Impact of training support on client satisfaction with treatment.|Assessment of Counselor Training Satisfaction with Satisfaction Survey administration.|Assessment of Counselor Satisfaction with Training and Training Support with Focus Group Outcomes",https://ClinicalTrials.gov/show/NCT02740881
306,NCT02740868,Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease,Recruiting,No Results Available,Cystic Fibrosis|Asthma,Drug: Xenon-129|Device: Magnetic Resonance Imaging|Device: Lung Clearance Index,The Hospital for Sick Children,Both,Child|Adult|Senior,Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,1000048243,"August 19, 2015",Aug-15,Aug-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Dec-16,Significant differences in lung function between CF and healthy group and asthma and healthy group for ventilation defect percent (VDP) measurement,https://ClinicalTrials.gov/show/NCT02740868
307,NCT02740816,Comparative Study of Menstrual Blood and Systemic Blood,Recruiting,No Results Available,Retention; Menstruation,Other: Comparative blood analysis,Stanford University,Female,Adult,,30,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,35817,"April 7, 2016",Mar-16,Dec-17,"April 14, 2016",Apr-16,No Study Results Posted,null,Mar-17,Health Markers in Systemic Blood vs. Menstrual Blood,https://ClinicalTrials.gov/show/NCT02740816
308,NCT02740777,Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females,Recruiting,No Results Available,Human Papillomavirus|Cervical Intraepithelial Neoplasia|Persistent Infection,Biological: HPV-16/18 vaccine,"Shanghai Zerun Biotechnology Co.,Ltd|Guangxi Center for Disease Control and Prevention",Female,Child|Adult,Phase 2,900,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,311-HPV-1004,"April 5, 2016",Feb-16,May-19,"April 14, 2016",Apr-16,No Study Results Posted,null,Nov-16,HPV-16 and HPV-18 antibody titers (GMT)|HPV-16 and HPV-18 antibody titers (GMT) and the seroconversion rate|Local and systemic adverse events (AEs),https://ClinicalTrials.gov/show/NCT02740777
309,NCT02740764,Optimization of Drug Prescribing in an Elderly Population of Geriatric Consultations,Recruiting,No Results Available,Functional Autonomy Level,Other: Optimization of drug prescribing,Hospices Civils de Lyon,Both,Adult|Senior,,302,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,69HCL15-0104,"April 6, 2016",Mar-16,Sep-18,"April 15, 2016",Mar-16,No Study Results Posted,OPTIM,Sep-18,The evolution of the level of functional autonomy of the patients assessed using the scale IADL of Lawton|The evolution of the level of functional autonomy of the patients assessed using the scale DAD-6.|Number of Hospitalizations|Number of days before hospitalizations|Occurrence of recourse to emergency service|Number of days before the recourse to emergency service|The occurrence of admission in institution|Number of days before admission in institution|Death|Number of days before death|Falls|Number of days before falls|Cognitive functions|Quality of life 1|Quality of life 2|depression disorders|Anxiety disorders|Compliance of patients with treatment|Pain|Proportion of potential inappropriate medication|Problems associated with drug therapy|acceptance rate by the referring physicians of pharmaceutical recommendation,https://ClinicalTrials.gov/show/NCT02740764
310,NCT02740751,Efficacy of Herbal Galactogogues in Breastfeeding Mothers,Recruiting,No Results Available,Weight Gain,Dietary Supplement: Still-Tee,Dr. Sami Ulus Children's Hospital,Both,Child,,90,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",SamiUlusCH-trials-stilltee,"April 12, 2016",Apr-16,Apr-17,"April 15, 2016",Apr-16,No Study Results Posted,Galactogogue,Jan-17,Weight gain|Breast milk volume,https://ClinicalTrials.gov/show/NCT02740751
311,NCT02740738,Preoperative Pain Threshold and Rapid Recover Programs,Recruiting,No Results Available,Knee Arthritis|Hip Arthritis,Device: Wagner Pain Algometer|Device: Dynamometer,Duke University,Both,Adult|Senior,,200,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,Pro00069521,"March 16, 2016",Mar-16,Jun-18,"April 13, 2016",Apr-16,No Study Results Posted,null,Mar-18,Inpatient length of stay in days|pain control average visual analogue scale 1 - 10 of hospital stay|physical therapy performance on the first day after surgery|discharge location placement|Outpatient narcotic pill consumption|Outpatient narcotic consumption refill needed|Outpatient narcotic consumption multiple refills needed,https://ClinicalTrials.gov/show/NCT02740738
312,NCT02740725,The Role of Interactive Binocular Treatment System in Amblyopia Therapy,Recruiting,No Results Available,Amblyopia,Other: Patching Therapy|Device: Interactive Binocular Treatment System,Shahid Beheshti University of Medical Sciences,Both,Child,,50,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,sbmu.rec.1393.591,"April 6, 2016",Dec-14,null,"April 14, 2016",Apr-16,No Study Results Posted,null,Nov-16,"Best Corrected Visual Acuity, Stereopsis",https://ClinicalTrials.gov/show/NCT02740725
313,NCT02740712,Pharmacokinetic Drug-Drug Interaction Study of Rucaparib,Recruiting,No Results Available,Neoplasms,Drug: Caffeine|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: digoxin|Drug: Vitamin K|Drug: Rucaparib,"Clovis Oncology, Inc.",Both,Adult|Senior,Phase 1,16,Industry,Interventional,Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label,CO-338-044,"March 30, 2016",Mar-16,Apr-17,"April 19, 2016",Mar-16,No Study Results Posted,DDI,Oct-16,"PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data|Tolerability and safety of rucaparib with and without co-administration of the probe drugs assessed by incidence of Adverse Events (AEs), clinical laboratory abnormalities, and dose modifications""|PK parameters will be calculated for rucaparib at steady-state",https://ClinicalTrials.gov/show/NCT02740712
314,NCT02740699,CT COMPARE: CT COronary Angiography to Measure PlAque REduction,Recruiting,No Results Available,Cardiovascular Disease,Drug: Rosuvastatin|Drug: Atorvastatin,National Institutes of Health Clinical Center (CC),Both,Adult|Senior,Phase 4,300,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,160089|16-CC-0089,"April 14, 2016",Apr-16,May-19,"April 14, 2016",Mar-16,No Study Results Posted,null,Dec-17,To prospectively compare the change in coronary artery plaque burden determined by CCTA in asymptomatic individuals with moderate CVD risk treated either a) according to 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athe...,https://ClinicalTrials.gov/show/NCT02740699
315,NCT02740660,Body Composition Changes With Albuterol and Caffeine Versus Placebo in Adolescents,Recruiting,No Results Available,Pediatric Obesity,Drug: Caffeine 100mg / Albuterol 4mg|Drug: Placebo|Radiation: DXA scan for body composition|Behavioral: Family weight management counseling|Behavioral: Visual Analog Scale for hunger and satiety,Pennington Biomedical Research Center|Leverage Innovation for Technology Transfer Fund (LSU LIFT2),Both,Child,,20,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)",PBRC 2015-065,"April 7, 2016",Apr-16,Oct-17,"April 12, 2016",Apr-16,No Study Results Posted,CAMP,Oct-16,Change in Fat Mass and Lean Body Mass with Caffeine/Albuterol|Change in Hunger and Satiety with Caffeine/Albuterol|Adverse Events Reporting|EKG|Labs|Vanderbilt Assessment scale for ADHD,https://ClinicalTrials.gov/show/NCT02740660
316,NCT02740621,The Impact of Opioids in Coronary Heart Disease,Recruiting,No Results Available,Coronary Heart Disease,,Ruhr University of Bochum|Mundipharma Research GmbH & Co KG,Both,Adult|Senior,,500,Other|Industry,Observational,Observational Model: Case Control|Time Perspective: Prospective,MIOP,"March 30, 2016",Jan-16,Jul-16,"April 14, 2016",Apr-16,No Study Results Posted,MIOP,Jul-16,"Number of patients with opioid treatment (WHO II/ WHO III) within the last 10 years before present hospitalization, Interview with standardized CRF",https://ClinicalTrials.gov/show/NCT02740621
317,NCT02740595,E-cigarettes and Blood Vessel Function,Recruiting,No Results Available,Nicotine Dependence,Other: one time exposure to e-cig with nicotine|Other: one time exposure to e-cig without nicotine|Other: one time exposure to empty e-cig,"University of California, Los Angeles",Both,Adult,,120,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label,14-000743,"April 12, 2016",Aug-15,Dec-19,"April 12, 2016",Apr-16,No Study Results Posted,null,Dec-18,Flow mediated dilatation (FMD)|Paraoxonse,https://ClinicalTrials.gov/show/NCT02740595
318,NCT02740569,Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement,Recruiting,No Results Available,"Scleroderma, Systemic|Sleep Apnea, Obstructive|Pulmonary Disease",Other: No intervention,Marmara University,Both,Adult|Senior,,60,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,09.2016.208,"April 6, 2016",Apr-16,Mar-17,"April 14, 2016",Apr-16,No Study Results Posted,OSASPI,Dec-16,Occurrence of OSA defined by apnea-hypopnea index (AHI) of at least 15/h on the overnight sleep study|Occurrence of pulmonary involvement based on computer tomography findings,https://ClinicalTrials.gov/show/NCT02740569
319,NCT02740556,Evaluation of HepCure Toolkit to Improve Harvoni Adherence,Recruiting,No Results Available,Hepatitis C|Medication Adherence,Other: HepCure ToolKit|Device: AdhereTech Active Features|Other: AdhereTech Passive Monitoring,Icahn School of Medicine at Mount Sinai|Gilead Sciences,Both,Adult|Senior,,99,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Supportive Care|Masking: Open Label,GCO 15-1273|GS-IN-US-337-3933,"April 12, 2016",Feb-16,May-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Feb-17,Medication Adherence|HCV RNA,https://ClinicalTrials.gov/show/NCT02740556
320,NCT02740543,Biomarkers of Irritant-Induced and Allergic Asthma,Recruiting,No Results Available,Asthma,Drug: Fluticasone propionate HFA 220|Drug: Placebo,New York University School of Medicine,Both,Adult|Senior,Phase 2,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,10-01191,"April 8, 2016",Dec-13,May-17,"April 12, 2016",Mar-16,No Study Results Posted,null,May-17,Change in TSLP Gene Expression,https://ClinicalTrials.gov/show/NCT02740543
321,NCT02740465,Anxiety and COPD Evaluation,Recruiting,No Results Available,Chronic Obstuctive Pulmonary Disease,Behavioral: Anxiety Inventory for Respiratory Disease (AIR)|Behavioral: Hospital Anxiety and Depression Scale (HADS),New York University School of Medicine,Both,Adult|Senior,,200,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label,15-00336,"April 12, 2016",Jan-16,Aug-17,"April 12, 2016",Apr-16,No Study Results Posted,ACE,Aug-16,Montreal Cognitive Assessment (MoCA)|COPD Assessment Test (CAT)|Modified Medical Research Council dyspnea scale (MMRC)|Pittsburgh Sleep Quality Index (PSQI)|Patient-Reported Outcomes Measurement Information System Questionnaires: Emotional Distress‰ÛÓAnxiety Function -(PROMIS-29)|Patient-Reported Outcomes Measurement Information System Questionnaires: Physical Function - Short Form 20a (PROMIS-20a)|EuroQol EQ-5D- 5L|Patient Health Questionnaire for Depression (PHQ9)|Patient Health Questionnaire for Anxiety (GAD7)|Hospital Anxiety and Depression Scale (HADS)|Mini International Neuropsychiatric Interview (MINI)|6 Minute Walk Distance|Pulmonary function Spirometry pre and post bronchodilator,https://ClinicalTrials.gov/show/NCT02740465
322,NCT02740439,Persea Americana for Total Health (PATH ) Study,Recruiting,No Results Available,"Obesity, Abdominal|Insulin Resistance|Insulin Sensitivity",Other: Avocado|Other: Control,University of Illinois at Urbana-Champaign|Hass Avocado Board,Both,Adult,,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,16277,"April 11, 2016",Feb-16,Feb-19,"April 11, 2016",Apr-16,No Study Results Posted,PATH,Feb-19,Abdominal obesity|Glycemic Control|Insulin Resistance|Insulin Sensitivity|Gastrointestinal Microbiota Composition and Short Chain Fatty Acids|Cognitive Function|Retinal Lutein|Serum Lutein|Blood Lipid Panel|Resting Energy Expenditure|Neuroelectric Assessment|DNA Analyses|Dietary Intake|Sleep and Fatigue|Physical Activity|Blood Pressure|Liver Enzymes|Inflammatory Markers,https://ClinicalTrials.gov/show/NCT02740439
323,NCT02740400,A Comparison Between EBUS-GS and CT-guided Lung Biopsy in Diagnosis of Peripheral Pulmonary Lesions.,Recruiting,No Results Available,Lung Neoplasms,Procedure: EBUS-GS|Procedure: CT-TTNB,Peking University People's Hospital,Both,Child|Adult|Senior,,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,CDI2014-2-4084,"April 5, 2016",Apr-15,May-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Jun-16,Safety. It is measured by the incidence rate of all adverse events during or after EBUS-GS or CT-TTNB.|Diagnostic value. It is measured by the diagnostic accurate rate between the two groups.,https://ClinicalTrials.gov/show/NCT02740400
324,NCT02740348,Point-of-Care Discharge Follow-Up,Recruiting,No Results Available,All Health Conditions Are Eligible,Behavioral: ZocDoc Assistance|Behavioral: ZocDoc Information,George Washington University,Both,Adult|Senior,,402,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Double Blind (Investigator, Outcomes Assessor)",91554,"April 13, 2016",Nov-15,Dec-18,"April 21, 2016",Apr-16,No Study Results Posted,null,Dec-17,Self-reported follow-up visit|Satisfaction with the ED visit|Satisfaction with the primary care visit|Recovery from health problem|Additional ED visit(s),https://ClinicalTrials.gov/show/NCT02740348
325,NCT02740322,Validating the Hum Test,Recruiting,No Results Available,Hearing Loss,Procedure: Hum Test|Procedure: Weber Test|Device: Audiogram,New York University School of Medicine,Both,Adult,,50,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,15-00102,"April 5, 2016",Sep-15,May-16,"April 11, 2016",Mar-16,No Study Results Posted,null,May-16,The correlation of the results between the Hum Test and the Audiogram|The correlation between the Hum Test and the Weber Test,https://ClinicalTrials.gov/show/NCT02740322
326,NCT02740296,Depression and Immune Function in Multiple Sclerosis (MS),Recruiting,No Results Available,"Multiple Sclerosis|Depressive Disorder, Major",Other: No intervention,"Charite University, Berlin, Germany|National Multiple Sclerosis Society|UniversitÌ_tsklinikum Hamburg-Eppendorf",Both,Adult,,200,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,DENIM,"April 12, 2016",Nov-15,Apr-18,"April 14, 2016",Apr-16,No Study Results Posted,DENIM,Apr-18,Beck Depression Inventory - II,https://ClinicalTrials.gov/show/NCT02740296
327,NCT02740257,Smartphone Application to Detect Skin Lesions,Recruiting,No Results Available,Skin Lesion,Other: Photos,Northwestern University,Both,Adult,,25,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STU00202166,"March 31, 2016",Mar-16,Jul-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Apr-17,Sensitivity of an automated total body digital photography (TBDP),https://ClinicalTrials.gov/show/NCT02740257
328,NCT02740231,A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis,Recruiting,No Results Available,Knee Osteoarthritis,Drug: JTA-004 intra-articular injection|Device: Reference product intra-articular injection,Bone Therapeutics S.A,Both,Adult|Senior,Phase 2|Phase 3,150,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",JTA-KOA1,"April 13, 2016",Feb-16,Jul-17,"April 15, 2016",Apr-16,No Study Results Posted,null,Jul-17,Change from baseline in WOMAC VA3.1 pain subscale score|WOMACå¨ pain subscale|WOMACå¨ pain subscale over time|WOMACå¨ total score|WOMACå¨ physical function subscale|Well-being score|Consumption of analgesics and NSAIDs,https://ClinicalTrials.gov/show/NCT02740231
329,NCT02740205,Efficacy and Safety of the Implementation of an Algorithm for Enteral Nutrition Support.,Recruiting,No Results Available,Malnutrition,Other: Algorithm for enteral nutrition support,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Both,Adult|Senior,,45,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Subject),1390,"April 12, 2016",Oct-14,Jul-16,"April 15, 2016",Apr-16,No Study Results Posted,null,Jun-16,Adequacy of enteral nutrition|Security variable,https://ClinicalTrials.gov/show/NCT02740205
330,NCT02740192,Pain Control After Total Knee Arthroplasty: Is There Benefit In Adding Single Shot Adductor Canal Block to Existing Multimodal Pain Regimen and Periarticular Injection Protocol?,Recruiting,No Results Available,Pain,Procedure: Adductor Canal Block|Procedure: Periarticular Injection|Drug: Ropivacaine|Drug: Bupivacaine,Henry Ford Health System,Both,Adult|Senior,Phase 0,120,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",10221,"March 24, 2016",Apr-16,Dec-16,"April 14, 2016",Apr-16,No Study Results Posted,null,Dec-16,Post-operative pain level (Visual Analog Scale)|Knee flexion and extension ROM (Range of Motion)|Distance Walked (meters)|Pain with Ambulation (VAS)|Pain Medication Intake|Time to discharge readiness,https://ClinicalTrials.gov/show/NCT02740192
331,NCT02740166,Preventing Recurrent Bleeding After Eradication of Esophageal Varices,Recruiting,No Results Available,Esophageal Varices,Drug: propranolol,Kaohsiung Veterans General Hospital.,Both,Adult|Senior,Phase 4,212,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,VGHKS13-CT6-06,"April 12, 2016",Jun-13,null,"April 12, 2016",Apr-16,No Study Results Posted,null,Jan-18,recurrent esophageal variceal bleeding|mortality or liver transplantation|adverse effects,https://ClinicalTrials.gov/show/NCT02740166
332,NCT02740153,PCORI Urea Cycle Disorder Study,Recruiting,No Results Available,Urea Cycle Disorders,Other: No Intervention Given,Children's Research Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Advancing Translational Science (NCATS)|Patient-Centered Outcomes Research Institute,Both,Child|Adult,,321,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,7282,"March 29, 2016",Mar-16,Feb-19,"April 12, 2016",Apr-16,No Study Results Posted,null,Feb-19,Survival|Neurocognitive Function|Patient Reported Quality of Life|Caretaker Decision Making|Medical Provider Decision Making|Dissemination of Information (Aim 3),https://ClinicalTrials.gov/show/NCT02740153
333,NCT02740075,Effect of Mode of Transport Ventilation on Respiratory Parameters After Cardiac Surgery,Recruiting,No Results Available,Complication of Ventilation Therapy,,"University of California, San Diego",Both,Adult|Senior,,32,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB# 150836,"February 5, 2016",Aug-15,null,"April 11, 2016",Apr-16,No Study Results Posted,null,Jun-16,Measure the collective differences in end-tidal carbon dioxide upon arrival in the ICU between mechanical ventilation and hand-ventilation|Measure the collective differences in pulmonary arterial pressures upon arrival in the ICU between mechanical ventilation and hand-ventilation,https://ClinicalTrials.gov/show/NCT02740075
334,NCT02740062,Non Invasive Brain Evaluation and Treatment for Neuropathic Pain,Recruiting,No Results Available,Neuropathic Pain,Device: NIBS system for evaluation and non invasive current stimulation,NIBS NeuroScience Technologies,Both,Adult|Senior,,30,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label,Reuth-01,"March 27, 2016",Mar-16,null,"April 11, 2016",Apr-16,No Study Results Posted,NIBSNP,Jun-16,Change in pain as measured by VAS (visual analog scale)|Von Frey sensitivity evaluation in neuropathic area,https://ClinicalTrials.gov/show/NCT02740062
335,NCT02740049,In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma,Recruiting,No Results Available,Asthma,Drug: VR588,Imperial College London|Vectura Limited,Both,Adult|Senior,Phase 0,9,Other|Industry,Interventional,Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,15IC2844,"April 12, 2016",Feb-16,Aug-16,"April 12, 2016",Feb-16,No Study Results Posted,null,Aug-16,Cytokine production epithelial cell supernatant|Cell Viability Assay|JAK/STAT signal activation,https://ClinicalTrials.gov/show/NCT02740049
336,NCT02739997,Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013),Recruiting,No Results Available,Intra-abdominal Infection|Complicated Intra-abdominal Infection,Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|Drug: metronidazole 500 mg,Merck Sharp & Dohme Corp.,Both,Adult|Senior,Phase 3,100,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,7625A-013|MK-7625A-013,"March 30, 2016",Apr-16,Aug-17,"April 20, 2016",Apr-16,No Study Results Posted,null,Aug-17,"Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Test of Cure (TOC)|Percentage of Participants With Adverse Events (AEs)|Percentage of Participants Discontinuing Study Drug Due to AEs|Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at End Of Therapy (EOT) and Late Follow-Up (LFU)|Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) at EOT and TOC|Percentage of Participants with Microbiological Response (Eradication, Persistence, or Indeterminate) by Pathogen at EOT and TOC",https://ClinicalTrials.gov/show/NCT02739997
337,NCT02739932,Adolescent Mental Health: Canadian Psychiatric Risk and Outcome Study,Recruiting,No Results Available,"Psychotic Disorders|Depressive Disorder, Major|Bipolar Disorder",,University of Calgary|Brain Canada|Sunnybrook Health Sciences Centre,Both,Child|Adult,,240,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MIRI-14-3377,"March 22, 2016",Mar-15,Jun-18,"April 14, 2016",Apr-16,No Study Results Posted,PROCAN,Jun-17,Diagnosis of serious mental illness (SMI)|Level of risk on a Clinical Staging Model for Mental Health Disorders based on the Scale of Prodromal Symptoms (SOPS)|Level of risk on a Clinical Staging Model for Mental Health Disorders based on the Calgary Depression Scale for Schizophrenia (CDSS).|Level of risk on a Clinical Staging Model for Mental Health Disorders based on the Young Mania Scale|Clinical symptoms on the Young Mania Scale.|Clinical symptoms on the SOPS.|Clinical symptoms on the CDSS.|Functioning|Structural brain changes|Structural Brain changes|Functional Brain changes|Changes in cognition,https://ClinicalTrials.gov/show/NCT02739932
338,NCT02739906,A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBetå¨ Compared to Insulin Lispro (Humalogå¨) and Regular Human Insulin (Huminsulinå¨ Normal) After Ingestion of a Standardized Meal in Subjects With T1DM,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Drug: BioChaperone Human Insulin (HinsBetå¨)|Drug: Insulin Lispro (Humalogå¨)|Drug: Regular human insulin (Huminsulinå¨ Normal),Adocia,Both,Adult,Phase 1|Phase 2,36,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)",BC3-CT021,"April 12, 2016",Apr-16,Aug-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Aug-16,"BG1h|ëÓBG1h|AUCBG,0-1h|ëÓAUCBG,0-1h|AUCIns,0-1h|Adverse Events|Local tolerability (Number of injection site reactions)",https://ClinicalTrials.gov/show/NCT02739906
339,NCT02739893,Usefulness of A Scope Guide Assisted Colonoscopy Versus Conventional Colonoscopy,Recruiting,No Results Available,"Colonoscopy, Colorectal",Procedure: Scope Guide Assist|Procedure: Standard procedure for colonoscopy,University of Alabama at Birmingham,Both,Adult|Senior,,300,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Single Blind (Subject),F141223002,"March 25, 2016",Jan-16,null,"April 14, 2016",Jan-16,No Study Results Posted,null,Jan-18,Mean cecum intubation time for each arm|Mean time in minutes to complete colonoscopy|Mean number of mechanical loops required to complete procedure for each arm|Number of mean external maneuvers per procedure between groups|Mean amount of sedation per arm|Percent of subjects with detectable polyps per arm,https://ClinicalTrials.gov/show/NCT02739893
340,NCT02739828,Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients,Recruiting,No Results Available,Hidradenitis Suppurativa,Biological: Adalimumab,AbbVie,Both,Adult|Senior,,50,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,P15-692,"April 12, 2016",Apr-16,Mar-17,"April 12, 2016",Apr-16,No Study Results Posted,HOPE,Mar-17,Changes in Dermatology Life Quality Index (DLQI)|Change in Patient's Global Assessment of Skin Pain - numerical rating scale (NRS)|Change in EuroQol 5 Dimensions (EQ-5D)|Change in Hidradenitis Suppurativa Impact Assessment (HSIA)|Change in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP)|Change in Hidradenitis Suppurativa Clinical Response (HiSCR),https://ClinicalTrials.gov/show/NCT02739828
341,NCT02739815,Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section,Recruiting,No Results Available,Hemorrhage of Cesarean Section and/or Perineal Wound,Drug: Normal Saline containing a prophylactic Antibiotic 1 g|Drug: Tranexamic Acid,Talkha Central Hospital|Al-Azhar University,Female,Adult,Phase 4,200,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Investigator, Outcomes Assessor)",OG1,"April 4, 2016",Apr-16,May-16,"April 17, 2016",Apr-16,No Study Results Posted,null,May-16,Blood Loss Volume|Duration of surgery|Hemoglobin level (Hb)|Maternal weight (W)|Hematocrit value (Hct)|Need for blood or blood products transfusion|Need for additional ecbolics|Need for hysterectomy|Need for uterine artery ligation|Need for B-lynch|APGAR Score|Any sign for developing a thromboembolic disorder (Maternal)|Blood pressure|Pulse rate,https://ClinicalTrials.gov/show/NCT02739815
342,NCT02739750,Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease,Recruiting,No Results Available,Polycystic Kidney Diseases,Other: No intervention,Indiana University,Both,Adult,,28,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Indiana U 1511993513,"March 23, 2016",Jan-16,Dec-18,"April 14, 2016",Apr-16,No Study Results Posted,null,Dec-18,"The percent change in the bone marrow lipid fraction averaged between L2, L3 and L4 at baseline to 12 months and 12 months to 24 months.",https://ClinicalTrials.gov/show/NCT02739750
343,NCT02739659,Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer,Recruiting,No Results Available,Prostate Carcinoma,Device: carbon-ion radiotherapy,Shanghai Proton and Heavy Ion Center,Male,Adult|Senior,Phase 1|Phase 2,61,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,SPHIC-TR-PCa 2015-01,"April 7, 2016",Mar-16,null,"April 11, 2016",Apr-16,No Study Results Posted,null,Mar-20,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Overall survival of all patients|biochemical failure-free survival•_ÎbFFS|Progression-free survival of all patients,https://ClinicalTrials.gov/show/NCT02739659
344,NCT02739620,Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors,Recruiting,No Results Available,Breast Cancer,Device: Neuromuscular electrical stimulation,University of Vermont,Female,Adult|Senior,Phase 1|Phase 2,24,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Outcomes Assessor),M16-333,"April 8, 2016",Apr-16,Mar-18,"April 11, 2016",Apr-16,No Study Results Posted,null,Mar-18,Maximal calcium-activated tension single muscle fiber tension|Cross-sectional area of skeletal muscle fibers|Intermyofibrillar mitochondrial content|Mitochondrial function|Single muscle fiber contractile velocity,https://ClinicalTrials.gov/show/NCT02739620
345,NCT02739607,Internet-delivered Transdiagnostic Intervention for Anxiety and Depression,Recruiting,No Results Available,Depression|Dysthymic Disorder|Panic Disorder|Social Phobia|Specific Phobia|Obsessive-Compulsive Disorder|Generalized Anxiety Disorder,Behavioral: Transdiagnostic program,West University of Timisoara,Both,Adult|Senior,,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,WUTimisoara-iTAD,"April 12, 2016",Apr-16,Mar-17,"April 14, 2016",Apr-16,No Study Results Posted,iTAD,Sep-16,Penn State Worry Questionnaire (PSWQ)|Social Phobia Inventory (SPIN)|Yale-Brown Obsessive Compulsive Scale (YBOCS)|Panic Disorder Severity Scale - Self Report (PDSS-SR)|PTSD Checklist for DSM-5 (PCL-5)|Beck Depression Inventory-II (BDI-II)|Emotion Regulation Questionnaire (ERQ)|Anxiety Sensitivity Index (ASI)|Beck Anxiety Inventory (BAI)|Almost Perfect Scale-Revised (APS-R),https://ClinicalTrials.gov/show/NCT02739607
346,NCT02739542,Assessment of Tecfideraå¨ in Radiologically Isolated Syndrome (RIS),Recruiting,No Results Available,Multiple Sclerosis (MS),Drug: Tecfidera|Drug: Placebo,University of Texas Southwestern Medical Center|Biogen,Both,Adult|Senior,Phase 4,210,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",102014-019,"March 16, 2016",Mar-16,Mar-20,"April 14, 2016",Apr-16,No Study Results Posted,ARISE,Dec-19,The time from randomization to the first demyelinating event (acute or development of an initial symptom resulting in a progressive clinical course),https://ClinicalTrials.gov/show/NCT02739542
347,NCT02739529,Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer,Recruiting,No Results Available,Gynecologic Cancer,Drug: Genexol-PM,Samyang Biopharmaceuticals Corporation,Female,Adult|Senior,Phase 1,18,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,GPMOC101,"March 21, 2016",Apr-16,Mar-18,"April 14, 2016",Mar-16,No Study Results Posted,null,Mar-18,The maximum tolerated dose (MTD) and the recommended dose for the phase II study|The dose limiting toxicity (DLT) and toxicities,https://ClinicalTrials.gov/show/NCT02739529
348,NCT02739464,Effect of In-Patient Exercise Training on Length of Hospitalization in Burned Patients,Recruiting,No Results Available,"Muscle Weakness|Late Effect of Burn|Muscle; Fatigue, Heart|Burn Rehabilitation",Other: Exercise + SOC PT/OT|Other: Standard of Care PT/OT,"The University of Texas Medical Branch, Galveston|United States Army Institute of Surgical Research|University of Texas Southwestern Medical Center|California State University, Sacramento",Both,Child|Adult,,96,Other|U.S. Fed,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label,SHC; IRB #14-0432,"March 12, 2015",Jul-15,Oct-19,"April 14, 2016",Apr-16,No Study Results Posted,MP-10,Oct-18,Dual X-ray Absorptiometry (DEXA)|Peak VO2 treadmill test|Six minute Walk test,https://ClinicalTrials.gov/show/NCT02739464
349,NCT02739399,Effects of Phenylephrine on Cardiac Preload,Recruiting,No Results Available,Arterial Hypotension|Anaesthesia,Drug: Phenylephrine,Algemeen Ziekenhuis Maria Middelares,Both,Adult|Senior,Phase 4,20,Other,Interventional,Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,MM2015.037,"April 6, 2016",Feb-16,Aug-16,"April 11, 2016",Apr-16,No Study Results Posted,null,Jun-16,Cardiac output|Pulse Pressure Variation|End-Tidal CO2|Arterial Blood Pressure,https://ClinicalTrials.gov/show/NCT02739399
350,NCT02739334,PALS-CATCH Intervention for Obesity Prevention Among At-risk Toddlers,Recruiting,No Results Available,Childhood Obesity,Behavioral: ENRICH|Behavioral: Control - monthly handouts,"The University of Texas Health Science Center, Houston",Both,Child,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),HSC-MS-15-0293,"March 24, 2016",Mar-16,null,"April 14, 2016",Apr-16,No Study Results Posted,ENRICH,Jun-17,change in child Body Mass Index|change in intake of servings of sugar sweetened beverages for the child as assessed using 24 hour parent-reported recalls|change in total intake of servings fruits and vegetables for the child as assessed using 24 hour parent-reported recalls|change in daily minutes of physical activity for the child as assessed using accelerometers,https://ClinicalTrials.gov/show/NCT02739334
351,NCT02739308,Effects of Proprioceptive Training on Neurofunctional Control and Ankle Sprains Incidence,Recruiting,No Results Available,Ankle Injuries,Other: Proprioceptive Training|Other: Control Group,Federal University of Rio Grande do Sul,Both,Child|Adult,,18,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor),436620,"April 6, 2016",Apr-16,Apr-16,"April 14, 2016",Apr-16,No Study Results Posted,null,Apr-16,Onset muscle|Muscle Strength|Star Excursion Balance Test (SEBT)|Drop Vertical Jump Test (DVJT)|Cumberland Ankle Instability Tools (CAIT)|Injury questionnaire,https://ClinicalTrials.gov/show/NCT02739308
352,NCT02739256,Early Versus Late Voiding Trials After Prolapse Repair,Recruiting,No Results Available,Urinary Retention|Pelvic Organ Prolapse,Procedure: Retrograde voiding trial,University of Pittsburgh,Female,Adult|Senior,,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Single Blind (Subject),PRO15100653,"March 10, 2016",Feb-16,Jul-18,"April 14, 2016",Apr-16,No Study Results Posted,null,Aug-17,time to return of normal bladder function|time to first ambulation|anxiety level|pain level|patient preference in the timing of the voiding trial|catheter associated urinary tract infections,https://ClinicalTrials.gov/show/NCT02739256
353,NCT02739217,Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With AlstrÌ¦m Syndrome,Recruiting,No Results Available,Inflammation and Fibrosis|Diabetes,Drug: PBI-4050,ProMetic BioSciences Inc.,Both,Child|Adult|Senior,Phase 2,18,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,PBI-4050-ATX-9-05,"February 25, 2016",Dec-15,Mar-17,"April 11, 2016",Feb-16,No Study Results Posted,null,Jan-17,Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment|Change from baseline in fasting plasma glucose over time|Change from baseline in plasma insulin over time|Change from baseline in glycated hemoglobin (HbA1c) over time|Change from baseline in blood glucose as measured by weekly 4 point profile|Change from baseline in blood glucose as measured by monthly 7 point profile|Change from baseline of antidiabetic treatment|Change from baseline in biomarkers in blood and urine over time,https://ClinicalTrials.gov/show/NCT02739217
354,NCT02739204,Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma,Recruiting,No Results Available,Oral Squamous Cell Carcinoma,Drug: Celecoxib,"China Medical University Hospital|Ministry of Health and Welfare, Taiwan",Both,Adult|Senior,Phase 2,270,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,CMUH102-REC1-071,"March 22, 2016",Nov-13,Dec-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Dec-16,Relapse-free recurrence|Relapse-free survival,https://ClinicalTrials.gov/show/NCT02739204
355,NCT02739191,Negative Pressure Wound Therapy for Surgical Wounds of the Foot and Ankle,Recruiting,No Results Available,Negative Pressure Wound Therapy|Vacuum Therapy|Closed Incisions,"Device: PICO, Smith & Nephew",J.C. Goslings|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Both,Adult|Senior,Phase 4,60,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,METC 2015_280,"April 9, 2016",Apr-16,Apr-17,"April 12, 2016",Apr-16,No Study Results Posted,NEWTON,Oct-16,Number patients with postoperative wound infections (POWI) as classified bij the Centers for Disease Control and prevention (CDC)-criteria.|The American Orthopaedic Foot and Ankle Score (AOFAS) will be measured at six months|EuroQol five dimensions questionnaire (EQ-5D)will be measured at six months,https://ClinicalTrials.gov/show/NCT02739191
356,NCT02739152,TRIAGE: TRIage of Sepsis At emerGency dEpartment,Recruiting,No Results Available,Sepsis|Severe Sepsis,,"BioMÌ©rieux|Centre Investigation Clinique, Limoges",Both,Adult|Senior,,515,Industry|Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,TRIAGE,"March 22, 2016",Apr-15,null,"April 11, 2016",Apr-16,No Study Results Posted,TRIAGE,Dec-16,"patient worsening within a time frame of 72h,change, from day of inclusion, in Sequential Organ Failure Assessment score (SOFA) and/or sepsis classification|patient status at D28 (alive or death)",https://ClinicalTrials.gov/show/NCT02739152
357,NCT02739126,Comparing the Diagnostic Yield of Radial EBUS Guided Biopsies When Using a Thick (1.7mm) Vs. Thin (1.4 mm) USS Probe.,Recruiting,No Results Available,Pulmonary Parenchymal Lesions,Procedure: Radial EBUS biopsy|Device: Types of Radial Ultrasound probes,"Middlemore Hospital, New Zealand",Both,Adult|Senior,,88,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Single Blind (Subject),R- EBUST 2,"February 19, 2016",Jan-15,Dec-17,"April 10, 2016",Apr-16,No Study Results Posted,R-EBUST2,Dec-16,Comparing the diagnostic yield (sensitivity) from the biopsies taken using the thick USS and Guide sheath to that of biopsies taken using the thin USS and Guide sheath.|Suitability of the biopsy samples from each arm to perform EGFR mutation testing.|Compare the procedure related bleeding and pneumothorax rates between the two arms.,https://ClinicalTrials.gov/show/NCT02739126
358,NCT02739087,Radiation-Free Heart Catheterization Using MRI,Recruiting,No Results Available,Aortic Coarctation|Cardiomyopathy|Atrial Septal Defect|Aortic Stenosis|Post Heart Transplant Catheter Procedure|Patent Ductus Arteriosus,Procedure: MRI guided cardiac catheterization|Device: Magnetic resonance imaging,Joshua Kanter|National Institutes of Health (NIH)|Children's Research Institute,Both,Child|Adult|Senior,Phase 1,50,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,3860|HHSN26821500001C,"February 17, 2016",Mar-15,Mar-25,"April 13, 2016",Apr-16,No Study Results Posted,null,Mar-20,Test the feasibility of navigating catheters into right heart structures using real-time MRI|Number of participants whose MRI cardiac catheterization procedure was prematurely terminated|Measurement of radiation exposure,https://ClinicalTrials.gov/show/NCT02739087
359,NCT02739074,"Effectiveness of Metal Protheses Covered in ""Diabolo"" in Treatment of Necrosis of Origin Pancreatic: Trial ""DIABOLOPIG""",Recruiting,No Results Available,Pancreatic Diseases,,Centre Hospitalier Universitaire de Nice,Both,Adult|Senior,,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,15-PP-01,"March 31, 2016",Mar-16,Aug-18,"April 11, 2016",Mar-16,No Study Results Posted,DIABOLOPIG,Apr-18,Rate of patients who complete treatment of pancreatic necrosis,https://ClinicalTrials.gov/show/NCT02739074
360,NCT02739061,The Study of the Pathogenesis and Cognitive Behavioral Group Therapy in Obsessive-Compulsive Disorder,Recruiting,No Results Available,Obsessive-Compulsive Disorder,"Behavioral: cognitive behavioral group therapy|Drug: sertraline, fluvoxamine|Other: cognitive behavioral group therapy and drug therapy",Shanghai Mental Health Center,Both,Adult,,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),HYZhang,"April 12, 2016",Apr-16,Jul-17,"April 14, 2016",Apr-16,No Study Results Posted,null,Jul-17,Y-BOCS (The Yale-Brown Obsessive Compulsive Scale),https://ClinicalTrials.gov/show/NCT02739061
361,NCT02739048,Changes of Immunologic Function in Patients of Prostate Cancer Induced After Cryoablation.,Recruiting,No Results Available,Prostate Cancer,,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Male,Adult|Senior,,80,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,XH-16-011,"April 12, 2016",Sep-15,Sep-18,"April 20, 2016",Apr-16,No Study Results Posted,null,Sep-18,humoral immunity and cellular immunity will be activated after CSAP for patients of prostate cancer,https://ClinicalTrials.gov/show/NCT02739048
362,NCT02739009,First in Human Single Dose of MOR106,Recruiting,No Results Available,Healthy,"Drug: MOR106 single ascending doses, intravenous|Drug: Placebo single ascending doses, intravenous",Galapagos NV|MorphoSys AG,Male,Adult,Phase 1,56,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",MOR106-CL-101,"April 1, 2016",Apr-16,Nov-16,"April 11, 2016",Apr-16,No Study Results Posted,null,Oct-16,Difference as compared to placebo in the number of subjects with treatment-emergent adverse events|Difference as compared to placebo in the number of subjects with deviating physical examination results|Difference as compared to placebo in the number of subjects with abnormal vital signs|Difference as compared to placebo in the number of subjects with abnormal 12-lead ECG results|Difference as compared to placebo in the number of subjects with abnormal laboratory findings|Difference as compared to placebo in the occurrence of infusion related reactions|Serum concentration (Cinf) of MOR106|Area under the curve (AUC) of MOR106|terminal elimination half-life (t1/2) of MOR106|total serum clearance (CL) of MOR106|volume of distribution at steady state (Vss) of MOR106|The presence of anti-drug antibodies in serum over time after single intravenous dose,https://ClinicalTrials.gov/show/NCT02739009
363,NCT02738983,RT Plus EGFR-TKI for Wild-type NSCLC,Recruiting,No Results Available,Non-small Cell Lung Cancer|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI),Drug: Erlotinib (trade name: Tarcevaå¨) or Icotinib (trade name: Conmanaå¨)|Radiation: Radiotherapy,Hangzhou Cancer Hospital,Both,Adult|Senior,Phase 2,22,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,HangzhouCH04,"April 4, 2016",Jan-12,Dec-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Dec-16,Response rate|Number of participants with treatment-related adverse events as assessed by CTCAE v3.0.|Progression-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT02738983
364,NCT02738918,Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.,Recruiting,No Results Available,Renal Transplant|Acute Antibody Mediated Rejection|Mild Immunologic Risk Factor,Drug: Nulojix (Belatacept),Assistance Publique - HÌ«pitaux de Paris,Both,Adult|Senior,Phase 2,91,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,P121203,"January 5, 2016",Dec-14,Dec-17,"April 11, 2016",Mar-16,No Study Results Posted,BELACOR,Dec-17,"Incidence of Acute Antibody Mediated Rejection (AAMR) (According to BANFF 2011 Criteria)|Incidence of subclinical AAMR diagnosed on protocol biopsy|Number of patient survival|Number of graft survival|Renal function measure by creatinine clearance (ml/min) (MDRD formula)|Incidence of clinical and subclinical cellular rejection|Renal function by level of proteinuria (urine volume/24 hours (ml))|Donor Specific Antibody (DSA) level, evaluate by the measure of maximal Mean Fluorescence Intensity (MFI)by Luminex Single Antigen",https://ClinicalTrials.gov/show/NCT02738918
365,NCT02738892,Preventing Preterm Birth in Zambia,Recruiting,No Results Available,Pregnancy|Stillbirth|Preterm Birth,,"University of North Carolina, Chapel Hill|Global Alliance to Prevent Prematurity and Stillbirth|Seattle Children's Hospital",Female,Adult,,4000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,14-2113,"April 6, 2016",Aug-15,Jan-19,"April 11, 2016",Apr-16,No Study Results Posted,null,Jun-18,Rate of preterm births per 100 person years,https://ClinicalTrials.gov/show/NCT02738892
366,NCT02738827,Diode Laser Treatment of Bladder Tumors,Recruiting,No Results Available,Bladder Cancer,Procedure: Laser treatment,Gregers Gautier Hermann|University Hospital Bispebjerg and Frederiksberg,Both,Adult|Senior,Phase 2|Phase 3,20,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,URU05,"December 21, 2015",Nov-15,Jun-16,"April 13, 2016",Apr-16,No Study Results Posted,null,Jun-16,Tumour clearance,https://ClinicalTrials.gov/show/NCT02738827
367,NCT02738801,"Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690",Recruiting,No Results Available,Idiopathic Pulmonary Fibrosis,Drug: GLPG1690 group 1|Drug: Placebo group 2,Galapagos NV,Both,Adult|Senior,Phase 2,24,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",GLPG1690-CL-202|2015-004157-41,"April 11, 2016",Mar-16,Mar-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Jan-17,Difference versus placebo in the number of subjects with adverse events|Difference versus placebo in the number of subjects with abnormal lab values|Difference versus placebo in the number of subjects with abnormal vital signs|Difference versus placebo in the number of subjects with abnormal ECG|Difference versus placebo in the number of subjects with abnormal Physical examination|The maximum observed plasma concentration of GLPG1690|The time at which maximum observed plasma concentration of GLPG1690 is reached|The area under the plasma drug concentration-time curve of a dosing interval|trough plasma concentration (just before the next dosing)|Concentration in blood/BALF of LPA (lysophosphatidic acid)|Changes in pulmonary function assessed by spirometry|Changes in biomarkers in blood and BALF|Change in HRCT images|Changes in quality of life measures,https://ClinicalTrials.gov/show/NCT02738801
368,NCT02738788,Airway Changes in Patients Undergoing Elective Surgical Procedures in the Prone and Trendelenburg Positions,Recruiting,No Results Available,Airway Management,Other: Intubation,Tufts Medical Center,Both,Adult|Senior,,180,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB 11705,"April 11, 2016",May-15,Jul-17,"April 14, 2016",Apr-16,No Study Results Posted,null,May-17,Changes in MMS after surgery,https://ClinicalTrials.gov/show/NCT02738788
369,NCT02738749,Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study,Recruiting,No Results Available,"Death, Sudden, Cardiac",Device: Implantable cardioverter-defibrillator (ICD),Rhode Island Hospital,Both,Adult|Senior,,450,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,426228-16,"April 7, 2016",Jun-14,Jul-20,"April 12, 2016",Nov-15,No Study Results Posted,null,Jul-19,"The levels of sodium channel splicing variants measured by gene expression that are related to arrhythmic events, change every 3 months from baseline to one 1 year after ICD therapy.|The levels of sodium channel splicing variants measured by gene expression that are related to the type of ICD implanted, change every 3 months from baseline to one 1 year after ICD therapy.",https://ClinicalTrials.gov/show/NCT02738749
370,NCT02738723,SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC,Recruiting,No Results Available,Small Cell Lung Cancer,Radiation: SBRT|Radiation: IMRT|Drug: EP,Third Military Medical University,Both,Adult|Senior,Phase 2,50,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,STIM,"March 25, 2016",Jan-16,Jan-20,"April 10, 2016",Apr-16,No Study Results Posted,null,Jan-19,progression-free survival|Overall survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Tumor response rate,https://ClinicalTrials.gov/show/NCT02738723
371,NCT02738697,Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection,Recruiting,No Results Available,"Carcinoma, Hepatocellular",Drug: Adjuvant chemotherapy|Procedure: Follow-up,Sun Yat-sen University,Both,Adult|Senior,Phase 3,290,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,SYSUCC-HCC-ADCHEMO,"March 24, 2016",Jan-16,Dec-21,"April 10, 2016",Apr-16,No Study Results Posted,null,Dec-20,Overall survival|Disease-free survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,https://ClinicalTrials.gov/show/NCT02738697
372,NCT02738671,Relationship Between Diabetes and Cognitive Impairment Based on Olfactory Function Assessment and Functional MRI,Recruiting,No Results Available,Diabetes Mellitus|Cognitive Impairment|Obesity,Behavioral: Cognitive assessment|Other: functional magnetic resonance imaging|Other: olfactory function measurement|Procedure: bariatric surgery,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Both,Adult|Senior,,150,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,ZZ2016,"February 25, 2016",Jan-16,May-18,"April 13, 2016",Mar-16,No Study Results Posted,null,May-18,Participants' personal information|Glycaemic control measured by blood test.|Physical assessments.|Olfactory threshold test|Olfactory memory test:|Montreal Cognitive Assessment (MoCA)|Functional MRI of the brain tracking testing.|Change form baseline Glycaemic control measured by blood test.|Change from baseline Functional magnetic resonance imagine,https://ClinicalTrials.gov/show/NCT02738671
373,NCT02738632,Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients,Recruiting,No Results Available,Essential Hypertension,Drug: Telmisartan/Amlodipine+Hydrochlorothiazide|Drug: Telmisartan/Amlodipine|Drug: Placebo for Hydrochlorothiazide,IlDong Pharmaceutical Co Ltd,Both,Adult|Senior,Phase 3,150,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",ID-TAH-301,"April 11, 2016",May-15,Aug-16,"April 13, 2016",Jan-16,No Study Results Posted,null,Aug-16,The change of sitting systolic blood pressure|The change of sitting diastolic blood pressure|The ratio of subjects who get normalized blood pressure|Response Rate,https://ClinicalTrials.gov/show/NCT02738632
374,NCT02738619,"Allergic Rhinitis, Immunotherapy and Vitamin d",Recruiting,No Results Available,Allergy,Drug: Vitamin D3|Drug: placebo,Hospital General de Mexico,Both,Child,Phase 2|Phase 3,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",DI/15/309/04/042,"April 6, 2016",Mar-16,Dec-16,"April 13, 2016",Apr-16,No Study Results Posted,null,Dec-16,Rhino-conjunctivitis Questionnaire (symptom severity),https://ClinicalTrials.gov/show/NCT02738619
375,NCT02738554,Off Treatment Durability in Chronic Hepatitis B With Good Immune Control,Recruiting,No Results Available,Chronic Hepatitis B,Other: Treatment cessation,The University of Hong Kong,Both,Adult|Senior,,140,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,UW 15-548,"April 8, 2016",Jan-16,Jan-20,"April 8, 2016",Apr-16,No Study Results Posted,null,Jan-19,Off-treatment durability|HBV DNA <200 IU/mL|HBV DNA <20 IU/mL|HBsAg seroclearance (<0.05 IU/mL),https://ClinicalTrials.gov/show/NCT02738554
376,NCT02738489,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Melanoma Subjects,Recruiting,No Results Available,Neoplasm,Biological: SHR-1210,"Jiangsu HengRui Medicine Co., Ltd.",Both,Adult|Senior,Phase 1,36,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,SHR-1210-102,"April 10, 2016",Apr-16,Apr-17,"April 19, 2016",Mar-16,No Study Results Posted,null,Dec-16,dose limited toxicity,https://ClinicalTrials.gov/show/NCT02738489
377,NCT02738476,Outcomes of MAKOplasty Patellofemoral Arthroplasty in Younger Active Patients,Recruiting,No Results Available,"Osteoarthritis, Knee",Procedure: Patellofemoral arthroplasty,Cincinnati Sportsmedicine Research and Education Foundation,Both,Adult,,60,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MAKOplasty PFA-001,"April 11, 2016",Apr-16,Feb-20,"April 13, 2016",Apr-16,No Study Results Posted,null,Dec-19,"Short-term clinical outcomes of patellofemoral arthroplasty|Comparison clinical outcomes of patellofemoral arthroplasty with historical controls|Comparison of complications, reoperation, and failures rates of patellofemoral arthroplasty with historical controls",https://ClinicalTrials.gov/show/NCT02738476
378,NCT02738450,"Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome",Recruiting,No Results Available,Down Syndrome,Biological: ACI-24 low dose|Biological: ACI-24 high dose|Biological: Placebo,AC Immune SA|National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)|LuMind Research Down Syndrome Foundation,Both,Adult,Phase 1,24,Industry|NIH|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",ACI-24-1301|1R01AG047922-01,"April 1, 2016",Mar-16,Aug-19,"April 11, 2016",Apr-16,No Study Results Posted,3 Star,Aug-19,Percentage of patients with treatment emergent adverse events and serious adverse events|Antibody titer (serum anti-Aë_ Ig)|Change from baseline over 25 months on CANTAB battery|Change from baseline over 25 months on RBANS|Change from baseline over 25 months on Vineland|Change from baseline over 25 months on NPI scale|Global Impression of Change over 25 months|Change from baseline over 13 months in amyloid load assessed by PET|Change from baseline over 25 months in plasma/CSF amyloid|Change from baseline over 25 months in plasma/CSF tau|Change from baseline in whole brain and hippocampal volume measured by MRI|Incidence of ARIA on MRI scans over 25 months|Change from baseline over 25 months in Brief Praxis Test (BPT),https://ClinicalTrials.gov/show/NCT02738450
379,NCT02738398,FDG PET/CT in Lung Cancer Staging,Recruiting,No Results Available,Non-Small Cell Lung Cancer (NSCLC),Radiation: FDG PET/CT,Abramson Cancer Center of the University of Pennsylvania,Both,Adult|Senior,,30,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,UPCC 20515,"April 12, 2016",Apr-16,null,"April 14, 2016",Apr-16,No Study Results Posted,null,Apr-17,Number of Adverse Events,https://ClinicalTrials.gov/show/NCT02738398
380,NCT02738385,Intensity Training and Cardiovascular Health in Colombian Adults,Recruiting,No Results Available,Metabolic Diseases,Behavioral: High Intensity Interval Training|Behavioral: Moderate Intensity Interval Training,Universidad Santo Tomas,Both,Adult,,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Investigator),01-1802-2013,"March 23, 2016",Jun-15,Nov-16,"April 8, 2016",Apr-16,No Study Results Posted,HIIT-Heart,Oct-16,Change from Baseline in endothelial function as measured by flow-mediated vasodilation (FMD)|Change from Baseline in LDL Cholesterol|Change from Baseline in HDL Cholesterol|Change from Baseline in Triglycerides|Change from Baseline in Glucose|Change from Baseline in Heart rate variability|Aortic pulse wave velocity (PWVao)|Change from Baseline in muscular fitness|Change from Baseline in Flexibility using the sit and reach test|Change from Baseline in peak uptake of volume of oxygen|Change from Baseline in Blood Pressure|Change from Baseline in Body Mass Index|Change from Baseline in Body Mass|Change from Baseline in Quality & satisfaction with life by SF Community - short-form survey (SF-12‰ã¢) Colombian version|Augmentation index (AIx),https://ClinicalTrials.gov/show/NCT02738385
381,NCT02738346,SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013,Recruiting,No Results Available,Small Cell Lung Cancer,Drug: Carboplatin|Drug: Etoposide|Drug: Topotecan|Device: CT scans,"University Hospital, Angers",Both,Adult|Senior,Phase 3,164,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CHU-P 2012-08|GFPC 01-2013,"April 4, 2016",Jul-13,Jul-17,"April 22, 2016",Apr-16,No Study Results Posted,CBPC,Jul-17,"Benefit in terms of progression-free survival of a therapeutic strategy|Objective response rate assessed by RECIST|Overall survival|Name and number of with treatment-related adverse events as assessed by CTCAE v4.0"".|The quality of life",https://ClinicalTrials.gov/show/NCT02738346
382,NCT02738333,Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection,Recruiting,No Results Available,Hepatitis C Virus Infection,Drug: LDV/SOF|Drug: SOF|Drug: RBV,Gilead Sciences,Both,Adult|Senior,Phase 3,225,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,GS-US-337-1903,"April 11, 2016",Apr-16,Aug-17,"April 22, 2016",Apr-16,No Study Results Posted,null,May-17,Proportion of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)|Proportion of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event|Proportion of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)|Proportion of Participants With HCV RNA < LLOQ by Visit While on Treatment|HCV RNA Change from Baseline|Proportion of Participants With Virologic Failure,https://ClinicalTrials.gov/show/NCT02738333
383,NCT02738307,"Effect of High Altitude Exposure, Acclimatization and Re-exposure on Sustained Attention in Lowlanders",Recruiting,No Results Available,Effect of High Altitude,Other: Altitude exposure,Marc Poulin|University of Zurich|University of Calgary,Both,Adult,,18,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,REB15 - 2709_MOD2,"April 4, 2016",Mar-16,Dec-17,"April 8, 2016",Apr-16,No Study Results Posted,null,Dec-16,"Change in global cognitive function assessed by neuropsychological test battery|Change in cognitive subdomains (visual memory, executive function, working memory and planning, attention, semantic/verbal memory, decision-making and response control) assessed by neuropsychological test battery|Change in oxidative stress measured by venous blood sampling",https://ClinicalTrials.gov/show/NCT02738307
384,NCT02738281,Natural History of Rett Syndrome & Related Disorders,Recruiting,No Results Available,Rett Syndrome|MECP2 Duplication dIsorder|RTT-related Conditions,,University of Alabama at Birmingham|National Institutes of Health (NIH)|National Center for Advancing Translational Science (NCATS)|Rare Diseases Clinical Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Neurological Disorders and Stroke (NINDS),Both,Child|Adult|Senior,,1200,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,RDCRN 5211,"November 22, 2015",Nov-15,Dec-19,"April 13, 2016",Apr-16,No Study Results Posted,null,Jul-19,Clinical longitudinal assessments in Rett syndrome (RTT) as measured by mean growth over 5 years.|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as measured by mean change in head circumference over 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as measured by mean number of stereotypic movements at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as the percent of subjects with reported epilepsy at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as the percent of subjects with reported scoliosis at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as the percent of subjects with MECP2 mutations at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as reported by the mean Clinical Severity Scale (CSS) at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as measured by the mean Motor Behavioral Assessment (MBA) at 5 years|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: mean growth rate over 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: mean change in head circumference 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: mean number of stereotypic movements in a 24 hour period at 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: percent of subjects reporting scoliosis 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: percent of subjects surviving at 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: the mean CSS score at 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: the mean MAB score at 5 years with subjects having MECP2 duplication syndrome|Quality of Life Measures in RTT|Quality of Life Measures in MECP2 duplication syndrome|Quality of Life Measures in RTT-related disorders.|Quality of Life Measures in RTT-related disorders,https://ClinicalTrials.gov/show/NCT02738281
385,NCT02738268,Laser Therapy for the Prevention of Radiodermatitis in Head and Neck Patients,Recruiting,No Results Available,Head Cancer|Neck Cancer,Device: Low-level laser therapy|Device: sham laser,Hasselt University|Jessa Hospital,Both,Child|Adult|Senior,,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Outcomes Assessor)",Dermishead-001,"April 11, 2016",Jan-16,Jan-18,"April 11, 2016",Apr-16,No Study Results Posted,DERMISHEAD,Jan-18,Radiation Dermatitis Grade|Radiation Dermatitis Assessment|Objective measurement of trans epidermal water loss of the skin|Objective measurement of the skin hydration|Objective measurement of degree of erythema of the skin|Analyze the skin cytokine content of the irradiated and non-irradiated breast|Pain|Quality of life|Satisfaction with therapy|moist desquamation,https://ClinicalTrials.gov/show/NCT02738268
386,NCT02738216,Wellness for 2: Understanding How to Foster Well Being for Mom and Her Baby,Recruiting,No Results Available,Pregnancy,Behavioral: Prenatal Yoga|Behavioral: Mother Baby Wellness,Butler Hospital,Female,Adult|Senior,,178,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),R01HD081868,"April 11, 2016",Mar-16,Jan-20,"April 13, 2016",Apr-16,No Study Results Posted,WF2,Jan-20,Quick Inventory of Depression Symptoms - Clinician Rating|Edinburgh Postnatal Depression Screen|State-Trait Anxiety Inventory|Pittsburgh Sleep Quality Index|Maternal & Neonatal Outcomes Checklist (MNOC),https://ClinicalTrials.gov/show/NCT02738216
387,NCT02738190,Albumin vs. Plasma for PEdiAtric pRiming Trial,Recruiting,No Results Available,Hemorrhage,Drug: Albumin|Biological: Fresh Frozen Plasma,IRCCS Policlinico S. Donato,Both,Child|Adult|Senior,Phase 4,80,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject),APPEAR,"March 15, 2016",Jan-15,Jun-16,"April 11, 2016",Apr-16,No Study Results Posted,APPEAR,Jun-16,Volume of postoperative bleeding|Number of units of blood components transfused|Hours on artificial ventilation|Days of hospital stay|Thromboembolic complications,https://ClinicalTrials.gov/show/NCT02738190
388,NCT02738177,Misoprostol Versus Effox as Cervical Ripening Agent Prior Surgical Evacuation,Recruiting,No Results Available,Cervical Ripening,Drug: Misoprostol|Drug: Isosorbide-5-mononitrate|Drug: misoprostol and Isosorbide-5-mononitrate,Cairo University,Female,Adult,Phase 2,90,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment|Masking: Single Blind (Subject),17480,"April 9, 2016",Nov-15,null,"April 13, 2016",Apr-16,No Study Results Posted,null,Jun-16,cervical dilatation|misoprostol side effects|effox side effects,https://ClinicalTrials.gov/show/NCT02738177
389,NCT02738112,Hyoid Suspension to the Mandible for the Treatment of Obstructive Sleep Apnea,Recruiting,No Results Available,Obstructive Sleep Apnea,Device: Encore System,"Abidin, Michael, M.D.",Both,Adult,,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HS 2016.0,"April 11, 2016",Mar-16,Jun-18,"April 11, 2016",Apr-16,No Study Results Posted,null,Mar-18,Apnea-Hypopnea Index (AHI)|Hyoid position and airway dimension measurement|Functional Outcomes of Sleep Questionnaire (FOSQ)|Snoring Scale (Visual Acuity Scale)|Epworth Sleeping Scale,https://ClinicalTrials.gov/show/NCT02738112
390,NCT02738099,Risk Stratification of Patients Presenting With Cardiac Arrest,Recruiting,No Results Available,Cardiac Arrest,,Essentia Health,Both,Adult|Senior,,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CardiacArrestSCAI,"April 11, 2016",Apr-16,Apr-22,"April 13, 2016",Apr-16,No Study Results Posted,null,Apr-21,Death from any cause,https://ClinicalTrials.gov/show/NCT02738099
391,NCT02738073,Effects of Tranexamic Acid on Blood Loss and Transfusion Requirement Following Hip Fracture,Recruiting,No Results Available,Hip Fracture,Drug: Control: Saline|Drug: Tranexamic Acid,Rothman Institute Orthopaedics,Both,Adult|Senior,,null,Other,Interventional,,14RGOOD01,"February 10, 2014",null,null,"April 8, 2016",Apr-16,No Study Results Posted,null,Feb-17,calculation of blood loss during the perioperative period,https://ClinicalTrials.gov/show/NCT02738073
392,NCT02738060,The Effect of Baked Milk on Cow's Milk Allergy,Recruiting,No Results Available,Cow's Milk Allergy,Dietary Supplement: Baked Milk,Hossein Esmaielzadeh|Shiraz University of Medical Sciences,Both,Child|Adult,Phase 2,80,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,9401359338,"April 5, 2016",Sep-15,Mar-17,"April 14, 2016",Apr-16,No Study Results Posted,null,Nov-16,Tolerance to cow's milk assessed by oral food challenge test|Tolerance to cow's milk by measuring serum specific IgE levels|Tolerance to cow's milk using skin prick test|Tolerance to cow's milk by measuring serum IgG4,https://ClinicalTrials.gov/show/NCT02738060
393,NCT02738047,Radar PharmocogenomicTesting for Medication Management -,Recruiting,No Results Available,Pharmacogenomic Testing for Medication Management,,OSA Healthcare,Both,Adult|Senior,,300000,Industry,Observational,,2142016,"March 28, 2016",Mar-16,May-17,"April 8, 2016",Apr-16,No Study Results Posted,PGx,Apr-17,"Radar, Pharmocogenomic",https://ClinicalTrials.gov/show/NCT02738047
394,NCT02738021,Managing PPD at Gouverneur,Recruiting,No Results Available,Post-Partum Depression,Behavioral: STRONG,New York University School of Medicine,Female,Adult|Senior,,40,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,15-00416,"April 8, 2016",Mar-16,Mar-17,"April 15, 2016",Mar-16,No Study Results Posted,null,Mar-17,Patient Health Questionnaire-9 (PHQ-9)|Maternal Depression Management Inventory,https://ClinicalTrials.gov/show/NCT02738021
395,NCT02738008,Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection,Recruiting,No Results Available,Hepatitis B,Drug: ARC-520 Injection,Arrowhead Pharmaceuticals,Both,Adult|Senior,Phase 2,50,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,Heparc-2007|2014-004201-33,"April 11, 2016",Apr-16,Mar-18,"April 11, 2016",Apr-16,No Study Results Posted,null,Dec-17,Percentage of initial responders to ARC-520 therapy achieving a 1-log reduction in Hepatitis B Surface Antigen (HBsAg) as a measure of efficacy|Incidence and frequency of adverse events (AEs) as a measure of the safety and tolerability of ARC-520|Percentage of initial responders to ARC-520 therapy with HBsAg loss (qualitative) compared to baseline,https://ClinicalTrials.gov/show/NCT02738008
396,NCT02737982,Sex and Gender Differences in Ischemic Heart Disease - Endocrine Vascular Disease Approach,Recruiting,No Results Available,Myocardial Ischemia,Procedure: percutaneous coronary intervention,"University of Roma La Sapienza|Ministry of Education, Universities and Research, Italy",Both,Adult|Senior,,210,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RBSI14HNVT,"April 1, 2016",Oct-15,Oct-18,"April 22, 2016",Apr-16,No Study Results Posted,EVA,Mar-17,"Assessment of corrected Thrombolysis In Myocardial Infarction frame count and myocardial blush grade|Sexual hormones levels in patients with IHD undergoing PCI|Platelet activation markers including Thromboxane, soluble CD40-Ligand and soluble P-selectin in patients with IHD undergoing PCI|Clinical outcomes including cardiovascular mortality, re-hospitalization and restenosis|Microvascular dysfunction assessed by cardiac magnetic resonance",https://ClinicalTrials.gov/show/NCT02737982
397,NCT02737943,Effect of Mebo Dressing Versus Standard Care on Managing Donor and Recipient Sites of Split-thickness Skin Graft,Recruiting,No Results Available,Burns,Drug: Moist Exposed Burn Ointment (MEBO)|Drug: Zagazig,Zagazig University,Both,Child|Adult,Phase 1,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),2579,"April 5, 2016",Mar-16,Jul-16,"April 13, 2016",Apr-16,No Study Results Posted,EMD-SCZ-SGS,Jun-16,Healing Assessment|Recovery Time|Rate of Infections|Pain Assessment|Total Treatment Costs|Rate of Complications|Quality of Life,https://ClinicalTrials.gov/show/NCT02737943
398,NCT02737891,Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: Tesofensine/Metoprolol|Drug: Placebo,Saniona|Profil Institut fÌ_r Stoffwechselforschung GmbH,Both,Adult|Senior,Phase 2,60,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",TM001,"April 5, 2016",Apr-16,null,"April 13, 2016",Apr-16,No Study Results Posted,null,Mar-17,Change from baseline to end of treatment in mean 24 hour HR|Change from baseline to end of treatment in HbA1c,https://ClinicalTrials.gov/show/NCT02737891
399,NCT02737878,Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription,Recruiting,No Results Available,Mild Cognitive Impairment,Behavioral: Aerobic Training|Behavioral: Resistance Training|Behavioral: Balance and Tone Training|Behavioral: Balance and Tone Program,University of British Columbia,Both,Adult|Senior,,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),H15-02181,"April 11, 2016",Apr-16,Dec-18,"April 20, 2016",Apr-16,No Study Results Posted,null,Dec-18,Change in cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Plus)|Executive functions as measured by standard neuropsychological tests|Changes in cardiometabolic risk factors as measured by blood panel|Changes in health related quality of life as measured by the EuroQol five dimensions questionnaire (EQ-5D)|Mood as measured by the Geriatric Depression Scale Shortened Version (GDS)|Changes in brain structure as measured by functional magnetic resonance imaging (fMRI)|Memory as measured by standard neuropsychological tests|Functional Capacity as measured by 6 minute walk test|Cardiometabolic risk factors as measured by waist to hip ratio|Cardiometabolic risk factors as measured by body mass index|Cortisol levels through saliva samples|Changes in lower body strength as measured by the 30 sec sit-to-stand|Change in upper body strength as measured by grip strength|Sleep monitoring as measured by Motion Watch actigraphy,https://ClinicalTrials.gov/show/NCT02737878
400,NCT02737813,Cardiac Output Changes During Hyperbaric and Isobaric Bupivacaine in Patients Undergoing Cesarean Section,Recruiting,No Results Available,"Cardiac Output|Hypotension|Anesthesia, Spinal",Drug: Isobaric marcaine|Drug: Hyperbaric marcaine,Mahidol University,Female,Adult|Senior,Phase 4,144,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",Marcaine,"March 23, 2016",Mar-16,Jan-18,"April 9, 2016",Apr-16,No Study Results Posted,null,Jan-18,Change of cardiac output (L/min) after spinal block|Total dose of vasopressor|Number of patients who experience systolic blood pressure < 25% of preoperative measurement,https://ClinicalTrials.gov/show/NCT02737813
401,NCT02737800,Effect of Prolonged GnRh Agonists on Results of Intracytoplasmic Sperm Injection (ICSI ) in Endometrioma Patients,Recruiting,No Results Available,Endometrioma,Procedure: endometrioma aspiration|Drug: GnRh agonist ( Decapeptyl )|Procedure: standard long stimulation protocol,Kasr El Aini Hospital,Female,Adult,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,obgynivf,"March 31, 2016",Aug-15,Sep-16,"April 9, 2016",Apr-16,No Study Results Posted,GnRh,Aug-16,Number of patients with urine pregnancy test positive 2 weeks after embryo transfer,https://ClinicalTrials.gov/show/NCT02737800
402,NCT02737787,A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,Recruiting,No Results Available,Ovarian Cancer|Fallopian Tube|Primary Peritoneal Cancer|Recurrent Ovarian Cancer,Biological: WT1 Vaccine|Drug: Nivolumab,Memorial Sloan Kettering Cancer Center,Female,Adult|Senior,Phase 1,10,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,15-247,"April 5, 2016",Apr-16,null,"April 8, 2016",Apr-16,No Study Results Posted,null,Apr-18,Dose limiting toxicity (DLT),https://ClinicalTrials.gov/show/NCT02737787
403,NCT02737735,The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: standard chemotherapy medicine combined with Chinese herbs|Drug: standard chemotherapy medicine,"First Affiliated Hospital, Sun Yat-Sen University",Both,Adult|Senior,Phase 1,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,SBao-guo,"March 26, 2016",Mar-16,Jan-20,"April 9, 2016",Mar-16,No Study Results Posted,null,Dec-19,Overall survival rate|progression-free survival rate,https://ClinicalTrials.gov/show/NCT02737735
404,NCT02737670,Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus,Recruiting,No Results Available,"Tinnitus, Subjective",Drug: Sulodexide|Drug: Placebo,"St Joseph University, Beirut, Lebanon",Both,Adult|Senior,Phase 2,70,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",SULO-TINNITUS,"April 3, 2016",Aug-15,Aug-16,"April 10, 2016",Apr-16,No Study Results Posted,SECIST,Jun-16,Tinnitus Handicap Inventory (THI)|Mini Tinnitus Questionnaire (Mini-TQ)|Mini Tinnitus Questionnaire+Tinnitus Handicap Questionnaire|Adverse effects,https://ClinicalTrials.gov/show/NCT02737670
405,NCT02737644,Peri-conception Key Nutritional Factors and Congenital Heart Disease,Recruiting,No Results Available,Congenital Heart Disease,Other: observation,Children's Hospital of Fudan University,Both,Child|Adult|Senior,,60000,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,GWIV24_v1,"April 3, 2016",Mar-16,Jul-18,"April 13, 2016",Apr-16,No Study Results Posted,PKNFCHD,Dec-17,preconceptional maternal serum folate level|early conceptional maternal serum folate deficiency|The status of serum Vitamin D level|Pre-conceptional maternal diet folic acid supplement intake|Peri-conceptional maternal plasma homocysteine level|neonatal congenital heart disease(CHD) status|Peri-conceptional paternal serum folate level,https://ClinicalTrials.gov/show/NCT02737644
406,NCT02737592,A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects,Recruiting,No Results Available,Erythema|Edema,"Device: Trojan ""Simply Pleasure"" Personal Lubricant","Church & Dwight Company, Inc.",Female,Adult,,33,Industry,Interventional,"Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",ST-7610,"March 22, 2016",Feb-16,null,"April 11, 2016",Apr-16,No Study Results Posted,null,Apr-16,Number of subjects that showed no erythema based on the 5 point scoring scale|Number of subjects that showed no edema based on the 5 point scoring scale,https://ClinicalTrials.gov/show/NCT02737592
407,NCT02737579,XFM: (X-ray Fused With MRI) Guided Cardiac Catheterization,Recruiting,No Results Available,Congenital Heart Defect,Procedure: XFM guidance,"Joshua Kanter|National Heart, Lung, and Blood Institute (NHLBI)|Children's Research Institute",Both,Child|Adult|Senior,,200,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,3879|HHSN 268201500001C,"February 17, 2016",Nov-13,Jun-21,"April 11, 2016",Apr-16,No Study Results Posted,null,Dec-20,Radiation exposure measurement|Fluoroscopy time measurement|Contrast volume measurement|Procedure time measurement,https://ClinicalTrials.gov/show/NCT02737579
408,NCT02737553,Laparoscopic Enclosed Morcellation; Electromechanic Morcellation vs Vaginal Removal,Recruiting,No Results Available,Myoma,Procedure: Enclosed morcellation|Procedure: vaginal morcellation,Ege University,Female,Adult,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Caregiver),AAkdemir1,"March 21, 2016",Oct-15,Oct-17,"April 15, 2016",Apr-16,No Study Results Posted,null,Oct-17,Operation time|Morcellation time,https://ClinicalTrials.gov/show/NCT02737553
409,NCT02737514,"Comparing the ADR With Air Insufflation, Water Immersion and Water Exchange During Two-endoscopist Colonoscopy",Recruiting,No Results Available,Adenoma,Procedure: Air insufflation|Procedure: water immersion|Procedure: water exchange,Dalin Tzu Chi General Hospital,Both,Adult|Senior,,450,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Outcomes Assessor)",DalinHsieh201402,"August 25, 2015",Dec-15,Dec-17,"April 8, 2016",Feb-16,No Study Results Posted,null,Dec-17,adenoma detection rate in the right colon|overall adenoma detection rate|post-procedure discomfort|30 days complication rate,https://ClinicalTrials.gov/show/NCT02737514
410,NCT02737488,Helping Children With Trauma,Recruiting,No Results Available,Trauma|Post-Traumatic Stress Disorder,Behavioral: Trauma Systems Therapy (TST)|Behavioral: Treatment as Usual (TAU),New York University School of Medicine,Both,Child,Phase 3,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver)",15-01251,"April 8, 2016",Feb-16,null,"April 8, 2016",Mar-16,No Study Results Posted,null,Feb-17,UCLA-Post Traumatic Stress Disorder-Reaction Index-DSM-IV (UCLA-PTSD-RI-DSM-IV)|Child Stress Disorder Checklist (CSDC),https://ClinicalTrials.gov/show/NCT02737488
411,NCT02737436,Intranasal Oxytocin and Maternal Neglect,Recruiting,No Results Available,Maternal Behavior,Drug: Intranasal Oxytocin|Drug: Placebo,Baylor College of Medicine|University of Iowa,Both,Adult,,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)",H-26732,"March 16, 2016",May-10,Dec-17,"April 8, 2016",Apr-16,No Study Results Posted,OT-MOM,Apr-17,Differences in brain activation of dopamine reward regions and prefrontal cortex after intranasal oxytocin administration in mothers|Differences in brain activation of dopamine reward regions and prefrontal cortex after intranasal oxytocin administration in fathers,https://ClinicalTrials.gov/show/NCT02737436
412,NCT02737345,"Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure",Recruiting,No Results Available,Cirrhosis,Other: Rotem,Scott Allen|University of Utah,Both,Adult|Senior,,75,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,86371,"April 1, 2016",Nov-15,null,"April 12, 2016",Apr-16,No Study Results Posted,null,Nov-16,The percentage of patients who exhibit fibrinolysis,https://ClinicalTrials.gov/show/NCT02737345
413,NCT02737332,A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Drug: Zytigaå¨ (Abiraterone Acetate)|Drug: SoluMatrix‰ã¢ (Abiraterone Acetate),Churchill Pharmaceutical LLC,Male,Adult|Senior,Phase 2,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CHL-AA-201,"March 25, 2016",Feb-16,null,"April 12, 2016",Apr-16,No Study Results Posted,null,Sep-16,Total Testosterone levels by intervention|PSA levels by intervention|Treatment-emergent adverse events will be calculated for each body system by treatment group. All Serious Adverse Events and Withdrawals due to Adverse events will be reported by intervention,https://ClinicalTrials.gov/show/NCT02737332
414,NCT02737293,Whole Egg Intake and the Mediterranean Diet,Recruiting,No Results Available,Overweight|Obesity,Other: Control Diet|Other: Med Diet|Other: Med Diet + Whole Egg,USDA Grand Forks Human Nutrition Research Center|Egg Nutrition Center,Both,Adult|Senior,,20,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Prevention|Masking: Open Label,GFHNRC147,"March 31, 2016",Apr-16,Dec-19,"April 7, 2016",Apr-16,No Study Results Posted,null,Dec-18,Change in lipoprotein metabolism|Change in inflammatory markers,https://ClinicalTrials.gov/show/NCT02737293
415,NCT02737280,High Flow Nasal Cannula Use in Infants With Bronchiolitis,Recruiting,No Results Available,Bronchiolitis,"Device: Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy|Device: MedKit Finland - Usual oxygen therapy",University of Oulu,Both,Child,,84,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,EETTMK2015,"February 26, 2016",Mar-16,Mar-19,"April 12, 2016",Apr-16,No Study Results Posted,null,Mar-18,Respiratory rate (RR) measured by the study physician/nurse|Respiratory rate measured by the study physician/nurse|Oxygen saturation (%)|Modified Wood's Clinical Asthma Score (mWCAS)|Time from hospital admission to discharge (hours)|Number of participants needing admission to intensive care unit (ICU),https://ClinicalTrials.gov/show/NCT02737280
416,NCT02737267,Development of a Nutrigenetic Test for Personalized Prescription of Body Weight Loss Diets (Obekit),Recruiting,No Results Available,Body Weight Changes,Behavioral: Moderately high protein diet|Behavioral: Low fat diet,"Clinica Universidad de Navarra, Universidad de Navarra",Both,Adult|Senior,,260,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,132/2015,"March 10, 2016",Nov-15,Dec-17,"April 7, 2016",Nov-15,No Study Results Posted,Obekit,Dec-17,Change in body weight at Week 16|Change in body weight at Week 40|Height|Change in waist and hip circumferences at 16 Weeks|Change in waist and hip circumferences at 40 Weeks|Change in body fat mass at 16 Weeks|Change in body fat mass at 40 Weeks|Single nucleotide polymorphisms (SNPs)|Changes in DNA methylation levels at 16 Weeks|Changes in DNA methylation levels at 40 Weeks|Changes in metabolic profiling at 16 Weeks|Changes in metabolomic profile at 40 Weeks|Changes in lipidomic profile at 16 Weeks|Changes in lipidomic profile at 40 Weeks|Changes in proteomic profile at 16 Weeks|Changes in proteomic profile at 40 Weeks|Changes in gut microbiota composition at 16 Weeks|Changes in gut microbiota composition at 40 Weeks|Changes in messenger ribonucleic acid (mRNA) expression at 16 Weeks|Changes in mRNA expression at 40 Weeks|Changes in microARNs in exosomes at 16 weeks|Changes in microARNs in exosomes at 40 weeks|Changes in DNA oxidation at 16 weeks|Changes in DNA oxidation at 40 weeks|Changes in serum glucose levels at 16 Weeks|Changes in serum glucose levels at 40 Weeks|Changes in serum insulin concentration at 16 Weeks|Changes in serum insulin concentration at 40 Weeks|Changes in serum lipid metabolism markers at 16 Weeks|Changes in serum lipid metabolism markers at 40 Weeks|Changes in serum total protein concentration at 16 Weeks|Changes in serum total protein concentration at 40 Weeks|Changes in serum uric acid levels at 16 Weeks|Changes in serum uric acid levels at 40 Weeks|Changes in serum transaminases concentrations at 16 Weeks|Changes in serum transaminases concentrations at 40 Weeks|Changes in serum homocystein concentration at 16 Weeks|Changes in serum homocystein concentration at 40 Weeks|Changes in vascular endothelial growth factor (VEGF) at 16 Weeks|Changes in vascular endothelial growth factor (VEGF) at 40 Weeks|Changes in asymmetric dimethylarginine (ADMA) at 16 Weeks|Changes in asymmetric dimethylarginine (ADMA) at 40 Weeks|Changes in PAI-1 concentration at 16 Weeks|Changes in plasminogen activator inhibitor-1 (PAI-1) concentration at 40 Weeks|Changes in nitric oxide levels at 16 Weeks|Changes in nitric oxide levels at 40 Weeks|Changes in blood pressure at 16 Weeks|Changes in blood pressure at 40 Weeks|Changes in plasma C-Reactive Protein levels at 16 Weeks|Changes in plasma C-Reactive Protein levels at 40 Weeks|Changes in plasma interleukin-6 (IL-6) and interleukin-10 (IL-10) levels at 16 Weeks|Changes in plasma IL-6 and IL-10 levels at 40 Weeks|Changes in plasma tumor necrosis factor-alpha (TNF-alpha) levels at 16 Weeks|Changes in plasma TNF-alpha levels at 40 Weeks|Changes in adiponectin levels at 16 Weeks|Changes in adiponectin levels at 40 Weeks|Changes in chemerin levels at 16 Weeks|Changes in chemerin levels at 40 Weeks|Changes in leptin levels at 16 Weeks|Changes in leptin levels at 40 Weeks|Changes in apelin levels at 16 Weeks|Changes in apelin levels at 40 Weeks|Changes in haptoglobin levels at 16 Weeks|Changes in haptoglobin levels at 40 Weeks|Changes in amyloid A levels at 16 Weeks|Changes in amyloid A levels at 40 Weeks|Changes in leukocytes levels at 16 Weeks|Changes in leukocytes levels at 40 Weeks|Changes in plasma LDL-ox levels at 16 Weeks|Changes in plasma LDL-ox levels at 40 Weeks|Changes in glutathione peroxidase activity at 16 Weeks|Changes in glutathione peroxidase activity at 40 Weeks|Changes in reduced and oxidized glutathione levels at 16 Weeks|Changes in reduced and oxidized glutathione levels at 40 Weeks|Changes in superoxide dismutase levels at 16 Weeks|Changes in superoxide dismutase levels at 40 Weeks|Changes in serum isoprostanes levels at 16 Weeks|Changes in serum isoprostanes levels at 40 Weeks|Changes in plasma malonyldialdehyde (MDA) concentration at 16 Weeks|Changes in plasma malonyldialdehyde (MDA) concentration at 40 Weeks|Changes in monoamines levels at 16 Weeks|Changes in monoamines levels at 40 Weeks|Changes in physical activity at 16 Weeks|Changes in physical activity at 40 Weeks|Changes in depression degree at 16 Weeks|Changes in depression degree at 40 Weeks|Changes in anxiety degree at 16 Weeks|Changes in anxiety degree at 40 Weeks|Changes in the chronotype at 16 Weeks|Changes in the chronotype at 40 Weeks|Changes in food intake at 16 Weeks|Changes in food intake at 40 Weeks|Changes in satiety at 16 Weeks|Changes in satiety at 40 Weeks,https://ClinicalTrials.gov/show/NCT02737267
417,NCT02737254,Oxytocin and Attachment-related Interpretation Bias,Recruiting,No Results Available,Trust,Drug: Oxytocin|Drug: Placebo|Other: Secure CBM training|Other: Neutral CBM training,Universitaire Ziekenhuizen Leuven|Katholieke Universiteit Leuven,Both,Child,Phase 4,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",S57012|2014-005352-25,"March 23, 2016",Mar-16,null,"April 12, 2016",Feb-16,No Study Results Posted,null,Nov-16,Change in trust in mother|Change in attachment-related behavior towards mother|Change in secure interpretation of ambiguous maternal behavior|Change in insecure interpretation of ambiguous maternal behavior|Interpretation speed of positive maternal behavior|Interpretation speed of negative maternal behavior,https://ClinicalTrials.gov/show/NCT02737254
418,NCT02737241,HoLEP (50W) vs. HoLEP (100W) for Treatment of BPH,Recruiting,No Results Available,Prostatic Hyperplasia,Procedure: Low power Holmium laser enucleation of the prostate|Procedure: High power Holmium laser enucleation of the prostate,Mansoura University,Male,Adult|Senior,Phase 4,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),Mans 26-11-2015,"March 27, 2016",Jun-15,Apr-17,"April 9, 2016",Apr-16,No Study Results Posted,null,Dec-16,Operative time (minutes)|Operative efficacy (gm/minute)|Enucleation efficacy (gm/minute)|dysuria score|Maximum urine flow rate (ml/sec),https://ClinicalTrials.gov/show/NCT02737241
419,NCT02737228,Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer,Recruiting,No Results Available,Pancreatic Neoplasms,Drug: CG200745 PPA|Drug: Gemcitabine|Drug: Erlotinib,"CrystalGenomics, Inc.",Both,Adult|Senior,Phase 1|Phase 2,72,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,CG200745-2-03,"March 22, 2016",Mar-16,Jul-18,"April 12, 2016",Apr-16,No Study Results Posted,null,Jul-18,Disease control rate (DCR)|Overall Response Rate (ORR)|Area Under the Curve [AUC]|Maximum Plasma Concentration [Cmax]|Adverse Events|Clinical laboratory tests,https://ClinicalTrials.gov/show/NCT02737228
420,NCT02737215,Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea,Recruiting,No Results Available,Atrial Fibrillation|Obstructive Sleep Apnea|Coronary Artery Bypass Grafting,Device: CPAP,Rodrigo Pinto Pedrosa|University of Pernambuco,Both,Adult|Senior,Phase 2|Phase 3,144,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,PAFOS01,"April 10, 2016",Dec-15,Nov-17,"April 10, 2016",Apr-16,No Study Results Posted,PAFOS,Jun-17,atrial fibrillation,https://ClinicalTrials.gov/show/NCT02737215
421,NCT02737202,Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis,Recruiting,No Results Available,Pulmonary Lymphangioleiomyomatosis,Drug: saracatinib,Baylor College of Medicine|University of Cincinnati|Brigham and Women's Hospital|Stanford University|Loyola University|University of South Florida|National Institutes of Health (NIH),Female,Adult,Phase 2,28,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,SLAM 7602|4UH3TR000961-02,"March 31, 2016",Apr-16,Dec-17,"April 12, 2016",Apr-16,No Study Results Posted,SLAM-2,Dec-17,FEV1|Angiomyolipoma measured volumetrically on MRI|Lung Cyst size measured on chest CT|VEGF-D serum levels,https://ClinicalTrials.gov/show/NCT02737202
422,NCT02737176,Tobacco Cessation Intervention Study for Oral Diseases,Recruiting,No Results Available,Smoking Cessation|Mouth Diseases|Periodontal Diseases|Leukoplakia|Lichen Planus|Keratosis|Implant,Other: Tobacco cessation intervention,Association for the Japanese Academy of Maxillofacial Implants,Both,Adult|Senior,,812,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,AssociationJAMI,"March 31, 2016",Apr-16,Dec-18,"April 8, 2016",Apr-16,No Study Results Posted,TISOD,Dec-17,Pocket depth in peridontitis|Per-implant marginal bone loss|Size reduction of oral mucosal diseases|Tobacco abstinence rate|HPV-DNA detection (p16 & 18),https://ClinicalTrials.gov/show/NCT02737176
423,NCT02737163,Strata Programmable CSF Shunt Valve Study,Recruiting,No Results Available,Hydrocephalus,,All Children‰Ûªs Hospital Johns Hopkins Medicine,Both,Child|Adult,,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Allkids,"April 1, 2016",Mar-16,May-20,"April 8, 2016",Apr-16,No Study Results Posted,null,Apr-19,"Frequency of inadvertent reprogramming of strata CSF shunt valves.|The likelihood of MRI field strength in reprogramming the strata valve.|Increased signs, symptoms and radiographic changes suggestive of shunt malfunction in participants with inadvertent reprogramming of the strata valve compared to those without inadvertent reprogramming.|The likelihood of inadvertent reprogramming with exposure to household devices with electromagnetic charge.",https://ClinicalTrials.gov/show/NCT02737163
424,NCT02737137,Dynamic Multimodal Monitoring for Ultrasound Guided Peripheral Nerve Blockade,Recruiting,No Results Available,Orthopedic Surgery,Procedure: Manual measurement|Procedure: Measurement with a gauge,"University Hospital, Montpellier",Both,Adult|Senior,,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Investigator),9654|2015-A01850-49,"March 1, 2016",Jan-16,Jan-17,"April 12, 2016",Jan-16,No Study Results Posted,null,Jan-17,Manual measurement|Measured by a pressure gauge,https://ClinicalTrials.gov/show/NCT02737137
425,NCT02737098,TOP Implementation Project,Recruiting,No Results Available,Posttraumatic Stress Disorder,Other: Enhanced Implementation Strategy|Other: Standard Implementation Strategy,VA Office of Research and Development,Both,Adult|Senior,,600,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Health Services Research|Masking: Open Label,QUX 16-005|QUE 15-282,"March 21, 2016",Apr-16,Sep-19,"April 12, 2016",Apr-16,No Study Results Posted,null,Jun-19,Reach: the proportion of sampled patients who received the core element of the TOP intervention|PTSD symptom severity|Perceived travel burden: Degree to which sampled patients report that traveling interferes with getting services.|Perceived wait time: Degree to which sampled patients report that appointment wait time interferes with getting services.|Perceived trust: Degree to which sampled patients report that lack of trust in providers interferes with getting services.,https://ClinicalTrials.gov/show/NCT02737098
426,NCT02737085,the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL),Recruiting,No Results Available,"Lymphoma, Large B-Cell, Diffuse",Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells,"Southwest Hospital, China",Both,Child|Adult|Senior,Phase 1|Phase 2,40,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,"Southwest Hospital, China","April 8, 2016",Mar-16,Mar-19,"April 8, 2016",Apr-16,No Study Results Posted,null,Mar-18,Adverse Events That Are Related to Treatment,https://ClinicalTrials.gov/show/NCT02737085
427,NCT02736981,Low Intensity Weight Loss for Young Adults,Recruiting,No Results Available,Obesity,Behavioral: Behavioral Weight Loss (BWL)|Behavioral: BWL + Autonomous Motivation|Behavioral: BWL + Extrinsic Motivation,Virginia Commonwealth University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Both,Adult,,381,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),HM20002772|R01DK103668,"February 18, 2016",Jan-16,Sep-19,"April 7, 2016",Apr-16,No Study Results Posted,REACH,Feb-19,Weight Loss|Percent Weight Loss|Change in Body Mass Index|Waist Circumference|Body Composition (percent fat mass)|Blood Pressure|Minutes of Moderate to Vigorous Physical Activity|Dietary Intake,https://ClinicalTrials.gov/show/NCT02736981
428,NCT02736916,HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer,Recruiting,No Results Available,"Carcinoma, Small Cell Lung",Radiation: HS-WBRT PCI|Radiation: Conventional PCI,General Hospital of Ningxia Medical University,Both,Adult|Senior,,3,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),Radiation Oncology 20160101,"March 25, 2016",Mar-16,Dec-18,"April 7, 2016",Mar-16,No Study Results Posted,null,Mar-18,Evaluate delayed recall as assessed by the Hopkins Verbal Learning Test-Revised (HVTL-R) 4 months after hippocampal sparing during whole-brain radiotherapy (HS-WBRT) for PCI of limited stage small cell lung cancer patients.|Evaluate the rate of brain metastasis in hippocampal region after HS-WBRT PCI for limited stage small cell lung cancer patients.,https://ClinicalTrials.gov/show/NCT02736916
429,NCT02736890,Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury,Recruiting,No Results Available,Neuropathic Back Pain|Spinal Cord Injury,Drug: Botulinum Toxin A|Drug: Placebo,Icahn School of Medicine at Mount Sinai,Both,Adult|Senior,Phase 2,32,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",GCO 14-2212,"April 8, 2016",Mar-16,Dec-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Jun-17,Numeric pain rating scale (NPRS)|7-Point Guy/Farrar Patient Global Impression of Change|International Basic Pain Dataset|Static Mechanical Allodynia testing|Dynamic Mechanical Allodynia testing,https://ClinicalTrials.gov/show/NCT02736890
430,NCT02736825,Simulines Non-Inferiority Pivotal Study,Recruiting,No Results Available,Skin Laxity,Device: Ultherapyå¨|Device: Standard transducer|Device: Simulines transducer,"Ulthera, Inc",Both,Adult|Senior,,260,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",ULT-146,"April 4, 2016",Apr-16,Jul-17,"April 7, 2016",Apr-16,No Study Results Posted,null,Mar-17,Quantitative measurements of neck and submental lift|Overall lifting and tightening of skin|Mean change from baseline to post treatment on the validated Merz Jawline Grading Scale (MJGS)|Volumetric changes from baseline|Treatment times using Simulines versus Standard transducers|Subjects' treatment-related comfort level|90-day Subject Global Aesthetic Improvement (SGAIS) Scale|180-day Subject Global Aesthetic Improvement (SGAIS) Scale|365-day Subject Global Aesthetic Improvement (SGAIS) Scale|90-day Clinician Global Aesthetic Improvement (CGAIS) Scale|180-day Clinician Global Aesthetic Improvement (CGAIS) Scale|365-day Clinician Global Aesthetic Improvement (CGAIS) Scale|Patient Satisfaction and Patient-Reported Improvement,https://ClinicalTrials.gov/show/NCT02736825
431,NCT02736812,Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO),Recruiting,No Results Available,Shock Hemorrhagic,Biological: French Lyophilized Plasma|Biological: Normale Saline Solution,"French Defence Health Service|Bataillon des marins pompiers de Marseille, France|Military Hospital Laveran,Marseille, France|Samu of Marseille, France|Samu of Lyon, France|Lyon-South Hospital, France|HÌ«pital Edouard Herriot|Fire Brigade Of Paris Emergency Medicine Dept|Hospital center of Annecy Genevois,France|Institut de Recherche Biomedicale des Armees|Marseille North Hospital, France|Samu of Necker, Paris, France|Samu of Annecy, France|Military Hospital Percy , Clamart, France|Military Hospital Begin, Saint-MandÌ©, France|Centre de transfusion sanguine des ArmÌ©es, Clamart, France",Both,Adult|Senior,Phase 3,140,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2014RC04,"March 27, 2016",Apr-16,Dec-18,"April 14, 2016",Apr-16,No Study Results Posted,PREHO-PLYO,Nov-18,Prothrombin level change (percentage)|international normalized ratio change (international unit) international normalized ratio level change (international unit IU)|Coagulation factors level change (international unit IU)|FLYP prehospital usability in civilian population (questionnaire)|Fibrinogen level variation (grams)|Total Intensive care unit of stay (days)|Survival|Thromboelastometry median clotting time (CT) (minutes).|Thromboelastometry median Clot Formation Time (CFT) in minutes and seconds|Thromboelastometry median Maximal Clot Firmness (MCF) time in minutes and seconds|Thromboelastometry median maximal lysis (ML) time in minutes ans seconds|Thromboelastometry alpha angle (degrees)|Number of RBC Concentrates units administered|Number of platelet concentrates units administered|Quantity of fibrinogen administered in grams|quantity of coagulation factors administered (international units IU)|number of plasma units administered,https://ClinicalTrials.gov/show/NCT02736812
432,NCT02736799,"Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers: A Sham Device Controlled, Single Center Pilot Study",Recruiting,No Results Available,Gastric Motility|Gastric Contractility|Gastric Emptying,Device: Sham vibrating capsule|Device: Vibrant Capsule (1 vibration)|Device: Vibrant Capsule (3 vibration)|Device: Vibrant Capsule (5 vibration),Vibrant Ltd.,Both,Adult,,24,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)",V102,"March 30, 2016",Mar-16,null,"April 6, 2016",Apr-16,No Study Results Posted,null,Dec-16,Gastroduodenal manometry measurement of first hour postprandial distal antral motility index.|Gastric emptying of solids:T1/2 in minutes (scintigraphy)|Gastric emptying of solids: lag time in minutes (scintigraphy)|Gastric emptying at 1h (scintigraphy)|Gastric emptying at 2h (scintigraphy)|First 0.5h postprandial distal antral motility index (Gastroduodenal manometry)|Abdominal Symptom assessments - VAS,https://ClinicalTrials.gov/show/NCT02736799
433,NCT02736786,A Study of Mucosal Sparing Proton Beam Therapy (PBT) in Resected Oropharyngeal Tumors,Recruiting,No Results Available,Oropharyngeal Tumor,,Mayo Clinic,Both,Adult|Senior,,67,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,16-000040,"April 8, 2016",Mar-16,Mar-20,"April 12, 2016",Apr-16,No Study Results Posted,null,Mar-20,Local Control Rate in Patients Treated with Proton Beam Therapy after Resection Using Transoral Surgery,https://ClinicalTrials.gov/show/NCT02736786
434,NCT02736773,Xenograft and Posterior Mandibular Socket Filling,Recruiting,No Results Available,Xenograft Model,Other: xenograft material to slow resorption,"University Hospital, Montpellier",Both,Adult|Senior,,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,9631,"February 24, 2016",Nov-15,Dec-17,"April 7, 2016",Feb-16,No Study Results Posted,Flapless,Dec-17,Cone beam diagnostic examination|Cone beam pre implant examination|Clinical measures,https://ClinicalTrials.gov/show/NCT02736773
435,NCT02736760,Daylight-PDT With MAL for AK and Photodamaged Skin,Recruiting,No Results Available,Actinic Keratoses|Photodamaged Skin,Drug: Daylight photodynamic therapy using Methylaminolevulinate (MAL)|Procedure: Cryosurgery,University Hospital Regensburg,Both,Adult|Senior,Phase 4,58,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,Daylight_01,"March 11, 2016",Mar-16,Dec-19,"April 7, 2016",Apr-16,No Study Results Posted,null,May-19,"The cumulative number of observed AKs at time points 2 to 6 (3 months after the first treatment to 24 months after the first treatment).|Complete clearance of AKs on lesion basis|Complete clearance of AKs on patient basis|Photodamage parameters (fine lines, mottled pigmentation, tactile roughness, teleangiectasias, sallowness and global score for photoaging) will be evaluated on a 5-point scale according to Dover et al.|Visual pain score|Adverse events|Patient satisfaction with cosmetic results|Skin-related quality of life",https://ClinicalTrials.gov/show/NCT02736760
436,NCT02736747,Effects of Cryotherapy on Ankle Movements and Gait of Spastic Hemiparetic Subjects,Recruiting,No Results Available,Stroke|Muscle Spasticity,Other: Cryotherapy|Other: Placebo,Carolina Carmona de AlcÌ¢ntara|Universidade Federal de Sao Carlos,Both,Adult|Senior,,18,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Investigator),Cryotherapy_LAFIN,"March 18, 2016",Apr-16,Mar-18,"April 19, 2016",Apr-16,No Study Results Posted,null,Jul-17,Change from baseline in spasticity level|Change from baseline in angular kinematic variables during gait|Change from baseline in linear kinematic variables during gait|Change from baseline in joint sense position (proprioception) during plantarflexion and dorsiflexion|Change from baseline in passive resistance of plantarflexors and dorsiflexors|Change from baseline in torque during isometric contractions|Change from baseline in torque during concentric contractions|Change from baseline in torque during eccentric contractions|Change from baseline in electromyography assessment,https://ClinicalTrials.gov/show/NCT02736747
437,NCT02736708,Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy for PSC Biliary Strictures,Recruiting,No Results Available,Primary Sclerosing Cholangitis,Device: probe based confocal laser endomicroscopy,"University of Colorado, Denver|University of Pittsburgh|Weill Medical College of Cornell University|Northwell Health|Methodist Health System|Ochsner Health System|Mauna Kea Technologies",Both,Adult|Senior,,100,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,12-1516,"December 9, 2015",Jan-13,Sep-17,"April 12, 2016",Apr-16,No Study Results Posted,PSCRegistry,Sep-16,Sensitivity of ERCP with probe-based endomicroscopy|Differentiation between PSC and PSC-malignant stenosis|Feasibility of Technical Performance based on image quality|Feasibility of Technical Performance based on tissue sampling accuracy,https://ClinicalTrials.gov/show/NCT02736708
438,NCT02736669,CARE Trial: Comparing Different Levels of Calorie Reduction for Weight Loss,Recruiting,No Results Available,Overweight|Obesity,Behavioral: Energy Reduction,University of Alabama at Birmingham,Both,Adult|Senior,,218,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),R01DK103863,"April 4, 2016",Oct-15,Apr-20,"April 7, 2016",Apr-16,No Study Results Posted,CARE,Apr-20,Body weight|Resting energy expenditure|Body composition|Laboratory analyses|Blood pressure|Hormones - ghrelin|Hormones - leptin|Satiety/hunger|Energy intake|Physical activity - objective|Physical activity - self-report|Treatment adherence|Treatment novelty|Treatment burden|Treatment satisfaction|Side effects,https://ClinicalTrials.gov/show/NCT02736669
439,NCT02736656,Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 Extended Release (ER),Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: SPN-812 ER,"Supernus Pharmaceuticals, Inc.",Both,Child,Phase 3,200,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,812P310,"April 4, 2016",Apr-16,Apr-19,"April 12, 2016",Apr-16,No Study Results Posted,null,Apr-19,Incidence of adverse events|Trends in Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score|Trends in Clinical Global Impression-Improvement (CGI-I) and Clinical Global Impression-Severity (CGI-S) score,https://ClinicalTrials.gov/show/NCT02736656
440,NCT02736552,"Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.",Recruiting,No Results Available,Gastric Cancer,Drug: S-1 for 6 months|Drug: S-1 for 1 year,Sun Yat-sen University|Anhui Provincial Hospital|The First Affiliated Hospital of Anhui Medical University|Anqing Municipal Hospital|Yuebei People's Hospital|The First Affiliated Hospital of Guangdong Pharmaceutical University|Guangdong Provincial Hospital of Traditional Chinese Medicine|Shenzhen People's Hospital|First Affiliated Hospital of Wannan Medical College|Lishui hospital of Zhejiang University,Both,Adult|Senior,Phase 3,680,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CGCG001,"April 4, 2016",Mar-16,Mar-23,"April 16, 2016",Apr-16,No Study Results Posted,null,Mar-18,Disease-free survival|Overall survival|Side effects,https://ClinicalTrials.gov/show/NCT02736552
441,NCT02736526,Study of Surgical Treatment Versus Observation in Children With Moderate Intermittent Exotropia,Recruiting,No Results Available,Moderate Intermittent Exotropia,Procedure: recession or resection of the horizontal extraocular muscles,Sun Yat-sen University,Both,Child|Adult,,280,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,ZX201304,"April 3, 2016",Nov-15,Nov-20,"April 7, 2016",Apr-16,No Study Results Posted,SOMIX,Nov-20,Ocular alignment (Prism alternative cover test)|Binocular stereopsis at distance and near (Random dot stereopsis test)|Newcastle control scores|The intermittent exotropia questionnaire,https://ClinicalTrials.gov/show/NCT02736526
442,NCT02736500,PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 177Lu-DOTATATE ASSOCIATED WITH METRONOMIC CAPECITABINE IN PATIENTS AFFECTED BY AGGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMORS,Recruiting,No Results Available,Neuroendocrine Tumors|Gastro Entero Pancreatic Neuroendocrine Tumors,Drug: 28 GBq 177Lu-DOTATATE|Drug: 22 GBq 177Lu-DOTATATE,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|Istituto Europeo di Oncologia IEO MILANO,Both,Adult|Senior,Phase 1|Phase 2,37,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IRST100.19,"April 7, 2016",Jul-15,Jul-17,"April 7, 2016",Apr-16,No Study Results Posted,LuX,Jul-17,Objective Overall Response Rate|toxicity rate|Progression free survival in association with histopathology characteristics|Progression free survival in association with the receptor and metabolic status at OctreoScan and FDG PET,https://ClinicalTrials.gov/show/NCT02736500
443,NCT02736422,"Assessment of New Magnetic Resonance Imaging (MRI) Pulse Sequences for Imaging Hyperpolarised Xenon in Lung, Heart and Brain in Volunteers",Recruiting,No Results Available,Healthy Volunteers,Other: Hyperpolarised Xenon,Sheffield Teaching Hospitals NHS Foundation Trust,Both,Adult|Senior,Phase 1,40,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,STH15603,"March 18, 2016",Jul-11,Nov-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Nov-17,Qualitative assessment of images 1|Qualitative assessment of images 2|Qualitative assessment of images 3,https://ClinicalTrials.gov/show/NCT02736422
444,NCT02736409,An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE),Recruiting,No Results Available,Eosinophilic Esophagitis (EoE),Drug: Oral Budesonide Suspension (OBS)|Drug: Placebo,Shire,Both,Child|Adult,Phase 3,200,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",SHP621-302,"March 22, 2016",Apr-16,Mar-19,"April 15, 2016",Apr-16,No Study Results Posted,ORBIT2,Mar-19,Efficacy of SHP621 as measured by peak esophangeal eosinophil count|Efficacy of SHP621 measured by the Dysphagia Symptom Questionnaire (DSQ) score|Participant long-term treatment response measured by peak eosinophil count from baseline to 36 weeks for subjects who were randomized to OBS treatment but did not respond after 16 weeks in SHP621-301 induction study|Participant response to OBS treatment over 36 weeks as meaured by reduction in DSQ score for subjects who received placebo in the SHP621-301 induction study|Participant response to reinitiating OBS treatment as measured by change in total endoscopy score for subjects who relapse after being randomized to placebo in the randomized withdrawal period|Participant response as assessed by endoscopically identified esophageal features as measured by the EoE Endoscopic Reference Score (EREFS)|Number of participants with adverse events by MedDRA preferred term as a measure of safety and tolerability|Participant long-term treatment response measured by reduction in DSQ combined score from baseline to 36 weeks for subjects who were randomized to OBS treatment but did not respond after 16 weeks in SHP621-301 induction study|Participant response to OBS treatment over 36 weeks as meaured by peak eosinophil count for subjects who received placebo in the SHP621-301 induction study|Participant response to OBS treatment over 36 weeks as meaured by change in total endoscopy score for subjects who received placebo in the SHP621-301 induction study|Participant response to reinitiating OBS treatment as measured by change in EREFS for subjects who relapse after being randomized to placebo in the randomized withdrawal period,https://ClinicalTrials.gov/show/NCT02736409
445,NCT02736357,The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study,Recruiting,No Results Available,Non-Hodgkin Lymphoma,,Mayo Clinic|Emory University|University of Iowa|M.D. Anderson Cancer Center|Washington University School of Medicine|University of Rochester|Weill Medical College of Cornell University|University of Miami,Both,Adult|Senior,,12900,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,15-007282,"April 4, 2016",Jul-15,Jun-20,"April 7, 2016",Apr-16,No Study Results Posted,LEO,Jun-20,Overall Survival (OS)|Event Free Survival (EFS)|Lymphoma Specific Survival (LSS),https://ClinicalTrials.gov/show/NCT02736357
446,NCT02736331,Different Types of Fruits on Metabolic Function and Cognitive Performance,Recruiting,No Results Available,Healthy,Dietary Supplement: Beverage 1|Dietary Supplement: Beverage 2,"Institute for Food Safety and Health, United States",Both,Adult,,40,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Single Blind (Subject),IRB2015-105,"March 31, 2016",Mar-16,Jul-18,"April 12, 2016",Apr-16,No Study Results Posted,WBB2,Jul-18,Changes in memory function using the Montreal Cognitive Assessment after intake of different types of fruits|Changes in plasma glucose concentrations after intake of different types of fruits|Changes in insulin concentrations after intake of different types of fruits|Changes in Plasma Triglycerides Concentrations after intake of different types of fruits|Changes in Plasma Total Cholesterol Concentrations after intake of different types of fruits,https://ClinicalTrials.gov/show/NCT02736331
447,NCT02736305,Use of Regorafenib in Recurrent Epithelial Ovarian Cancer,Recruiting,No Results Available,Ovarian Neoplasms,Drug: Regorafenib,"National Cancer Centre, Singapore",Female,Adult|Senior,Phase 2,34,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,NCC OV-01,"October 13, 2015",Feb-16,Jun-18,"April 13, 2016",Apr-16,No Study Results Posted,null,Dec-17,Investigator assessed progression free survival (PFS)|Overall survival (OS)|Overall tumour response rate (ORR) as per Gynecological Cancer Intergroup (GCIG) and RECIST v1.1 criteria|Treatment Emergent Adverse Events,https://ClinicalTrials.gov/show/NCT02736305
448,NCT02736279,Impact of Tecfidera on Gut Microbiota,Recruiting,No Results Available,Multiple Sclerosis,Drug: Dimethyl fumarate,Virginia Simnad|Biogen|EvergreenHealth,Both,Adult|Senior,,25,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,VIS2014,"March 22, 2016",May-15,Dec-20,"April 7, 2016",Apr-16,No Study Results Posted,null,Jun-20,Measure change in the diversity and relative abundance of bacterial and archaeal species in the gut microbiota following the start of DMF therapy.|Measure change in anxiety level within the first 6 months following the start of dimethyl fumarate therapy.|Measure change in depression level within the first 6 months following the start of dimethyl fumarate therapy.|Define pre-existing functional bowel disturbance as a predictor of GI symptoms development and severity following the start of dimethyl fumarate treatment.,https://ClinicalTrials.gov/show/NCT02736279
449,NCT02736227,Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation,Recruiting,No Results Available,Liver Transplantation,Drug: Tacrolimus Withdrawal and Everolimus Monotherapy,Northwestern University|Novartis Pharmaceuticals,Both,Adult|Senior,,40,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,STU00201794,"March 24, 2016",Mar-16,Mar-19,"April 7, 2016",Apr-16,No Study Results Posted,null,Mar-18,Amount of Treg cells and mRNA observed in peripheral blood prior to and during tacrolimus withdrawal plus everolimus treatment.,https://ClinicalTrials.gov/show/NCT02736227
450,NCT02736175,Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery,Recruiting,No Results Available,Post Ocular Surgical Inflammation and Pain,Drug: OTX-DP (Dexamethasone punctum plug)|Drug: Placebo Vehicle Punctum Plug,"Ocular Therapeutix, Inc.",Both,Adult|Senior,Phase 3,436,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",OTX-15-003,"February 10, 2016",Oct-15,Jan-17,"April 7, 2016",Apr-16,No Study Results Posted,null,Sep-16,"The anterior chamber will be examined for the presence of signs of ocular inflammation. Anterior chamber cell count and flare will be graded using the SUN* Working Group grading scheme: 0, 0.5+, 1+, 2+, 3+, 4+|Absence of pain in the study eye is assessed utilizing NIH Numerical Rating Scale graded from 0 to 10 with ""0"" being no pain",https://ClinicalTrials.gov/show/NCT02736175
451,NCT02736058,Surgical Classification of Abnormal Placentation,Recruiting,No Results Available,Placenta,Device: Trans- abdominal sonography|Device: Trans-vaginal sonography|Procedure: post-operative pathological specimen examination,Cairo University,Female,Adult,,100,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,PP2202016,"February 22, 2016",Feb-16,Dec-16,"April 7, 2016",Apr-16,No Study Results Posted,null,Dec-16,intraoperative blood loss,https://ClinicalTrials.gov/show/NCT02736058
452,NCT02736045,Ameliorating Work Burnout and Medical Residents,Recruiting,No Results Available,"Burnout, Professional|Depression|Stress|Anxiety|Distress",Device: emWave,Larkin Community Hospital,Both,Adult,Phase 1|Phase 2,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),LCH-1-032015,"April 27, 2015",Jul-15,Feb-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Dec-16,"Change in Work Burnout Symptoms ( measured by Maslach Burnout Inventory) (Of note, changes in Work Burnout Symptoms & Findings by Medical Residents will be attempted to be observed)|Change in Depression ( measured by Epidemiologic Studies Depression Scale) (Of note, changes in Depressive Symptoms by Medical Residents will be attempted to be observed)",https://ClinicalTrials.gov/show/NCT02736045
453,NCT02736032,Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist,Recruiting,No Results Available,Infertility,Procedure: Embryo transfer|Procedure: Serum Estradiol and Progesterone levels|Drug: GnRH agonist|Drug: External Estradiol|Drug: Progesterone,"Cairo University|Nile Ivf Center, Cairo, Egypt|Kamal Shaeer center of infertility",Female,Adult,Phase 3,310,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,12016,"March 30, 2016",Mar-16,May-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Mar-17,"Clinical pregnancy rate|Live birth rate|Estradiol and Progesterone levels on day of start of progesterone supplementation|Endometrial thickness on day of start of progesterone supplementation|Number of days needed for adequate (> 8mm) endometrial thickness|Cycle cancellation: not related to thawing, thin endometrium, high P. OR related to embryos not surviving thawing.|Chemical pregnancy rate|Implantation rate.|Early miscarriage rate|Ongoing pregnancy rate",https://ClinicalTrials.gov/show/NCT02736032
454,NCT02736006,Decreases in Diffusing Lung Capacity for Carbon Monoxide (DLCO) in Occupational Divers and Their Impact on Decompression Sickness Risks,Recruiting,No Results Available,Decompression Sickness,Other: 20 meters air dive,"University Hospital, Brest",Both,Adult|Senior,,16,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,RB15.173 (DACODEC),"March 16, 2016",Mar-16,Apr-18,"April 12, 2016",Apr-16,No Study Results Posted,DACODEC,Apr-18,Venous bubbles will be detected by precordial Doppler|Vascular abnormality|Coagulation activation|Inflammatory activation,https://ClinicalTrials.gov/show/NCT02736006
455,NCT02735954,Colorado Marijuana Users Health Cohort,Recruiting,No Results Available,COPD|Insomnia|Cannabis,Other: Marijuana,National Jewish Health|Colorado Department of Public Health and Environment,Both,Adult|Senior,,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,HS 2854,"January 6, 2016",Sep-14,Dec-19,"April 12, 2016",Apr-16,No Study Results Posted,null,Dec-18,Long term medical effects of marijuana use|Quality of sleep,https://ClinicalTrials.gov/show/NCT02735954
456,NCT02735928,Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to First Platinum-Resistant Recurrence of Ovarian Tumor,Recruiting,No Results Available,First Platinum-resistant Recurrent of Epithelial Ovarian Cancer,Device: Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin,Catholic University of the Sacred Heart,Female,Adult|Senior,Phase 1|Phase 2,50,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,PARROT,"February 8, 2016",Jan-16,Jan-18,"April 7, 2016",Apr-16,No Study Results Posted,PARROT,Jan-18,"Clinical Benefit Rate (CBR) according to RECIST/GCOG criteria after three cycles of PIPAC with PIPAC cisplatin and doxorubicin|The median time to progression according to RECIST criteria after three cycles of PIPAC with cisplatin|PCI, as assessed by laparoscopy|The degree of histological regression assessed by pathological review of repeated peritoneal biopsies|The proportion of women with a reduction of serum CA-125 of at least 50% after PIPAC|Evaluation of the Quality Of Life (QOL) on the basis of the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaires",https://ClinicalTrials.gov/show/NCT02735928
457,NCT02735915,"Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older",Recruiting,No Results Available,Herpes Zoster,Biological: Herpes Zoster Vaccine GSK1437173A,GlaxoSmithKline,Both,Senior,Phase 3,73,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,204926|2015-004400-30,"April 7, 2016",Apr-16,Mar-19,"April 21, 2016",Apr-16,No Study Results Posted,null,Sep-16,"Antigen-specific antibody (Ab) concentrations.|Cell-Mediated Immunity (CMI) in terms of frequencies of antigen-specific CD4 T-cells.|Occurrence of all serious adverse events (SAEs) related to study participation or to a concurrent GSK medication/vaccine (including HZ/su administered during the Zoster-003 (NCT00434577) study).|Antigen-specific antibody (Ab) concentrations post re-vaccination.|Cell-Mediated Immunity (CMI) in terms of frequencies of antigen-specific CD4 T- cells.|Occurrence and intensity of each solicited local and general symptom in all subjects.|Occurrence, intensity and relationship to vaccination of unsolicited AEs according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects.|Occurrence and relationship to vaccination of all SAEs.|Occurrence of any fatal SAEs.|Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs).",https://ClinicalTrials.gov/show/NCT02735915
458,NCT02735889,Fizzy Drinks Study,Recruiting,No Results Available,Glycemic Response|Gastric Emptying|Satiety,Other: No Carbonation|Other: Low carbonation|Other: High carbonation,"Clinical Nutrition Research Centre, Singapore",Both,Adult,,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject),2015/01079,"March 13, 2016",Dec-15,Jun-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Dec-16,Changes in blood glucose concentrations in capillary blood using Hemocue|Changes in cross sectional area of antrum imaged using ultrasound|Satiety|Amount of food consumed|Energy intake,https://ClinicalTrials.gov/show/NCT02735889
459,NCT02735824,Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies,Recruiting,No Results Available,Immunologic Deficiency Syndromes,Procedure: blood sampling and skin biopsy|Procedure: blood sampling or mouth swap|Procedure: blood sampling,"University Children's Hospital, Zurich",Both,Child|Adult|Senior,,500,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,GSI KEK_2015-0555,"March 10, 2016",Feb-16,Jul-19,"April 7, 2016",Feb-16,No Study Results Posted,GSI,Jan-19,Number of patients with suspected PID for whom a genetic cause has been identified,https://ClinicalTrials.gov/show/NCT02735824
460,NCT02735811,OBSERVational Registry on Long-term Outcome of ICD Patients,Recruiting,No Results Available,Cardiomyopathies,Device: Assesment of long-term outcome of ICD patients,Azienda Ospedaliera Cardinale G. Panico,Both,Adult|Senior,,1300,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,OBSERVO,"April 2, 2016",Mar-15,May-16,"April 12, 2016",Apr-16,No Study Results Posted,OBSERVO,May-16,Death for any cause|Complications related to ICD implantation,https://ClinicalTrials.gov/show/NCT02735811
461,NCT02735785,Adapting the HOPE Social Media Intervention to Reduce Prescription Drug Abuse,Recruiting,No Results Available,Non-Cancer Chronic Pain,Behavioral: Harnessing Online Peer Education (HOPE) Social Media Intervention,"University of California, Los Angeles",Both,Adult|Senior,,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject),1R21DA039458,"February 5, 2016",Sep-14,null,"April 7, 2016",Apr-16,No Study Results Posted,null,Aug-16,Reduction in Current Opioid Misuse Measure (COMM) Score,https://ClinicalTrials.gov/show/NCT02735785
462,NCT02735707,Adaptive Platform Trial for Severe Community Acquired Pneumonia (AD-SCAP),Recruiting,No Results Available,Community Acquired Pneumonia,Drug: Antibiotic A|Drug: Antibiotic B|Drug: Hydrocortisone|Device: Minimal distension|Device: Maximal recruitment|Device: ECCO2R,UMC Utrecht,Both,Adult|Senior,Phase 4,4000,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Open Label,AD-SCAP|2015-002340-14|602525,"December 11, 2015",Dec-15,Feb-19,"April 6, 2016",Apr-16,No Study Results Posted,AD-SCAP,Feb-19,Mortality (%) measured at day 60 after randomization of the patients included in this trial.|ICU length of stay of the patients included in this trial.|Hospital length of stay of the patients included in this trial.|Ventilator free days.|Organ failure free days.,https://ClinicalTrials.gov/show/NCT02735707
463,NCT02735668,Physiotherapy in Chronic Shoulder Pain After Breast Cancer Treatment,Recruiting,No Results Available,Shoulder Pain|Breast Cancer,Other: Shoulder Conventional Exercises|Other: Invasive PT|Device: Control Motor Exercises|Behavioral: Therapeutic Education,University of Alcala,Female,Adult|Senior,,80,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),FPSM_UAH_VPG,"April 3, 2016",Feb-14,Sep-16,"April 12, 2016",Apr-16,No Study Results Posted,null,Jun-16,"Root-Mean-Square (RMS) EMG Amplitude|Onset EMG|Active myofascial trigger points of the muscles involved in shoulder. Travell and Simon's Criteria were used.|Scapular Dyskinesis|Knowledge about chronic pain|Pain and Disability|Range of motion Real-Time (flexion, abduction and external rotation movements)|Muscle Strength of the muscles involved in the movement of flexion, abduction and external rotation",https://ClinicalTrials.gov/show/NCT02735668
464,NCT02735655,Global State of Digestive Endoscopy Training Survey,Recruiting,No Results Available,Gastrointestinal Endoscopy Training,Other: Physician's opinion,Al-Azhar University,Both,Adult|Senior,,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,WEO-ES-1,"April 7, 2016",Apr-16,Mar-17,"April 15, 2016",Apr-16,No Study Results Posted,null,Jan-17,Training status|Unmet needs,https://ClinicalTrials.gov/show/NCT02735655
465,NCT02735629,Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia,Recruiting,No Results Available,Opiate Induced Respiratory Depression,Drug: CX1739 - 300 mg|Drug: CX1739 - 600 mg|Drug: CX1739 - 900 mg|Drug: Placebo,RespireRx|Duke University,Male,Adult,Phase 2,18,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)",CRTX-05,"March 23, 2016",Mar-16,Jul-16,"April 6, 2016",Apr-16,No Study Results Posted,null,Jun-16,Respiratory depression|Pain tolerance threshold|Maintenance of sedation|The number of patients that experience an adverse drug reaction upon ingestion of CX1739 when used alone or in conjunction with remifentanil|Change in pupil size,https://ClinicalTrials.gov/show/NCT02735629
466,NCT02735603,Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants,Recruiting,No Results Available,Heart Repolarization,Drug: Naltrexone HCl/bupropion HCl|Other: Placebo|Drug: Moxifloxacin,Takeda,Both,Adult,Phase 1,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",NaltrexBuprop-1001|U1111-1171-3290,"April 5, 2016",Apr-16,Jul-16,"April 22, 2016",Apr-16,No Study Results Posted,null,Jul-16,"The time-matched change from Baseline in QT interval with Fridericia correction method (QTcF)|Time-Matched Change From Baseline in QT Interval With Bazett Correction Method (QTcB) at Day 11|Time-Matched Change From Baseline in QT Interval With Individual Correction Method (QTcI) at Day 11|Time-Matched Change From Baseline in Uncorrected QT at Day 11|Time-Matched Increases From Baseline in QTcF, QTcB, QTcI, and QT > 30 msec and > 60 msec at Day 11|QTcF, QTcB, QTcI, and QT intervals >450 msec, >480 msec or >500 msec at Day 11|T-U wave complex morphology on Day 11|Cmax- Maximum Observed Plasma Concentration for Naltrexone, Bupropion, and their Metabolites|Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for Naltrexone, Bupropion, and their Metabolites|9. Percentage of Participants Reporting at least one Treatment-Emergent Adverse Event (TEAE)",https://ClinicalTrials.gov/show/NCT02735603
467,NCT02735577,Neural Mechanisms of Disulfiram Effects,Recruiting,No Results Available,Alcohol Use Disorder,Drug: Disulfiram,New York State Psychiatric Institute,Both,Adult,Phase 4,40,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,7193,"April 6, 2016",Mar-16,Mar-19,"April 6, 2016",Mar-16,No Study Results Posted,null,Mar-19,Alcohol use,https://ClinicalTrials.gov/show/NCT02735577
468,NCT02735564,Change in Reward System Activation and Gut Microbiota Following RYGB and Sleeve Gastrectomy for Weight Loss vs. Control-Heads Up Ancillary,Recruiting,No Results Available,Bariatric Surgery Candidate,Procedure: Bariatric Surgery,Pennington Biomedical Research Center,Both,Adult|Senior,,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,PBRC 2015-064,"April 6, 2016",Apr-16,Apr-18,"April 6, 2016",Apr-16,No Study Results Posted,null,Apr-17,Neural reward sensitivity|gut microbiota,https://ClinicalTrials.gov/show/NCT02735564
469,NCT02735551,LARC Forward Contraceptive Counseling at MHCC,Recruiting,No Results Available,Contraception,Drug: Long Acting Reversible Contraception (LARC)|Other: Referral for Long Acting Reversible Contraception (LARC)|Other: Prescription for Short-Acting Hormonal Contraception,Oregon Health and Science University|Merck Sharp & Dohme Corp.|Bayer|Society of Family Planning,Female,Child|Adult,Phase 4,200,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label,OHSU IRB 15715,"April 6, 2016",Apr-16,Jun-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Jun-17,LARC uptake evaluated based on participants' self-reported LARC usage through survey,https://ClinicalTrials.gov/show/NCT02735551
470,NCT02735512,MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer,Recruiting,No Results Available,No Evidence of Disease|Stage II Bladder Cancer|Stage III Bladder Cancer|Stage IVA Bladder Cancer|Stage IVB Bladder Cancer,Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis,University of Southern California|National Cancer Institute (NCI),Both,Child|Adult|Senior,,63,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,4B-15-2|NCI-2016-00265|P30CA014089,"March 15, 2016",Feb-16,Feb-18,"April 6, 2016",Apr-16,No Study Results Posted,null,Feb-17,"Change in MDSC level in patients with known localized, muscle-invasive bladder cancer who undergo surgical treatment|Change in MDSC level in patients with known metastatic bladder cancer who undergo systemic treatment|Change in MDSC level in patients with no history of cancer|Change in tumor burden evaluated by radiographic imaging|Change in urine cytology analysis",https://ClinicalTrials.gov/show/NCT02735512
471,NCT02735499,Instillation of Botox in the Bladder,Recruiting,No Results Available,Overactive Bladder,Drug: onabotulinum toxin A,The Hospital of Vestfold|South-Eastern Norway Regional Health Authority,Female,Adult|Senior,Phase 2,15,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,Botox instillation study,"April 6, 2016",Mar-16,Jan-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Nov-16,Change in number of leakage episodes|Change in grams leakage|Change in number of voids|Change in mean voided volume|Change in Urinary Distress Inventory-6 score (UDI-6)|Change in Incontinence Impact Questionnaire-7 score (IIQ-7)|Change in International Consultation on Incontinence Questionnaire-Short Form score (ICIQ-SF)|Change in flow rate,https://ClinicalTrials.gov/show/NCT02735499
472,NCT02735460,Usability of Andago V2.0 in Gait Rehabilitation of Stroke Patients,Recruiting,No Results Available,Brain Ischemia|Intracranial Haemorrhage,Device: Andago V2.0,Rehaklinik Zihlschlacht AG,Both,Adult|Senior,Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,RZI_01_2015,"March 15, 2016",Mar-16,null,"April 6, 2016",Mar-16,No Study Results Posted,null,Dec-16,Usability of the IMD according to the number of participants that are able to use the Andago V2.0|Acceptance of the IMD as measured by a therapist satisfaction questionnaire|Acceptance of the IMD as measured by a patient satisfaction questionnaire,https://ClinicalTrials.gov/show/NCT02735460
473,NCT02735408,Kinesiotape Tensiomyography in Low Back Region,Recruiting,No Results Available,Bandages|Muscle Tonus|Low Back Pain,Other: Kinesiotape (KT),Universidad Europea de Madrid,Both,Adult,Phase 1,50,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",P2015/35RM,"December 18, 2015",Oct-15,Sep-16,"April 6, 2016",Apr-16,No Study Results Posted,null,Sep-16,Tensiomyography changes (seconds): Delay time (Td) ; Contraction time (Tc) ; Sustain time (Ts) ; Relaxation time (Tr),https://ClinicalTrials.gov/show/NCT02735408
474,NCT02735369,A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR,Recruiting,No Results Available,Proliferative Diabetic Retinopathy (PDR),Drug: 2% OC-10X|Drug: Placebo Comparator,"OcuCure Therapeutics, Inc.|Semler Research Center Pvt. Ltd.",Both,Adult|Senior,Phase 2,40,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",OC10X-CT-BD2 PDR,"January 19, 2016",Dec-14,Dec-16,"April 6, 2016",Apr-16,No Study Results Posted,null,Dec-16,"The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the mean change of area of neovascularization of the disc (NVD) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area of neovascularization elsewhere in the retina (NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area of ""Posterior NVE"" from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by regression of total area of neovascularization (NVD+NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Change from baseline of regression of intraretinal microvascular abnormalities (IRMA) in PDR patients as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Change from baseline of regression of intraretinal hemorrhage as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Change from baseline of regression of venous beading as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Change from baseline of regression of area of capillary non-perfusion beading as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Change from baseline of regression of intraretinal exudation (lipid) as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Change from baseline of regression of macular edema (central subfield thickness) as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Change from baseline of regression of macular volume as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Change from baseline of best-corrected ETDRS visual acuity as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Change from baseline of macular thickness as measured by Optical Coherence Tomography (OCT) compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.|Number of patients requiring rescue treatment at the end of the study.|Number of patients requiring pars plana vitrectomy surgery due to presence of vitreous hemorrhage at the end of the study.|Number of patients requiring pars plana vitrectomy surgery due to traction retinal detachment at the end of the study.",https://ClinicalTrials.gov/show/NCT02735369
475,NCT02735356,Topical Itraconazole in Treating Patients With Basal Cell Cancer,Recruiting,No Results Available,Skin Basal Cell Carcinoma,Drug: Itraconazole|Other: Placebo,Jean Yuh Tang|National Cancer Institute (NCI)|Stanford University,Both,Adult|Senior,Phase 0,5,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,SKIN0030|NCI-2016-00452|P30CA124435,"March 31, 2016",Mar-16,Sep-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Mar-17,Percentage change of GLi levels in treated vs untreated tumors|Change in BCC tumor size,https://ClinicalTrials.gov/show/NCT02735356
476,NCT02735291,Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia,Recruiting,No Results Available,Leukemia,Biological: CD19-targeted CAR-T cells,"Sinobioway Cell Therapy Co., Ltd.|The Second Hospital of Anhui Medical University",Both,Child|Adult|Senior,Phase 1|Phase 2,24,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,ACCO-2015-06-01,"March 29, 2016",Nov-15,May-19,"April 11, 2016",Mar-16,No Study Results Posted,EECNTL,Oct-16,The overall efficiency,https://ClinicalTrials.gov/show/NCT02735291
477,NCT02735226,Stroke Prevention and Treatment System in Shanghai: a Network of Public Healthcare of Stroke,Recruiting,No Results Available,Stroke,,Shanghai Stroke Service System|Huashan Hospital|Shanghai Zhongshan Hospital|Ruijin Hospital|theTenth Peoples Hospital|the Sixth Peoples Hospital|RenJi Hospital|ShuGuang Hospital|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine|Shanghai Changzheng Hospital|Changhai Hospital|the Ninth Peoples Hospital,Both,Adult|Senior,,100000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Shanghai Stroke Service System,"March 31, 2016",Jan-14,Dec-18,"April 11, 2016",Apr-16,No Study Results Posted,SSSS,Dec-18,The acute stroke service and treatment provided in Shanghai area|The secondary prevention of stroke provided after discharge in Shanghai area|To assess the rate of antiplatelet agent used for stroke prevention.|To assess the rate of using anticoagulant medication for stroke prevention in patients with atrial fibrillation.,https://ClinicalTrials.gov/show/NCT02735226
478,NCT02735213,Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy,Recruiting,No Results Available,Central Serous Choroidopathy,Device: 577-MPL|Device: TLT,The Eye Hospital of Wenzhou Medical University,Both,Adult,Phase 4,80,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",Y-2016005,"March 16, 2016",Mar-16,Mar-18,"April 15, 2016",Apr-16,No Study Results Posted,null,Mar-17,the number of eyes without any subretinal fluid (SRF)|Change of the central retinal thickness (CRT)|Change of Best Corrected Visual Acuity (BCVA)|laser scar in area lasered on|Change of leakages on fundus fluorescence angiography,https://ClinicalTrials.gov/show/NCT02735213
479,NCT02735200,Topical Delivery of Vitamin D3 as Vitamin D Supplementation,Recruiting,No Results Available,Vitamin D Deficiency,Drug: topical vitamin D3 in intervention group,Dammam University,Both,Adult|Senior,Phase 1|Phase 2,550,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,DammamU,"March 12, 2016",Mar-16,Aug-16,"April 6, 2016",Apr-16,No Study Results Posted,null,Aug-16,Change in the serum levels of 25OHD after 4 months of treatment with topical Vitamin D3.,https://ClinicalTrials.gov/show/NCT02735200
480,NCT02735187,Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D.,Recruiting,No Results Available,Psoriasis Vulgaris,Device: Blue light treatment|Drug: Vitamin D,Light and Health Venture,Both,Adult|Senior,,50,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),Psoriasis-CT03,"March 16, 2016",Mar-16,null,"April 12, 2016",Apr-16,No Study Results Posted,null,Jul-16,Change from baseline (visit 2) of the local PSI of the blue light treated area (group 30) as compared to the VitaminD treated area (control) at end of treatment (Week 12).|Change from baseline (visit 2) of the local PSI of the blue light treated area(Group 15) as compared to the VitaminD treated (control) area at end of treatment (Week 12).|Change from baseline in patient self-assessment of severity of Psoriasis of the blue light treated area (group 30) compared to the VitaminD treated (control) area at week 12 (VAS scale).|Change from baseline in patient self-assessment of severity of Psoriasis of the blue light treated area (group 15) compared to the VitaminD treated (control) area at week 12 (VAS scale).|Lesional erythema measured by Mexameter measured at study visits.|Patient satisfaction (Week 12),https://ClinicalTrials.gov/show/NCT02735187
481,NCT02735174,Improving Asthma Care by Partnering With School Nurses to Bring Asthma Care Into the Inner-City Schools,Recruiting,No Results Available,Asthma,Device: Sensor cap system for inhalers|Other: App for SmartPhone|Behavioral: Motivational interviews|Other: Telehealth clinic visits,"Children's Hospital Medical Center, Cincinnati|Verizon Foundation|Luther Foundation",Both,Child,,30,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,CIN001_AFS4,"February 17, 2016",Jan-16,Jul-18,"April 6, 2016",Apr-16,No Study Results Posted,AFS4,Jul-17,Change in composite asthma severity index (CASI) score,https://ClinicalTrials.gov/show/NCT02735174
482,NCT02735161,Fatigue and Exercise Training in Patients With Sarcoidosis,Recruiting,No Results Available,Sarcoidosis|Fatigue,Other: Muscle strength training|Other: Endurance exercise training,LHL Helse|University of Oslo|Hasselt University,Both,Adult|Senior,,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,2015/23131,"March 28, 2016",Apr-16,Jun-18,"April 12, 2016",Apr-16,No Study Results Posted,null,Jun-18,Change in fatigue|Change in blood lactate|Change in sarcoidosis related fatigue|Change in metabolic and ventilatory variables from CPET|Change in maximal oxygen uptake,https://ClinicalTrials.gov/show/NCT02735161
483,NCT02735109,Interest of the Confocal Microscope in the Diagnosis of Epidermoid Carcinoma of the Vulva and Their Precursors,Recruiting,No Results Available,Vulvar Mucosa Lesions|Vulvar Intraepithelial Neoplasia,Other: photographies|Procedure: biopsy normal area,Centre Hospitalier Universitaire de Nice,Female,Adult|Senior,,30,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Screening|Masking: Open Label,14-AOI-13,"March 17, 2015",Apr-15,Apr-16,"April 6, 2016",Apr-16,No Study Results Posted,null,Apr-16,"Caracteristics of thorny layer, of granular layer,of basal layer of normal vulvar mucosa lesions VIN, and vulvar squamous cell carcinoma with confocal microscope|Caracteristics of thorny layer, of granular layer,of basal layer of normal vulvar mucosa lesions VIN, and vulvar squamous cell carcinoma with histological method|Caracteristics of thorny layer, of granular layer,of basal layer of vulvar mucosa lesions VIN to descriptions and the observations of with the normal mucosa",https://ClinicalTrials.gov/show/NCT02735109
484,NCT02735044,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Drug: insulin glargine (U300)|Drug: insulin glargine|Drug: fast-acting insulin analogue,Sanofi,Both,Child,Phase 3,450,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,EFC13957|2015-002084-42|U1111-1168-4546,"March 30, 2016",Apr-16,Apr-18,"April 12, 2016",Apr-16,No Study Results Posted,EDITION JUNIOR,Apr-18,Change from baseline in HbA1c|Percentage of patients with HbA1c values of <7.5% without any episode of severe and/or documented (SMPG <54 mg/dL; 3.0 mmol/L) symptomatic hypoglycemia during the last 3 months of the main 6-month randomized period|Change from baseline in Fasting Plasma Glucose (FPG)|Percentage of patients with FPG of ‰ä_130 mg/dL (7.2 mmol/L) without any episode of severe and/or documented (SMPG <54 mg/dL; 3.0 mmol/L) symptomatic hypoglycemia during the last 3 months of the main 6-month randomized period|Change from baseline in 24-hour mean plasma glucose based on 8-point self-monitored plasma glucose (SMPG) profiles|Change from baseline in variability of 24-hour mean plasma glucose based on 8-point SMPG profiles|Number (%) of patients with hypoglycemia|Number (%) of patients with hyperglycemia with ketosis|Number (%) of patients with adverse events,https://ClinicalTrials.gov/show/NCT02735044
485,NCT02735005,Determining the Needs of Aging People With Disabilities,Recruiting,No Results Available,Disabled People|Aging|Mental Handicap,Other: SMAF assessment,Centre Hospitalier de la RÌ©gion d'Annecy|Agence RÌ©gionale de SantÌ© RhÌ«ne-Alpes|Conseil DÌ©partemental de haute-Savoie,Both,Adult|Senior,,800,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research|Masking: Open Label,2015-A00642-47,"March 24, 2016",Aug-15,null,"April 13, 2016",Apr-16,No Study Results Posted,PHV,Apr-16,Needs in supports for aging disabled patients,https://ClinicalTrials.gov/show/NCT02735005
486,NCT02734979,Prospective Evaluation of the Biobridge Scaffold as an Adjunct to Lymph Node Transfer for Upper Extremity Lymphedema,Recruiting,No Results Available,Lymphedema|Edema,Device: Biobridge and lymph node transfer,Stanford University,Both,Adult|Senior,,60,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,37161,"April 5, 2016",Apr-16,Jan-20,"April 19, 2016",Apr-16,No Study Results Posted,Biobridge,May-19,Limb volume reduction|Serial lymphoscintigraphy|Bioimpedance spectroscopy|Caliper skin fold thickness|Cutaneous punch biopsy of skin|Quality of life,https://ClinicalTrials.gov/show/NCT02734979
487,NCT02734940,Multimodal Analgesia in Cardiac Surgery (Pilot Study),Recruiting,No Results Available,Heart Diseases,"Drug: Lidocaine, Dexmedetomidine and Ketamine|Drug: Unrestricted Fentanyl",Virginia Commonwealth University,Both,Adult|Senior,Phase 4,50,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)",HM20004692,"March 9, 2016",Mar-16,Jul-16,"April 5, 2016",Apr-16,No Study Results Posted,null,Jul-16,"Pain Scores - numerical rating scale, 0-10|Postoperative Opioid Consumption|Patient Satisfaction|Extubation|ICU length of stay|Delirium Scores|Ionotropic Requirement|Bowel Function",https://ClinicalTrials.gov/show/NCT02734940
488,NCT02734927,Motivation and Executive Control in Schizophrenia,Recruiting,No Results Available,Schizophrenia,Other: realization of computerized exercises,HÌ«pital le Vinatier,Both,Adult,,70,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,2012-A00026-37,"March 7, 2016",Nov-12,Jan-17,"April 7, 2016",Apr-16,No Study Results Posted,null,Sep-16,reaction time,https://ClinicalTrials.gov/show/NCT02734927
489,NCT02734901,Effects of Acute Red Raspberry Consumption on Vascular Function in Healthy Individuals,Recruiting,No Results Available,Healthy,Dietary Supplement: 400 g frozen raspberries|Dietary Supplement: 200 g frozen raspberries|Dietary Supplement: Placebo,"Heinrich-Heine University, Duesseldorf",Male,Adult,,10,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)",Rapsberry|15-038,"March 9, 2016",Mar-16,Aug-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Aug-16,Change from baseline to 2 hour and 24 hour in Endothelial function|Change from baseline to 2 hour and 24 hour in Pulse wave velocity|Change from baseline to 2 hour and 24 hour in Central blood pressure|Peripheral blood pressure|Change from baseline to 2 hour and 24 hour in Heart rate,https://ClinicalTrials.gov/show/NCT02734901
490,NCT02734888,Arterial Inflammation and E-Cigarettes,Recruiting,No Results Available,Arterial Inflammation,"Other: No drug or device, only a test. The test is called a PET/CT","University of California, Los Angeles",Both,Adult,,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,15-000552,"April 1, 2016",Jul-15,Feb-17,"April 5, 2016",Apr-16,No Study Results Posted,null,Feb-17,target-to-background ratio (TBR),https://ClinicalTrials.gov/show/NCT02734888
491,NCT02734849,Study to Evaluate Multiple Doses in Patients With Nasal Polyposis,Recruiting,No Results Available,Nasal Polyposis,Drug: AK001 low dose|Drug: AK001 high dose|Drug: Placebo,"Allakos, Inc.",Both,Adult,Phase 2,70,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",AK001-002,"March 24, 2016",Apr-16,Jul-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Jun-17,Evaluation of AK001 in combination with an intranasal steroid versus intranasal steroid alone in the reduction of nasal polyp size.|Size of polyps as evaluated by Lund-Mackay score at selected sites by computed tomography (CT) scan,https://ClinicalTrials.gov/show/NCT02734849
492,NCT02734836,Drug Eluting Stent for the Management of PERipheral Arterial Disease Of the SFA (DESPERADO-SFA Study),Recruiting,No Results Available,Peripheral Arterial Disease,Device: Ballon Angioplasty|Other: Optimal Coherence Tomography,Arkansas Heart Hospital,Both,Adult|Senior,Phase 4,20,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,AHH-2016-020,"April 6, 2016",Apr-16,null,"April 6, 2016",Apr-16,No Study Results Posted,DESPERADO,Dec-16,Optimal Coherence Tomograpy,https://ClinicalTrials.gov/show/NCT02734836
493,NCT02734823,Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor,Recruiting,No Results Available,"Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Gastrointestinal Stromal Tumor|Premenopausal",Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration|Procedure: Ultrasonography,University of Southern California|National Cancer Institute (NCI),Female,Adult,,20,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,0S-15-7|NCI-2016-00352|P30CA014089,"April 6, 2016",Mar-16,Mar-19,"April 6, 2016",Apr-16,No Study Results Posted,null,Mar-18,Changes in markers of ovarian reserve in premenopausal women undergoing tyrosine kinase inhibitor therapy for cancer|Ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo IVF for fertility preservation,https://ClinicalTrials.gov/show/NCT02734823
494,NCT02734797,"Clinical Outcomes, Nutritional Status, Exercise and Psychosocial Factors in Pediatric Hematopoietic Cell Transplant",Recruiting,No Results Available,Malnutrition|Obesity,,"Sung Choi, M.D.|University of Michigan Cancer Center",Both,Child|Adult,,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,UMCC 2015.108|HUM00102331,"March 17, 2016",Nov-15,Nov-17,"April 5, 2016",Apr-16,No Study Results Posted,CONSEPT,Nov-17,Feasibility of comprehensive nutrition assessments in pediatric HCT patients|Dietary intake|Determination of lean body mass measured using air displacement plethysmography (BOD POD)|Hand grip strength|PedsQL Pediatric Quality of Life Inventory|PedsQL Cognitive Functioning Scale|Dietary Patient Self-Efficacy Survey,https://ClinicalTrials.gov/show/NCT02734797
495,NCT02734758,Markers of Atrial Fibrillation,Recruiting,No Results Available,Stroke|Atrial Fibrillation,,"University of California, Davis",Both,Adult|Senior,,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,248994,"March 31, 2016",Mar-16,Apr-17,"April 5, 2016",Apr-16,No Study Results Posted,null,Apr-17,Gene expression,https://ClinicalTrials.gov/show/NCT02734758
496,NCT02734732,Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole,Recruiting,No Results Available,Prostate Infection,Drug: Trimethoprim/Sulfamethoxazole|Drug: Ciprofloxacin,UmeÌ´ University,Male,Child|Adult|Senior,Phase 2,2800,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",2014--‰Û002999--‰Û83,"April 6, 2016",Apr-15,May-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Apr-17,Admitted to hospital due to infection|Filled antibiotic prescription|Positive urinary or blood culture|Any hospital admission|Overall Mortality|Bacteriological characteristics|Hospitalisation time|Total doses of antibiotics filled|Risk factors for infection,https://ClinicalTrials.gov/show/NCT02734732
497,NCT02734719,Increasing Bone Density by Application of Surface Electrical Stimulation,Recruiting,No Results Available,Osteoporosis|Electrical Stimulation|Posture,Device: Bonestim,University of Belgrade,Both,Child|Adult|Senior,Phase 1|Phase 2,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,LK-2,"March 29, 2016",Mar-16,Sep-17,"April 5, 2016",Apr-16,No Study Results Posted,null,Sep-16,density of bone measured by central Dxa measurement|sagittal flexibility measured by Schober measurement|daily activities measured by Oswestry disability index,https://ClinicalTrials.gov/show/NCT02734719
498,NCT02734706,Efficacy of a LRC‰ã¢ (L. Reuteri NCIMB 30242) Capsule on Managing Cholesterol in Adults,Recruiting,No Results Available,Hypercholesterolemia,Dietary Supplement: LRC‰ã¢ capsule|Other: Placebo capsule,UAS Labs LLC,Both,Adult|Senior,Phase 2,120,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",15LCHU,"March 23, 2016",Mar-16,Sep-16,"April 5, 2016",Apr-16,No Study Results Posted,null,Sep-16,Serum LDL-cholesterol after 9 weeks of product consumption.|Serum LDL-cholesterol after 6 weeks of product consumption.|Serum total cholesterol after 6 and 9 weeks of product consumption.|Serum HDL-cholesterol after 6 and 9 weeks of product consumption.|Serum non-HDL-cholesterol after 6 and 9 weeks of product consumption.|Serum triglycerides after 6 and 9 weeks of product consumption.|Serum apolipoprotein B-100 after 6 and 9 weeks of product consumption.|Serum hs-CRP after 9 weeks of product consumption.|Plasma fibrinogen after 9 weeks of product consumption.|Plasma homocysteine after 9 weeks of product consumption.|GI health questionnaire score after 6 and 9 weeks of product consumption.,https://ClinicalTrials.gov/show/NCT02734706
499,NCT02734680,IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer,Recruiting,No Results Available,Pancreatic Cancer,Radiation: Concurrent chemoradiotherapy(CCRT)|Radiation: Stereotactic Radiotherapy(SBRT)|Drug: S-1,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",Both,Adult|Senior,,70,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),LC2015L11,"April 7, 2016",Feb-16,Feb-19,"April 12, 2016",Apr-16,No Study Results Posted,IFCSLAPC,Feb-18,Overal survival|Disease-specific survival|Progression-free survival|Local control rate,https://ClinicalTrials.gov/show/NCT02734680
500,NCT02734667,Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Device: CGM at diagnosis of T1D,"Korey Hood|University of Colorado, Denver|Stanford University",Both,Child,,60,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Open Label,35990,"March 9, 2016",Feb-16,Mar-19,"April 5, 2016",Apr-16,No Study Results Posted,null,Mar-19,Pediatric Quality of Life Inventory|Time spent in blood glucose range|Problem Areas in Diabetes|Diabetes Distress Scale|Patient Health Questionnaire 9|State-Trait Anxiety Inventory|Pittsburgh Sleep Quality Index|Hypoglycemic Fear Survey|Hypoglycemic Confidence Questionnaire|Glucose Monitoring System Satisfaction Survey|General and diabetes-specific technology use|Center for Epidemiologic Studies Depression Measure|Child Health Utility 9D|A1c|C-peptide,https://ClinicalTrials.gov/show/NCT02734667
501,NCT02734602,Imaging SV2A in Mood Disorders,Recruiting,No Results Available,Major Depressive Disorder|Post-Traumatic Stress Disorder,Drug: Ketamine|Behavioral: Cognitive Testing|Radiation: PET|Device: MRI,Yale University|VA Office of Research and Development,Both,Adult,,30,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,SV2A,"March 17, 2016",Apr-16,Mar-21,"April 5, 2016",Apr-16,No Study Results Posted,null,Jan-21,Evidence of synaptic changes in psychiatric disorders confirmed by PET data.|Evidence of synaptic density at time of its greatest anti-depressant response in psychiatric disorders confirmed with PET data.,https://ClinicalTrials.gov/show/NCT02734602
502,NCT02734537,Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery,Recruiting,No Results Available,"Head and Neck Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Laryngeal Verrucous Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oral Cavity Verrucous Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Verrucous Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oral Cavity Verrucous Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma",Drug: Cisplatin|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,Both,Adult|Senior,Phase 2,345,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,EA3132|NCI-2015-01911|U10CA180820,"April 6, 2016",Mar-16,null,"April 6, 2016",Apr-16,No Study Results Posted,null,Dec-21,DFS in patients with disruptive p53 mutation|DFS in patients with non-disruptive p53 mutation|DFS in patients with wild type p53 mutation|Incidence of adverse events graded using Common Terminology Criteria for Adverse Events version 4|p53 as a predictive marker of recurrence,https://ClinicalTrials.gov/show/NCT02734537
503,NCT02734524,A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer,Recruiting,No Results Available,Non-small Cell Lung Cancer,Biological: NK cells|Drug: Taxol|Drug: Carboplatin,"Southwest Hospital, China",Both,Adult|Senior,Phase 2,104,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,TMMU-BTC-004,"November 8, 2015",Mar-16,Mar-19,"April 5, 2016",Apr-16,No Study Results Posted,null,Mar-18,Number of participants responding to treatment|Progress free survival(PFS) time|Overall survival time,https://ClinicalTrials.gov/show/NCT02734524
504,NCT02734420,Effect of Photodynamic Therapy With Low-level Laser on Infected Dentin in Primary Teeth: A Controlled Clinical Trial,Recruiting,No Results Available,Dental Caries,Drug: PapacarieMBlue and PDT|Drug: Toluidine Blue O and PDT|Device: Laser,University of Nove de Julho,Both,Child,Phase 1,3,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Caregiver, Outcomes Assessor)",ZENILDOJUNIOR,"September 13, 2013",Sep-13,Oct-16,"April 11, 2016",Apr-16,No Study Results Posted,null,Oct-16,Microbiological analysis - collection of dentinal tissue and restoration with glass ionomer cement|Radiographs evaluation,https://ClinicalTrials.gov/show/NCT02734420
505,NCT02734394,UW WELL-FIT Exercise Program for Cancer Patients,Recruiting,No Results Available,Cancer,Behavioral: Exercise,University of Waterloo,Both,Child|Adult|Senior,,200,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label,ORE18987-A,"February 9, 2016",Jun-14,Dec-20,"April 11, 2016",Apr-16,No Study Results Posted,WELL-FIT,Dec-18,Maximal Exercise Test|Upper and Lower Limb Strength|Body Mass Index|Percent Body Fat|Glucose|Lipids,https://ClinicalTrials.gov/show/NCT02734394
506,NCT02734342,Mixed Methods Assessment of Exercises for Knee OA,Recruiting,No Results Available,Knee Osteoarthritis,Other: exercise,University of Salford,Both,Adult|Senior,,75,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,IRAS ID 154227,"February 15, 2016",Feb-16,Apr-17,"April 14, 2016",Apr-16,No Study Results Posted,null,Apr-17,Change in the level of kinesiophobia with exercise assessed using the Tampa Kinesiophobia Scale during an exercise programme and 6 weeks after the programme.|Change in the level of psychological and functional relationships using the Y balance test during an exercises programme and 6 weeks after the programme.|Change in the understanding of key factors that patients think about exercise as an intervention using a semistructured interview.,https://ClinicalTrials.gov/show/NCT02734342
507,NCT02734251,"Effect of Relora Supplement on Anxiety, Cognitive Performance & Mood Tested After Induced Stress",Recruiting,No Results Available,Mood (Psychological Function),Dietary Supplement: Relora|Dietary Supplement: Placebo,"InterHealth Nutraceuticals, Inc.|MB Clinical Research, LLC",Both,Adult,,35,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",MC-1514,"April 5, 2016",Feb-16,null,"April 11, 2016",Apr-16,No Study Results Posted,null,Jun-16,Mean STAI-Part 1 post-dose score (collected as part of the test battery at the t = 90 and 180 min timepoints) at the end (day 7) of each of the two treatment conditions.|Total area under the curve (AUC) for salivary cortisol from 90 to 150 min and 180 to 240 min at the end (day 7) of each of the two treatment conditions|Bond-Lader post-dose VAS scores (collected as part of the test battery at the t = 90 and 180 min timepoints) at the end (day 7) of each of the two treatment conditions.|Cognitive function post-dose test scores (collected as part of the test battery at the t = 90 and 180 min timepoints) at the end (day 7) of each of the two treatment conditions.,https://ClinicalTrials.gov/show/NCT02734251
508,NCT02734238,Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery,Recruiting,No Results Available,Caloric Restriction|Exercise,Drug: Sesame Oil|Drug: testosterone enanthate,Pennington Biomedical Research Center|United States Army Research Institute of Environmental Medicine|MyoSyntax|KineMed|Defence Research and Development Canada|United States Department of Defense,Male,Adult,Phase 4,60,Other|U.S. Fed|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",PBRC 2015-063,"March 31, 2016",Apr-16,Dec-18,"April 5, 2016",Apr-16,No Study Results Posted,OPS,Dec-17,Change in Total Body Mass|Change in Skeletal Muscle Mass|Change in Body Water Enrichment|Change in Muscle Protein Synthesis Rates|Determination of Proteome Dynamics|Change in Muscle Fiber Type (fast/slow)|Change in Muscle Cross-Sectional Area|Cell-Specific Response In Vitro to Anabolic Agents|Inflammatory Profiles in Blood Derived Cells and Muscle Tissue Derived Leukocytes|Determination of Muscular Strength|Determination of Energy Expenditure|Determination of Substrate Oxidation|Change in Minnesota Multiphasic Personality Inventory Scores|Change in Aggression Impulses|Change in Mood States|Change in Perceived Hunger and Fullness|Change in Willingness to Take Risks|Change in Cooperation|Change in Ability to Infer Intentions of Others|Change in Vigilance|Change in Visual Reaction Time|Change in Short-Term Spatial Memory and Pattern Recognition Skills|Change in Language-Based Logical Reasoning|Change in Rating of Perceived Exertion|Change in Working Memory Load|Change in Sleep Cycle|Change in Risk-Taking Propensity|Change in Retaliatory Aggression Against a Provoking Adversary|Change in Inhibitory Control Function|Change in Working Memory in Continuous Performance Task|Change in Attentional and Inhibitory Control|Change in Emotional Reactivity|Change in Endocrine Mediators of Appetite|Change in Gut Microbiome Composition|Change in Gastrointestinal Permeability|Change in Eating Attitudes|Change in Eating Behaviors,https://ClinicalTrials.gov/show/NCT02734238
509,NCT02734186,Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis,Recruiting,No Results Available,Schistosomiasis,Drug: Praziquantel,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),Both,Child|Adult|Senior,Phase 4,800,NIH,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,999916084|16-I-N084,"April 6, 2016",Mar-16,Sep-17,"April 6, 2016",Mar-16,No Study Results Posted,null,Sep-17,Peak percentage change from baseline eosinophil count|Peak absolute change from the baseline eosinophil count and peakpercentage change in eosinophil granule protein levels|Frequency and severity of adverse events|Number of subjects with detectable Sh eggs in urine,https://ClinicalTrials.gov/show/NCT02734186
510,NCT02734173,Pilot HCV DAA and Metabolism,Recruiting,No Results Available,Hepatitis C,Drug: ABT450r-ABT267-ABT333 +/- Ribavirin,Ottawa Hospital Research Institute|AbbVie,Both,Adult|Senior,Phase 4,24,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,20150305-01H,"October 21, 2015",Jul-15,Mar-17,"April 5, 2016",Apr-16,No Study Results Posted,3D,Dec-16,"Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin Hepatitis C Antiviral Therapy on Insulin Resistance|Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin Hepatitis C Antiviral Therapy Lipid Homeostasis",https://ClinicalTrials.gov/show/NCT02734173
511,NCT02734108,Transcranial Direct Current Stimulation (tDCS) and Anorexia Nervosa,Recruiting,No Results Available,Anorexia Nervosa,Device: Transcranial direct current stimulation,"University Hospital, Montpellier",Female,Adult,,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,UF 9587|2015-A00872-47,"March 8, 2016",Jan-16,May-17,"April 11, 2016",Dec-15,No Study Results Posted,STAR,May-17,Evolution of the Eating Disorders Examination Questionnaire (EDEq) score|Number of participants with treatment-related adverse events assessed by tDCS adverse effect questionnaire|Evolution of depressive symptoms assessed by patients with Beck Depression Inventory (BDI) questionnaire|Evolution of depressive symptoms assessed by the psychiatrist by Montgomery Asberg Depression Rating Scale (MADRS)|Evolution of mania symptoms assessed by the physician with Young Mania Rating Scale (YMRS)|Evolution of the Exercise Dependence Scale (EDS-R) score|Evolution of the Global Physical Activity Questionnaire (GPAQ) score|Evolution of the Maudsley Obsessive Compulsive Inventory (MOCI) score|Evolution of the sensitivity to punishment and sensitivity reward questionnaire|Evolution of the neuropsychological performance measured with the National Adult Reading Test (NART)|Evolution of the neuropsychological performance measured with the Iowa Gambling Task (IGT)|Evolution of the neuropsychological performance measured with the Brixton test|Evolution of the neuropsychological performance measured with the Rey-Osterrieth Complex Figure|Evolution of the neuropsychological performance measured with the D2 test|Evolution of the patient's level of function measured with the Work and Social Adjustment Scale (WSAS)|Evolution of the patient's level of function measured with the Global Assessment of Functioning (GAF),https://ClinicalTrials.gov/show/NCT02734108
512,NCT02734069,Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC,Recruiting,No Results Available,Lung Cancer|Sarcopenia|Toxicity,Drug: Carboplatin,Instituto Nacional de Cancerologia de Mexico,Both,Adult|Senior,,132,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,INCAN/TOX/CBP,"March 31, 2016",Feb-16,Dec-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Jul-17,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Compare different formulas to calculate Glomerular Filtration Rate taking as gold standard cystatin c,https://ClinicalTrials.gov/show/NCT02734069
513,NCT02734004,A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.,Recruiting,No Results Available,Ovarian|Breast|SCLC|Gastric Cancers,Drug: Olaparib|Drug: MEDI4736,"AstraZeneca|Quintiles, Inc.",Both,Adult|Senior,Phase 1|Phase 2,139,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,D081KC00001|2015-004005-16,"March 17, 2016",Mar-16,Jul-19,"April 6, 2016",Apr-16,No Study Results Posted,MEDIOLA,Jul-19,Disease control rate (DCR) [Complete response + Partial response + Stable disease (CR+PR+SD)] based on modified RECIST 1.1|The safety and tolerability of MEDI4736 in combination with olaparib by assessment of the number and grade of adverse events|The safety and tolerability of MEDI4736 in combination with olaparib by assessment of the number of participants with adverse events|The safety and tolerability of MEDI4736 in combination with olaparib by assessment of the number and grade of immune-related adverse events|The safety and tolerability of MEDI4736 in combination with olaparib by assessment of the number of participants with immune-related adverse events|The safety and tolerability of MEDI4736 in combination with olaparib by assessment of physical examination|The safety and tolerability of MEDI4736 in combination with olaparib by assessment of vital signs|The safety and tolerability of MEDI4736 in combination with olaparib by assessment of blood samples|PD-L1 expression in serum samples|Time to study treatment discontinuation (TDT)|Overall Survival (OS)|Percentage change from baseline in tumor size|Best percentage change from baseline in tumor size|Serum concentrations of anti-drug antibody (ADA)|Olaparib pharamacokinetic sample|MEDI4736 pharmacokinetic sample|Objective response rate (Complete response+Partial response) based on modified RECIST 1.1|Duration of response based on modified RECIST 1.1|PFS based on modified RECIST 1.1,https://ClinicalTrials.gov/show/NCT02734004
514,NCT02733952,Intravenous Tranexamic Acid Versus Pericervical Tourniquet To Decrease Blood Loss In Trans-Abdominal Myomectomy,Recruiting,No Results Available,Post Operative Hemorrhage,Drug: Tranexamic Acid|Procedure: Pericervical Tourniquet,Ain Shams Maternity Hospital,Female,Adult,Phase 3,70,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject),ASUObGyn,"March 27, 2016",Aug-15,Aug-17,"April 6, 2016",Apr-16,No Study Results Posted,null,Aug-17,Estimated intra-operative blood loss measured in milliliters|The need for intra-operative blood transfusion|The need for conversion from myomectomy to hysterectomy|Operative time in minutes|Intra-operative or post-operative complications|Difference between Pre and post-operative hemoglobin and hematocrit levels|Duration of hospital stay in days,https://ClinicalTrials.gov/show/NCT02733952
515,NCT02733913,Clinical Impact of Autonomic Modulation After Pulmonary Vein Isolation,Recruiting,No Results Available,Atrial Fibrillation,,"Klinik fÌ_r Kardiologie, Pneumologie und Angiologie|Heinrich-Heine University, Duesseldorf",Both,Adult|Senior,,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PVI,"February 18, 2016",Aug-14,Aug-16,"April 5, 2016",Apr-16,No Study Results Posted,null,Aug-16,"recurrence of AF|effect of PVI on cardiac autonomic system utilizing HRT measurement|effect of PVI on cardiac autonomic system utilizing BRS measurement|association between measured parameters (HRT, BRS) and the recurrence of AF",https://ClinicalTrials.gov/show/NCT02733913
516,NCT02733900,Modifications of the Subchondral Bone in Aseptic Osteonecrosis of the Femoral Head,Recruiting,No Results Available,Femur Head Necrosis,Procedure: femoral head removal,Lille Catholic University,Male,Adult|Senior,,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,RC-P0044,"March 23, 2016",Feb-16,Nov-17,"April 5, 2016",Apr-16,No Study Results Posted,ONTF,Aug-17,Osseous modifications responsible of osteonecrosis|Total cross-sectional area|cortical bone area|cortical area fraction|cortical thickness|bone volume fraction|trabecular number|trabecular separation|trabecular thickness|Physico-chemical composition of the trabecular subchondral bone|Existence and extent of edema|Perfusion MRI sequence|Medullary fat fraction in T1-weighted DIXON method,https://ClinicalTrials.gov/show/NCT02733900
517,NCT02733887,MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma,Recruiting,No Results Available,Lymphoma,Device: magnetic resonance imaging|Device: positron emission tomography/computed tomography|Radiation: fludeoxyglucose F 18,Guangxi Medical University,Both,Child|Adult|Senior,,66,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,PET-MRI/lymphoma,"March 17, 2016",Feb-16,null,"April 5, 2016",Apr-16,No Study Results Posted,null,Jun-17,18F-FDG uptake in lymphomas with PET/CT|Agreement between DWI-MRI and 18F-FDG PET/CT at diagnosis|Agreement between DWI-MRI and 18F-FDG PET/CT in follow-up examinations|Overall Survival|Progression Free Survival,https://ClinicalTrials.gov/show/NCT02733887
518,NCT02733861,Evaluation of the Related Factors Influencing the Stability of Dental Implants,Recruiting,No Results Available,Teeth Missing,,Fourth Military Medical University|National Natural Science Foundation of China,Both,Adult|Senior,,1,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IRB-REV-2016012,"March 29, 2016",May-15,Jan-18,"April 5, 2016",Apr-16,No Study Results Posted,null,May-16,Implant stability quotient (ISQ) was tested by Osstell‰ã¢ Mentor|Measure the bone density of the implant locations by CBCT.|Measure the thickness of the bone around the implant by CBCT.|Measure the crestal bone resorption by X-ray images,https://ClinicalTrials.gov/show/NCT02733861
519,NCT02733809,Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma,Recruiting,No Results Available,Hepatocellular Carcinoma,Drug: Sorafenib,King Saud University|King Faisal Specialist Hospital & Research Center,Both,Adult|Senior,Phase 4,40,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,KSULDRCSSMH001,"February 15, 2016",Jan-14,Dec-24,"April 5, 2016",Apr-16,No Study Results Posted,null,Dec-24,Overall and disease-free survival genes.|The predictors of survival ( response to Sorafenib )|Potential genetic targets for resistance.,https://ClinicalTrials.gov/show/NCT02733809
520,NCT02733796,Persistence of Zika Virus in Semen After Acute Infection,Recruiting,No Results Available,Zika Virus|Zika Virus Disease|Virus Shedding|Transmission,,"Institute of Tropical Medicine, Belgium",Male,Adult|Senior,,20,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,B300201628191,"March 30, 2016",Mar-16,Jan-17,"April 5, 2016",Apr-16,No Study Results Posted,null,Jan-17,Incidence rate of ZIKV persistence in semen|kinetics of ZIKV persistence in semen|replication fitness of ZIKV in semen|comparison of ZIKV sequences from semen vs. non-semen samples,https://ClinicalTrials.gov/show/NCT02733796
521,NCT02733731,The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis,Recruiting,No Results Available,Atrophic Vaginitis,Drug: Chinese Herbal Compound Ointment|Drug: Estriol,"First Affiliated Hospital, Sun Yat-Sen University",Female,Adult|Senior,Phase 1,80,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",Zxin,"March 20, 2016",Feb-16,Jun-16,"April 8, 2016",Mar-16,No Study Results Posted,null,May-16,symptom questionnaire scores|sign questionnaire scores|recurrence rate retreatment effect|retreatment effective rate|PH value of vaginae secretion|sIgA value of vaginae secretion|IL-1ë_value of vaginae secretion,https://ClinicalTrials.gov/show/NCT02733731
522,NCT02733718,The Impact of Different Feeding Strategies During Packed Red Cell Transfusion on Intestinal Oxygenation,Recruiting,No Results Available,Necrotizing Enterocolitis,Device: NIRS (near-infrared spectroscopy),Marmara University,Both,Child,,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Screening|Masking: Open Label,MR-01022016,"February 28, 2016",Nov-15,Sep-17,"April 8, 2016",Apr-16,No Study Results Posted,null,Jun-17,mesenteric oxygenisation (number of participants that has low mesenteric oxygenisation after transfusion)|Feeding intolerance (number of participants that has feeding intolerance after transfusion)|NEC (number of participants that has occurred transfusion related NEC),https://ClinicalTrials.gov/show/NCT02733718
523,NCT02733705,Intravenous Propofol and Fentanyl vs Propofol for Sedation in TRUS Biopsy,Recruiting,No Results Available,Pain,Other: Control|Drug: Fentanyl|Drug: propofol,Mahidol University,Male,Adult|Senior,Phase 4,124,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",TRUS,"March 27, 2016",Apr-16,Jan-18,"April 20, 2016",Apr-16,No Study Results Posted,null,Jan-18,"Pain assess using Numeric rating scale (NRS) score|Number of participants with hypoxia defined as oxygen saturation <92%|Number of participants with hypotension, defined as systolic blood pressure <90 mmHg",https://ClinicalTrials.gov/show/NCT02733705
524,NCT02733692,"Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation",Recruiting,No Results Available,HIV|STDs,Behavioral: Understanding Reproductive Health for Ladeez (GURHL) Code,"City University of New York, School of Public Health",Female,Adult,Phase 0,110,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject),381039,"January 11, 2016",Jul-15,Jun-16,"April 8, 2016",Apr-16,No Study Results Posted,null,Jun-16,Preliminary Efficacy1 Improvement in Sexual Health Knowledge Condom Use|Preliminary Efficacy 2 Improvement in Sexual Health Knowledge Sexual and Reproductive Health Services|Preliminary Efficacy 2 Improvement in Sexual Health Knowledge HIV and STD|Preliminary Efficacy 3 Improvement in Sexual Health Knowledge Connection to Services|Usability 1 Number of Times Used|Usability 2 Actions Taken|Usability 3 Duration|Usability 4A App performance|Usability 4B Ease of App usage|Usability 5 Facilitators and Barriers|Usability 6 User Friendliness,https://ClinicalTrials.gov/show/NCT02733692
525,NCT02733588,Delivery of G-Pump‰ã¢ (Glucagon Infusion) From an OmniPodå¨ to Prevent Hypoglycemia in Post-Bariatric Surgery Patients,Recruiting,No Results Available,Hypoglycemia|Complications of Bariatric Procedures,Drug: G-Pump‰ã¢ (glucagon infusion),Xeris Pharmaceuticals|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Both,Adult,Phase 2,5,Industry|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,XSGO-PB01|1R44DK107114-01,"March 30, 2016",Mar-16,Nov-16,"April 5, 2016",Apr-16,No Study Results Posted,null,Aug-16,Detection/notification of hypoglycemia|Prevention of severe hypoglycemia|Prevention of rebound hyperglycemia|Glucose time in range,https://ClinicalTrials.gov/show/NCT02733588
526,NCT02733575,Compassion Focused Therapy for Distressing Experiences,Recruiting,No Results Available,Psychosis,Other: Compassion Focused Therapy,King's College London,Both,Adult|Senior,,9,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,R&D2018/024,"February 25, 2016",Sep-15,Jun-17,"April 5, 2016",Apr-16,No Study Results Posted,null,Jun-17,"Attrition rate measured by number dropping out of therapy|Psychotic symptoms measured by PSYRATS|Depression and anxiety symptoms measured by DASS-21|Subjective wellbeing, symptoms, functioning, and risk/harm measured by CORE|Dissociative experiences measured by DES-II",https://ClinicalTrials.gov/show/NCT02733575
527,NCT02733510,The Impact of Early Protocol Biopsy in Kidney Transplant,Recruiting,No Results Available,Chronic Renal Failure,Drug: methylprednisolone,Samsung Medical Center,Both,Adult|Senior,,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SMC 2016-02-108-002,"April 5, 2016",Apr-16,Apr-19,"April 5, 2016",Apr-16,No Study Results Posted,null,Apr-19,biopsy proven acute rejection event|incidence of opportunistic infection|histologic feature at 1 year protocol biopsy,https://ClinicalTrials.gov/show/NCT02733510
528,NCT02733484,Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Obesity,Recruiting,No Results Available,Obesity,Dietary Supplement: Probiotics|Dietary Supplement: Placebo,Shanghai 10th People's Hospital,Both,Child|Adult,,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)",PTD02,"April 5, 2016",Oct-15,Dec-16,"April 5, 2016",Apr-16,No Study Results Posted,null,Dec-16,change from baseline in fasting blood-glucose at 1 month|change from baseline in fasting blood-glucose at 3 months|change from baseline in glycosylated hemoglobin change at 1 month|change from baseline in glycosylated hemoglobin change at 3 months|change from baseline in gut microbiota at 1 month|change from baseline in gut microbiota at 3 months|change from baseline in triglyceride at 1 month|change from baseline in triglyceride at 3 months|change from baseline in cholesterol at 1 month|change from baseline in cholesterol at 3 months|change from baseline in high-density lipoprotein at 1 month|change from baseline in high-density lipoprotein at 3 months|change from baseline in low-density lipoprotein at 1 month|change from baseline in low-density lipoprotein at 3 months|change from baseline in glutamic oxalacetic transaminase at 1 month|change from baseline in glutamic oxalacetic transaminase at 3 months|change from baseline in alkaline transaminase at 1 month|change from baseline in alkaline transaminase at 3 months|change from baseline in alkaline phosphatase at 1 month|change from baseline in alkaline phosphatase at 3 months|change from baseline in superoxide dismutase at 1 month|change from baseline in superoxide dismutase at 3 months|change from baseline in C-reactive protein at 1 month|change from baseline in C-reactive protein at 3 months|change from baseline in uric acid at 1 month|change from baseline in uric acid at 3 months|change from baseline in tumor necrosis factor-a at 1 month|change from baseline in tumor necrosis factor-a at 3 months|change from baseline in interleukin-6 at 1 month|change from baseline in interleukin-6 at 3 months|change from baseline in interleukin-8 at 1 month|change from baseline in interleukin-8 at 3 months|change from baseline in fasting insulin at 1 month|change from baseline in fasting insulin at 3 months|change from baseline in c peptide at 1 month|change from baseline in c peptide at 3 months|change from baseline in visceral fat fraction at 1 month|change from baseline in visceral fat fraction at 3 months|change from baseline in body age at 1 month|change from baseline in body age at 3 months|change from baseline in percentage of body fat at 1 month|change from baseline in percentage of body fat at 3 months,https://ClinicalTrials.gov/show/NCT02733484
529,NCT02733471,Evaluation of the Efficacy and Safety of Administering Lidocaine Spray in Oesophago-gastro-duodenoscopy,Recruiting,No Results Available,Tolerance,Drug: Lidocaine|Drug: Placebo,Basque Health Service,Both,Adult|Senior,Phase 4,586,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver)",LIDOGTC,"March 2, 2016",Apr-16,Apr-17,"April 5, 2016",Apr-16,No Study Results Posted,LIDOGTC,Apr-17,Degree of tolerance referred by the endoscopist in each group.|Degree of tolerance referred by the patient in each group|Endoscopist's level of satisfaction with the procedure in each group|Patient's level of satisfaction with the procedure in each group.|Number of completed procedures in control and lidocaine group|Estimate the total dose of propofol used in each group|Establish and compare the number of adverse events detected in control and lidocaine group|Estimate the number of patients with retrograde amnesia in each group|Estimate the number of patients with cough in each group|Estimate the number of patients with oropharyngeal discomfort in each group.,https://ClinicalTrials.gov/show/NCT02733471
530,NCT02733458,GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma,Recruiting,No Results Available,"Extranodal NK-T-Cell Lymphoma, Nasal Type",Drug: GELAD|Radiation: Radiotherapy,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Both,Adult|Senior,Phase 3,51,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,XHLSG-NK-1601,"April 5, 2016",Mar-16,Dec-20,"April 5, 2016",Apr-16,No Study Results Posted,null,Dec-20,Progression free survival|Overall survival|Response rate|Treatment-Related Adverse Events as Assessed by CTCAE v4.0,https://ClinicalTrials.gov/show/NCT02733458
531,NCT02733393,Sphenopalatine Ganglion Block to Treat Shoulder Pain After Thoracotomy,Recruiting,No Results Available,Ipsilateral Shoulder Pain,Procedure: Sphenopalatine Ganglion (SPG) Block|Drug: lidocaine,New York University School of Medicine,Both,Adult|Senior,Phase 1,10,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,15-00618,"April 5, 2016",Sep-15,null,"April 8, 2016",Mar-16,No Study Results Posted,null,Sep-16,Shoulder Pain Reduction,https://ClinicalTrials.gov/show/NCT02733393
532,NCT02733367,Extension Study for Patients Entered Into Study Infacort 003,Recruiting,No Results Available,Adrenal Insufficiency,Drug: Infacortå¨,Diurnal Limited,Both,Child,Phase 3,24,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,Infacort 004,"March 16, 2016",Mar-16,Aug-17,"April 5, 2016",Mar-16,No Study Results Posted,null,Aug-17,Incidence of serious adverse events (SAEs) and adverse events (AEs)|Growth velocity|Cortisol levels,https://ClinicalTrials.gov/show/NCT02733367
533,NCT02733289,Standard Follow-up Program Cervix Cancer (SFP CERVIX),Recruiting,No Results Available,Cervical Cancer Radiation Complications,,University Medical Center Groningen,Female,Child|Adult|Senior,,10000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,201600207,"March 17, 2016",Jun-15,Dec-25,"April 12, 2016",Apr-16,No Study Results Posted,SFPCERVIX,Dec-25,Complications,https://ClinicalTrials.gov/show/NCT02733289
534,NCT02733276,Electroacupuncture vs. Sham Electroacupuncture for Treatment of Fatigue in Patients With Inflammatory Bowel Disease,Recruiting,No Results Available,Fatigue|Inflammatory Bowel Disease,Other: electroacupuncture|Other: Sham: Electroacupuncture sham,Corporacion Parc Tauli,Both,Adult|Senior,,54,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),2014067,"March 5, 2016",Jan-16,Oct-16,"April 11, 2016",Apr-16,No Study Results Posted,null,Oct-16,Evaluate the effectiveness of acupuncture in the treatment of fatigue in patients with inflammatory bowel disease (assessed by the FACIT-F scale).|Evaluate the effectiveness of acupuncture in the treatment of depression in patients with fatigue and inflammatory bowel disease (assessed by the Depression Beck scale).|Evaluate the effectiveness of acupuncture in the treatment of anxiety in patients with fatigue and inflammatory bowel disease (assessed by the Hamilton scale).|Evaluate the effectiveness of acupuncture in the treatment of sleepiness in patients with fatigue and inflammatory bowel disease (assessed by the Epworth scale).,https://ClinicalTrials.gov/show/NCT02733276
535,NCT02733237,Oxytocin Effects on the Tolerance of Infidelity,Recruiting,No Results Available,Healthy,Drug: oxytocin treatment|Drug: placebo treatment,University of Electronic Science and Technology of China,Both,Adult,,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)",UESTC-neuSCAN-04,"March 30, 2016",Apr-15,Apr-16,"April 12, 2016",Apr-16,No Study Results Posted,null,Apr-16,attitude towards fidelity and infidelity potential mate.,https://ClinicalTrials.gov/show/NCT02733237
536,NCT02733172,Profiling Vulvodynia Based on Neurobiological and Behavioral Endophenotypes,Recruiting,No Results Available,Vulvodynia,,"University of California, Los Angeles",Female,Adult,,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,13-001113,"December 2, 2015",Jul-13,Aug-18,"April 4, 2016",Apr-16,No Study Results Posted,Vulvodynia,Aug-18,Brain morphometry measured by magnetic resonance imaging (MRI)|Functional connectivity measured by magnetic resonance imaging (MRI)|Genotyping for candidate gene polymorphism,https://ClinicalTrials.gov/show/NCT02733172
537,NCT02733120,Metabolic Processes in Adults With Autism Spectrum Disorder,Recruiting,No Results Available,Autism Spectrum Disorder,Other: stable isotope infusion,Texas A&M University,Both,Adult|Senior,,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label,2015-0542,"February 1, 2016",Oct-15,Oct-18,"April 8, 2016",Apr-16,No Study Results Posted,ASD,Oct-17,"Tryptophan turnover|leucine turnover|Whole body myofibrillar protein breakdown rate (reflecting muscle protein breakdown)|glutathione turnover|hydroxyproline breakdown (reflecting collagen breakdown)|glutamate turnover|taurine turnover|urea production|Group differences in state of mood as measured by the Hospital Anxiety and Depression Scale (HADS),|Group differences in learning and memory as measured by Auditory Verbal Learning Test (AVLT)|Group differences in learning and memory as measured by Controlled Oral Word Association Test (COWAT),|Group differences in learning and memory as measured by Digit Span|Group differences in overall cognitive abilities as measured by Montreal Cognitive Assessment (MoCA)|Group differences in attention and executive functions as measured by Trail Making Test (TMT),|Group differences in attention and executive functions as measured by Stroop Color-Word Test (SCWT),|Adolescent/Adult Sensory Profile|Group differences in attention and executive functions as measured by Brief-A|Group differences in attention and executive functions as measured by PASAT",https://ClinicalTrials.gov/show/NCT02733120
538,NCT02733107,The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer,Recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: Apatinib|Drug: Etoposide,Third Military Medical University,Both,Adult|Senior,Phase 2,25,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,ACEL,"April 5, 2016",Mar-16,Dec-20,"April 10, 2016",Apr-16,No Study Results Posted,null,Dec-19,Progression free survival|Objective Response Rate|Overall survival|Side effects,https://ClinicalTrials.gov/show/NCT02733107
539,NCT02733003,Implementation Research for Vulnerable Women in South Africa,Recruiting,No Results Available,HIV|Substance Abuse,Behavioral: Women's Health CoOp (WHC),RTI International|Kheth'Impilo,Female,Adult,,432,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research|Masking: Open Label,R01AA022882,"January 21, 2016",Sep-14,Sep-18,"April 4, 2016",Apr-16,No Study Results Posted,null,Sep-18,"Change in the perceived appropriateness of WHC intervention by interventionists|Change in the perceived appropriateness of WHC intervention by interventionists and administrators|Change in the perceived appropriateness of WHC intervention by clinicians, community women and administrators|Acceptability of WHC intervention by patients|Change in the perceived acceptability of WHC intervention by interventionists (clinicians)|Change in the perceived acceptability of WHC intervention by setting (clinic)|Change in the perceived acceptability of WHC intervention by clinicians, community women and administrators|Adoption of WHC intervention by interventionists (clinicians)|Adoption of WHC intervention by setting (clinic)|Change in the perceived adoption of WHC intervention by interventionists (clinicians) and administrators|Change in the perceived adoption of WHC intervention by interventionists|Start-up cost of WHC intervention|Ongoing cost of WHC intervention|Feasibility of WHC implementation|Feasibility of WHC intervention|Fidelity to WHC intervention|Penetration of the WHC intervention|Sustainability of the WHC intervention|Change in the perceived sustainability of the WHC intervention|Sexual Risk|Alcohol use|Substance use|Victimization|Communication|Relationship Power|Medical evaluation initiation and treatment amongst HIV-positive women",https://ClinicalTrials.gov/show/NCT02733003
540,NCT02732990,Peripheral Metabolic Function in Chronic Heart Failure Patients,Recruiting,No Results Available,Chronic Heart Failure,Behavioral: Exercise training,"Anders Rasmussen Rinnov|Rigshospitalet, Denmark",Both,Adult|Senior,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Single Blind (Subject),VEK-H-3-2013-048,"November 6, 2014",Feb-14,Aug-16,"April 4, 2016",Apr-16,No Study Results Posted,null,Aug-16,Change from baseline sympathetic nerve activity after 6 weeks of training|The effect of exercise training on exercise capacity in regards to oxygen uptake|The effect of exercise training on exercise capacity in regards to maximal workload|The effect of exercise training on exercise capacity in regards to a 6 min walk test,https://ClinicalTrials.gov/show/NCT02732990
541,NCT02732964,"Impact of Music on Satisfaction, Anxiety, and Hemodynamics During Spinal Anesthesia for Cesarean Delivery",Recruiting,No Results Available,Anxiety|Hypotension,Other: Pandora Music|Other: Mozart Music,Brigham and Women's Hospital,Female,Adult|Senior,Phase 1,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2015P002043,"April 1, 2016",Nov-15,Sep-16,"April 8, 2016",Apr-16,No Study Results Posted,null,Sep-16,"Change in maternal blood pressure after spinal anesthesia induction compared to baseline blood pressure.|maternal anxiety level, VAS|maternal anxiety level, STAI|Overall patient satisfaction, questionnaire|Overall patient satisfaction, pain control|Vasopressor requirement, phenylephrine|Vasopressor requirement, ephedrine",https://ClinicalTrials.gov/show/NCT02732964
542,NCT02732899,Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD,Recruiting,No Results Available,Exudative Age Related Macular Degeneration,Drug: Sirolimus|Drug: EYLEA,"Maturi, Raj K., M.D., P.C.",Both,Adult|Senior,Phase 3,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),RKM009,"April 5, 2016",Apr-16,Jul-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Jul-17,change in edema|change in best corrected visual acuity (BCVA)|number of injections required,https://ClinicalTrials.gov/show/NCT02732899
543,NCT02732886,Betafoam Diabetes Mellitus Foot Study,Recruiting,No Results Available,Diabetes Mellitus|Foot Ulcer,Device: Medifoamå¨|Device: Betafoamå¨,Mundipharma Korea Ltd,Both,Adult|Senior,Phase 4,70,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,BTF15-KR-402,"March 15, 2016",Mar-16,Dec-17,"April 4, 2016",Apr-16,No Study Results Posted,null,Dec-16,Proportion of subjects with a target ulcer which achieves complete wound closure in 8 weeks|Proportion of subjects with a target ulcer which achieves complete wound closure in 4 weeks|Wound infection rate until completion of skin re-epithelialization|Patient's level of satisfaction with treatment measured weekly using numeric rating scale (NRS)|Number of days till completion of wound healing from baseline|Number of total dressing changes by the time of the 8th week|Safety as determined through collection of adverse events|Change in size of target ulcer as an indicator of wound healing,https://ClinicalTrials.gov/show/NCT02732886
544,NCT02732834,Doctor-Patient Communication in Lung Cancer Care,Recruiting,No Results Available,Lung Cancer,Behavioral: Questionnaire|Behavioral: Patient Interview|Behavioral: Audio recordings of clinical consultations,Memorial Sloan Kettering Cancer Center|Hamad Medical Corporation|University of Arizona|Weill Medical College of Cornell University,Both,Adult|Senior,,66,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,16-001,"March 14, 2016",Jan-16,null,"April 4, 2016",Apr-16,No Study Results Posted,null,Jan-17,# of patients referred to MSK's Tobacco Treatment Program (TTP),https://ClinicalTrials.gov/show/NCT02732834
545,NCT02732821,G-POEM for Treatment of Refractory Gastroparesis,Recruiting,No Results Available,Diabetic Gastroparesis|Idiopathic Gastroparesis|Gastroparesis Postoperative,Procedure: Gastric POEM,Johns Hopkins University,Both,Adult|Senior,Phase 2,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,IRB00066924,"March 30, 2016",May-15,May-17,"April 4, 2016",Apr-16,No Study Results Posted,null,Dec-16,Efficacy of the G-POEM|Patient symptom improvement|Delayed gastric emptying using a Gastric emptying study|Quality of life|Distensibility of pyloric sphincter using Endoluminal functional lumen imaging probe (EndoFLIP)|Postoperative hospitalizations.|Use of Prokinetic medication|Post-operative emergency visits,https://ClinicalTrials.gov/show/NCT02732821
546,NCT02732808,Dual Ovarian Stimulation in the Same IVF/ICSI Cycles for Treatment of Poor Ovarian Responders,Recruiting,No Results Available,Infertility,Drug: Ovulation stimulation,Royan Institute,Female,Adult,Phase 3,50,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,Royan-Emb-022,"July 7, 2015",Sep-14,Apr-16,"April 4, 2016",Feb-16,No Study Results Posted,null,Apr-16,Total number of retrieved oocytes|Quality of obtained embryos,https://ClinicalTrials.gov/show/NCT02732808
547,NCT02732795,Predicting Risk Factors in Children With Obstructive Sleep Apnea Undergoing Adenotonsillectomy Surgery,Recruiting,No Results Available,Pediatric Sleep Apnea|Obesity|Morphine Metabolism,Drug: Ideal versus Actual body weight dosing of morphine,Johns Hopkins University,Both,Child,,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)",IRB00034512,"February 4, 2016",Jul-15,null,"April 4, 2016",Mar-16,No Study Results Posted,null,Jan-17,Biomarker concentrations|Pain score in obese patients,https://ClinicalTrials.gov/show/NCT02732795
548,NCT02732782,Effectiveness of Isometric vs. Eccentric Exercise in Chronic Achilles Tendinopathy,Recruiting,No Results Available,Tendinopathy,Other: Isometric exercise|Other: Eccentric exercise,"Humboldt-UniversitÌ_t zu Berlin|Charite University, Berlin, Germany",Male,Adult,,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),PR020151100167|AZ: ZMV14-070102/16-17,"March 22, 2016",Jan-16,Mar-18,"April 4, 2016",Apr-16,No Study Results Posted,null,Dec-17,"Morphological tendon properties, Tendon cross sectional area (CSA)|Mechanical tendon properties, Tendon stiffness|Mechanical tendon properties, Modulus|Morphological tendon properties, Tendon length|Morphological tendon properties, Tendon vascularization level|Clinical functional score|Interleukin 6 level|Functional tendon properties, Ground contact time|Functional tendon properties, Maximum jump height|Pain level via Visual Analogue Scale (VAS)",https://ClinicalTrials.gov/show/NCT02732782
549,NCT02732769,Clinical Evaluation of the Treatment of Intellectual Metastases by Radiosurgery Gamma Knife by Means of a Support System by Mask.,Recruiting,No Results Available,Lung Cancer|Brain Metastases,Device: GammaKnifePerfexionå¨|Device: GammaKnifeIconå¨|Device: Efficastå¨|Device: MRI,Assistance Publique Hopitaux De Marseille,Both,Adult|Senior,,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,2015-40|2015-A01673-46,"March 30, 2016",Feb-16,Feb-17,"April 8, 2016",Apr-16,No Study Results Posted,Mask,Feb-17,Evaluation of digital scale of pain|Evaluation of tumor control|Occurrence of clinical side effects,https://ClinicalTrials.gov/show/NCT02732769
550,NCT02732756,Cognitive and Behavioral Effects of Sleep Restriction in Adolescents With ADHD,Recruiting,No Results Available,Attention Deficit Hyperactivity Disorder,Behavioral: Healthy Sleep Duration|Behavioral: Shortened Sleep Duration,"Children's Hospital Medical Center, Cincinnati|National Institute of Mental Health (NIMH)",Both,Child,,54,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label,CIN_ADHDsleep_001,"March 24, 2016",Apr-16,Aug-17,"April 19, 2016",Apr-16,No Study Results Posted,null,Aug-17,Change in sleep duration|Change in ADHD symptoms|Change in internalizing symptoms|Change in behavioral functioning|Change in cognitive functioning|Change in academic functioning|Change in emotion regulation|Change in daily life executive functioning,https://ClinicalTrials.gov/show/NCT02732756
551,NCT02732743,Food Supplement Physiomannaå¨ Baby in Pediatric Patients,Recruiting,No Results Available,Irritable Bowel Syndrome Characterized by Constipation,Dietary Supplement: Physiomannaå¨ Baby,Iuppa Industriale Srl|Opera Contract Research Organization SRL,Both,Child,,45,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Screening|Masking: Open Label,IU01/016,"March 31, 2016",Feb-16,Apr-16,"April 7, 2016",Feb-16,No Study Results Posted,null,Apr-16,Number of Spontaneous Bowel Movements (SBM) per week|Safety: Adverse Events (AE) check; Investigator and Patient Global Assessment,https://ClinicalTrials.gov/show/NCT02732743
552,NCT02732626,The Low Voltage Guided Ablation Trail of Persistent Atrial Fibrillation,Recruiting,No Results Available,Persistent Atrial Fibrillation,Procedure: radiofrequency ablation,MÌ¦dling Hospital,Both,Adult|Senior,,320,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,1,"March 23, 2016",Apr-16,Dec-19,"April 24, 2016",Apr-16,No Study Results Posted,ERASE-AF,Dec-18,recurrence of atrial fibrillation,https://ClinicalTrials.gov/show/NCT02732626
553,NCT02732561,The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults,Recruiting,No Results Available,Depression|Anxiety,Device: Alpha Stim device|Device: Sham device,Wake Forest School of Medicine,Both,Adult,,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),IRB00036461,"March 23, 2016",Mar-16,Mar-18,"April 4, 2016",Apr-16,No Study Results Posted,null,Mar-17,Depressive Symptoms|Anxiety,https://ClinicalTrials.gov/show/NCT02732561
554,NCT02732509,Chronic Inflammation and Exercise Responsiveness,Recruiting,No Results Available,Metabolic Syndrome,,Mayo Clinic,Both,Adult,,45,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,16-000437,"March 22, 2016",Mar-16,Dec-18,"April 4, 2016",Apr-16,No Study Results Posted,null,Apr-18,Maximal oxygen consumption rates in mitochondria isolated from skeletal muscles,https://ClinicalTrials.gov/show/NCT02732509
555,NCT02732457,Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients,Recruiting,No Results Available,HIV-1 Infection,,Kirby Institute,Both,Adult|Senior,,10,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IVPPHSCT01,"March 23, 2016",Sep-14,Sep-19,"April 7, 2016",Apr-16,No Study Results Posted,HSCT-HIV,Sep-18,Reduction in HIV-1 DNA levels in CD4+ T cells measured by real-time PCR|Reduction in HIV-1 Antigens and Antibodies measured by ELISA and Western Blot,https://ClinicalTrials.gov/show/NCT02732457
556,NCT02732431,Obstructive Sleep Apnea and Down Syndrome: Clinical Examination Issue,Recruiting,No Results Available,Obstructive Sleep Apnea,Other: Sleep Symptom,Fondation Lenval,Both,Child|Adult,,150,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,14-HPNCL-06,"March 22, 2016",Oct-13,Apr-16,"April 4, 2016",Apr-16,No Study Results Posted,null,Apr-16,determine the reliability of the Sensitivity of four questionnaires used in paediatric patients in screening of OSA in DS population|determine the reliability of the specificity of four questionnaires used in paediatric patients in screening of OSA in DS population|determine the reliability of positive predictive value of four questionnaires used in paediatric patients in screening of OSA in DS population|determine the reliability of negative predictive value of four questionnaires used in paediatric patients in screening of OSA in DS population|determine the reliability of positive likelihood ratio of four questionnaires used in paediatric patients in screening of OSA in DS population|determine the reliability of negative likelihood ratio of four questionnaires used in paediatric patients in screening of OSA in DS population|determine the reliability of area under a receiver operating characteristic (ROC) curve of four questionnaires used in paediatric patients in screening of OSA in DS population,https://ClinicalTrials.gov/show/NCT02732431
557,NCT02732392,Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer,Recruiting,No Results Available,Patient With Prostate Cancer,Procedure: standard lymphadenectomy|Procedure: lymphadenectomy radio-isotope method,Assistance Publique Hopitaux De Marseille,Male,Adult|Senior,,200,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,2012-07|2012-A-000287-36,"March 30, 2016",Nov-12,May-17,"April 7, 2016",Apr-16,No Study Results Posted,SENTINELLE,May-17,Number of sentinel nodes radiolabeled,https://ClinicalTrials.gov/show/NCT02732392
558,NCT02732379,"Effect of Aromatherapy on Postoperative Nausea, Vomiting and Quality of Recovery",Recruiting,No Results Available,Postoperative Nausea and Vomiting,Procedure: Lavender Aromatherapy|Procedure: Rose Aromatherapy|Procedure: Ginger Aromatherapy|Procedure: Placebo Aromatherapy,Tokat Gaziosmanpasa University,Both,Adult,Phase 4,152,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),PONV,"March 30, 2016",Apr-16,Oct-16,"April 12, 2016",Apr-16,No Study Results Posted,null,Oct-16,Quality of recovery|The change of the nausea scores|The change of the vomiting score|The consumption of the antiemetic drug,https://ClinicalTrials.gov/show/NCT02732379
559,NCT02732340,Triple-branch Stent Graft Placement and Hemi-arch Replacement for the Treatment of Acute DeBakey I Aortic Dissection,Recruiting,No Results Available,Acute Aortic Dissection,Procedure: triple-branched stent graft|Procedure: hemi-arch replace,"Liang-Wan Chen MD|Xinqiao Hospital of Chongqing|RenJi Hospital|First Affiliated Hospital of Chongqing Medical University|The First City Hospital, LongYan|The First City Hospital, ZhangZhou|Fujian Medical University",Both,Adult,Phase 0,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),CLW2015AD,"November 15, 2015",Oct-15,Feb-18,"April 4, 2016",Apr-16,No Study Results Posted,TBSGPT,Dec-17,the occluded rate of false lumen by CTA|the survive rate by the questionaire|complication by the case report|reoperation rate by the case report|the growth rate of thoracic descending aorta by CTA|life quality by the questionaire,https://ClinicalTrials.gov/show/NCT02732340
560,NCT02732301,Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers,Recruiting,No Results Available,Thoracic Surgical Procedures|Gastrointestinal Tract|Cardiopulmonary Bypass|Biomarkers,Procedure: Cardiopulmonary bypass|Procedure: Thoracic cardiovascular surgical procedures,Region ÌÐrebro County,Both,Adult|Senior,,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,188051,"April 4, 2016",Nov-15,null,"April 4, 2016",Apr-16,No Study Results Posted,GAINDYSFUNCS,Dec-17,Acute gastrointestinal injury score|Plasma protein expression|Gastrointestinal complications|All cause mortality,https://ClinicalTrials.gov/show/NCT02732301
561,NCT02732275,A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas,Recruiting,No Results Available,"Lymphoma|Lymphoma, B-cell|Lymphoma, Follicular|Adult T-Cell Leukemia Lymphoma (ATLL)",Drug: DS-3201b,"Daiichi Sankyo Co., Ltd.|Daiichi Sankyo Inc.",Both,Adult|Senior,Phase 1,36,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,DS3201-A-J101,"April 4, 2016",Mar-16,Apr-18,"April 4, 2016",Apr-16,No Study Results Posted,null,Mar-18,number of dose limiting toxicities|maximum concentration Cmax|time of maximum concentration Tmax|area under the plasma concentration time curve up to the last quantifiable time AUClast|area under the plasma concentration time curve during dosing interval AUCtau|response rate based on international consensus criteria|disease control rate based on international consensus criteria|the change of tri-methylated histone H3 lysine 27 (H3K27Me3) status by Immunohistochemistry,https://ClinicalTrials.gov/show/NCT02732275
562,NCT02732249,Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment,Recruiting,No Results Available,Helicobacter Pylori Infection,Drug: Esomeprazole|Drug: Bismuth Potassium Citrate|Drug: Clarithromycin|Drug: Amoxicillin|Drug: Metronidazole,Shanghai Jiao Tong University School of Medicine,Both,Adult|Senior,Phase 4,393,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,rjkls2016068,"April 4, 2016",Apr-16,Oct-16,"April 9, 2016",Apr-16,No Study Results Posted,null,Oct-16,Helicobacter pylori eradication rate|Rate of adverse effects|Compliance rate,https://ClinicalTrials.gov/show/NCT02732249
563,NCT02732236,Marginal Zone Lymphoma Cohort in Korea,Recruiting,No Results Available,"Lymphoma, B-Cell, Marginal Zone",Other: Rituximab,Dong-A University Hospital,Both,Adult|Senior,,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CISL-12-07,"April 4, 2016",Mar-13,Feb-18,"April 4, 2016",Apr-16,No Study Results Posted,null,Feb-18,Hepatitis B virus reactivation in patients with marginal zone B-cell lymphoma after rituximab containing treatment,https://ClinicalTrials.gov/show/NCT02732236
564,NCT02732171,PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer,Recruiting,No Results Available,Breast Cancer,Other: Plasma/Buffy Coat|Other: Serum|Other: Bone Marrow Aspirate,Abramson Cancer Center of the University of Pennsylvania,Both,Adult|Senior,Phase 0,600,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Screening,UPCC 28115,"April 4, 2016",Apr-16,null,"April 4, 2016",Apr-16,No Study Results Posted,null,Apr-19,Number of disseminated tumor cells,https://ClinicalTrials.gov/show/NCT02732171
565,NCT02732145,"The Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis",Recruiting,No Results Available,Lichen Sclerosus|Lichen Planus|Lichen Simplex Chronicus|Vulvodynia,Other: ISSVD Questionnaire|Procedure: Three Rings Vulvoscopy|Procedure: Histopathology,GinekoloÁka Poliklinika Dr. Vesna Harni|Klini€ki Bolni€ki Centar Zagreb,Female,Child|Adult|Senior,,200,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,PH20111201001,"March 15, 2016",Dec-11,Dec-16,"April 3, 2016",Apr-16,No Study Results Posted,DATRIV,Dec-16,"The Diagnostic Accuracy of ""Three Rings Vulvoscopy"" for Detection of Vulvar Dermatosis.|Epidemiological characteristics of the patients with and without vulvar discomfort.|Distribution of colposcopy lesions of the vulva in patients with and without vulvar discomfort according to the three vulvar rings and their specificity.|Aceto-whitening pattern in patients with vulvodynia and vulvar dermatosis according to the three vulvar rings.",https://ClinicalTrials.gov/show/NCT02732145
566,NCT02732067,"Death Rate in Anesthesia, a Study in a Tertiary Hospital",Recruiting,No Results Available,Sudden Death,Other: anesthesia related deaths,University of Jordan,Both,Child|Adult|Senior,,30,Other,Observational,Time Perspective: Prospective,270/14a/tk,"April 4, 2016",Jan-16,Jun-18,"April 10, 2016",Apr-16,No Study Results Posted,null,Dec-17,number of anesthetized patients who died in the perioperative period inside the hospital,https://ClinicalTrials.gov/show/NCT02732067
567,NCT02732054,Hepatitis B Vaccination in HIV-infected Adults With Low CD4 Cell Counts,Recruiting,No Results Available,Hepatitis B,"Biological: Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]",Chiang Mai University,Both,Adult,Phase 4,16,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,Research ID: 02891,"March 31, 2016",May-15,Mar-17,"April 7, 2016",Mar-16,No Study Results Posted,null,Mar-17,Proportion of participants with protective immunity against HBV|The geometric means of anti-HBs titers|Proportion of participants with high level of immune response against HBV,https://ClinicalTrials.gov/show/NCT02732054
568,NCT02731950,Presternal Bupivacaine Plus Magnesium Sulfate Infusion After Cardiac Surgery,Recruiting,No Results Available,Pain|Postoperative Pain,Drug: Magnesium Sulfate|Other: B opioid and non steroidal antinflammatory,Assiut University,Both,Adult,,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,IRB00009904,"March 26, 2016",Apr-15,May-17,"April 7, 2016",Apr-16,No Study Results Posted,null,Apr-17,Pain assessment using a VAS,https://ClinicalTrials.gov/show/NCT02731950
569,NCT02731924,Point of Care Ultrasound for Evaluation of Suspected Appendicitis in the Emergency Department,Recruiting,No Results Available,Acute Appendicitis,Procedure: Ultrasound for Appendicitis,WellSpan Health,Both,Child|Adult|Senior,,261,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,549570-8,"April 1, 2016",May-14,Mar-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Jan-17,Diagnostic Accuracy of Point-of-care Ultrasound for Suspected Appendicitis|Intraabdominal Free Fluid|Dilated Loops of Bowel in RLQ|Appendicolith|Appendiceal Dilation|Appendiceal Wall Thickening|Appendiceal Hyperemia|Inter-rater Agreement|Patient Length of Stay/Time to Disposition|Comparison to Alvarado Score|Body Mass Index,https://ClinicalTrials.gov/show/NCT02731924
570,NCT02731872,The Effect of Oxygen Therapy With Airvo High-flow Heated Humidification,Recruiting,No Results Available,COPD,Device: Airvo humidifier,Aalborg Universitetshospital|Fisher and Paykel Healthcare|AGA The Linde Group,Both,Adult|Senior,,200,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,N-20110057,"March 14, 2016",Jan-12,Oct-16,"April 15, 2016",Apr-16,No Study Results Posted,HHCOPD,Sep-16,"Reduction in the number of exacerbations and thus hospital admissions, based on data on hospital admissions.|increase in quality of life, measured by St George's Respiratory Questionnaire (SGRQ),|improved lung function, using Spida 5 equipment.|Improved physical ability, based on six-minute walk test.",https://ClinicalTrials.gov/show/NCT02731872
571,NCT02731859,EndoBarrier Register Deutschland-Safety and Efficacy of the Endoscopic Duodenal-Jejunal Bypass Sleeve,Recruiting,No Results Available,Obesity|Diabetes Mellitus,Device: Insertion of EndoBarrier for approximately one year,UniversitÌ_tsklinikum Hamburg-Eppendorf|GI Dynamics,Both,Adult|Senior,,1000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,EBRD 001,"January 27, 2016",Jan-14,Jan-19,"April 2, 2016",Apr-16,No Study Results Posted,EBRD,Jan-19,Reduction of HbA1C|Reduction of Antidiabetic Medication|Excess weight loss|Reduction of BMI|Weight reduction|Number of participants with treatment-related adverse events|Improvement of subjective Arhtropathia|Smoking Status|Time of implantation and explantation|Reduction of fasting glucose|Reduction of fasting insulin|Recution of fasting C-Peptide|Reduction of systolic blood pressure|Reduction of diastolic blood pressure|Reduction of antihypertensive medication|Reduction of total cholesterol|Reduction of LDL-cholesterol|Increase of HDL-cholesterol|Reduction of fasting triglycerides|Reduction of antihyperlipidemic medication|Reduction of 25OHD3|Reduction of Calcium|Reduction of Ferritin|Reduction of Hemoglobin|Reduction of Vitamin B12|Reduction of Albumin|Reduction of Folic acid|Reduction of Vitamin B1|Reduction of Vitamin B6|Reduction of CK|Reduction of AST|Reduction of ALT|Reduction of hsCRP|Duration of implantation process of the EndoBarrier in minutes|Duration of ithe explantation process of the EndoBarrier in minutes|Reduction of waist circumference|Reduction of daily caloric intake,https://ClinicalTrials.gov/show/NCT02731859
572,NCT02731833,Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity,Recruiting,No Results Available,Dentin Sensitivity,Drug: stannous fluoride|Drug: sodium monofluorophosphate,GlaxoSmithKline,Both,Adult,Phase 4,214,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),205710,"April 4, 2016",Apr-16,Jun-16,"April 21, 2016",Apr-16,No Study Results Posted,null,Jun-16,Change from baseline in Schiff sensitivity score at Day 3|Change from baseline in tactile threshold at Day 3|Change from baseline in Schiff sensitivity score after a single use|Change from baseline in tactile threshold after a single use,https://ClinicalTrials.gov/show/NCT02731833
573,NCT02731820,Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia,Recruiting,No Results Available,"Osteopenia|Bone Disease, Metabolic",Dietary Supplement: Potassium citrate|Dietary Supplement: Placebo|Dietary Supplement: Vitamin D3|Dietary Supplement: Calcium carbonate,Istituto Ortopedico Rizzoli,Female,Child|Adult|Senior,,40,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",6013_IOR|1676,"March 31, 2016",May-15,Jun-17,"April 7, 2016",Apr-16,No Study Results Posted,ACAROS,Jan-17,"Changes in serum level of Carboxyterminal cross-linked telopeptide of type I collagen (CTX); over time, i.e. baseline, 3 months, 6 months.|Changes in serum levels of ""Tartrate-resistant acid phosphatase 5b isoenzyme"" (TRAcP5b) over time, i.e. baseline, 3 months, 6 months.|Changes in serum levels of ""N-terminal propeptide of type I procollagen"" (P1NP) over time, i.e. baseline, 3 months, 6 months.|Changes in serum levels of ""Bone-specific alkaline phosphatase"" (BAP) over time, i.e. baseline, 3 months, 6 months.",https://ClinicalTrials.gov/show/NCT02731820
574,NCT02731768,"Nutrition, Exercise, and Technology for Weight Loss",Recruiting,No Results Available,Overweight|Obesity,Behavioral: Standard|Behavioral: Social support-enhanced|Device: Fitbit Zip|Device: Digital body weight scale,University of South Carolina,Both,Adult|Senior,,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,1205,"February 23, 2016",Jan-16,Feb-17,"April 11, 2016",Mar-16,No Study Results Posted,null,Feb-17,Change from Baseline Body Weight at 4 and 12 months|Change from Baseline in Social Support for Exercise (Social Support for Exercise Scale) at 4 and 12 months|Change from 2-month Autonomy Support (Important Other Climate Questionnaire) at 4 and 12 months|Change from Baseline Motivation for Weight Control (Treatment Self-regulation Questionnaire) at 4 months|Change from Baseline Appropriate and Inappropriate Weight Control Practices (Weight Control Practices Checklist) at 4 and 12 months|Change from Baseline Social Support Through Technology (2-item questionnaire - level of support and type of support through technology) at 4 and 12 months|Change from Baseline Average Daily Step Counts measured via BodyMedia SenseWear armband (one-week time period) at 4 and 12 months|Change from Baseline in Social Support for Eating Habits (Social Support for Eating Habits Scale) at 4 and 12 months|Change from Baseline in Social Support for Weight Loss (Social Support for Weight Loss Scale) at 4 and 12 months,https://ClinicalTrials.gov/show/NCT02731768
575,NCT02731755,Phenolic-rich Oats for Gut-bacteria Relief and Artery Improvement,Recruiting,No Results Available,Healthy,Other: Oat|Other: Control,University of Reading|Biotechnology and Biological Sciences Research Council|Rothamsted Research|PepsiCo Global R&D|University of Roehampton,Male,Adult,,15,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",PROGRAIN2,"February 9, 2016",Jan-16,May-16,"April 7, 2016",Apr-16,No Study Results Posted,PROGRAIN2,May-16,Flow mediated dilatation|Laser Doppler Iontophoresis|Phenolic acids metabolites|Plasma nitric oxide analysis|NADPH oxidase activity in neutrophil blood cells|Plasma glucose|Plasma insulin|Renin activity,https://ClinicalTrials.gov/show/NCT02731755
576,NCT02731729,Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,Recruiting,No Results Available,Melanoma,Drug: ipilimumab|Drug: nivolumab,Memorial Sloan Kettering Cancer Center,Both,Adult|Senior,Phase 2,70,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,16-043,"April 4, 2016",Apr-16,null,"April 6, 2016",Apr-16,No Study Results Posted,null,Apr-18,objective response as defined by RECIST v1.1 criteria,https://ClinicalTrials.gov/show/NCT02731729
577,NCT02731703,"Conventional, Overdenture and Palateless Overdenture Oral Health Impact Comparison Study",Recruiting,No Results Available,"Jaw, Edentulous",Device: Overdenture treatment,"University of North Carolina, Chapel Hill|Dentsply Implants",Both,Adult|Senior,,20,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,16-0521,"March 22, 2016",Apr-16,Apr-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Apr-17,Overall Patient satisfaction OHIP 49 score|Change in OHIP 49 score of initial edentulous condition to new interim denture|Change in OHIP 49 score of new interim denture to implant retained interim denture|Change in OHIP 49 score of implant retained interim denture to final palateless implant retained overdenture.,https://ClinicalTrials.gov/show/NCT02731703
578,NCT02731664,GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans,Recruiting,No Results Available,Functional Gastrointestinal Disorders,Biological: GLP-1|Biological: Intravenous saline,Uppsala University|Karolinska Institutet,Both,Adult,Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Single Blind (Subject),PRANDMOTGLP,"March 6, 2016",Sep-12,Dec-16,"April 6, 2016",Apr-16,No Study Results Posted,GLPMOT,May-16,Motility index (measure of contraction amplitude x duration; area for mmHg x sec)|Smooth muscle relaxation induced by GLP-1|Presence of GLP-1 and GLP-2 receptors in gastric and small bowel tissue,https://ClinicalTrials.gov/show/NCT02731664
579,NCT02731521,Clinical Development of MR Spectroscopy and Imaging in Brain Cancers,Recruiting,No Results Available,Malignant Gliomas|Astrocytomas|Oligodendrogliomas,Device: 3 Tesla Scanning|Device: 7 Tesla Scanning,University of Texas Southwestern Medical Center|Cancer Prevention Research Institute of Texas,Both,Adult|Senior,,175,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,STU 122013-077,"March 2, 2016",Jan-14,Dec-17,"April 1, 2016",Apr-16,No Study Results Posted,null,Dec-17,"Amount of 2-hydroxyglutarate (2HG) bio-marker in 170 patients with clinically‰Ûproven brain metastasis, multiple sclerosis, epilepsy, stroke, or encephalitis using magnetic resonance spectroscopy (MRS).",https://ClinicalTrials.gov/show/NCT02731521
580,NCT02731508,Repetitive Bihemispheric Transcranial Direct Current Stimulation After Stroke,Recruiting,No Results Available,Stroke,Device: Bihemispheric transcranial direct current stimulation,"Taipei Veterans General Hospital, Taiwan",Both,Adult|Senior,Phase 1|Phase 2,32,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",2015-03-003C,"February 15, 2016",Oct-15,Oct-17,"April 1, 2016",Oct-15,No Study Results Posted,null,Oct-17,Fugl-Meyer test|Action Research Arm test|Motor evoked potential|Active motor threshold|Ipsilateral silent period|Short interval intracortical inhibition|Motor task ERD peak amplitude|Motor task ERS peak amplitude|Resting state functional connectivity,https://ClinicalTrials.gov/show/NCT02731508
581,NCT02731482,Short-and Long-term Effects of a Home-based Rehabilitation Program in Patients With Bronchiectasis,Recruiting,No Results Available,Bronchiectasis,Other: Training Group|Other: Control Group,University of Nove de Julho|University of Sao Paulo,Both,Adult|Senior,,48,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),Bronchiectasis Rehabilitation,"March 30, 2016",Jan-16,Dec-19,"April 6, 2016",Apr-16,No Study Results Posted,null,Dec-16,"Distance, in meters, performed in the Incremental Shuttle Walk Test|Time, in seconds, performed in the Endurance Shuttle Walk Test|Number of steps performed in the Incremental Step Test|Physical functioning domain scale in the Quality of Life Questionnaire-Bronchiectasis (QoL-B)|Kilogram-force (kgf) of quadriceps femoris|Number of steps per day, measured by a pedometer",https://ClinicalTrials.gov/show/NCT02731482
582,NCT02731456,"Effect of High Altitude Exposure, Acclimatization and Re-exposure on Psychomotor Performance in Lowlanders",Recruiting,No Results Available,Effect of High Altitude,Other: altitude exposure,Marc Poulin|University of Zurich|University of Calgary,Both,Adult,,18,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,REB15 - 2709_MOD1,"April 3, 2016",Mar-16,Dec-17,"April 6, 2016",Apr-16,No Study Results Posted,null,Dec-16,"Sustained attention measured by a visual pychomotor vigilance test (PVT)|Indices of sleep quality measured by actigraphy (total sleep time, sleep efficiency, sleep latency",https://ClinicalTrials.gov/show/NCT02731456
583,NCT02731443,The Impact of Epilepsy Surgery on Dream Content,Recruiting,No Results Available,Dream Content,Procedure: Epilepsy surgery|Procedure: Depth electrodes insertion,London Health Sciences Centre,Both,Child|Adult|Senior,,60,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,107654,"April 2, 2016",Mar-16,Jun-18,"April 6, 2016",Apr-16,No Study Results Posted,null,Jun-17,Dream Content (MOST RECENT DREAM questionnaire) - ESx group|Dream Content (MOST RECENT DREAM questionnaire) - DE group,https://ClinicalTrials.gov/show/NCT02731443
584,NCT02731391,Clinical Research on Bowel Symptoms of Patient With Pelvic Organ Prolapse,Recruiting,No Results Available,Bowel Symptoms,Procedure: Pelvic floor reconstruction•_öwith or without mesh•_ä,Peking University People's Hospital,Female,Adult|Senior,,200,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,pkuph-0103969,"January 28, 2016",Apr-16,null,"April 1, 2016",Apr-16,No Study Results Posted,null,Apr-19,change in the prevalence of bowel symptoms|change in the severity of intestinal symptoms|change in the quality of life|resting pressure recorded by anorectal manometry|squeeze pressure recorded by anorectal manometry|length of the high-pressure zone recorded by anorectal manometry|compliance of the rectum recorded by anorectal manometry|rectoanal inhibitory reflex recorded by anorectal manometry,https://ClinicalTrials.gov/show/NCT02731391
585,NCT02731365,Concurrent DBS Local Field Potential Analysis and Stimulation in a Closed-Loop Neuromodulation Device,Recruiting,No Results Available,Parkinson's Disease,Device: Activa PC+S,Ohio State University,Both,Adult|Senior,,10,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,2014H0423,"October 13, 2015",Feb-15,Feb-20,"April 2, 2016",Apr-16,No Study Results Posted,null,Feb-19,Identify and record LFP,https://ClinicalTrials.gov/show/NCT02731365
586,NCT02731352,Study of Apatinib in Patients With Differentiated Thyroid Cancer,Recruiting,No Results Available,Thyroid Cancer,Drug: Apatinib,Peking Union Medical College Hospital,Both,Adult|Senior,Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,Ahead-T301,"March 7, 2016",Feb-16,null,"April 6, 2016",Mar-16,No Study Results Posted,null,Dec-16,Disease control rate|Overall response rate,https://ClinicalTrials.gov/show/NCT02731352
587,NCT02731326,iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology,Recruiting,No Results Available,Atrial Fibrillation|Atrial Flutter,Device: AliveCor|Behavioral: Behavioral Altering Messaging,Columbia University,Both,Adult|Senior,,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Investigator),AAAO2555,"March 24, 2016",Mar-15,Aug-18,"April 6, 2016",Apr-16,No Study Results Posted,iHEART,Aug-18,Rate of recurrence of atrial arrhythmias|Difference in treatment outcomes initiated by recurrence|Difference in Mean Quality-Adjusted Life-Years between Groups|Change in Atrial Fibrillation Knowledge Scale (AFKS) Scores between Baseline and Six Months Chronic Cardiovascular Conditions,https://ClinicalTrials.gov/show/NCT02731326
588,NCT02731287,Topical Timolol for Infantile Hemangioma in Early Proliferative Phase,Recruiting,No Results Available,Hemangioma,Drug: Timolol|Drug: Placebo,FundaciÌ_ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Both,Child,Phase 2,70,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)",IIBSP-TIM-2013-156,"November 17, 2015",Mar-14,Dec-16,"April 6, 2016",Apr-16,No Study Results Posted,null,Dec-16,Complete or almost complete resolution of the lesions|Adverse reactions,https://ClinicalTrials.gov/show/NCT02731287
589,NCT02731248,Pulse Oximeter Screening in Congenital Heart Disease,Recruiting,No Results Available,Congenital Heart Disease,Other: Prospective screening study,Dr. Sami Ulus Children's Hospital,Both,Child,,50000,Other,Observational,Time Perspective: Prospective,SamiUlusCH-CHD,"April 2, 2016",Apr-16,May-17,"April 2, 2016",Apr-16,No Study Results Posted,POX,Apr-17,pulse oximeter positivity|echocardiographic confirmation,https://ClinicalTrials.gov/show/NCT02731248
590,NCT02731235,The Effect of Aerobic Exercise in Patients With Minor Stroke,Recruiting,No Results Available,"Stroke, Lacunar",Other: High-intensity training|Drug: prophylactic stroke medication|Behavioral: Recommendations for lifestyle changes,Herlev Hospital|University of Copenhagen|Association of Danish Physiotherapists,Both,Adult|Senior,,84,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor),H-15012371,"January 22, 2016",Jan-16,Mar-22,"April 6, 2016",Apr-16,No Study Results Posted,HITPALS,Mar-17,Difference in the 'Graded Cycling Test with Talk Test'|Endothelial response|Physical Activity Scale (PAS)|Short time activity measurements|The WHO-five Well-being Index (WHO-5)|Montreal Cognitive Assessment (MOCA)|Major Depression Inventory (MDI)|Multidimensional Fatigue Inventory (MFI-20)|Ull-Meter|Blood samples|Magnetic resonance Imaging (MRI),https://ClinicalTrials.gov/show/NCT02731235
591,NCT02731222,Prevalence of Onychodystrophy in Patients With Chronic Venous Disease of Lower Limbs,Recruiting,No Results Available,Lower Extremity Chronic Venous Insufficiency|Onychodystrophy,Other: observational - statistical / one single group,FundaciÌ_ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Both,Adult|Senior,,40,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Cross-Sectional,IIBSP-ONI-2015-67,"February 24, 2016",Nov-15,Mar-17,"April 1, 2016",Apr-16,No Study Results Posted,null,May-16,Prevalence of onycodystrophy,https://ClinicalTrials.gov/show/NCT02731222
592,NCT02731209,Functional Urodynamic Changes in Chronic Kidney Disease Patients and Does Insertion of Urinary Catheter Delay the Need for Kidney Dialysis,Recruiting,No Results Available,"Renal Insufficiency, Chronic",Device: urinary catheter,Assaf Harofeh MC|Assaf-Harofeh Medical Center,Both,Adult|Senior,,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,0308-15-ASF,"February 22, 2016",Feb-16,null,"April 2, 2016",Apr-16,No Study Results Posted,null,Feb-17,kidney function change|time to dialysis,https://ClinicalTrials.gov/show/NCT02731209
593,NCT02731196,Comparison of Exercise Intervention Effects Following Lumbar Microdiscectomy,Recruiting,No Results Available,Injury of Nerve Root of Lumbar and Sacral Spine,Behavioral: Exercise Intervention,Ottawa Hospital Research Institute|University of Ottawa,Both,Adult,,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,20150717-01H,"April 1, 2016",Apr-16,Jan-17,"April 6, 2016",Apr-16,No Study Results Posted,null,Dec-16,Oswestry Low Back Disability Questionnaire|Numeric Pain Rating Scale|Fear Avoidance Beliefs Questionnaire|Patient Specific Functional Scale|Lumbar mobility of flexion and extension|Slump test mobility|Straight leg raise|50 ft Walk test|Step count per day|Return to work,https://ClinicalTrials.gov/show/NCT02731196
594,NCT02731183,Efficacy and Safety of Fecal Microbiota Transplantation for Chronic Intestinal Pseudo-obstruction,Recruiting,No Results Available,Chronic Intestinal Pseudo Obstruction,Procedure: fecal microbiota transplantation,"Jinling Hospital, China",Both,Adult|Senior,Phase 1,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,FMT-CIPO,"April 2, 2016",Sep-15,Sep-16,"April 6, 2016",Apr-16,No Study Results Posted,null,Jun-16,the tolerance of enteral nutrition (EN) through nasojejunal tube|the time oral intake started|symptomatic relief|scoring evaluation of abdominal CT,https://ClinicalTrials.gov/show/NCT02731183
595,NCT02731092,Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants,Recruiting,No Results Available,Very Low Birth Weight Infants,Dietary Supplement: Lactoferrin,University of Virginia|The Gerber Foundation,Both,Child,Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IRB-HSR 18130,"March 18, 2016",Apr-16,Mar-17,"April 18, 2016",Apr-16,No Study Results Posted,null,Dec-16,Definitely related study solution serious adverse event|Number of infants reaching 120 ml/kg of enteral feeds|Number of days not receiving any feedings after lactoferrin administration,https://ClinicalTrials.gov/show/NCT02731092
596,NCT02731053,Effectiveness Trial of the French Blues Indicated Depression Prevention Program,Recruiting,No Results Available,Depression,Behavioral: Blues program,UniversitÌ© de MontrÌ©al,Both,Child|Adult,Phase 4,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Outcomes Assessor)",FRQSC2016-NP-191870,"March 15, 2016",Mar-16,Nov-16,"April 6, 2016",Apr-16,No Study Results Posted,French Blues,Nov-16,"Number of participants who develop a major depressive episode as measured using the SCID diagnostic interview|Change in depressive symptoms as measured using continuous SCID scores|Change in depressive symptoms as measured using the CES-D questionnaire|Change in depressive symptoms as measured using the PHQ-9 questionnaire|Change in social adjustment as measured using ""Ìävaluation sociale de Soi chez les jeunes adultes"" questionnaire (Michaud et al., 2006)|Change in anxiety symptoms as measured using the SCAS questionnaire|Change in parent-child relationship as measured using a scale from the MASPAQ questionnaire (Leblanc, 1996)|Change in affective school engagement as measured using a subscale of the school engagement questionnaire (Archambault et al., 2009)|Change in substance use as measured using a scale from the MASPAQ questionnaire (Leblanc, 1996)|Change in delinquent behaviors as measured using a scale from the MASPAQ questionnaire (Leblanc, 1996)",https://ClinicalTrials.gov/show/NCT02731053
597,NCT02731027,Biomarkers of Spontaneous Recovery From Traumatic Spinal Cord Injury,Recruiting,No Results Available,Spinal Cord Injury,,Northwell Health|United States Department of Defense|New York State Department of Health|University of Louisville|Kessler Foundation,Both,Adult|Senior,,100,Other|U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Prospective,14612,"March 17, 2016",Oct-15,Oct-18,"April 1, 2016",Apr-16,No Study Results Posted,null,Oct-18,Circulating inflammatory response from the peripheral blood for each SCI participant|ASIA Impairment Scale (AIS) Grade for each SCI participant|Spinal Cord Independence Measure (SCIM) for each SCI participant|Neuromuscular Recovery Scale (NRS) for each SCI participant,https://ClinicalTrials.gov/show/NCT02731027
598,NCT02730988,Effect of High Protein Weight Loss for Seniors,Recruiting,No Results Available,Obesity|Weight Loss,Behavioral: Weight Stable Group,Wake Forest University|Wake Forest School of Medicine,Both,Adult|Senior,,124,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor),33428,"February 21, 2016",Jul-15,Jul-17,"April 1, 2016",Apr-16,No Study Results Posted,null,Jul-17,"400 Meter Gait Walk Speed|24-week body composition change at baseline, 12-weeks and 24-weeks",https://ClinicalTrials.gov/show/NCT02730988
599,NCT02730975,Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Drug: AA Reduced dose-normal diet (A)|Drug: AA reduced dose-fat diet (B)|Drug: AA normal dose-fasting conditions (C),FundaciÌ_n PÌ¼blica Andaluza para la gestiÌ_n de la InvestigaciÌ_n en Sevilla,Male,Adult|Senior,Phase 1,42,Other,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,ABIFOOD01|2012-003226-25,"September 15, 2015",Jun-14,Sep-17,"April 1, 2016",Apr-16,No Study Results Posted,ABIFOOD01,Sep-16,Area under curve (AUC)|Peak Plasma Concentration (Cmax)|Time to reach peak plasma concentration (Tmax)|PSA (Prostate Specific Antigen) levels|Response rate|Pain intensity|Use of analgesics|Total daily dose of analgesics,https://ClinicalTrials.gov/show/NCT02730975
600,NCT02730910,Anthocyanin & Phenolic Acids Bioavailability & Antioxidant Capacity After Consumption of Purple Wheat Products in Adults,Recruiting,No Results Available,Healthy,Other: Purple Wheat Crackers|Other: Purple Wheat Granola Bars,University of Guelph,Both,Adult,,16,Other,Interventional,Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Single Blind (Outcomes Assessor),UGuelph,"January 21, 2016",Oct-15,Dec-16,"April 1, 2016",Apr-16,No Study Results Posted,null,Apr-16,Plasma concentrations of anthocyanin metabolites|Plasma concentrations of phenolic acids|Plasma antioxidant capacity|Urinary concentrations of phenolic acids|Urinary concentrations of anthocyanin metabolites,https://ClinicalTrials.gov/show/NCT02730910
601,NCT02730845,Intra-articular Versus Intravenous Dexmedetomidine in Arthroscopic Knee Surgeries Under Local Anesthesia,Recruiting,No Results Available,Knee Arthroscopy,Drug: Intra-articular dexmedetomidine|Drug: Intravenous dexmedetomidine,Mansoura University,Both,Adult,,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Investigator)",R‰ö¥ 15.10.40,"February 11, 2016",Dec-15,May-16,"April 6, 2016",Apr-16,No Study Results Posted,null,Apr-16,Pain scores|Heart rate|Blood pressure|Oxygen saturation|Respiratory rate|Level of sedation|Patient Satisfaction Score|Time to first postoperative analgesic requirement|Intraoperative and postoperative side effects|Time to mobilization out of bed|Post-anesthesia care unit (PACU) length of stay,https://ClinicalTrials.gov/show/NCT02730845
602,NCT02730819,Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma,Recruiting,No Results Available,Melasma,Drug: Illuminate Cream,Mayo Clinic,Both,Adult,Phase 3,20,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,15-005615,"March 29, 2016",Mar-16,Dec-16,"April 1, 2016",Apr-16,No Study Results Posted,null,Oct-16,Change in Melasma Area and Severity Index (MASI) score,https://ClinicalTrials.gov/show/NCT02730819
603,NCT02730728,Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block After TKA,Recruiting,No Results Available,Total Knee Athroplasty|Osteoarthritis|Post Operative Pain Control,Drug: 20ml bolus of 0.5% ropivicane|Drug: 0.2% Ropivicane at 8 milliliter/hour|Drug: 5ml bolus of 0.5% ropivicane,University of Pennsylvania,Both,Adult|Senior,,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,823219,"March 23, 2016",Nov-15,Jun-16,"April 15, 2016",Apr-16,No Study Results Posted,null,May-16,Pain Scores as measured by the Visual Analog Scale|Participants need for pain relief as measured by opiate consumption|Recovery after surgery as measured by manuel muscle strength testing|Risk of falling score,https://ClinicalTrials.gov/show/NCT02730728
604,NCT02730663,A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent',Recruiting,No Results Available,Pancreatic Pseudocyst,Device: Niti-S SPAXUS Stent,"Taewoong Medical Co., Ltd.",Both,Adult|Senior,Phase 3,35,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,SPAXUS-001,"March 28, 2016",Mar-16,Aug-17,"April 6, 2016",Mar-16,No Study Results Posted,null,Aug-17,Clinical success|Technical success|Stent lumen patency|Stent removal success|Procedure time|Procedural / Device related serious adverse events|Other adverse events,https://ClinicalTrials.gov/show/NCT02730663
605,NCT02730637,Prevention of Acute Kidney Injury Through Biomarker-guided Nephrological Intervention,Recruiting,No Results Available,Acute Kidney Injury,Other: Early nephrologist consultation,Robert Bosch Medical Center,Both,Adult|Senior,,250,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,RBK-348,"March 18, 2016",Mar-16,Mar-17,"April 6, 2016",Apr-16,No Study Results Posted,null,Feb-17,Incidence of AKI in both groups according to AKI KDIGO definition|Need for renal replacement therapy|Length of hospital stay|Death|Severety of AKI in both groups according to AKI KDIGO definition|Severity of AKI in both groups according to AKI KDIGO definition,https://ClinicalTrials.gov/show/NCT02730637
606,NCT02730611,"Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma",Recruiting,No Results Available,Morbid Obesity|Vertical Sleeve Gastrectomy|Metabolic Syndrome|Hepatocellular Carcinoma|Cholangiocarcinoma|Disorder of Bile Acid and Cholesterol Metabolism,,"Assistance Publique - HÌ«pitaux de Paris|National Cancer Institute, France|Centre International de la Recherche sur le Cancer|Institut National de la SantÌ© Et de la Recherche MÌ©dicale, France",Both,Adult|Senior,,120,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PRT-K14-038,"April 1, 2016",Apr-16,Apr-19,"April 8, 2016",Apr-16,No Study Results Posted,METSLIVER,Apr-19,Blood bile acids (micromols per liter)|Hepatic FXR expression,https://ClinicalTrials.gov/show/NCT02730611
607,NCT02730598,Combined Application of Electrical Stimulated Antagonist Contraction During Walking (Walking Study),Recruiting,No Results Available,Knee Osteoarthritis,Device: Hybrid Training System (HTS)|Device: Sensory TENS,University of Kansas Medical Center|Kurume University,Female,Adult|Senior,,28,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),STUDY00003435,"April 1, 2016",Feb-16,Sep-16,"April 1, 2016",Apr-16,No Study Results Posted,null,Sep-16,Change in Knee Extensor Strength|Change in Knee Pain,https://ClinicalTrials.gov/show/NCT02730598
608,NCT02730533,The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESD,Recruiting,No Results Available,Stomach Neoplasms,Drug: Esomeprazole|Drug: No PPI treatment,Xijing Hospital of Digestive Diseases,Both,Adult|Senior,,74,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor),KY20162024-1,"March 28, 2016",Mar-16,Dec-17,"April 5, 2016",Mar-16,No Study Results Posted,null,Sep-17,The total bleeding rate according to grading of intraoperative bleeding during ESD procedure|The frequency of coagrasper usage which reflects grade of major bleeding|Post-ESD ulcer quality as indicated in description|Intra-procedure injury to muscularis propria including perforation.|Mean haemoglobin reduction between intervention and control group.|Delayed bleeding rate as indicated by haematemesis and melaena|The mean percentage of mucosal defect reduction at follow-up endoscopy on 28 days after ESD procedure.,https://ClinicalTrials.gov/show/NCT02730533
609,NCT02730377,Efficacy in Controlling Glycaemia With Victozaå¨ (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes,Recruiting,No Results Available,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: alpha-glucosidase inhibitors|Drug: DPP-4 inhibitors|Drug: meglitinides|Drug: SGLT-2 inhibitors|Drug: sulfonylurea|Drug: thiazolidinediones,Novo Nordisk A/S,Both,Adult|Senior,Phase 4,1994,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,NN2211-4232|2015-002417-29|U1111-1170-7035,"March 23, 2016",Mar-16,Apr-19,"April 6, 2016",Apr-16,No Study Results Posted,LIRA-PRIME,Apr-19,Time to inadequate glycaemic control defined as HbA1c above 7.0% (53 mmol/mol)|Number of subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol)|Number of subjects who achieve HbA1c below or equal to 7.0% (53 mmol/mol) without weight gain|Change in fasting plasma glucose (FPG)|Change in Body weight,https://ClinicalTrials.gov/show/NCT02730377
610,NCT02730338,INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer,Recruiting,No Results Available,Prostate Cancer Metastatic,Behavioral: High intensity aerobic and resistance training|Behavioral: Psychosocial support,"Movember Foundation|University of California, San Francisco|Edith Cowan University, Australia|King's College London|Centre hospitalier de l'UniversitÌ© de MontrÌ©al (CHUM)",Male,Adult|Senior,Phase 3,866,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,GAP4,"March 10, 2016",Dec-15,null,"March 31, 2016",Mar-16,No Study Results Posted,INTERVAL,Dec-22,Overall Survival|Disease Progression|Symptomatic Skeletal Related Events (SSE)|Opiate Use|Analgesic Use|Biomarker analysis|Quality of Life|Physical Function|Pain,https://ClinicalTrials.gov/show/NCT02730338
611,NCT02730325,To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients,Recruiting,No Results Available,Clostridium Difficile,Other: Serum-derived bovine immunoglobulin/protein isolate (SBI)|Other: Placebo,"Northwestern University|Entera Health, Inc",Both,Adult|Senior,,100,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",STU00200335,"February 5, 2016",Dec-15,Sep-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Sep-17,Time (# of days) to resolution of diarrhea|Incidence of recurrent CDI|Incidence of C. difficile|UC status measured by P-SCCAI|UC status measured by BSS|UC status measured by Fecal calprotectin|UC status measured by CRP|UC status measured by colectomy rate|Nutritional Status measured by pre-albumin|Nutritional Status measured by albumin|Nutritional Status measured by hand grip strength|Nutritional Status measured by fecal alpha-1 antitrypsin|Safety and Tolerability evaluated by reported and observed treatment related adverse events|Quality of Life evaluated using the SF-36|Fecal Microbiome|Length of Hospitalization,https://ClinicalTrials.gov/show/NCT02730325
612,NCT02730221,Administrative Workload in the Intensive Care Unit,Recruiting,No Results Available,Critical Illness,,VU University Medical Center,Both,Child|Adult|Senior,,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2015.564,"March 31, 2016",Jan-16,May-17,"March 31, 2016",Mar-16,No Study Results Posted,AWIC,May-17,Login time in the PDMS per hour for nurses|Login time in the PDMS per hour for doctors|Amount of time spent on administrative work and documentation per shift for nurses|Amount of time spent on administrative work and documentation per shift for doctors|Amount of time spent on direct patient care per shift for nurses|Amount of time spent on direct patient care per shift for doctors,https://ClinicalTrials.gov/show/NCT02730221
613,NCT02730182,"Effect of High Altitude Exposure, Acclimatization and Re-exposure on Postural Control in Lowlanders",Recruiting,No Results Available,Effect of High Altitude,Other: altitude exposure,University of Zurich,Both,Adult,,18,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,REB15-2709_V3,"March 31, 2016",Mar-16,Dec-17,"April 12, 2016",Apr-16,No Study Results Posted,null,Dec-16,Center of pressure path length measured by Wii-balance board|Cerebral tissue oxygen saturation measured by near infrared spectroscopy|Postural stability measured by sharpened Romberg-test and heel-to-toe walk,https://ClinicalTrials.gov/show/NCT02730182
614,NCT02730156,"Effect of High Altitude Exposure, Acclimatization and Re-exposure on Right Ventricular Function in Lowlanders",Recruiting,No Results Available,Effect of High Altitude,Other: Altitude exposure,University of Zurich|University of Calgary,Both,Adult|Senior,,18,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,REB15-2709_V2,"March 31, 2016",Mar-16,Dec-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Dec-16,Systolic pulmonary artery pressure measured by echocardiography|Indices of right ventricular dysfunction,https://ClinicalTrials.gov/show/NCT02730156
615,NCT02730143,"Effect of High Altitude Exposure, Acclimatization and Re-exposure on Nocturnal Breathing Pattern in Lowlanders",Recruiting,No Results Available,Effect of High Altitude,Other: Altitude exposure,University of Zurich|University of Calgary,Both,Adult,,18,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,REB15-2709_V1,"March 31, 2016",Mar-16,Dec-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Dec-16,Mean nocturnal oxygen saturation measured by pulse oximetry|Apnea-/hypopnea index measured by respiratory polygraphy|Oxygen desaturation index measured by respiratory polygraphy|Acute mountain sickness measured by the Environmental Symptom questionnaire cerebral score (AMSc),https://ClinicalTrials.gov/show/NCT02730143
616,NCT02730117,Furosemide Stress Test Guiding Initiation of Renal Replacement Therapy,Recruiting,No Results Available,Acute Kidney Injury,Device: Dialysis with continuous renal replacement therapy|Device: Mechanical ventilator|Drug: Anti-Bacterial Agents|Drug: Vasopressors,Chulalongkorn University,Both,Adult|Senior,,116,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IRB.006/59,"March 18, 2016",Mar-16,Dec-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Mar-17,Net fluid balance during 7 days measured in milliliters after the enrollment|28-day mortality measured by number of deceased patients at 28-day after the enrollment|ICU-free days measured by number of days (28 days minus ICU length of stay)|mechanical ventilator-free days measured by number of days (28 days minus days using mechanical ventilator)|dialysis dependence measured by need for renal replacement therapy in 28 days,https://ClinicalTrials.gov/show/NCT02730117
617,NCT02730104,Community-based Neuroendocrine Tumor (NET) Research Study,Recruiting,No Results Available,Gastroenteropancreatic Neuroendocrine Tumors,,Ipsen,Both,Adult|Senior,,100,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,A-US-52030-340,"April 1, 2016",Nov-15,Dec-19,"April 1, 2016",Apr-16,No Study Results Posted,null,Dec-19,Time to disease progression|Overall survival|Adverse events|Change in flushing and diarrhea|Patient satisfaction with treatment,https://ClinicalTrials.gov/show/NCT02730104
618,NCT02730091,"A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",Recruiting,No Results Available,Breast Cancer,Drug: Letrozole|Drug: Anastrozole|Drug: Vinorelbine,Centre Hospitalier Universitaire de Besancon|Pierre Fabre Medicament,Both,Adult|Senior,Phase 3,340,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,P/2015/253,"March 25, 2016",Feb-16,Feb-23,"March 31, 2016",Mar-16,No Study Results Posted,VICTORIANE,Feb-18,"progression-free survival (PFS)|health-related quality of life using HRQoL QLQ-C30 and BR23|overall response rate (ORR)|clinical benefit rate (CBR)|Safety assessed by NCI CTCAE version 4.0"",",https://ClinicalTrials.gov/show/NCT02730091
619,NCT02730039,Meaning-Centered Psychotherapy Training for Cancer Care Providers,Recruiting,No Results Available,Cancer Care Providers,Behavioral: workshop|Behavioral: follow-up calls & webinars|Behavioral: assessments,Memorial Sloan Kettering Cancer Center,Both,Adult|Senior,,240,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,15-321,"March 15, 2016",Dec-15,null,"March 31, 2016",Mar-16,No Study Results Posted,null,Dec-20,participant's skills uptake at the end of the MCPT session score range 0-10,https://ClinicalTrials.gov/show/NCT02730039
620,NCT02729987,Increasing Engagement With Online Stress Management Interventions,Recruiting,No Results Available,Emotional Stress,Behavioral: WorkGuru,University of Sussex,Both,Adult|Senior,,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Investigator),ER/SC587/1,"March 18, 2016",Apr-16,Dec-16,"April 20, 2016",Mar-16,No Study Results Posted,null,Oct-16,"Number of log-in to the site|Number of modules completed|Number of pages visited|Self-report engagement|Depressions, anxiety and stress|Well-being at work",https://ClinicalTrials.gov/show/NCT02729987
621,NCT02729935,Parecoxib for Treatment of Catheter Related Bladder Discomfort,Recruiting,No Results Available,Postoperative Pain,Drug: Parecoxib|Drug: Placebo,University Tunis El Manar,Both,Adult|Senior,Phase 4,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",University Of Tunis El Manar,"March 31, 2016",Mar-16,Jun-16,"April 5, 2016",Apr-16,No Study Results Posted,null,May-16,Reducing of Catheter related bladder discomfort symptoms|Severity of Pain at suprapubic area|safety and tolerability of parecoxib,https://ClinicalTrials.gov/show/NCT02729935
622,NCT02729857,Postprandial Response After Intake of Meals With Different Fatty Acid Composition,Recruiting,No Results Available,Healthy|Familial Hypercholesterolemia,Dietary Supplement: SFA muffin|Dietary Supplement: PUFA muffin,University of Oslo|Oslo University Hospital|Mills DA,Both,Adult,,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",2015/2392/REK sÌür-Ìüst B,"March 31, 2016",Mar-16,Dec-16,"April 5, 2016",Apr-16,No Study Results Posted,null,Jun-16,Change in levels of circulating triglycerides|Changes in markers of lipid- and glucose metabolism|Changes in circulating levels of inflammatory markers|Changes in PBMC gene expression levels of markers of inflammation and lipid metabolism|Changes in lipid classes and lipoprotein size|Changes in plasma and urine metabolomics|Check DNA for single nuclear polymorphisms|Changes in PBMC Whole genome transcriptomics,https://ClinicalTrials.gov/show/NCT02729857
623,NCT02729818,Adaptation Time Required for the Optimisation of Maia Microperimetry Visual Field Testing,Recruiting,No Results Available,Retina; Change,,University of Oxford,Both,Adult|Senior,,40,Other,Observational,Time Perspective: Prospective,DarkAdapt,"February 25, 2016",Feb-16,Feb-17,"April 5, 2016",Mar-16,No Study Results Posted,null,Aug-16,"Change in average threshold of tests following different dark adaptation periods will be compared.|Change in fixation stability, as defined by the area in which 95% of the fixation points for any specific test fall, following different dark adaptation periods will be compared.",https://ClinicalTrials.gov/show/NCT02729818
624,NCT02729805,Intraoperative Ketamine on Chronic Pain After Mastectomy,Recruiting,No Results Available,Chronic Pain,Drug: Saline|Drug: Ketamine 0.5mg/kg|Drug: Ketamine 0.75mg/kg,The University of Hong Kong,Both,Adult|Senior,Phase 4,135,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",UW15-079,"June 28, 2015",Aug-15,Sep-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Aug-17,Severity of chronic pain|Incidence of neuropathic pain,https://ClinicalTrials.gov/show/NCT02729805
625,NCT02729792,Canadian rTMS Treatment and Biomarker Network in Depression Trial,Recruiting,No Results Available,Depression,Device: rTMS,"Centre for Addiction and Mental Health|University Health Network, Toronto|University of British Columbia|Brain Canada",Both,Adult,Phase 4,202,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",052-2015,"March 29, 2016",Mar-16,Dec-18,"March 31, 2016",Mar-16,No Study Results Posted,CARTBIND,Apr-18,17-item Hamilton Rating Scale for Depression (HRSD-17) Change,https://ClinicalTrials.gov/show/NCT02729792
626,NCT02729766,Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study,Recruiting,No Results Available,Inappropriate ADH Syndrome,Other: Induced hypotonic hyponatremia - SIAD model|Drug: Empagliflozin 25mg Tbl|Drug: Placebo P-Tablet,"University Hospital, Basel, Switzerland",Both,Adult,Phase 2|Phase 3,17,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",2015-00024,"March 24, 2016",Mar-16,Sep-16,"March 31, 2016",Mar-16,No Study Results Posted,DIVE,Jun-16,"serum sodium concentration after 7 hours of study medication administration|Serum sodium concentration at every time point of the study|Amount of urinary excretion|Serum osmolality at every time point of the study|Serum glucose at every time point of the study|Urinary osmolality at every time point of the study|Urinary glucose at every time point of the study|Serum electrolytes before induction of siad, at baseline and time point 7|Urinary electrolytes before induction of siad, at baseline and time point 7|Plasma level of Copeptin before induction of siad, at baseline and time point 7|Plasma level of Aldosterone before induction of siad, at baseline and time point 7|Plasma level of Renin before induction of siad, at baseline and time point 7|Plasma Level of atrial natriuretic peptide (ANP) before induction of siad, at baseline and time point 7|Plasma levels of brain natriuretic peptide (BNP) before induction of siad, at baseline and time point 7|Body weight at every time point of the study|Blood pressure at every time point of the study|Heart rate at every time point of the study|Symptoms of hyponatremia assessed by visual analogue scale (VAS) at every time point of the study",https://ClinicalTrials.gov/show/NCT02729766
627,NCT02729727,Clinical Study to Evaluate CryoBalloon Ablation System in Patients Undergoing Esophagectomy,Recruiting,No Results Available,Esophageal Cancer,Device: CryoBalloon Ablation System,"C2 Therapeutics, Inc.",Both,Adult|Senior,,5,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,CP-0008,"March 14, 2016",Mar-16,Oct-16,"March 31, 2016",Mar-16,No Study Results Posted,null,Aug-16,"Safety of CryoBalloon Ablation System by the incidence of serious device related events|Device Performance: ease of deployment of the CryoBalloon, procedure time pre and post procedure",https://ClinicalTrials.gov/show/NCT02729727
628,NCT02729714,A Pilot Study of Suvorexant for Insomnia in Parkinson Disease,Recruiting,No Results Available,Insomnia,Drug: Suvorexant|Drug: Placebo,"Burdick, Daniel, M.D.|Merck Sharp & Dohme Corp.",Both,Adult|Senior,Phase 4,20,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",DJB-2015-01,"January 26, 2016",Apr-16,Sep-18,"April 5, 2016",Apr-16,No Study Results Posted,null,Jul-18,Sleep Efficiency as measured by Polysomnogram|Wake after sleep onset- WASO|Latency to Persistent Sleep- LPS|Muscle Tonicity|Insomnia Severity Index- ISI|Epworth Sleepiness Scale-ESS|Subject's Global Impression of Change- SGI|Clinicians's Global Impression of Change- CGIC,https://ClinicalTrials.gov/show/NCT02729714
629,NCT02729701,Pilot Study of the Effect of Duaveeå¨ on Benign Breast Tissue Proliferation,Recruiting,No Results Available,Breast Cancer,Drug: Duavee,University of Kansas Medical Center|Pfizer,Female,Child|Adult,Phase 4,40,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,STUDY00002440,"March 21, 2016",Apr-16,May-17,"April 22, 2016",Apr-16,No Study Results Posted,null,Mar-17,Feasibility for a larger trial|Change in Ki-67|Change in benign breast tissue estrogen responsive genes|Change in hormone levels|Change in levels of Duavee in the blood|Change in body composition|Change in breast density,https://ClinicalTrials.gov/show/NCT02729701
630,NCT02729688,Effectiveness of a Pressure Indicator Guided and a Conventional Bandaging in Treatment of Venous Leg Ulcer,Recruiting,No Results Available,Venous Insufficiency,Device: customized pressure guide bandage|Device: Ordinary elastic bandage,Mahidol University,Both,Adult|Senior,,90,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,SIRIRAJ016/2559,"March 25, 2016",Mar-16,Mar-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Mar-17,Sub-bandage pressure,https://ClinicalTrials.gov/show/NCT02729688
631,NCT02729649,ArmAssist Robotic Device for Arm Training,Recruiting,No Results Available,Hemiparesis,Device: ArmAssist robotic training|Other: Conventional therapy|Other: Extended conventional therapy,University of Belgrade,Both,Child|Adult|Senior,Phase 1|Phase 2,90,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),LK-3,"March 29, 2016",Jan-16,Jan-17,"April 5, 2016",Apr-16,No Study Results Posted,null,Apr-16,Fugl Mayer motor score for upper extremity|Ashworth score|Action research arm score|Wolf motor function test|Barthel index,https://ClinicalTrials.gov/show/NCT02729649
632,NCT02729636,Multi-pad FES System for Drop Foot Treatment,Recruiting,No Results Available,Foot Drop,Device: multipad electrical stimulation (FES)|Other: Conventional therapy,University of Belgrade,Both,Child|Adult|Senior,Phase 2|Phase 3,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),LK-4,"March 29, 2016",Mar-16,Mar-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Sep-16,gait speed by 10m walking test|motor arm impairment by Fugl Mayer assessment|Activities of daily living by Barthel index|postural stability by Berg Balance scale,https://ClinicalTrials.gov/show/NCT02729636
633,NCT02729571,Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults,Recruiting,No Results Available,Tuberculosis,Biological: MTBVAC|Biological: BCG,"Biofabri, S.L|South African Tuberculosis Vaccine Initiative|TuBerculosis Vaccine Initiative|Triclinium Clinical Trial Project Management (Pty) Ltd.|Universidad de Zaragoza",Both,Child|Adult,Phase 1|Phase 2,54,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",MTBVAC-02,"March 15, 2016",Sep-15,Jan-17,"March 31, 2016",Mar-16,No Study Results Posted,MTBVAC-Ph1b,Jun-16,"Safety and reactogenicity in infants and adults: includes injection site and systemic and regional adverse events, solicited and unsolicited. A diary card will be for solicited local, regional, and systemic adverse event data.|Primary immunogenicity analysis (in infants only): Measure of frequencies and co-expression patterns of CD4 and CD8 T cells expressing specific cytokines in whole blood.",https://ClinicalTrials.gov/show/NCT02729571
634,NCT02729558,Local Radiotherapy Following Complete Resection of a Brain Metastasis,Recruiting,No Results Available,Brain Neoplasms,Radiation: local SRT,VU University Medical Center|The Netherlands Cancer Institute|UMC Utrecht,Both,Adult|Senior,Phase 3,70,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,NL5128302914,"February 19, 2016",May-15,May-17,"April 8, 2016",Apr-16,No Study Results Posted,null,May-17,"local control rate|Decrease in neurocognitive test results using the Hopkins Verbal Learning Test Revised (HVLT-R), in full cohorts|Decrease in specified neurocognitive test results using the Trail Making A and B, in full cohorts|Decrease in neurocognitive test results using the Controlled Oral Word Association (COWA), in full cohorts|Decrease in neurocognitive test results using using the Wechsler Adult Intelligence Scale (WAIS) III Digit Span and WAIS III Digit Symbol, in full cohorts|Decrease in neurocognitive test results using the Grooved Pegboard, in full cohorts",https://ClinicalTrials.gov/show/NCT02729558
635,NCT02729532,Effect of Xpert MTB/RIF on Patient Outcomes,Recruiting,No Results Available,Tuberculosis,Device: Xpert,"University of North Carolina, Chapel Hill|National Institutes of Health (NIH)",Both,Adult|Senior,,892,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,14-1697|US NIH Grant P30 AI50410-17,"January 5, 2016",Jan-16,Mar-17,"March 31, 2016",Feb-16,No Study Results Posted,null,Jan-17,Culture-positive patient drop-out before accessing treatment|Time to TB treatment|Percentage of participants who receive TB treatment within 14 days of enrolment (effect of Xpert on the accuracy of TB diagnosis)|Percentage of participants who did not receive TB treatment 14 days post-enrolment (effect of Xpert on the accuracy of TB diagnosis)|Time to TB Diagnosis|Number of TB patients lost to follow-up,https://ClinicalTrials.gov/show/NCT02729532
636,NCT02729506,Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma,Recruiting,No Results Available,Hepatocellular Carcinoma,Procedure: Transarterial Radioembolization|Procedure: Transarterial Chemoembolization using drug-eluting beads,King Faisal Specialist Hospital & Research Center,Both,Adult|Senior,Phase 4,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,RAC# 2131 134,"February 4, 2016",Jan-16,Dec-17,"April 5, 2016",Mar-16,No Study Results Posted,null,Dec-17,"Time to Progression (TTP) is the primary outcome.|Time to Local Progression (TLP)|Overall survival|Overall response to therapy according to mRECIST|Toxicities and adverse events|Quality of life|Treatment-related costs, in terms of cost of therapy and number of hospitalization days.",https://ClinicalTrials.gov/show/NCT02729506
637,NCT02729493,Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer,Recruiting,No Results Available,Liver Neoplasms,Biological: EPCAM-targeted CAR-T cells,"Sinobioway Cell Therapy Co., Ltd.",Both,Child|Adult|Senior,Phase 1|Phase 2,25,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,ACCO-2015-06-03,"March 23, 2016",Nov-15,May-19,"March 31, 2016",Mar-16,No Study Results Posted,EECLC,Oct-16,Disease control rates,https://ClinicalTrials.gov/show/NCT02729493
638,NCT02729467,A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults,Recruiting,No Results Available,Healthy,Drug: JNJ-53718678|Drug: Itraconazole|Drug: Rifampicin,"Janssen Research & Development, LLC",Both,Adult,Phase 1,30,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CR108127|53718678RSV1006,"March 18, 2016",Mar-16,Jun-16,"April 8, 2016",Apr-16,No Study Results Posted,null,Jun-16,"Maximum Observed Analyte Concentration (Cmax)|Area Under the Analyte Concentration-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC [0-last])|Area Under the Analyte Concentration-Time Curve From Time 0 to Infinite Time (AUC [0-infinity])|Area Under the Analyte Concentration-time curve From Time 0 to 24h (AUC24h)|Ratio of Individual Cmax Values Between Test and Reference Treatment (Ratio Cmax, test/reference)|Ratio of Individual AUC24h Values Between Test and Reference Treatment (Ratio AUC24h, test/reference)|Ratio of Individual AUClast Values Between Test and Reference Treatment (Ratio AUClast, test/reference)|Ratio of Individual AUC(infinity) Values Between Test and Reference Treatment (Ratio AUC[infinity], test/reference)|Number of Participants With Adverse Events and Serious Adverse Events",https://ClinicalTrials.gov/show/NCT02729467
639,NCT02729454,Mental Practice in Parkinson's Disease,Recruiting,No Results Available,Parkinson Disease,Other: Mental practice and physical therapy|Other: physical therapy,Universidade Federal de Pernambuco,Both,Adult|Senior,,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CAAE 46155315.3.0000.5208,"March 26, 2016",Oct-15,Aug-16,"April 5, 2016",Apr-16,No Study Results Posted,null,Jun-16,Dynamic Gait Index test to evaluate gait and risk of falls|Timed up and go Test to evaluate risk of falls|Walk Test of 10 meters to evaluate gait|history questionnaire falls to evaluate risk of falls,https://ClinicalTrials.gov/show/NCT02729454
640,NCT02729259,H2O VR for Burns 2015,Recruiting,No Results Available,Pain|Burn,Behavioral: Virtual Reality Snowworld|Behavioral: Virtual Reality slides of nature|Behavioral: Control standard nurse wound care,National Institute of General Medical Sciences (NIGMS)|University of Washington,Both,Child|Adult|Senior,,200,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver),50416EB,"March 31, 2016",Oct-15,Oct-20,"April 5, 2016",Dec-15,No Study Results Posted,H2OWC,Oct-19,"""Pain and anxiety"" as measured by Graphic Rating Scale",https://ClinicalTrials.gov/show/NCT02729259
641,NCT02729246,Bariatric Surgery for the Treatment of Type 2 Diabetes - Clinical Effects and Underlying Mechanisms,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Obesity,Procedure: Laparoscopic Gastric Bypass,Uppsala University,Both,Adult,,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,Dnr 2014/255,"March 16, 2016",Oct-14,Jun-17,"March 30, 2016",Mar-16,No Study Results Posted,Bariglykos,Dec-16,Change from Baseline of Glucose Turnover|Change from Baseline of homeostatic model assessment (HOMA) for insulin resistance|Change from Baseline of beta cell function,https://ClinicalTrials.gov/show/NCT02729246
642,NCT02729155,Single-cycle Remote Ischemic Preconditioning and Postconditioning for Prevention of Contrast-Induced Nephropathy (SCRIP-CIN) Trial,Recruiting,No Results Available,Ischemic Reperfusion Injury,Procedure: RIPre|Procedure: RIPost|Procedure: Sham-Pre|Procedure: Sham-Post,Phramongkutklao College of Medicine and Hospital,Both,Child|Adult|Senior,Phase 3,596,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",PMK-SCRIP-CIN,"March 31, 2016",Oct-15,May-17,"March 31, 2016",Mar-16,No Study Results Posted,null,May-17,"Incidence of CI-AKI, which was defined as an increment of serum creatinine 0.5 mg/dL or a relative increase of 25% over the baseline value|Change in sCr and eGFR from baseline|Major adverse cerebrovascular and cardiovascular events (MACCE) in each intervention group|Incidence(%) of CI-AKI in differrent subgroups of patient characteristics|Incidence(%) of CI-AKI in patients with vs without RIPre and RIPost|Incidence(%) of MACCE in differrent subgroups of patient characteristics|Incidence(%) of MACCE in patients with vs without RIPre and RIPost|Incidence(%) of MACCE in patients who have CI-AKI vs patients who have no CI-AKI",https://ClinicalTrials.gov/show/NCT02729155
643,NCT02729116,Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients,Recruiting,No Results Available,"Anti-Infective Agents, Urinary|Escherichia Coli Infections|Klebsiella Infections|Kidney Transplantation|Urinary Tract Infections",Drug: Sitafloxacin|Drug: Ertapenem,Khon Kaen University,Both,Adult|Senior,Phase 2|Phase 3,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,HE581520,"March 24, 2016",Mar-16,Jan-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Jan-17,Number of patients with clinical cure of acute urinary tract infection|Number of patients with micrological cure of acute urinary tract infection,https://ClinicalTrials.gov/show/NCT02729116
644,NCT02729090,"Effects of Exercise in the Functional Capacity, Central Artery and Rigidity Ankle Brachial Index",Recruiting,No Results Available,Peripheral Arterial Disease,Other: Device: treadmill|Other: Device: treadmill Train_Comb_aerobic,Hospital de Clinicas de Porto Alegre,Both,Adult,,70,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),14-0381,"February 18, 2016",May-15,May-19,"March 31, 2016",Mar-16,No Study Results Posted,null,May-19,Cardiopulmonary test - 6 minute walk test|Pulse wave velocity|One maximum repetition test|ankle brachial index|Edinburgh Claudication Questionnaire,https://ClinicalTrials.gov/show/NCT02729090
645,NCT02728999,Does Less Trendelenburg Make a Difference in Robotic Assisted Gynecological Procedures?,Recruiting,No Results Available,Benign Female Reproductive System Neoplasm,Procedure: Steep Trendelenburg|Procedure: Decreased Trendelenburg,Advocate Health Care,Female,Adult|Senior,,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),AHCIRB 5589 Trendelenburg,"March 1, 2016",Jun-13,Sep-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Sep-16,"‰Û¢ Mean Angle of Trendelenburg during surgery (Degrees of the operative head down, measured by electronic angle meter) and the difference in the two arms|Cardiovascular Outcomes- Heart rate|Respiratory Parameter- arterial CO2|Respiratory Outcomes- End Tidal CO2|Respiratory Outcomes- Peak Airway Pressure|Cardiovascular Outcomes- Mean arterial Pressure|Operative Time|Estimated Blood Loss|Redocking of the robot|Conversion of surgical approach",https://ClinicalTrials.gov/show/NCT02728999
646,NCT02728986,Cost Evaluation of Venous Leg Ulcers Management,Recruiting,No Results Available,Varicose Ulcer,Device: Profore|Device: Coban2,3M,Both,Child|Adult|Senior,,180,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label,FR Study No-05-000001|2014-A01128-39,"March 29, 2016",Jan-16,Dec-17,"March 31, 2016",Mar-16,No Study Results Posted,EPIC,Jul-17,Direct cost of leg ulcer management|Prevalence of adverse events related to compression|Patient's compression bandage acceptance score|Number of patients with fully healed ulcer|EuroQoL 5D-5L change between baseline and last visit|Average time to full healing,https://ClinicalTrials.gov/show/NCT02728986
647,NCT02728973,ERAS Protocol on the Incidence of Postoperative Complications Following Intestinal Surgery,Recruiting,No Results Available,Postoperative Complications,Other: ERAS program,First Affiliated Hospital of Chongqing Medical University,Both,Adult|Senior,,200,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,ERASCQ2016,"March 27, 2016",Feb-16,Mar-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Dec-16,The difference in postoperative morbidity rate|length of hospital stay|mortality,https://ClinicalTrials.gov/show/NCT02728973
648,NCT02728960,Traumatic Brain Injury Biological Diagnosis Via High Definition Tractography Asymmetry Screening,Recruiting,No Results Available,Traumatic Brain Injury,Procedure: MRI of the Brain (No Contrast) Scan,New York University School of Medicine,Both,Adult,,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Investigator)",12-03539,"March 8, 2016",Feb-15,Jan-17,"March 30, 2016",Mar-16,No Study Results Posted,null,Jan-17,Diagnosis reliability measured by MRI scanning data results|Amount of white matter damage using HDTAS DSI diffusion evaluation of volume and connectivity across 40 fiber tracts over 150 brain regions.|Comparison of severity of subjects with TBI using Diffusion Tension Imaging (DTI),https://ClinicalTrials.gov/show/NCT02728960
649,NCT02728934,Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis,Recruiting,No Results Available,"Arthritis, Rheumatoid",Biological: Golimumab Intravenous (IV)|Biological: Infliximab,"Janssen Scientific Affairs, LLC",Both,Adult|Senior,,1200,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CR108132|CNTO148ART4011,"March 31, 2016",Feb-16,Feb-21,"April 15, 2016",Apr-16,No Study Results Posted,AWARE,Feb-21,Proportion of Patients With an Infusion Reaction Through Week 52|Number of Patients With Serious Infusion Reaction and Discontinuation of Therapy due to Infusion Reaction|Number of Infusions With Infusion Reactions|Effectiveness of Disease Activity Defined by the Clinical Disease Activity Index (CDAI)|Discontinuation Rates due to Lack of Effectiveness|Persistency of use of Treatment and Adherence to the Treatment Regimen|Number of Patients with Adverse Events (AEs) and Serious AEs|Number of Patients With an Infusion Reaction|Cost Effectiveness Measured by Medical Resource Utilization and Healthcare Economics|Number of Patients With Severe Infusion Reaction and Discontinuation of Therapy due to Infusion Reaction,https://ClinicalTrials.gov/show/NCT02728934
650,NCT02728921,The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery,Recruiting,No Results Available,Pancreatic Neoplasms|Urogenital Neoplasm|Systemic Inflammatory Response Syndrome|Hypovolemia,Drug: Albumin infusion during 30 min|Drug: Albumin infusion during 3 hours,Region Skane,Both,Adult|Senior,Phase 3,70,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2013-004446-42,"March 31, 2016",Apr-14,Dec-16,"April 15, 2016",Mar-16,No Study Results Posted,AIR,Dec-16,Change in plasma volume|Change in plasma volume over time|Incidence of postoperative complications,https://ClinicalTrials.gov/show/NCT02728921
651,NCT02728908,Detecting Traumatic Intracranial Hemorrhage With Microwave Technology,Recruiting,No Results Available,Traumatic Intracranial Hemorrhage,Device: Medfield Strokefinder MD100,"Hans Granhed|Medfield Diagnostics|Chalmers University of Technology|Sahlgrenska University Hospital, Sweden",Both,Adult|Senior,,250,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,TICH 01,"March 31, 2016",Apr-16,Dec-17,"April 10, 2016",Apr-16,No Study Results Posted,null,Dec-17,The diagnostic ability as measured by the area under receiver operating characteristic curve (AUC) of the device for detecting TICH|The accuracy for estimating the position of the intracranial hemorrhage through a mathematical analysis of the microwave data|The accuracy for estimating the volume of the intracranial hemorrhage through a mathematical analysis of the microwave data|Mean time (å± standard deviation) needed to complete the measurement procedure|Any adverse events occurring within 12 hours from the measurement procedure(s),https://ClinicalTrials.gov/show/NCT02728908
652,NCT02728882,Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma,Recruiting,No Results Available,Lymphoma,Biological: CD19-targeted CAR-T cells,"Sinobioway Cell Therapy Co., Ltd.|The First Affiliated Hospital of Anhui Medical University",Both,Child|Adult|Senior,Phase 1|Phase 2,24,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,ACCO-2015-06-02,"March 29, 2016",Nov-15,May-19,"April 4, 2016",Mar-16,No Study Results Posted,EECBL,Oct-16,Objective Reaction Rates,https://ClinicalTrials.gov/show/NCT02728882
653,NCT02728700,Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT,Recruiting,No Results Available,"Adult Hodgkin Lymphoma|Adult Myelodysplastic Syndrome|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Hodgkin Lymphoma|Childhood Myelodysplastic Syndrome|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Myelofibrosis|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Non-Hodgkin Lymphoma",Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Drug: Sirolimus,Stanford University|National Cancer Institute (NCI),Both,Child|Adult,Phase 1|Phase 2,9,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,PEDSBMT295|NCI-2016-00387|P30CA124435,"March 30, 2016",Feb-16,null,"March 30, 2016",Mar-16,No Study Results Posted,null,Feb-18,"Incidence of acute GvHD grade 3 & 4, according to the Glucksberg staging criteria|Incidence of thrombotic microangiopathy defined according to the bone marrow transplant clinical trials network toxicity committee|Incidence of venous-occlusive disease (VOD) using Modified Seattle Criteria|Severity of mucositis determined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03|Time to neutrophil engraftment defined as first of 3 consecutive days with the absolute neutrophil count is > 500/ul in the peripheral blood|Time to platelet engraftment defined as the first day of a minimum of three consecutive measurements on different days when platelet count > 50,000/mm^3 and patient is transfusion-independent for a minimum of 7 days",https://ClinicalTrials.gov/show/NCT02728700
654,NCT02728557,Supportive and Supportive-Expressive Treatment for Depression,Recruiting,No Results Available,Major Depressive Disorder,Behavioral: Supportive-Expressive Therapy|Behavioral: Supportive Therapy,University of Haifa,Both,Adult,Phase 3,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",ISF 186.15,"March 15, 2016",Mar-16,Jan-20,"March 30, 2016",Mar-16,No Study Results Posted,SSETD,Jan-20,Hamilton rating scale for depression (HRSD)|Beck Depression Inventory (BDI)|Outcome Questionnaire (OQ),https://ClinicalTrials.gov/show/NCT02728557
655,NCT02728531,Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma,Recruiting,No Results Available,Mantle Cell Lymphoma,Drug: Bendamustine|Drug: Rituximab|Drug: Cytarabine|Drug: Pegfilgrastim|Procedure: Leukapheresis|Drug: Filgrastim|Procedure: Autologous stem cell transplant,Washington University School of Medicine,Both,Adult,Phase 0,15,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,201603149,"March 30, 2016",Apr-16,Apr-23,"April 18, 2016",Apr-16,No Study Results Posted,null,Sep-18,Stem cell mobilization success rate|Overall response rate|Pre-transplant complete response rate (CRR)|Progression-free survival (PFS)|Overall survival (OS)|Safety and tolerability of bendamustine and rituximab alternating with cytarabine and rituximab as measured by grades 3 or higher toxicities,https://ClinicalTrials.gov/show/NCT02728531
656,NCT02728505,SinuSurf vs. Saline Solution in Normal Subjects,Recruiting,No Results Available,Rhinosinusitis,Drug: SinuSurf irrigation twice daily|Drug: NeilMed Sinus rinse irrigation twice daily,Vanderbilt University|NeilMed Pharmaceuticals,Both,Adult,Phase 1,40,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label,151479,"March 30, 2016",Jan-16,Dec-18,"April 4, 2016",Apr-16,No Study Results Posted,SinuSurf,Jan-18,"Sense of smell assessed by change in UPSIT-40 score between when subjects use SinuSurf, as compared to saline control.|Tolerability",https://ClinicalTrials.gov/show/NCT02728505
657,NCT02728479,Percutaneous Transluminal Angioplasty Registry,Recruiting,No Results Available,Percutaneous Transluminal Angioplasty,,"Klinik fÌ_r Kardiologie, Pneumologie und Angiologie|Heinrich-Heine University, Duesseldorf",Both,Adult|Senior,,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PTA Registry,"February 18, 2016",Jan-14,Jan-17,"March 30, 2016",Mar-16,No Study Results Posted,null,Jan-17,Patency rate|Creatinine level|Mortality|Days of Hospitalization|Ankle-Brachial Index|walking distance|Restenosis rate,https://ClinicalTrials.gov/show/NCT02728479
658,NCT02728466,Effects of Cocoa Procyanidins on Vascular Function,Recruiting,No Results Available,Healthy,Dietary Supplement: Flavanol and procyanidin supplement|Dietary Supplement: Procyanidin-containing supplement|Dietary Supplement: control supplement deprived of flavanols and procyanidins,"Heinrich-Heine University, Duesseldorf",Male,Adult,,45,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)",Cocoa procyanidins|12-018,"March 9, 2016",Oct-14,May-16,"March 30, 2016",Mar-16,No Study Results Posted,null,May-16,Change form Baseline Endothelial function at 1 month|Plasma flavanol metabolites|Urinary flavanol metabolites|Urinary valerolactone metabolites,https://ClinicalTrials.gov/show/NCT02728466
659,NCT02728427,Multicenter Study on Suprapubic Catheterization Versus Transurethral Catheterization in Laparoscopic Surgery for Rectal Cancer,Recruiting,No Results Available,Rectal Cancer|Surgery,Device: Suprapubic catheterization using central venous catheter(CVC-2 7F)|Device: Transurethral catheterization using Foley catheter,Nanfang Hospital of Southern Medical University|Fujian Cancer Hospital|Fujian Provincial Hospital,Male,Adult|Senior,,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,SPCCVC-TUC,"March 22, 2016",Apr-16,Apr-17,"April 12, 2016",Apr-16,No Study Results Posted,MSSPC,Apr-17,Catherization time|Number of catheterization|Catheter-Associated Urinary Tract Infection|Pain score|International Prostatic Symptom Score|Time to first ambulation|Duration of hospital stay|Urinary extravasation|Hematuria|Catheter obstruction,https://ClinicalTrials.gov/show/NCT02728427
660,NCT02728414,Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Type 2 Diabetes,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: probiotics|Dietary Supplement: placebo,Shanghai 10th People's Hospital,Both,Adult|Senior,,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)",PTD01,"March 25, 2016",Oct-15,Dec-16,"March 30, 2016",Mar-16,No Study Results Posted,null,Dec-16,change from baseline in fasting blood-glucose at 1 month|change from baseline in fasting blood-glucose at 3 months|change from baseline in glycosylated hemoglobin change at 1 month|change from baseline in glycosylated hemoglobin change at 3 months|change from baseline in gut microbiota at 1 month|change from baseline in gut microbiota at 3 months|change from baseline in triglyceride at 1 month|change from baseline in triglyceride at 3 months|change from baseline in cholesterol at 1 month|change from baseline in cholesterol at 3 months|change from baseline in high-density lipoprotein at 1 month|change from baseline in high-density lipoprotein at 3 months|change from baseline in low-density lipoprotein at 1 month|change from baseline in low-density lipoprotein at 3 months|change from baseline in glutamic oxalacetic transaminase at 1 month|change from baseline in glutamic oxalacetic transaminase at 3 months|change from baseline in alkaline transaminase at 1 month|change from baseline in alkaline transaminase at 3 months|change from baseline in alkaline phosphatase at 1 month|change from baseline in alkaline phosphatase at 3 months|change from baseline in superoxide dismutase at 1 month|change from baseline in superoxide dismutase at 3 months|change from baseline in C-reactive protein at 1 month|change from baseline in C-reactive protein at 3 months|change from baseline in uric acid at 1 month|change from baseline in uric acid at 3 months|change from baseline in tumor necrosis factor-a at 1 month|change from baseline in tumor necrosis factor-a at 3 months|change from baseline in interleukin-6 at 1 month|change from baseline in interleukin-6 at 3 months|change from baseline in interleukin-8 at 1 month|change from baseline in interleukin-8 at 3 months|change from baseline in fasting insulin at 1 month|change from baseline in fasting insulin at 3 months|change from baseline in c peptide at 1 month|change from baseline in c peptide at 3 months,https://ClinicalTrials.gov/show/NCT02728414
661,NCT02728401,Genotypes and Phenotypes in Pediatric SIRS and Sepsis,Recruiting,No Results Available,Systemic Inflammatory Response Syndrome (SIRS)|Sepsis,,Seattle Children's Hospital|Immunexpress,Both,Child|Adult,,90,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,14761,"March 30, 2016",Dec-13,Jul-16,"March 30, 2016",Mar-16,No Study Results Posted,GAPPSS,Jul-16,Gene Expression Levels|Serum Protein Expression Profiles,https://ClinicalTrials.gov/show/NCT02728401
662,NCT02728349,Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma,Recruiting,No Results Available,Glioblastoma,Drug: Chlorogenic acid,"Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd|Beijing Shijitan Hospital",Both,Adult,Phase 1,30,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,LYS-I-03,"March 28, 2016",Feb-16,Dec-17,"March 30, 2016",Feb-16,No Study Results Posted,null,Feb-17,Number of adverse events|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0•_Îgrade ‰ä´3 (DLT)|Maximum Tolerated Dose|Area under the plasma concentration versus time curve (AUC) of chlorogenic acid|Peak Plasma Concentration (Cmax) of chlorogenic acid|Improvement in cancer-related symptoms|disease control rate(DCR)|objective response rate (ORR)|progress free survival(PFS)|overall survival (OS)|Improvement in quality of life,https://ClinicalTrials.gov/show/NCT02728349
663,NCT02728336,MRI Assessment of Patient Suitability for Cardiac Resynchronization Therapy (CRT),Recruiting,No Results Available,Cardiac Resynchronization Therapy|Magnetic Resonance Imaging (MRI),Procedure: Cardiac MRI,New York University School of Medicine,Both,Adult|Senior,,110,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,14-01686,"March 30, 2016",Nov-14,Nov-16,"March 30, 2016",Mar-16,No Study Results Posted,null,Nov-16,Derivation of score of patient suitability for CRT,https://ClinicalTrials.gov/show/NCT02728336
664,NCT02728284,Evaluation of Cardiac Function With Cardio-respiratory Synchronized MRI,Recruiting,No Results Available,Heart Disease,Procedure: CMR|Procedure: Conventional Cardiologic Evaluation,New York University School of Medicine,Both,Child|Adult|Senior,,100,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,14-00601,"March 30, 2016",Dec-15,Sep-16,"March 30, 2016",Mar-16,No Study Results Posted,null,Sep-16,Image Quality measured by resolution|Image Quality measured by signal to noise|Suitability for routine use measured by imaging time and ease of use,https://ClinicalTrials.gov/show/NCT02728284
665,NCT02728232,Internal Iliac Artery Ligation and Placenta Percreta,Recruiting,No Results Available,Placenta Percreta,Procedure: internal iliac artery ligation|Procedure: Cesarean Hysterectomy,Cairo University,Female,Adult,,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,PP2302019,"March 31, 2016",Feb-16,Sep-16,"April 4, 2016",Mar-16,No Study Results Posted,null,Sep-16,amount of intra-operative hemorrhage,https://ClinicalTrials.gov/show/NCT02728232
666,NCT02728089,Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014),Recruiting,No Results Available,Urinary Tract Infection (UTI)|Complicated Urinary Tract Infection|Pyelonephritis|Uncomplicated Pyelonephritis,Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g),Merck Sharp & Dohme Corp.,Both,Adult|Senior,Phase 3,115,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,7625A-014|MK-7625A-014,"March 30, 2016",Apr-16,May-17,"April 20, 2016",Apr-16,No Study Results Posted,null,May-17,"Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) at Test of Cure (TOC)|Percentage of Participants With Adverse Events (AEs)|Percentage of Participants Discontinuing Study Drug Due to AEs|Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) at End Of Therapy (EOT) and Late Follow-up (LFU)|Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at TOC, EOT, and LFU|Percentage of Participants With a Composite Response of Both Microbiological Response (Eradication, Persistence, or Indeterminate) and Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at TOC|Microbiological Response (Eradication, Persistence, or Indeterminate) by Pathogen at EOT, TOC, and LFU",https://ClinicalTrials.gov/show/NCT02728089
667,NCT02728063,Lactibiane TolÌ©ranceå¨ in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance,Recruiting,No Results Available,Diarrhoea Predominant Irritable Bowel Syndrome,Dietary Supplement: Lactibiane Tolerance,Pileje,Both,Adult|Senior,Phase 1|Phase 2,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,PEC15144,"March 8, 2016",Mar-16,May-17,"April 5, 2016",Apr-16,No Study Results Posted,PILATE,Feb-17,Change from baseline of intestinal permeability|Change from baseline of intestinal permeability - secondary 1|Change from baseline of intestinal permeability - secondary 2|Change from baseline of intestinal permeability - secondary 3|Change from baseline of intestinal permeability - secondary 4|Change from baseline of intestinal permeability - secondary 5|Change from baseline of intestinal permeability - secondary 6|Change from baseline of intestinal permeability - secondary 7|Change from baseline of intestinal permeability - secondary 8|Change from baseline of intestinal permeability - secondary 9|Change from baseline of intestinal permeability - secondary 10|Change from the baseline of the inflammatory status - secondary 11|Change from the baseline of the symptomatology - secondary 12|Change from the baseline of the symptomatology - secondary 13|Change from the baseline of the symptomatology - secondary 14|Change from the baseline of the symptomatology - secondary 15|Change from the baseline of the symptomatology - secondary 16,https://ClinicalTrials.gov/show/NCT02728063
668,NCT02727998,Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy,Recruiting,No Results Available,Posttraumatic Stress Disorder,Drug: Ketamine|Drug: Midazolam,Yale University,Both,Adult,Phase 2,40,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",1509016530|23260,"March 14, 2016",Dec-15,Dec-22,"March 30, 2016",Mar-16,No Study Results Posted,PTSD,Dec-20,Change from baseline to 90 days post treatment in Clinician-Administered PTSD Scale scores|Change from baseline to 90 days post treatment in Beck Depression Inventory (BDI-II),https://ClinicalTrials.gov/show/NCT02727998
669,NCT02727985,Opioid Reduction Following Spinal Cord Stimulation,Recruiting,No Results Available,Chronic Pain,Procedure: Pharmacist weaning schedule,Regina Qu'Appelle Health Region,Both,Adult|Senior,Phase 4,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Investigator),REB15-118,"March 18, 2016",Mar-16,Dec-19,"March 30, 2016",Mar-16,No Study Results Posted,REDUCE,Sep-19,"Change in number of opioids from baseline to post-intervention at 6-months follow-up|Proportion of patients that reach a 30% reduction in opioid dose (morphine-equivalent) from baseline to post-intervention at 6-months follow-up|Change in Number of opioids used at 1, 3, 9 and 12 months follow-up|Change in Mean dose of opioids at 1, 3, 6, 9, 12 months follow up|Proportion of patients that reach a 30% reduction in opioid dose (morphine-equivalent) from baseline to post-intervention at 1, 3, 9 and 12 months follow-up|Change in VAS pain score|Change in EQ-5D score|Change in SF-36 score|Change in ODI score|Change in PSQI score|Change in medication costs ($)|Number of opioid-related adverse events",https://ClinicalTrials.gov/show/NCT02727985
670,NCT02727972,Examination of Glutamate and mGluR5 in Psychiatric Disorders,Recruiting,No Results Available,Major Depressive Disorder|Post-Traumatic Stress Disorder|Bipolar Disorder,Behavioral: Cognitive Testing|Other: MRI|Radiation: PET,Yale University|VA Office of Research and Development,Both,Adult,,180,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,1101007933,"March 17, 2016",Aug-11,Aug-20,"April 4, 2016",Mar-16,No Study Results Posted,null,Aug-20,Evidence of glutamate availability (mGluR5) in psychiatric disorders confirmed by MRI and PET data.,https://ClinicalTrials.gov/show/NCT02727972
671,NCT02727933,Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea,Recruiting,No Results Available,Hepatitis C,,Bristol-Myers Squibb,Both,Adult|Senior,,3000,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,AI444-335,"March 18, 2016",Oct-15,Sep-20,"April 12, 2016",Apr-16,No Study Results Posted,null,Sep-20,Frequency of expected and unexpected adverse reactions (AEs) and serious adverse events (SAEs)/reactions. These include laboratory abnormalities|Incidence proportion of AEs leading to discontinuation of study therapy|Incidence rate of AEs leading to discontinuation of study therapy|Timing of laboratory abnormalities by toxicity grade|Percentage of patients with HCV (Hepatitis C Virus) RNA (Ribonucleic acid)< lower limit of quantification (LLQ) target not detected and detected|The sustained virologic response (SVR12) of the combination of Daklinza and Sunvepra (HCV RNA < lower limit of quantification [LLQ] target not detected and detected (HCV RNA < 25 IU/mL),https://ClinicalTrials.gov/show/NCT02727933
672,NCT02727920,Effects of Energy Drinks,Recruiting,No Results Available,Energy Drinks,Dietary Supplement: Energy drink|Other: Placebo,Johns Hopkins Bloomberg School of Public Health,Both,Adult|Senior,,200,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)",6831,"March 26, 2016",Mar-16,Jul-16,"April 4, 2016",Apr-16,No Study Results Posted,null,Jul-16,attention-memory score,https://ClinicalTrials.gov/show/NCT02727920
673,NCT02727881,Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD,Recruiting,No Results Available,Age-related Macular Degeneration,"Drug: Squalamine lactate ophthalmic solution, 0.2%|Drug: Placebo Ophthalmic solution|Drug: ranibizumab",Ohr Pharmaceutical Inc.,Both,Adult|Senior,Phase 3,650,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",OHR-1601,"March 28, 2016",Apr-16,Apr-19,"April 19, 2016",Apr-16,No Study Results Posted,MAKO,Dec-17,Functional change in visual acuity|Functional changes in visual acuity,https://ClinicalTrials.gov/show/NCT02727881
674,NCT02727868,Assessment of the Mutation of Pig-A Gene as Biomarker of Genotoxic Exposure in Humans,Recruiting,No Results Available,Patient With Breast Cancer,Genetic: blood samples,Assistance Publique Hopitaux De Marseille,Female,Adult|Senior,,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,2015-42|2015-A01753-46,"March 30, 2016",Mar-16,Mar-18,"March 30, 2016",Mar-16,No Study Results Posted,PIG-A,Mar-18,analysis of the frequency of granulocytes PIG-A mutated|analysis of the binucleated cell micronuclei frequency in culture,https://ClinicalTrials.gov/show/NCT02727868
675,NCT02727855,Cholera Vaccine Investment Strategy in Bangladesh,Recruiting,No Results Available,Cholera,Biological: Shanchol,"International Centre for Diarrhoeal Disease Research, Bangladesh|GAVI - The Vaccine Alliance|Government of Bangladesh",Both,Child,,85000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PR-15091,"January 16, 2016",Jan-16,Mar-18,"March 30, 2016",Dec-15,No Study Results Posted,CVIS,Mar-18,Number of participants with two doses of oral cholera vaccine (Shanchol) will get protection|Cholera vaccine coverage|Vaccine acceptability|Vaccine feasibility|Incidence of cholera among vaccinated individuals in vaccination area,https://ClinicalTrials.gov/show/NCT02727855
676,NCT02727751,A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C,Recruiting,No Results Available,Constipation Predominant Irritable Bowel Syndrome,Drug: Tenapanor,Ardelyx,Both,Adult|Senior,Phase 3,300,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,TEN-01-303,"March 23, 2016",Mar-16,Dec-17,"April 13, 2016",Apr-16,No Study Results Posted,T3MPO-3,Oct-17,Incidence of Treatment - Emergent Adverse Events [Safety and Tolerability],https://ClinicalTrials.gov/show/NCT02727751
677,NCT02727725,An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images,Recruiting,No Results Available,Myocardial Fibrosis|Cardiovascular Disease,Other: Traminer MRI Sequence,"Advocate Health Care|Siemens Corporation, Corporate Technology",Both,Adult|Senior,,80,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,AHC IRB 5886,"February 24, 2016",Jan-16,Jan-18,"April 6, 2016",Apr-16,No Study Results Posted,null,Jan-17,Sensitivity of the TRAMINER sequence in detecting myocardial fibrosis or acute infarction compared to the gold standard sequence will be measured.|Reduction in clinical Magnetic Resonance (MRI) procedure time.,https://ClinicalTrials.gov/show/NCT02727725
678,NCT02727686,Post-Operative Water Load Following Transsphenoidal Pituitary Surgery,Recruiting,No Results Available,Hyponatremia|Pituitary Adenoma,Other: Water Load (WL) Post-Operative Day 1,"St. Joseph's Hospital and Medical Center, Phoenix|Barrow Brain and Spine|Barrow Neurological Institute",Both,Adult|Senior,,15,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label,PHX1600103012,"March 23, 2016",Apr-16,Jan-18,"April 4, 2016",Apr-16,No Study Results Posted,null,Dec-17,POD1 Response Serum Sodium|POD1 Response Serum Osmolality|POD1 Response Urine Output|POD1 Response Vasopressin|Post-Discharge Response,https://ClinicalTrials.gov/show/NCT02727686
679,NCT02727621,Dexmedetomidine Sedation and Cardiopulmonary Bypass,Recruiting,No Results Available,Coronary Artery Bypass Grafting,Drug: Dexmedetomidine|Drug: propofol,Assiut University,Both,Adult|Senior,Phase 2,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",IRB000087801,"March 30, 2016",Apr-16,Aug-16,"April 3, 2016",Apr-16,No Study Results Posted,null,Aug-16,cardiac index|heart rate|mean arterial blood pressure|central venous pressure|pulmonary capillary wedge pressure|mean pulmonary artery pressure|systemic vascular resistance index|pulmonary vascular resistance index|stroke volume index|left ventricular stroke work index|cardiac output|inotrope score|duration of mechanical ventilation|sedation score,https://ClinicalTrials.gov/show/NCT02727621
680,NCT02727582,Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment,Recruiting,No Results Available,Multidrug-resistant Tuberculosis,,University of Cape Town|Baylor Research Institute,Both,Adult|Senior,,142,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,PODrtb,"March 29, 2016",Jul-15,Feb-19,"March 29, 2016",Mar-16,No Study Results Posted,PODrtb,Jul-17,To characterize the effects of 2nd-line drug exposures on treatment response in MDR-TB patients.|To identify drug exposures associated with the risk of treatment-related toxicities in patients on a standard 2nd-line regimen for MDR-TB.,https://ClinicalTrials.gov/show/NCT02727582
681,NCT02727556,Physiological Response and Visual Attention to Visual Food Images in Healthy Subjects and in Functional Dyspepsia Patients,Recruiting,No Results Available,Functional Dyspepsia,Behavioral: visual images,University Hospital Tuebingen,Both,Adult,,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,041/2016BO2,"March 21, 2016",Mar-16,null,"April 14, 2016",Apr-16,No Study Results Posted,null,Mar-17,Psychological response|visual attention|Subjective rating,https://ClinicalTrials.gov/show/NCT02727556
682,NCT02727543,Medication Adherence Improvement Support App For Engagement - Blood Pressure,Recruiting,No Results Available,Hypertension,Other: Medisafe,"Brigham and Women's Hospital|Medisafe, Inc.|Evidation Health",Both,Adult|Senior,,390,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Single Blind (Investigator),Pro00015278,"March 31, 2016",Apr-16,Aug-16,"April 4, 2016",Apr-16,No Study Results Posted,MedISAFE-BP,Jul-16,Change in systolic blood pressure|Self-reported medication adherence|Change in number of subjects who have well controlled blood pressure,https://ClinicalTrials.gov/show/NCT02727543
683,NCT02727530,The Effectiveness of the Manual Therapy on Infant Colic (MT-IF),Recruiting,No Results Available,Infant Colic,Other: VISCERAL MANUAL THERAPY-ADVICES|Other: ADVICES,University of Seville,Both,Child,,50,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)",USeville-RMartinez,"March 29, 2016",Apr-16,Jul-16,"April 5, 2016",Apr-16,No Study Results Posted,null,Jun-16,Change from parents-reported infant colic severity at 3 weeks|Change from parents-reported infant cry at 3 weeks,https://ClinicalTrials.gov/show/NCT02727530
684,NCT02727517,Early or Late Cord Clamping in the Depressed Neonate,Recruiting,No Results Available,Neonatal Disorder|Asphyxia Neonatorum,Procedure: Early (‰ä_ 60 seconds) cord clamping|Procedure: Delayed (‰ä´ 180 seconds) cord clamping,"Uppsala University|UNICEF|Ministry of Health and Population, Nepal|Swedish Society for Medical Research",Both,Child,,90,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",NEPRESUSC16,"March 29, 2016",Apr-16,Aug-16,"April 19, 2016",Apr-16,No Study Results Posted,NepCord III,Aug-16,Blood oxygen saturation|Timing of reaching > 90 % in oxygen saturation|Newborn heart rate|Apgar score|Pulsatility index|Timing of establishing spontaneous breathing|Timing of first cry|Timing of moving baby from mother to resuscitation table (if applicable|Rectal temperature,https://ClinicalTrials.gov/show/NCT02727517
685,NCT02727478,Effectiveness and Implementation of the HiBalance Program in Clinical Practice,Recruiting,No Results Available,Parkinson Disease,Other: HiBalance training program,Karolinska Institutet|Karolinska University Hospital,Both,Adult|Senior,,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2016/210-31/2,"March 22, 2016",Mar-16,Dec-18,"March 29, 2016",Mar-16,No Study Results Posted,BETA-PD,Dec-17,Mini-BESTest|10-meter walking test|Timed Up and Go (TUG) test - with and without cognitive and motor tasks|Physical activity level and intensity|European Quality of Life- 5 dimensions (EQ-5D)|The Activities-specific Balance Confidence (ABC) Scale,https://ClinicalTrials.gov/show/NCT02727478
686,NCT02727439,Acute Exercise and Microvascular Function,Recruiting,No Results Available,Physical Exertion,Other: Acute Exhausting Exercise (AE),Josip Juraj Strossmayer University of Osijek,Both,Adult,,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,2.15861E+11,"March 18, 2016",Feb-16,Dec-17,"March 29, 2016",Mar-16,No Study Results Posted,null,May-17,Skin microcirculation post occlusive reactive hyperemia|Skin microcirculation acetylcholine induced dilation,https://ClinicalTrials.gov/show/NCT02727439
687,NCT02727426,Dietary Salt and Microvascular Function,Recruiting,No Results Available,Salt; Excess,Other: Low Salt (LS) diet|Other: High Salt (HS) diet,Josip Juraj Strossmayer University of Osijek,Both,Adult,,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label,2.15861E+11,"March 15, 2016",Feb-16,Dec-17,"April 3, 2016",Apr-16,No Study Results Posted,null,May-17,microvascular reactivity|oxidative stress|modification of immunological response by high salt diet|antioxidant capacity,https://ClinicalTrials.gov/show/NCT02727426
688,NCT02727387,Protocol for the Treatment of Metastatic Ewing Sarcoma,Recruiting,No Results Available,Ewing's Sarcoma (ES),Drug: TEMIRI|Drug: ADM|Drug: IFO|Drug: CYC|Drug: ETO|Drug: BUMEL|Drug: VIN,Italian Sarcoma Group,Both,Child|Adult,Phase 2,70,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,ISG/AIEOP EW-2,"March 23, 2016",May-09,May-20,"April 4, 2016",Mar-16,No Study Results Posted,EW-2,May-18,Overall Survival (OS)|Event Free Survival (DFS)|Safety - Incidence and grade of treatment-emergent Adverse Events|Quality of life,https://ClinicalTrials.gov/show/NCT02727387
689,NCT02727374,Fear to Fall Reduction in Geriatric Patients Who Suffered Previous Falls,Recruiting,No Results Available,Geriatric Disorder,Other: Physiotherapy intervention|Behavioral: Psychology Intervention,University of Valencia,Both,Adult|Senior,Phase 1,20,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",CI_UValencia1,"March 22, 2016",Dec-15,Sep-16,"April 1, 2016",Mar-16,No Study Results Posted,FFALL_GER,Sep-16,Barthel Index|EuroQol-5D|Berg Balance Scale|Timed Up & Go Test,https://ClinicalTrials.gov/show/NCT02727374
690,NCT02727361,Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia,Recruiting,No Results Available,Dystonia,Radiation: PET (Positron Emission Tomography) imaging|Other: MRI : Magnetic Resonance Imaging,"University Hospital, Bordeaux",Both,Adult|Senior,Phase 3,40,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research|Masking: Open Label,CHUBX2014/20,"March 21, 2016",Jan-16,Jan-18,"March 29, 2016",Mar-16,No Study Results Posted,DYSCHOL,Jan-18,Intensity of fixation (binding),https://ClinicalTrials.gov/show/NCT02727361
691,NCT02727309,A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients,Recruiting,No Results Available,Hepatocellular Carcinoma,Drug: Apatinib,"Beijing Cancer Hospital|Jiangsu HengRui Medicine Co., Ltd.",Both,Adult|Senior,Phase 1|Phase 2,30,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,AHEAD-HBH001,"March 28, 2016",Oct-15,Mar-19,"March 30, 2016",Mar-16,No Study Results Posted,null,Dec-18,Progression free survival|Overall survival|Objective response rates,https://ClinicalTrials.gov/show/NCT02727309
692,NCT02727231,Closing the Loop in Adults With Type 1 Diabetes and HbA1C<7.5% Under Free Living Conditions,Recruiting,No Results Available,Type 1 Diabetes,Device: Florence D2A or similar closed loop glucose control system|Device: CSII with CGM,University of Cambridge|Medical University of Graz,Both,Adult|Senior,,34,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label,AP@home04 phase2,"March 29, 2016",Mar-16,Feb-17,"March 29, 2016",Mar-16,No Study Results Posted,null,Sep-16,Time spent in the target glucose range (3.9 to 10.0 mmol/l) based on subcutaneous glucose monitoring|Continuous subcutaneous glucose monitoring (CGM) based outcome|Continuous subcutaneous glucose monitoring (CGM) based outcome during overnight period between 23:00 and 08:00|Continuous subcutaneous glucose monitoring (CGM) based outcome during day period between 08:00 to 23:00|Insulin dose|Adverse Events|Utility Evaluation,https://ClinicalTrials.gov/show/NCT02727231
693,NCT02727179,Open vs Laparoscopic Liver Surgery for Colorectal Liver Metastases,Recruiting,No Results Available,Colorectal Liver Metastasis|Laparoscopic Liver Resection,Procedure: Liver resection,Hospital Universitario Virgen de la Arrixaca,Both,Adult|Senior,,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,HUVA-0515,"March 14, 2016",Feb-05,Jun-16,"March 29, 2016",Mar-16,No Study Results Posted,LapOpHuva,Jun-16,Overall survival|Surgical operative time|Blood losses|Transfusion|Hospital stay|Time between surgery and adjuvant chemotherapy|Mortality|Morbidity,https://ClinicalTrials.gov/show/NCT02727179
694,NCT02727127,"Brain Ion Homeostasis, Lithium and Bipolar Disorder",Recruiting,No Results Available,Healthy|Bipolar Disorder,,New York University School of Medicine,Both,Adult,,115,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,S12-03629,"March 29, 2016",Sep-15,Sep-16,"April 4, 2016",Apr-16,No Study Results Posted,null,Sep-16,"Study the relationship between BLC and brain sodium ion homeostasis, as measured by concurrent Single / Triple quantum sodium MRI in BPD patients|To investigate the measurement of sodium ion homeostasis in the brain of BPD patients, at clinical magnetic field strengths (3 Tesla), as a non-invasive surrogate marker of BLC during Lithium Carbonate therapy",https://ClinicalTrials.gov/show/NCT02727127
695,NCT02727114,Echographic Measurement of Skin Thickness in Children,Recruiting,No Results Available,Skin Thickness,Other: Echographic measurement of skin thickness,Timothi Van Mulder|Novosanis NV,Both,Child|Adult,,256,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2015_NOV_VX_003,"March 23, 2016",Feb-16,Aug-16,"March 29, 2016",Mar-16,No Study Results Posted,PIDIC-1,Aug-16,skin thickness (in millimeters) of the proximal dorsal forearm (both left and right)|skin thickness (in millimeters) of the proximal ventral forearm (both left and right)|skin thickness (in millimeters) of the deltoid region (both left and right)|skin thickness (in millimeters) of the medial thigh region (both left and right),https://ClinicalTrials.gov/show/NCT02727114
696,NCT02727101,Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.,Recruiting,No Results Available,Epilepsy,Drug: perampanel,"Mid-Atlantic Epilepsy and Sleep Center, LLC|Eisai Inc.",Both,Adult,Phase 4,72,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,maes 008,"March 29, 2016",Nov-15,Apr-18,"April 1, 2016",Apr-16,No Study Results Posted,null,Aug-17,responder rate|seizure freedom rate|treatment discontinuation rate,https://ClinicalTrials.gov/show/NCT02727101
697,NCT02727049,Motion Capture and Analysis of NYIT Athletes,Recruiting,No Results Available,Athletic Injuries,Other: Osteopathic manipulative medicine (OMM),New York Institute of Technology,Both,Adult,,200,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,BHS1064,"February 12, 2015",Feb-15,Dec-18,"April 1, 2016",Jan-16,No Study Results Posted,null,Dec-18,change in joint angles (degrees),https://ClinicalTrials.gov/show/NCT02727049
698,NCT02727036,Effect of Pumpkin Seed Oil or Pumpkin Seeds on Blood Pressure and Menopausal Symptoms in Postmenopausal Women,Recruiting,No Results Available,Hypertension|Dyslipidemia,Dietary Supplement: Pumpkin seed oil|Dietary Supplement: Pumpkin seeds,Texas Woman's University,Female,Child|Adult|Senior,,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,17696,"March 21, 2016",Nov-15,May-17,"April 1, 2016",Mar-16,No Study Results Posted,null,Dec-16,Change in systolic and diastolic blood pressure|Change in Total Cholesterol level (mg/dl)|Change in Plasma Triglycerides (mg/dl)|Change in Plasma High-Density Lipoprotein Cholesterol (mg/dl)|Change in Plasma Low-Density Lipoprotein Cholesterol (mg/dl)|Change in C-reactive protein (CRP)|Change in Endothelial Function,https://ClinicalTrials.gov/show/NCT02727036
699,NCT02727023,Effect of OMM on Anandamide Levels in Saliva,Recruiting,No Results Available,Anandamide|Endocannabinoids,Other: Osteopathic Manipulative Medicine,New York Institute of Technology|Cold Spring Harbor Laboratory,Both,Adult|Senior,,30,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,BHS-1152,"January 19, 2016",Dec-15,Dec-16,"March 29, 2016",Dec-15,No Study Results Posted,null,Dec-16,Osteopathic Manipulative Lymphatic Pump Treatment and Its Relationship To Anandamide levels,https://ClinicalTrials.gov/show/NCT02727023
700,NCT02726984,Carotid Plaque Assessment Using 18Fluorine (18F) -Sodium Fluoride Positron Emission Tomography (PET) /MR,Recruiting,No Results Available,Carotid Artery Plaque,Drug: 18F-sodium fluoride PET/MR,Hospices Civils de Lyon,Both,Adult|Senior,,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,69HCL15_0283,"December 15, 2015",Jan-16,Jul-17,"March 29, 2016",Dec-15,No Study Results Posted,CARTIS,Jul-17,"Measure of SUV (standardized uptake value) among carotid plaques ‰ä´ 50%|Measure of TBR (tissue-to-background ratio) among carotid plaques ‰ä´ 50%|Number of participants with image of lipid-rich necrotic core accounting for more than 50% of the surface of the plate on a 2D section.|Number of participants with image of intraplaque hemorrhage defined as an hyperintense region within the plaque on T1-weighted sequence.|Number of participants with image of thinning/rupture of the fibrous cap on a T1-weighted sequence following intravenous gadolinium administration.|Quantitative assessement of the wall shear stresses (WSS, measured in Pa) along the carotid wall in 3D.|Quantitative assessement of oscillatory shear indexes (OSI, unitless) along the carotid wall in 3D.|Number of participants with histological image of intraplaque hemorrhage, and/or lipid-rich necrotic core and /or thinning/rupture of the fibrous cap in surgical patients.|Measure of systemic markers of inflammation: Interleukine 1-Beta (IL1-beta), Tumor Necrosis Factor-alpha (TNF-alpha)",https://ClinicalTrials.gov/show/NCT02726984
701,NCT02726971,Comparison of Different Doses of Oestrogen Therapy for Preventing Intrauterine Adhesion,Recruiting,No Results Available,Asherman Syndrome,Drug: Femoston,"Fu Xing Hospital, Capital Medical University",Female,Adult,Phase 1|Phase 2,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Investigator),LYuhuan,"March 22, 2016",Jan-16,null,"March 29, 2016",Mar-16,No Study Results Posted,null,Dec-16,The improvement in stage of Intrauterine Adhesion according to the American Fertility Society Classification of Uterine(AFS)|The baseline endometrial thickness|The restoration of normal menstrual pattern,https://ClinicalTrials.gov/show/NCT02726971
702,NCT02726932,Intra-abdominal View and Inflammatory Markers in Secondary Peritonitis - Correlation to Recovery,Recruiting,No Results Available,Peritonitis,"Other: No intervention, merely observational",Helsinki University Central Hospital,Both,Adult|Senior,,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Dnro 6/13/03/02/2016,"March 29, 2016",Mar-16,null,"March 29, 2016",Mar-16,No Study Results Posted,PERICLASS,Mar-19,Mortality|ICU admission|Length of hospitalization|Reoperations|Complications,https://ClinicalTrials.gov/show/NCT02726932
703,NCT02726919,Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy,Recruiting,No Results Available,Epilepsy,Drug: Clobazam,"Pavel Klein|H. Lundbeck A/S|Mid-Atlantic Epilepsy and Sleep Center, LLC",Both,Adult,Phase 4,20,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,maes 007,"March 13, 2015",Feb-15,Jun-17,"March 29, 2016",Mar-16,No Study Results Posted,null,Jun-16,seizure freedom|>75% seizure frequency reduction and median seizure frequency reduction for the whole treatment duration|median seizure frequency reduction for the whole treatment duration|comparing seizure frequency per 28 day periods during treatment vs. baseline|quality of life questionnaire (QOLIE-31-P) scores,https://ClinicalTrials.gov/show/NCT02726919
704,NCT02726880,Reducing Internet Gaming,Recruiting,No Results Available,Internet Gaming Disorder,Behavioral: Behavioral therapy|Behavioral: Referral for care,University of Connecticut Health Center|National Institute on Drug Abuse (NIDA),Both,Child|Adult|Senior,,40,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,16-114-3|P50DA009241,"March 31, 2016",Mar-16,Jan-18,"March 31, 2016",Mar-16,No Study Results Posted,null,Jan-18,Proportion of participants who complete sessions|Proportion of days of game playing,https://ClinicalTrials.gov/show/NCT02726880
705,NCT02726815,Developing a Symptom List for Children With Cancer,Recruiting,No Results Available,Paediatric Oncology Palliative Care,Other: Questionnaire,Royal Marsden NHS Foundation Trust,Both,Child|Adult,,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CCR4385,"March 22, 2016",Mar-16,Sep-17,"March 29, 2016",Mar-16,No Study Results Posted,null,Sep-17,Prevalence of all symptoms identified by child using the age appropriate Memorial Symptom Assessment Scale.|Prevalence of all symptoms identified by the parent using the same assessment tool as the child|Prevalence of all symptoms identified by the nurse,https://ClinicalTrials.gov/show/NCT02726815
706,NCT02726802,Effectiveness of Two Different Entry Portal Pathways Into Primary Care for Musculoskeletal Injury,Recruiting,No Results Available,Physical Therapy Direct Access|Physical Therapy Primary Care,Other: physical therapy vs. primary care interventions,Reynolds Army Community Hospital|Brooke Army Medical Center|Temple University,Both,Adult|Senior,Phase 1|Phase 2,102,U.S. Fed|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)",413803-1,"January 11, 2016",Jan-16,Dec-17,"April 1, 2016",Mar-16,No Study Results Posted,null,Jul-17,Patient Specific Functional Scale|PROMIS physical function scale|Global Rating of Change (GROC)|Defense and Veterans Pain Rating Scale|Self-Report Medical Readiness Questionnaire|Medical Profile Status|Overall Healthcare Consumption|Patient Satisfaction|Report of adverse events,https://ClinicalTrials.gov/show/NCT02726802
707,NCT02726763,Feasibility and Tolerability of Transcranial Direct Current Stimulation With Concurrent Cognitive Training,Recruiting,No Results Available,Breast Cancer Survivors,Device: Transcranial Direct Current Stimulation (tDCS)|Behavioral: Questionnaires,Memorial Sloan Kettering Cancer Center,Female,Adult,,16,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,16-034,"March 30, 2016",Mar-16,null,"March 30, 2016",Mar-16,No Study Results Posted,null,Mar-17,number of subjects recruited,https://ClinicalTrials.gov/show/NCT02726763
708,NCT02726750,Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies,Recruiting,No Results Available,Monoclonal Gammopathy of Unknown Significance|Smoldering Multiple Myeloma,Procedure: Blood Collection,"M.D. Anderson Cancer Center|Signal Genetics, Inc.",Both,Adult|Senior,,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PA15-0575,"March 30, 2016",Dec-15,null,"April 1, 2016",Apr-16,No Study Results Posted,null,Dec-21,Rate of Progression to Multiple Myeloma,https://ClinicalTrials.gov/show/NCT02726750
709,NCT02726724,Does the Presence of Observers Influence the Success of the Neonatal Endotracheal Intubation?,Recruiting,No Results Available,Stress,Other: 5 observers|Other: 1 observer,Maisonneuve-Rosemont Hospital,Both,Child|Adult|Senior,,51,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label,Hopital Maisonneuve Rosemont,"March 22, 2016",Oct-15,Oct-16,"April 1, 2016",Mar-16,No Study Results Posted,null,Oct-16,Evaluating the differences in the duration (seconds) to reach intubation of the mannequin between the two experimental conditions.|Variability of the heart rate of the operator between the condition A and B.|The number of wrong ET length position between the condition A and B,https://ClinicalTrials.gov/show/NCT02726724
710,NCT02726672,Fatigue and Inspiratory Muscles Training in Patients With Multiple Sclerosis,Recruiting,No Results Available,Multiple Sclerosis,Device: respiratory rehabilitation using Powerbreathe,Lille Catholic University,Both,Adult,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,RC-P0043|2015-A01451-48,"March 22, 2016",Feb-16,Feb-18,"April 1, 2016",Mar-16,No Study Results Posted,AIRSEP,Aug-17,Fatigue graded according to EMIF-SEP questionnaire|Sleep disorders graded according to the Epworth Sleepiness Scale|Quality of life graded according to the SEP-59 questionnaire|Maximal inspiratory pressure graded according to the Black and Hyatt method|Maximal expiratory pressure graded according to Black and Hyatt method|Forced vital capacity (FVC) graded with a portable spirometer|Tidal volume graded with a portable spirometer|Forced expiratory volume in one second (FEV1) graded with a portable spirometer|FEV1/ FVC ratio graded with a portable spirometer|Energy consumption during repeated effort|Depression graded according to the French version of the Beck Depression Inventory Fast-Screen|Swallowing problems graded according to the DYMUS score|Level of disability graded by the EDSS (Expanded Disability Status Scale)|Collection of the drug treatments received evaluated by a questionnaire,https://ClinicalTrials.gov/show/NCT02726672
711,NCT02726646,Evaluation of Local Doxycycline in Smokers With Chronic Periodontitis,Recruiting,No Results Available,Chronic Periodontitis,Drug: Doxycycline|Procedure: Mechanical debridement|Drug: Placebo,"University of Campinas, Brazil|Pontificia Universidade Catolica de Sao Paulo",Both,Adult,Phase 2,40,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",952015,"February 29, 2016",Jun-15,Mar-17,"April 4, 2016",Mar-16,No Study Results Posted,null,Aug-16,Relative Clinical Attachment Level,https://ClinicalTrials.gov/show/NCT02726646
712,NCT02726633,Evaluate the Utility of the ProLung Test in the Diagnosis of Lung Cancer,Recruiting,No Results Available,Solitary Pulmonary Nodule|Multiple Pulmonary Nodules,,Chinese Alliance Against Lung Cancer,Both,Adult|Senior,,500,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,CAALC-004-Prolung,"March 29, 2016",May-15,Jan-17,"April 1, 2016",Apr-16,No Study Results Posted,ProLung,Dec-16,Safety and Efficacy of the ProLung Test,https://ClinicalTrials.gov/show/NCT02726633
713,NCT02726594,Evaluation of Patient Comfort and Image Quality in Magnetic Resonance Imaging,Recruiting,No Results Available,"Patient Satisfaction, Diagnostic Accuracy",,University of Zurich,Both,Adult|Senior,,1000,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,KEK-ZH-Nr. 2015-0081,"March 29, 2016",Aug-15,Dec-19,"April 1, 2016",Apr-16,No Study Results Posted,null,Jun-18,Patient comfort|Image quality,https://ClinicalTrials.gov/show/NCT02726594
714,NCT02726568,High Dose Icotinib For NSCLC Patients Harboring EGFR Mutation With Brain Metastases,Recruiting,No Results Available,Non-small Cell Lung Cancer|Brain Metastases,Drug: Icotinib|Radiation: WBRT|Drug: chemotherapy,"Betta Pharmaceuticals Co.,Ltd.",Both,Adult|Senior,Phase 2,30,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,BD-IC-IV-65,"March 29, 2016",Mar-16,null,"March 31, 2016",Mar-16,No Study Results Posted,null,Mar-18,iPFS|Progress-free survival (PFS)|Quality of life measured by FACT-L/LCS 4.0 and FACT-Br|Neurocognitive effects evaluated according to Mini-Mental Status Examination,https://ClinicalTrials.gov/show/NCT02726568
715,NCT02726555,The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin•__Comparing With Standardized Statin,Recruiting,No Results Available,Dyslipidemia|Atherosclerosis,Drug: Red yeast rice and atorvastatin|Drug: Atorvastatin alone,Wenzhou Medical University,Both,Adult|Senior,Phase 3,240,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",wzfeyxzk,"March 29, 2016",Nov-15,May-17,"April 3, 2016",Apr-16,No Study Results Posted,null,May-17,Mean percentage change from baseline at week 24 (or the last assessment) on serum low-density lipoprotein cholesterol (LDL-C) level|Mean percentage change from baseline at week 24 (or the last assessment on serum total cholesterol (TC) level|Mean percentage change from baseline at week 24 (or the last assessment) on serum high-density lipoprotein cholesterol (HDL-C) level|Mean percentage change from baseline at week 24 (or the last assessment) on serum triglyceride (TG) level|Mean percentage change from baseline at week 24 (or the last assessment) on serum non-HDL cholesterol level|Percentage of Participants Who Experienced Statin-associated muscle symptoms (SAMs),https://ClinicalTrials.gov/show/NCT02726555
716,NCT02726516,Effects of PRJ-205 on Performance in Trained Young Subjects,Recruiting,No Results Available,Healthy,Dietary Supplement: PRJ-205|Other: Placebo,Bioiberica|University of Valencia,Male,Adult,,20,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",PRJ-205,"March 23, 2016",Mar-16,Apr-16,"March 29, 2016",Mar-16,No Study Results Posted,null,Apr-16,Aerobic performance determined by VO2max|Pressure pain threshold of calf muscle|Serum markers of muscular damage|Oxidative stress parameters,https://ClinicalTrials.gov/show/NCT02726516
717,NCT02726503,Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer,Recruiting,No Results Available,Anaplastic Thyroid Cancer,Drug: Lenvatinib,"Translational Research Informatics Center, Kobe, Hyogo, Japan",Both,Adult|Senior,Phase 2,39,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,TRIHN1504|UMIN000020773,"March 29, 2016",Jan-16,Jul-18,"April 5, 2016",Apr-16,No Study Results Posted,HOPE,Jul-18,Overall Survival (OS)|Progression-Free Survival (PFS)|Best Overall Response (BOR)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Clinical Benefit Rate (CBR)|Safety assessment on the incidence ratio of adverse events,https://ClinicalTrials.gov/show/NCT02726503
718,NCT02726464,Testing the Characteristics of Platelet Rich Plasma in Sports Medicine,Recruiting,No Results Available,Musculoskeletal Pain|Osteoarthritis,,University of British Columbia|LightIntegra Technology,Both,Adult|Senior,,40,Other|Industry,Observational,Observational Model: Case Control|Time Perspective: Prospective,H16-00328,"March 29, 2016",Mar-16,Feb-17,"April 7, 2016",Apr-16,No Study Results Posted,PRiSM,Sep-16,Change in pre- and post- pain score at 3 and 6 weeks|The impact of microparticle content on pain scores|Correlation of platelet count to ThromboLUX results|The use of dynamic light scattering (ThromboLUX) as a patient screening tool,https://ClinicalTrials.gov/show/NCT02726464
719,NCT02726438,Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery,Recruiting,No Results Available,"Bone Diseases, Infectious",Drug: Debio 1450,Debiopharm International SA,Both,Adult|Senior,Phase 1,13,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,Debio 1450-108|226488,"March 29, 2016",Apr-16,Jun-16,"April 21, 2016",Apr-16,No Study Results Posted,null,Jun-16,Bone to plasma ratio for Debio 1452 (the Debio 1450 active moiety)|Plasma ratios for Debio 1452|Area under the curve at steady state (AUCìã) of Debio 1452|Maximum observed plasma concentration (Cmax) of Debio 1452|Measured concentration at the end of a dosing interval at steady state (Ctrough) of Debio 1452,https://ClinicalTrials.gov/show/NCT02726438
720,NCT02726412,PACU Stay After Lower Limb Revascularisation,Recruiting,No Results Available,"Perioperative, Enhanced Recovery",Procedure: Acute vs elective,"Rigshospitalet, Denmark",Both,Adult|Senior,,180,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PACU revascularisation 2016,"March 29, 2016",Feb-16,Jun-16,"April 1, 2016",Apr-16,No Study Results Posted,null,Jun-16,Complications assessed by aldrete score,https://ClinicalTrials.gov/show/NCT02726412
721,NCT02726399,Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,Recruiting,No Results Available,Gastric Cancer|Gastroesophageal Junction Cancer,Drug: Ramucirumab|Drug: Trastuzumab|Drug: Capecitabine/Cisplatin,Memorial Sloan Kettering Cancer Center,Both,Adult|Senior,Phase 2,37,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,15-301,"March 29, 2016",Mar-16,null,"March 29, 2016",Mar-16,No Study Results Posted,null,Mar-19,progression free survival,https://ClinicalTrials.gov/show/NCT02726399
722,NCT02726360,Physician Use of Non-English Language Skills in Cancer Care,Recruiting,No Results Available,Breast Cancer|Colon Cancer|Lung Cancer,Behavioral: survey|Behavioral: Audio record,Memorial Sloan Kettering Cancer Center|Elmhurst Hospital Center|Johns Hopkins University|Lincoln Medical and Mental Health Center|Queens Cancer Center of Queens Hospital,Both,Adult|Senior,,24,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,15-316,"March 15, 2016",Dec-15,null,"April 6, 2016",Apr-16,No Study Results Posted,null,Dec-17,study-specific coding structure,https://ClinicalTrials.gov/show/NCT02726360
723,NCT02726334,"A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.",Recruiting,No Results Available,Colorectal Cancer,Drug: BNC101 Solution for Infusion|Drug: BNC101 in combination with FOLFIRI,"Bionomics Limited|CPR Pharma Services Pty Ltd, Australia",Both,Adult|Senior,Phase 1,54,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,BNC101. 001,"March 28, 2016",Mar-16,null,"April 20, 2016",Apr-16,No Study Results Posted,null,Apr-19,Maximum Tolerated Dose,https://ClinicalTrials.gov/show/NCT02726334
724,NCT02726282,Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences,Recruiting,No Results Available,Thyroid Cancer,,Mayo Clinic,Both,Adult|Senior,,300,Other,Observational,Time Perspective: Prospective,15-008166,"March 29, 2016",Mar-16,Mar-17,"March 29, 2016",Mar-16,No Study Results Posted,null,Mar-17,Treatment choice,https://ClinicalTrials.gov/show/NCT02726282
725,NCT02726243,Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease,Recruiting,No Results Available,Inflammatory Bowel Disease|Colorectal Cancer,,"Assistance Publique - HÌ«pitaux de Paris|Institut National de la SantÌ© Et de la Recherche MÌ©dicale, France",Both,Adult|Senior,,240,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,NI13006,"March 29, 2016",Nov-14,Apr-17,"March 31, 2016",Mar-16,No Study Results Posted,DYSCOLIC,Apr-17,Composition of fecal microbiota by 16S sequencing|Profile of fecal bile acids,https://ClinicalTrials.gov/show/NCT02726243
726,NCT02726217,NYULMC CareSmarts Pilot,Recruiting,No Results Available,Diabetes|Type 2 Diabetes (T2D),Behavioral: CareSmarts Mobile Health Diabetes Program|Behavioral: Standard of Care Reminders and Self Assessments,New York University School of Medicine,Both,Adult|Senior,,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Subject),15-00923,"March 29, 2016",Mar-16,Nov-17,"March 29, 2016",Mar-16,No Study Results Posted,null,Nov-16,Measure of glucose|Satisfaction with Care measured by Diabetes Treatment Satisfaction Questionnaire (DTSQ).|Adherence to the diabetes self-management regimen using the Diabetes Self Management Questionnaire (DSMQ).|Acceptability of the intervention protocol will be evaluated using a satisfaction survey.,https://ClinicalTrials.gov/show/NCT02726217
727,NCT02726087,Quality of Life After Ministernotomy Versus Full Sternotomy Aortic Valve Replacement,Recruiting,No Results Available,Aortic Valve Stenosis|Heart Valve Diseases|Aortic Valve Disease,Procedure: ministernotomy|Procedure: Full sternotomy,FundaciÌ_n PÌ¼blica Andaluza para la InvestigaciÌ_n de MÌÁlaga en Biomedicina y Salud,Both,Adult|Senior,,96,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),CALIDAD-SVAO,"March 13, 2016",Mar-16,Mar-19,"March 31, 2016",Mar-16,No Study Results Posted,QUALITY-AVR,Sep-18,"Differences between intervention groups in change from baseline Questionnaire EQ-5D-5Lå¨ Index at 1, 6 and 12 months|Differences between intervention groups in change from baseline Questionnaire EQ-5D-5Lå¨ Visual Analogic Scale for pain at 1, 6 and 12 months|Early postoperative combined endpoint of 6 complications|Satiscore Questionnaire|Differences between intervention groups in change from baseline Questionnaire EQ-5D-5Lå¨ severity index at 1, 6 and 12 months|Differences between intervention groups in change from baseline Questionnaire EQ-5D-5Lå¨ health index (severity index inverse) at 1, 6 and 12 months|Late postoperative combined endpoint of 6 complications|Total in-Hospital and Intensive Care Unit stay (in days)|Cardiopulmonary bypass time in minutes and cross-clamp ischemic heart time in minutes needed in the surgery|Mechanical Ventilatory Support time needed after surgery (in hours)|Transfusional requirements (number of red packed cells, fresh frozen plasma and platelets)|New York Heart Association functional class scale for heart failure|Number of participants alive (Survival)",https://ClinicalTrials.gov/show/NCT02726087
728,NCT02726061,Computer-based Dartmouth Research Problem Solving Therapy (DrPST) for Depression in Employee Assistance Programs (EAP),Recruiting,No Results Available,Depression,Behavioral: Computer Based PST,Dartmouth-Hitchcock Medical Center,Both,Adult|Senior,,500,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,STUDY00028777,"February 29, 2016",Feb-16,Feb-21,"March 29, 2016",Mar-16,No Study Results Posted,null,Feb-21,Proportion of participants referred to the DrPST program that log on to the program.|Participant reports of the acceptability of the DrPST program as a stand-alone treatment for depression,https://ClinicalTrials.gov/show/NCT02726061
729,NCT02725866,"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, å± Dasabuvir, å± Ribavirin in Participants With Chronic Hepatitis C",Recruiting,No Results Available,Chronic Hepatitis C,,AbbVie,Both,Adult|Senior,,200,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,P15-842,"March 24, 2016",Apr-16,Jul-17,"April 11, 2016",Apr-16,No Study Results Posted,null,Jul-17,The percentage of participants achieving sustained virological response 12 weeks post-treatment (SVR12)|The percentage of participants with virological response at end of treatment (EoT).|The percentage of participants with relapse at EoT|The percentage of participants with breakthrough|The percentage of participants meeting on-treatment virologic failure|The percentage of participants meeting relapse|The number of participants meeting premature study drug discontinuation|The percentage of participants meeting missing SVR12 data and/or none of the above criteria,https://ClinicalTrials.gov/show/NCT02725866
730,NCT02725814,Sucrose Practices for Pain in Neonates Part B,Recruiting,No Results Available,Pain,Other: Sucrose,The Hospital for Sick Children|Sunnybrook Health Sciences Centre|IWK Health Centre|The Ottawa Hospital|Children's Hospital of Eastern Ontario,Both,Child,,160,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label,REB1000051066|126167,"March 9, 2016",Feb-16,Aug-19,"March 28, 2016",Mar-16,No Study Results Posted,SPiN,Aug-19,Impact on neurodevelopment assessed by the the Bayley Scales of Infant Development (BSID-III)|Pain intensity assessed by the Premature Infant Pain Profile - Revised (PIPP-R),https://ClinicalTrials.gov/show/NCT02725814
731,NCT02725801,Comparison of One-port and Two-port Tissue Expanders for Breast Reconstruction,Recruiting,No Results Available,Breast Cancer,Device: Allergen one-port tissue expander placement|Device: AlloX2 two-port tissue expander placement,University of Kentucky,Female,Adult|Senior,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,16-0064,"February 27, 2016",Feb-16,Jun-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Mar-17,Successful replacement of tissue expander with permanent implant|need for additional intervention,https://ClinicalTrials.gov/show/NCT02725801
732,NCT02725775,An Investigation of the Acute and Chronic Effects of 100% Florida Orange Juice Consumption on Cognitive Performance in 7-10 Year Old Children,Recruiting,No Results Available,No Conditions - Daily OJ Consumption on Cognition,Dietary Supplement: 100% Florida OJ|Dietary Supplement: Placebo Equicaloric Orange Drink,"University of Leeds|Department of Citrus, State of Florida USA|University of East Anglia",Both,Child,,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",RFP 15-01,"March 22, 2016",Mar-16,Dec-16,"March 28, 2016",Mar-16,No Study Results Posted,null,Dec-16,Immediate and delayed picture recognition|Delayed spatial memory|Tower of Hanoi|Corsi block tapping test,https://ClinicalTrials.gov/show/NCT02725775
733,NCT02725762,Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration,Recruiting,No Results Available,Age Related Macular Degeneration,Device: LT-300 Active (PBM)|Device: LT-300 Inactive (Sham),"LumiThera, Inc.|National Eye Institute (NEI)",Both,Adult|Senior,,30,Industry|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",CSP001|1R43EY025508-01,"March 23, 2016",Mar-16,Aug-17,"April 7, 2016",Apr-16,No Study Results Posted,LIGHTSITE1,Aug-17,Visual Acuity changes from baseline to month 12.|Contrast Sensitivity|Optical Coherence Tomography (OCT),https://ClinicalTrials.gov/show/NCT02725762
734,NCT02725697,Treatment of Complaints Following Sports Injuries With Traditional Chinese Medicine,Recruiting,No Results Available,Athletic Injuries,Other: TCM treatment,Sabine Klein|Swiss Professional Organization for Traditional Chinese Medicine,Both,Adult|Senior,,60,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,SBO-TCM 001,"March 20, 2016",Apr-16,Mar-18,"April 21, 2016",Apr-16,No Study Results Posted,null,Oct-17,change in minimal and maximal pain|change in limitation during sports|medication intake|patient satisfaction with therapy|number of therapeutic sessions|TCM methods applied,https://ClinicalTrials.gov/show/NCT02725697
735,NCT02725684,Using Genomic Analysis to Guide Individual Treatment in Glioblastoma,Recruiting,No Results Available,Glioblastoma,"Other: Observational study, no intervention",Rockefeller University|Memorial Sloan Kettering Cancer Center|Lenox Hill Hospital|North Shore University Hospital|New York University Langone Medical Center|Weill Medical College of Cornell University|Albert Einstein College of Medicine of Yeshiva University|New York Genome Center,Both,Child|Adult|Senior,,25,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RDA-837,"December 8, 2015",Feb-15,Dec-17,"March 28, 2016",Mar-16,No Study Results Posted,null,Dec-17,Identification of targetable variants in the tumor,https://ClinicalTrials.gov/show/NCT02725684
736,NCT02725671,Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography,Recruiting,No Results Available,Coronary Heart Disease|Coronary Artery Disease|Ischemic Heart Disease,Device: Explorer,Johns Hopkins University|Enverdis Corp.,Both,Adult|Senior,,356,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,33908,"March 10, 2016",Apr-15,Apr-20,"March 31, 2016",Mar-16,No Study Results Posted,null,Apr-19,"Accuracy of identifying patients with at least one 50% or greater coronary artery stenosis by CT angiography|Accuracy of identifying patients with any coronary atherosclerotic disease by CT angiography|Incidence of death, myocardial infarction, coronary artery revascularization, hospitalization for cardiac causes at follow up",https://ClinicalTrials.gov/show/NCT02725671
737,NCT02725658,Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI,Recruiting,No Results Available,Breast Tumor,Device: DOSI,"Beckman Laser Institute and Medical Center|Beckman Laser Institute University of California Irvine|University of California, San Francisco|University of California, Irvine",Female,Adult|Senior,,200,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research|Masking: Open Label,NIH/LAMMP-2015-2355,"January 29, 2016",Dec-15,Dec-19,"April 15, 2016",Apr-16,No Study Results Posted,null,Dec-19,"Concentration of oxy-hemoglobin (HbO2), in blood.|Concentration of deoxy-hemoglobin (HHb) in blood.|Concentration of total hemoglobin in blood.|Water content of tissue (%)|Bulk lipid in tissue (%)",https://ClinicalTrials.gov/show/NCT02725658
738,NCT02725632,Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA),Recruiting,No Results Available,Sleep Apnea Syndromes,Device: CPAP,Rhode Island Hospital|University of Illinois at Chicago,Both,Adult|Senior,,160,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,411013,"March 14, 2016",Aug-15,Jul-18,"April 1, 2016",Mar-16,No Study Results Posted,null,Jul-18,"The levels of sodium channel splicing variants that are related to the severity of OSA, change from baseline to one month after CPAP treatment.|The levels of potassium channels that are related to the severity of OSA, change from baseline to one month after CPAP treatment.",https://ClinicalTrials.gov/show/NCT02725632
739,NCT02725606,"Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer",Recruiting,No Results Available,Chemotherapy-induced Neutropenia,Biological: Pegylated Recombinant Human G-CSF|Biological: GW003,"Jiangsu T-Mab Biopharma Co.,Ltd",Female,Adult|Senior,Phase 1,24,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,Tmab-GW003-NP-04,"March 24, 2016",Mar-16,Nov-16,"March 31, 2016",Mar-16,No Study Results Posted,null,Nov-16,Frequency of adverse events (AEs) and serious adverse events (SAEs) which are related to GW003 as assessed by CTCAE v4.03|Maximum observed maximum plasma concentration [Cmax]|Time to reach the maximum observed plasma concentration [Tmax]|Area under the plasma concentration-time curve from time zero to infinity[AUC0-inf]|Area under the plasma concentration-time curve from time zero to time 't' where t is a defined time point after administration [AUC0-t]|Terminal elimination half-life[T1/2]|Absolute neutrophil count[ANC]|CD34+ count|Time to absolute neutrophil count(ANC) recovery|Incidence of severe neutropenia|Duration of severe neutropenia(DSN)|ANC nadir|Frequency of subjects with anti-GW003 antibody,https://ClinicalTrials.gov/show/NCT02725606
740,NCT02725580,Batten CLN6 Gene Therapy,Recruiting,No Results Available,Batten Disease|CLN6,Drug: scAVV9.CB.CLN6,Nationwide Children's Hospital|Gray Foundation,Both,Child|Adult|Senior,Phase 1|Phase 2,6,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,IRB15-00963,"March 16, 2016",Mar-16,Jul-18,"April 15, 2016",Apr-16,No Study Results Posted,null,Jul-18,"Development of unacceptable toxicity, defined as the occurrence of any one Grade III or higher, unanticipated, treatment-related toxicity.|Magnetic resonance imaging to document progression of the disease.|Cognitive testing|Language Delay|Visual Failure|EEG Monitoring",https://ClinicalTrials.gov/show/NCT02725580
741,NCT02725541,Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Trastuzumab emtansine,"The Methodist Hospital System|Genentech, Inc.",Female,Adult|Senior,Phase 2,36,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,Pro00013875,"March 18, 2016",Mar-16,Apr-19,"March 31, 2016",Mar-16,No Study Results Posted,NATURE,Apr-19,Objective response rate|Radiological response|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,https://ClinicalTrials.gov/show/NCT02725541
742,NCT02725515,A Study of the Effect of XmAbå¨5871 in Patients With Systemic Lupus Erythematosus,Recruiting,No Results Available,Systemic Lupus Erythematosus,Biological: XmAb5871|Biological: Placebo to match XmAb5871,"Xencor, Inc.|PPD|ICON plc",Both,Adult,Phase 2,90,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",XmAb5871-04,"January 8, 2016",Feb-16,Dec-18,"April 1, 2016",Apr-16,No Study Results Posted,null,Sep-18,"Percentage of patients without loss of systemic lupus erythematosus disease activity improvement on Day 169|Time to loss of systemic lupus erythematosus disease activity improvement achieved by a short intramuscular injection steroid therapy|Number of participants who experience Adverse Events (AE), Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) as assessed by CTCAE v4.3|Percentage of participants who experience Adverse Events (AE), Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) as assessed by CTCAE v4.3",https://ClinicalTrials.gov/show/NCT02725515
743,NCT02725502,Incretin Axis in Type 1 Diabetes Mellitus,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Drug: Linagliptin|Drug: Placebo,Postgraduate Institute of Medical Education and Research,Both,Child|Adult,,20,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",Type 1 Diabetes Mellitus,"January 20, 2014",Jul-13,May-16,"March 31, 2016",Mar-16,No Study Results Posted,null,Apr-16,Effect of Linagliptin on HbA1c in T1DM patients|Effect of Linagliptin on glycemic variability in T1DM patients|Effect of Linagliptin on insulin requirement in T1DM patients|Effect of linagliptin on GLP1 level during mixed meal test in T1DM patients|Effect of linagliptin on glucagon level during mixed meal test in T1DM patients,https://ClinicalTrials.gov/show/NCT02725502
744,NCT02725476,Study to Evaluate the Effect of XmAbå¨5871 on Disease Activity in Patients With IgG4-Related Disease (RD),Recruiting,No Results Available,IgG4-RD,Biological: XmAb5871,"Xencor, Inc.|Massachusetts General Hospital",Both,Adult|Senior,Phase 2,15,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,XmAb5871-03,"March 4, 2016",Mar-16,Dec-17,"March 28, 2016",Mar-16,No Study Results Posted,null,Oct-17,Proportion of patients with an improvement in IgG4-RD activity|Number of patients experiencing a treatment-emergent adverse event as assessed by CTCAE v4.3|Percent of patients experiencing a treatment-emergent adverse event as assessed by CTCAE v4.3,https://ClinicalTrials.gov/show/NCT02725476
745,NCT02725463,Multichannel Vestibular Implant Early Feasibility Study,Recruiting,No Results Available,"Other Disorders of Vestibular Function, Bilateral|Bilateral Vestibular Deficiency (BVD)|Gentamicin Ototoxicity|Labyrinth Diseases|Vestibular Diseases|Sensation Disorders",Device: Labyrinth Devices MVI‰ã¢ Multichannel Vestibular Implant,"Johns Hopkins University|National Institute on Deafness and Other Communication Disorders (NIDCD)|Labyrinth Devices, LLC",Both,Adult|Senior,,60,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,NA_00051349|R01DC013536|JHU80640,"January 12, 2016",Apr-16,Mar-18,"April 1, 2016",Apr-16,No Study Results Posted,null,Mar-18,Identified adverse events to assess the safety of the Labyrinth Devices Multichannel Vestibular Implant (MVI).|Change in 0.5/1/2/4 kilohertz (kHz) pure tone threshold average to assess the effects of MVI on cochlear function|Change in three-dimensional (3D) angular vestibulo-ocular reflex (VOR) gain [dimensionless] during ~150 deg/sec passive head impulse with modulated prosthetic input to assess the preliminary efficacy of the MVI|Consonant-vowel nucleus-consonant (CNC) speech recognition scores to assess the effects of MVI‰ã¢ implantation and use on cochlear function|Arizona Biomedical (AzBio) speech recognition scores to assess the effects of MVI‰ã¢ implantation and use on cochlear function|Vestibulo-ocular reflex (VOR) three-dimensional (3D) alignment to assess the preliminary efficacy of the MVI|Ocular Vestibular Evoked Myogenic Potentials (oVEMP) to assess the effects of MVI‰ã¢ implantation and use on utricular function|Cervical Vestibular Evoked Myogenic Potentials (cVEMP) to assess the effects of MVI implantation and use on saccular function|Changes in scores on 36-Item Short Form Health Survey (SF-36) to assess the effects of MVI implantation and use on activities of daily living and quality of life.|Changes in scores on Tinnitus Reaction Questionnaire (TRQ) to assess the effects of MVI implantation and use on activities of daily living and quality of life.|Changes in scores on Dizziness Handicap Inventory (DHI) to assess the effects of MVI implantation and use on activities of daily living and quality of life.|Changes in scores on the Health Utilities Index 3 (HUI3) to assess the effects of MVI implantation and use on activities of daily living and quality of life.|Changes in scores on the Vestibular Activities of Daily Living (VADL) to assess the effects of MVI implantation and use on activities of daily living and quality of life.|Changes in scores on the bilateral vestibular deficiency BVD-case definition subset of questions to assess the effects of MVI implantation and use on activities of daily living and quality of life.|Head thrust dynamic visual acuity (htDVA) to assess the feasibility and preliminary efficacy of the MVI‰ã¢|Bruininks-Oseretsky test of motor proficiency- balance subtest 2 (BOT2) to assess the feasibility and preliminary efficacy of the MVI‰ã¢|Dynamic Gait Index (DGI) to assess the feasibility and preliminary efficacy of the MVI‰ã¢|Gait speed to assess the feasibility and preliminary efficacy of the MVI‰ã¢,https://ClinicalTrials.gov/show/NCT02725463
746,NCT02725424,Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer,Recruiting,No Results Available,Gastric Cancer,Drug: S-1|Drug: Trastuzumab|Drug: Oxaliplatin|Drug: Docetaxel,Chinese Academy of Medical Sciences,Both,Adult|Senior,Phase 2,414,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CH-GI-071,"March 11, 2016",Aug-15,Jun-19,"April 13, 2016",Apr-16,No Study Results Posted,MATCH,Dec-18,Pathological response rate,https://ClinicalTrials.gov/show/NCT02725424
747,NCT02725398,Effect of Buscopan on Gastrointestinal Imaging Quality With Probe-based Confocal Laser Endomicroscopy,Recruiting,No Results Available,Gastrointestinal Imaging With pCLE,Drug: Buscopan|Drug: Scopolamine|Drug: physiological saline,Xijing Hospital of Digestive Diseases,Both,Adult|Senior,,150,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",pCLE-BSP,"March 21, 2016",Dec-13,Dec-16,"March 31, 2016",Mar-16,No Study Results Posted,null,Dec-16,high quality image ratio|spasm score|diagnosis accuracy rate|scale value of patient' comfort degree assessed by using visual analogue scale (VAS),https://ClinicalTrials.gov/show/NCT02725398
748,NCT02725385,Stress and Coping in Caregivers of Younger Patients With Cancer,Recruiting,No Results Available,Anxiety|Depression,Other: Laboratory Biomarker Analysis|Other: Physiologic Testing|Other: Questionnaire Administration,Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI),Both,Adult|Senior,,240,Other|NIH,Observational,Observational Model: Case Control|Time Perspective: Prospective,CCCWFU 01413|NCI-2014-01878|P30CA012197,"February 22, 2016",Mar-14,null,"March 28, 2016",Feb-16,No Study Results Posted,null,Mar-16,Level of Caregiver Distress as measured by multiple regressions analysis,https://ClinicalTrials.gov/show/NCT02725385
749,NCT02725359,Tizanidine and Superficial Cervical Block on Pain After Thyroidectomy,Recruiting,No Results Available,Thyroidectomy,Drug: Placebo|Drug: Tizanidine|Drug: Bupivacaine|Drug: Saline,Ataturk University,Both,Adult,Phase 4,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)",AUTF ANESTHESIA,"March 21, 2016",Apr-16,Oct-16,"April 12, 2016",Apr-16,No Study Results Posted,PTUSGSCB,Apr-16,Visual analog pain score|Opioid consumption,https://ClinicalTrials.gov/show/NCT02725359
750,NCT02725346,ArthroPlanner: A Surgical Planning Solution for Acromioplasty,Recruiting,No Results Available,Surgical Planning Solution|Acromioplasty|Shoulder Surgery|Critical Shoulder Angle,Procedure: Acromioplasty with planning|Procedure: Acromioplasty without planning,Adrien Schwitzguebel|La Tour Hospital,Both,Adult|Senior,,67,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",GE 15-151,"March 11, 2016",Jul-15,Dec-16,"March 26, 2016",Mar-16,No Study Results Posted,null,Feb-16,Volume in mm3 of bone removal in four zones determine between pre- and postoperative computed tomography|Tendon healing determine with ultrasound with Sugaya criteria|Pourcentage of gain of ROM between groups of postoperative range of motion|Constant score|ASES score|Simple shoulder value|SANE score,https://ClinicalTrials.gov/show/NCT02725346
751,NCT02725307,Non-invasive Peri- and Postoperative Monitoring of Femoral Artery Balloon Angioplasty,Recruiting,No Results Available,Cardiovascular Diseases,"Device: Noninvasive pulse wave analysis sensor, ECG-sensor",Tampere University Hospital|Tampere University of Technology|University of Tampere,Both,Child|Adult|Senior,,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,R15107,"March 16, 2016",Mar-16,Dec-17,"March 27, 2016",Mar-16,No Study Results Posted,null,Dec-16,Pulse wave change from baseline during PTA|Pulse wave characteristics after PTA,https://ClinicalTrials.gov/show/NCT02725307
752,NCT02725242,Efficacy of Once-daily Formoterol/Budesonide Turbuhaler 4.5/160 åµg in Step Down Asthma,Recruiting,No Results Available,Asthma,Drug: Formoterol/budesonide (4.5 ug/160ug)|Drug: Budesonide (200ug),Hat Yai Medical Education Center,Both,Adult|Senior,Phase 3,80,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,064/2014,"January 20, 2016",Mar-16,Dec-16,"April 3, 2016",Apr-16,No Study Results Posted,null,Dec-16,Change from baseline in Asthma Control Questionnaire (ACQ) score|Change from baseline in Asthma Controlled Test (ACT) score|Change from baseline in Peak expiratory flow (PEF)|Change from baseline in Forced Expiratory Volume in One Second (FEV1)|Percentage of participants who were categorized from asthma controlled assessment following GINA guideline,https://ClinicalTrials.gov/show/NCT02725242
753,NCT02725216,Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010),Recruiting,No Results Available,Proven or Suspected Gram-negative Bacterial Infection|Peri-operative Prophylaxis,Drug: ceftolozane/tazobactam,Merck Sharp & Dohme Corp.,Both,Child,Phase 1,36,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,7625A-010|CXA-PEDS-13-08,"March 28, 2016",Sep-14,Nov-16,"April 13, 2016",Apr-16,No Study Results Posted,null,Nov-16,Maximum plasma concentration (Cmax) of ceftolozane/tazobactam|Time to Cmax (Tmax) of ceftolozane/tazobactam|Concentration at last sampling point (Clast) of ceftolozane/tazobactam|Time of last sampling point (Tlast) of ceftolozane/tazobactam|Area under the plasma concentration-time curve from 0 to time of last sample collected (AUC0-tlast) of ceftolozane/tazobactam|Area under the plasma concentration-time curve from 0 to infinity (AUC0-‰ö_) of ceftolozane/tazobactam|Elimination half-life (t1/2) of ceftolozane/tazobactam|Volume of distribution at steady state (Vss) of ceftolozane/tazobactam|Plasma clearance (CL) of ceftolozane/tazobactam|Number of participants with one or more Adverse Events|Number of participants who discontinued study due to an Adverse Event,https://ClinicalTrials.gov/show/NCT02725216
754,NCT02725203,Unravelling Effectiveness of a Nurse-led Behavior Change Intervention to Enhance Physical Activity in Patients,Recruiting,No Results Available,Cardiovascular Diseases,Behavioral: Activate,UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development,Both,Adult|Senior,,297,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,NL54286.041.15,"March 25, 2016",Mar-16,May-17,"March 31, 2016",Mar-16,No Study Results Posted,null,May-17,"level of physical activity measured with the Personal Activity Monitor (PAM AM300)|Sedentary behaviour using the accelerometer using amount of minutes in the sedentary category (<1,8 METS)|Self-efficacy for physical activity using the Exercise Self-efficacy Scale (ESS)|Patient activation using the Patient Activation Measure (PAM-13)|Health status using the EQ-5D",https://ClinicalTrials.gov/show/NCT02725203
755,NCT02725177,Ocular Sarcoidosis Open Label Trial of ACTHAR Gel,Recruiting,No Results Available,Ocular Sarcoidosis|Panuveitis|Anterior Uveitis,Drug: Repository Corticotropin Injection|Drug: Repository Corticotropin Injection -Treatment Extension,The Cleveland Clinic|Mallinckrodt,Both,Adult|Senior,,20,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,Ocular Sarcoidosis 15-1072,"March 11, 2016",Mar-16,Dec-17,"April 4, 2016",Apr-16,No Study Results Posted,null,Dec-17,Proportion of patients with clinically significant improvement in visual acuity|Proportion of patients with clinically significant improvement in the resolution-intraocular inflammation|Proportion of patients experiencing a tapering of ocular/oral steroids by at least 50%|Proportion of patients with a clinically significant reduction-cystoid macular edema,https://ClinicalTrials.gov/show/NCT02725177
756,NCT02725151,Acute Heart Failure Monitoring Via Inferior Vena Cava Ultrasound,Recruiting,No Results Available,Chronic Heart Failure,,Haseki Training and Research Hospital,Both,Child|Adult|Senior,,60,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,231,"March 20, 2016",Aug-15,Apr-16,"March 30, 2016",Mar-16,No Study Results Posted,null,Apr-16,Vena cava inferior diameter change end of each 500cc urination|Arterial blood pressure change end of each 500cc urination|Pulse rate change end of each 500cc urination,https://ClinicalTrials.gov/show/NCT02725151
757,NCT02725138,Efficacy of Probiotics in the Gut Microbiota and H Pylori Density,Recruiting,No Results Available,Helicobacter,Dietary Supplement: Probiotic|Other: Placebo,National Taiwan University Hospital|Taiwan Sugar Cooperation Company,Both,Adult|Senior,Phase 2|Phase 3,40,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",201511071RIPA,"March 27, 2016",Mar-16,Dec-17,"April 6, 2016",Apr-16,No Study Results Posted,null,Dec-17,Reduction of bacterial load of H. pylori|changes in gut microbiota|adverse effects,https://ClinicalTrials.gov/show/NCT02725138
758,NCT02725125,Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer,Recruiting,No Results Available,Stomach Neoplasms,Biological: EPCAM-targeted CAR-T cells,"Sinobioway Cell Therapy Co., Ltd.",Both,Child|Adult|Senior,Phase 1|Phase 2,19,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,ACCO-2015-06-04,"March 25, 2016",Nov-15,May-19,"March 30, 2016",Mar-16,No Study Results Posted,EECSC,Oct-16,Disease control rates|Duration of remission,https://ClinicalTrials.gov/show/NCT02725125
759,NCT02725112,Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers,Recruiting,No Results Available,Healthy,Drug: Pregabalin ER|Drug: Pregabalin ER|Drug: Pregabalin ER|Drug: Pregabalin ER|Drug: Pregabalin ER|Drug: Pregabalin ER,Pfizer,Both,Adult,Phase 1,24,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label,A0081309,"February 10, 2016",Feb-16,May-16,"March 24, 2016",Mar-16,No Study Results Posted,null,May-16,"Cmax from time zero to infinity (AUCinf), when data permits, otherwise AUC from time zero to last quantifiable concentration (AUClast) of pregabalin ER 330 mg slow and fast release rate tablet formulations.|AUC from time zero to infinity (AUCinf), when data permits, otherwise AUC from time zero to last quantifiable concentration (AUClast) of pregabalin ER 330 mg slow and fast release rate tablet formulations.|Cmax of pregabalin.|Time to Cmax (Tmax) of pregabalin|Lag time (Tlag) of pregabalin|AUC of pregabalin|Terminal elimination half life (tå_) of pregabalin|Safety endpoints include evaluation of AEs.",https://ClinicalTrials.gov/show/NCT02725112
760,NCT02725086,Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostimå¨ Compared to Neupogenå¨ in Healthy Adult Volunteers,Recruiting,No Results Available,Healthy,Drug: Leucostimå¨|Drug: Neupogenå¨,"Dong-A ST Co., Ltd.",Male,Adult,Phase 1,56,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label,DA3030_NP_I,"March 22, 2016",Feb-16,null,"March 30, 2016",Mar-16,No Study Results Posted,null,Apr-16,AUCinf of Filgrastim|Cmax of Filgrastim|AUEC0-t of ANC(absolute neutrophil count)|Emax of ANC(absolute neutrophil count)|Tmax of Filgrastim|AUC0-t of Filgrastim|CL/F of Filgrastim|Vd/F of Filgrastim|AUEC0-t of CD34+ cell count|Emax of CD34+ cell count,https://ClinicalTrials.gov/show/NCT02725086
761,NCT02725073,Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma,Recruiting,No Results Available,Treatment Response|Adverse Events|Feasibility,Procedure: Photodynamic therapy,Asan Medical Center,Both,Adult|Senior,Phase 2,32,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,ERCP-PDT,"March 20, 2016",Jan-16,Dec-17,"April 12, 2016",Apr-16,No Study Results Posted,PDT,Dec-17,Treatment response using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria|Adverse events and overall survival,https://ClinicalTrials.gov/show/NCT02725073
762,NCT02725060,Autoimmune Basis for Postural Tachycardia Syndrome,Recruiting,No Results Available,"Postural Orthostatic Tachycardia Syndrome|Postural Tachycardia Syndrome|Tachycardia|Arrhythmias, Cardiac|Autonomic Nervous System Diseases|Orthostatic Intolerance|Cardiovascular Diseases|Primary Dysautonomias",Drug: phenylephrine|Drug: isoproterenol|Radiation: 25 micro-Ci of radiation|Procedure: Posture study with blood samples|Procedure: 24-hour heart rhythm and blood pressure monitoring|Procedure: Quantitative Axonal Sudomotor Reflex Testing|Procedure: Autonomic function tests,Vanderbilt University|University of Oklahoma,Both,Adult,,95,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,151791,"February 22, 2016",Feb-16,Jul-21,"March 30, 2016",Feb-16,No Study Results Posted,null,Feb-21,Autoantibody levels|Blood pressure after phenylephrine boluses|Heart rate after isoproterenol boluses|Orthostatic change in heart rate|Blood pressure response during phase IV of the Valsalva maneuver|Hear rate response during phase IV of the Valsalva maneuver,https://ClinicalTrials.gov/show/NCT02725060
763,NCT02725034,Diagnosis of Gastric Intestinal Metaplasia With High Definition Endoscopy and Optic Enhancement,Recruiting,No Results Available,Gastric Intestinal Metaplasia,Device: Standard endoscopy|Device: High definition endoscopy with Optic Enhancement,Shandong University,Both,Adult|Senior,,160,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Investigator)",2016SDU-QILU-02,"March 26, 2016",Jan-16,null,"March 30, 2016",Mar-16,No Study Results Posted,null,Aug-16,Difference of the detection rate of gastric intestinal metaplasia between high definition endoscopy with Optic Enhancement targeted biopsies and standard endoscopy with standard biopsy protocol in a per-patient analysis|Difference of the detection rate of gastric intestinal metaplasia between high definition endoscopy with Optic Enhancement targeted biopsies and standard endoscopy with standard biopsy protocol in a per-biopsy analysis|Number of biopsies needed in per group,https://ClinicalTrials.gov/show/NCT02725034
764,NCT02725008,Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation,Recruiting,No Results Available,Asthma,Drug: Dexamethasone|Drug: placebo,Geoffrey W Jara-Almonte|New York Methodist Hospital,Both,Child|Adult,Phase 3,220,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",714220-1,"March 18, 2016",Jul-15,null,"March 30, 2016",Mar-16,No Study Results Posted,R2D2,Jul-17,Treatment Failure|Patient Self Assessment Score,https://ClinicalTrials.gov/show/NCT02725008
765,NCT02724917,"Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia",Recruiting,No Results Available,Schizophrenia,Drug: APN1125|Drug: Placebo,"CoMentis|Alpharmagen, Inc.",Both,Adult,Phase 1|Phase 2,30,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",APN1125-002,"March 25, 2016",Apr-16,Dec-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Sep-16,"Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via adverse events|Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via vital signs (e.g., blood pressure, pulse rate, respiratory rate, oral temperature)|Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via ECGs|Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via physical exams|Assessment of safety and tolerability of APN1125 in subjects with schizophrenia via clinical laboratory tests (chemistry, hematology, coagulation and urinalysis)|Maximum observed plasma APN1125 concentration (Cmax)|Time corresponding to occurrence of Cmax (Tmax)|Area under the Curve from time zero to the last quantifiable plasma APN1125 concentration (AUClast)|Area under the Curve from time zero extrapolated to plasma APN1125 concentration at infinity (AUCinf)|Terminal plasma APN1125 rate constant (lambda z)|Apparent plasma APN1125 terminal half-life (t1/2)|Apparent APN1125 plasma clearance (CL/F)|Amount of unmetabolized APN1125 excreted in urine (Ae)|Fraction of unmetabolized APN1125 dose excreted in urine (Fe)",https://ClinicalTrials.gov/show/NCT02724917
766,NCT02724891,Web-based Validation Pelvic Floor Questionnaires,Recruiting,No Results Available,Pelvic Floor Dysfunction,Other: paper form|Other: web/smartphone form,"Columbia University|University of Wisconsin, Madison|University of Arkansas|The Methodist Hospital System|Virginia Polytechnic Institute and State University|University of South Carolina|Henry Ford Health System",Female,Adult|Senior,,216,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Prospective,AAAO8451,"February 4, 2016",Feb-15,Jan-18,"March 25, 2016",Mar-16,No Study Results Posted,null,Jan-18,Test-retest reliability of PFDI-20 in the electronic format|Test-retest reliability of PFIQ-7 in the electronic format|Test-retest reliability of PISQ-12 in the electronic format|Test-retest reliability of BSS in the electronic format,https://ClinicalTrials.gov/show/NCT02724891
767,NCT02724865,Somnodent vs Herbst in Mild and Moderate OSA Patients,Recruiting,No Results Available,Obstructive Sleep Apnea,Device: Somnodentå¨ (Oral appliance therapy)|Device: Herbstå¨ (Oral appliance therapy),Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Academic Centre for Dentistry in Amsterdam,Both,Adult|Senior,Phase 4,140,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,NL44085.018.13,"March 14, 2016",Jan-16,Jul-18,"April 12, 2016",Apr-16,No Study Results Posted,COSH,May-18,Apnea-hypnea-Index (AHI)|Oxygen-desaturation-Index|Epworth Sleeping Scale|Functional Outcome of Sleep Questionnaire|Blood pressure|Euroqol (EQ-5D-3L),https://ClinicalTrials.gov/show/NCT02724865
768,NCT02724839,Supporting Together Exercise and Play and Improving Nutrition,Recruiting,No Results Available,Obesity,Behavioral: Group nutrition sessions|Device: Fitbit,"Children's Hospital Medical Center, Cincinnati",Both,Child,,48,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,2015-3406,"March 14, 2016",Jun-15,Dec-17,"April 13, 2016",Apr-16,No Study Results Posted,STEP IN,Jun-17,"Change from baseline in parent-reported child's daily servings of fruits and vegetables, sugar-sweetened beverages, fast food, and snack foods consumed|Activity levels as measured by Fitbit|Number of participants reporting they were satisfied with the group nutrition sessions (4 or 5 on 5-point Likert scale)|Change in Child BMI|Change from baseline in child quality of life|Change from baseline in child self-efficacy related to physical activity|Change from baseline in child intention to be active|Change from baseline in parent-reported number of hours of screen time child watches daily",https://ClinicalTrials.gov/show/NCT02724839
769,NCT02724813,Tele-Rehabilitation Study for People With a History of Stroke,Recruiting,No Results Available,Stroke,Behavioral: Cognitive Orientation to Occupational Preformance (COOP),Baycrest|Health and Stroke Foundation-Canadian Partnership for Stroke recovery,Both,Adult|Senior,,24,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),REB#15-37,"February 9, 2016",Nov-15,Dec-16,"March 28, 2016",Mar-16,No Study Results Posted,null,Jun-16,Changes in Canadian Occupational Performance Measure (COPM)|Changes in Reintegration to Normal Living Index (RNL),https://ClinicalTrials.gov/show/NCT02724813
770,NCT02724722,Family-based Childhood Behavior Intervention to Decrease Environmental Melamine and Phthalate Exposure,Recruiting,No Results Available,Healthy Children and Their Main-care Giver,Behavioral: Assigned intervention|Behavioral: No intervention,Kaohsiung Medical University Chung-Ho Memorial Hospital,Both,Child|Adult,,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor),KMU-TP103A23,"March 10, 2015",Mar-15,Oct-16,"March 25, 2016",Mar-16,No Study Results Posted,null,Jul-16,"urinary excretion of melamine|urinary excretion of five DEHP metabolites (MEHP, 5OH-MEHP, 5oxo-MEHP, 5carboxy-MEPP, and 2carboxy-MMHP)|oxidative stress markers (8-OHdG, MDA)|other six phthalate metabolites of MnBP, MiBP, MEP, MBzP, MMP, and MiNP|renal injury markers (NAG, microalbumin, beta-2-microglobulin)",https://ClinicalTrials.gov/show/NCT02724722
771,NCT02724709,Semi-automatic assessMent of Aortic Roots by Three-dimensional transoEsophageal echocaRdiography (SMARTER),Recruiting,No Results Available,Aortic Valve Disease,Procedure: Three-dimensional transoesophageal echocardiography|Procedure: Computed tomography,"Chinese Academy of Medical Sciences, Fuwai Hospital|Siemens Corporation, Corporate Technology",Both,Child|Adult,,70,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2016-096,"March 21, 2016",Feb-16,null,"March 25, 2016",Mar-16,No Study Results Posted,null,Apr-16,Accuracy|Cost|Labor time,https://ClinicalTrials.gov/show/NCT02724709
772,NCT02724696,French National Observatory of Patients With Thymic Epithelial Tumor,Recruiting,No Results Available,Thymic Epithelial Tumor,,Intergroupe Francophone de Cancerologie Thoracique,Both,Adult|Senior,,1750,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IFCT-1104 RYTHMIC,"March 22, 2016",Jan-12,Dec-17,"March 25, 2016",Mar-16,No Study Results Posted,RYTHMIC,Dec-17,histological type|Masaoka-Koga stage|ITMIG/IASLC 2014/2015 stage|Questions raised at the national expert multidisciplinary tumor board,https://ClinicalTrials.gov/show/NCT02724696
773,NCT02724683,Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter.,Recruiting,No Results Available,Malignant Ascites,Device: Ascites drainage with vascular catheter.|Device: Interview.|Device: Quality of life.|Device: Quality of procedure.|Device: Risk of malnutrition.|Device: Paracentesis.,"Maciej Stukan, MD, PhD|Gdynia Oncology Center",Both,Adult|Senior,,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GCO-1,"March 20, 2016",Jan-16,Mar-17,"April 21, 2016",Apr-16,No Study Results Posted,null,Mar-17,Number of participants with successful catheter placement.|Number of participants with adverse events.|Change in quality of life.|Patient's experience on the treatment.|Change in nutrition status.|Number of ambulatory visits or hospital admissions.|Number of participants with adverse events during cancer treatment and ascites drainage.|Change in nutrition status among participants with prolonged ascites drainage.,https://ClinicalTrials.gov/show/NCT02724683
774,NCT02724657,Buteyko Method for Asthmatic Children With Mouth Breathing,Recruiting,No Results Available,Asthma|Mouth Breathing,Other: Buteyko Method,Universidade Federal do Rio Grande do Norte,Both,Child,,13,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,1.443.588,"March 7, 2016",Mar-16,Oct-16,"March 30, 2016",Mar-16,No Study Results Posted,null,Jul-16,"Change in Sleep disturbance (questionnaire)|Change in spirometry (FVC, FEV1, FEV1/FVC, FEF25-75%, PEF)|Change in ventilometry (minute volume and vital capacity)|Number of hospitalizations|Number of asthma exacerbations",https://ClinicalTrials.gov/show/NCT02724657
775,NCT02724644,EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite),Recruiting,No Results Available,Edematous Fibrosclerotic Panniculopathy|Cellulite,Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Biological: Placebo Comparator,Endo Pharmaceuticals,Female,Adult|Senior,Phase 2,350,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",EN3835-201,"March 10, 2016",Feb-16,Nov-16,"March 25, 2016",Mar-16,No Study Results Posted,null,Sep-16,Proportion of composite responders with a 2 level improvement at Day 71|Proportion of composite responders with a 1 level improvement at Day 71|Proportion of responders with 2 levels of improvement in the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS)|Proportion of responders with one level of improvement in the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS)|Proportion of responders with improvement in the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS)|Proportion of responders with one level improvement in the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS)|Proportion of responders at each level of the Investigator Global Aesthetic Improvement Scale (I-GAIS)|Proportion of responses at each level of the Subject Global Aesthetic Improvement Scale (S-GAIS)|Proportion of responders at each level of the subject satisfaction with cellulite treatment assessment|Change in the Hexsel CSS total score from day 1 (Baseline) to Day 71,https://ClinicalTrials.gov/show/NCT02724644
776,NCT02724618,Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT),Recruiting,No Results Available,Prostate Cancer,Drug: Curcumin|Radiation: RT|Drug: Placebo,"Shahid Beheshti University of Medical Sciences|Behnam Daheshpour Charity Organization, Tehran, Iran",Male,Child|Adult|Senior,Phase 2,64,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",406,"March 9, 2016",Mar-16,Mar-17,"March 30, 2016",Mar-16,No Study Results Posted,null,Feb-17,Proctitis [assessed using Common terminology criteria for adverse events (CTCAE)]|Cystitis [assessed using CTCAE Grading Criteria]|Biochemical progression-free survival (b-PFS),https://ClinicalTrials.gov/show/NCT02724618
777,NCT02724605,The Effect of Red Blood Cells Storage Duration on Biochemical Changes in Pediatric Patients,Recruiting,No Results Available,Red Blood Cells Transfusion,Biological: Red blood cells unit age 14 days or less|Biological: Red blood cells unit age more than 14 days,"Abdelrady S Ibrahim, MD|Assiut University",Both,Child,Phase 2,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label,IRB0000871236,"March 20, 2016",Jan-16,Nov-16,"March 30, 2016",Mar-16,No Study Results Posted,null,Sep-16,Serum potassium level|Serum ionised calcium|Serum glucose level|Blood Urea Nitrogen|Hemoglobin level,https://ClinicalTrials.gov/show/NCT02724605
778,NCT02724566,Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers,Recruiting,No Results Available,Diabetes,Drug: apelin|Drug: placebo,"University Hospital, Toulouse|SociÌ©tÌ© Francophone du DiabÌ¬te",Male,Adult,Phase 1,14,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)",15 7783 03,"March 18, 2016",Mar-16,Mar-17,"March 24, 2016",Mar-16,No Study Results Posted,APELINS-2,Mar-17,Delta between Glucose Infusion Rate|Measure of M-value (a glucose physiological parameter)|systolic blood pressure and diastolic blood pressure|heart rate|Measure of QTc interval with electrocardiogram examination|Clinic sign of apelin intolerance|Dosage of plasma proteins|Clinic sign of apelin allergy|Clinic sign of apelin toxicity,https://ClinicalTrials.gov/show/NCT02724566
779,NCT02724540,Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver,Recruiting,No Results Available,"Adults With Unresectable Liver-dominant Neuroendocrine Tumor Metastases That Are Are Symptomatic, Progressive, or Involve 25% of the Liver Volume","Device: Lobar or segmental bland embolization with tris-acryl gelatin microspheres (100-500 microns) to 2-5 heartbeat stasis|Device: Lobar or segmental lipiodol chemoembolization|Drug: Doxorubicin 50 mg, and Mitomycin C 10 mg dissolved in 10 mL dilute contrast and emulsified with 10 cc iodized oil, followed by 100-500 ë_m tris-acryl gelatin microspheres.|Device: Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU",Abramson Cancer Center of the University of Pennsylvania,Both,Adult|Senior,Phase 3,12,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,UPCC 01215,"March 28, 2016",Mar-16,null,"March 28, 2016",Mar-16,No Study Results Posted,null,Mar-20,Number of Adverse Events,https://ClinicalTrials.gov/show/NCT02724540
780,NCT02724527,Study of N91115 in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor,Recruiting,No Results Available,Cystic Fibrosis,Drug: N91115|Drug: Placebo,"Nivalis Therapeutics, Inc.",Both,Adult|Senior,Phase 2,20,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)",N91115-2CF-06,"March 11, 2016",Apr-16,Apr-17,"April 20, 2016",Apr-16,No Study Results Posted,SNO-7,Apr-17,"The absolute change in ppFEV1 in the N91115 treated group|The relative change from study baseline within the active treatment group in ppFEV1 values|Absolute change from study baseline within the active treatment group in sweat chloride|Changes in the respiratory domain of the Cystic Fibrosis Questionnaire - Revised, (CFQ-R)|Absolute change from baseline within the active treatment group in Patient Global Impression of Change|Safety as determined by adverse events assessment|Pharmacokinetic Assessment of Maximum Plasma Concentration [Cmax] for N91115 & ivacaftor|Pharmacokinetic Assessment of area under the plasma concentration verse time curve [AUC] for N91115 & ivacaftor",https://ClinicalTrials.gov/show/NCT02724527
781,NCT02724514,Multi-Parametric Assessment of Breast Lymphedema,Recruiting,No Results Available,Breast Cancer|Breast Lymphedema,Other: non-invasive image & bioimpedance based techniques,"University Health Network, Toronto",Female,Adult|Senior,,60,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,UHN REB 14-8503-C,"March 2, 2015",Jan-15,Dec-16,"March 24, 2016",Mar-16,No Study Results Posted,null,Dec-16,Measure Mid-Band Fit (MBF) in normal tissue controls and the corresponding regions of lymphedema|Measure Acoustic Scatterer Diameter (ASD) in normal tissue controls and the corresponding regions of lymphedema,https://ClinicalTrials.gov/show/NCT02724514
782,NCT02724488,Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies,Recruiting,No Results Available,Head and Neck Cancer|Melanoma,,"University Health Network, Toronto|Princess Margaret Hospital, Canada",Both,Adult|Senior,,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SPECIAL-001,"November 19, 2015",Apr-15,Dec-20,"March 24, 2016",Mar-16,No Study Results Posted,SPECIAL,Dec-20,Part 1: The detection of new mutations from circulating tumor DNA (ctDNA) analyses or change in the frequency of mutations found in archival tumor Whole Exome Sequencing (WES) analyses.|Part 2: Concordance between WES analyses of serial tumor biopsies.|Part 1: Concordance between DNA analyses of archival tumor and ctDNA analyses.|Part 2: Concordance between WES analyses of serial tumor biopsies and ctDNA analyses of serial blood samples.|Part 2: Changes in radiomic signatures of tumors between commencement of immune targeted therapies and disease progression assessed from serial CT scans.|Part 2: Correlation between tumor radiomic signatures from serial CT scans and genomic profiles (WES and gene expression analyses of serial tumor biopsies and ctDNA samples).|Part 2: Changes in levels of immune cells repertoire in peripheral circulation of patients using flow cytometry and related assays.,https://ClinicalTrials.gov/show/NCT02724488
783,NCT02724384,"Evaluating the Safety, Tolerability and Preliminary Efficacy of Plasma in Improving the Appearance of Onychomycosis",Recruiting,No Results Available,Onychomycosis,Device: MOE Plasma Delivery System A|Device: MOE Plasma Delivery System B,Moe Medical Devices,Both,Adult|Senior,,75,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,OM-0030,"March 22, 2016",Mar-16,null,"March 30, 2016",Mar-16,No Study Results Posted,null,Mar-18,"Number of Subjects with treatment-related adverse events as assessed by CTCAE v4.0|Efficacy as assessed by Clinical, Mycological and Complete Cure Rates assessed in accordance with FDA Guidance for onychomycosis trials issued March 7, 2016",https://ClinicalTrials.gov/show/NCT02724384
784,NCT02724254,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients",Recruiting,No Results Available,Condyloma,Drug: AP611074 5% gel|Drug: AP611074 matching placebo,Anaconda Pharma|Aviragen Therapeutics,Both,Adult,Phase 2,210,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",AP611074.CT4,"March 21, 2016",Jan-16,null,"March 30, 2016",Mar-16,No Study Results Posted,null,Dec-16,Percentage of patients with at least one local skin reaction (LSR)|Number of patients experiencing adverse events|Mean plasma concentrations of AP611074-04|Proportion of subjects with a complete clearance rate (100%) for baseline genital wart lesions|Reduction in the total condyloma area for lesions|Proportion of subjects with a complete clearance rate (100%) for all genital wart lesions|Time to complete clearance,https://ClinicalTrials.gov/show/NCT02724254
785,NCT02724241,E-Cigarettes and SNA,Recruiting,No Results Available,Nicotine Dependence,Other: one time exposure to e-cig with nicotine|Other: One time exposure to e-cigarette without nicotine|Other: one time exposure to empty e-cigarette,"University of California, Los Angeles",Both,Adult,,120,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label,14-000731,"March 17, 2016",Apr-15,Dec-19,"March 24, 2016",Mar-16,No Study Results Posted,null,Dec-18,Heart Rate variability|Paraoxonase|muscle sympathetic nerve activity,https://ClinicalTrials.gov/show/NCT02724241
786,NCT02724215,Effect of Sleep Apnea on Blood Pressure Control and Outcome Early After Subarachnoid Hemorrhage,Recruiting,No Results Available,Subarachnoid Hemorrhage|Sleep Apnea,Device: Sleep Apnea Screening (Out of Center Polysomnography Device),"University Hospital, Bonn",Both,Adult|Senior,,200,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,025/16,"March 1, 2016",Mar-16,Mar-18,"March 24, 2016",Mar-16,No Study Results Posted,null,Dec-17,"Time to blood pressure target|Medication needed to achieve blood pressure target|Change in modified ranking scale (mRS) from baseline to discharge and follow-up visit, respectively.|Change in NIH stroke scale score (NIHSS) from admission to discharge and follow-up visit, respectively.|Barthel Index at discharge at follow-up visit, respectively.",https://ClinicalTrials.gov/show/NCT02724215
787,NCT02724202,Curcumin in Combination With 5FU for Colon Cancer,Recruiting,No Results Available,Metastatic Colon Cancer,Drug: Curcumin|Drug: 5-flurorouracil,Baylor Research Institute,Both,Adult|Senior,Phase 0,14,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,014-143,"March 16, 2016",Mar-16,Mar-18,"March 31, 2016",Mar-16,No Study Results Posted,null,Mar-18,"Determine the safety using curcumin in patients with metastatic colon cancer; where toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.|Overall Response|Evidence of altered biomarker status (circulating DNA methylation status, miRNA profile) at 8 weeks post-treatment according to RECIST version 1.1 and survival criteria.|Duration of response|Duration of progression free survival|Duration of overall survival|Duration of Quality of Life",https://ClinicalTrials.gov/show/NCT02724202
788,NCT02724150,Comparison of Low Against High Regimen of Proton Pump Inhibitors for Treatment of Acute Peptic Ulcer Bleeding,Recruiting,No Results Available,Gastroduodenal Ulcer|Marginal Ulcer|Peptic Ulcer Hemorrhage,Drug: Omeprazole High dose|Drug: Omeprazole Low dose,Damascus Hospital,Both,Adult|Senior,Phase 4,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",G2,"March 14, 2016",Mar-16,Jun-19,"April 7, 2016",Mar-16,No Study Results Posted,null,May-19,Mortality|Rebleeding|Surgery|Length of hospital stay|Blood transfusions,https://ClinicalTrials.gov/show/NCT02724150
789,NCT02724085,"A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271",Recruiting,No Results Available,Pneumonia,Drug: TP-271,"Tetraphase Pharmaceuticals, Inc.|National Institute of Allergy and Infectious Diseases (NIAID)",Both,Adult,Phase 1,56,Industry|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",TP-271-001|HHSN272201100028C,"September 4, 2015",Dec-15,Oct-16,"March 24, 2016",Mar-16,No Study Results Posted,null,Sep-16,Adverse Events (AE)|Physical Exams|Vital Signs|Safety Laboratory|ECG measurements|Plasma Pharmacokinetic (PK) Analysis|Urine Pharmacokinetic (PK) Analysis|PK parameters - Cmax|PK parameters - Tmax|PK parameters - C8|PK parameters - C12|PK parameters - C24|PK parameters - AUC(0-last)|PK parameters - AUC(0-inf)|PK parameters - AUC%extrap|PK parameters - Lambda-z|PK parameters - T1/2el|PK parameters - CL|PK parameters - Vd|PK parameters - epimer/parent,https://ClinicalTrials.gov/show/NCT02724085
790,NCT02724059,The Role of Endobronchial Ultrasound Elastography in the Diagnosis of Mediastinal Lesions,Recruiting,No Results Available,Mediastinum,Procedure: EBUS with elastography followed by TBNA,Tanta University,Both,Adult|Senior,,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,TFMEC221015,"March 19, 2016",Nov-15,Jun-16,"March 24, 2016",Mar-16,No Study Results Posted,null,Apr-16,Number of participants with correct diagnosis of mediastinal lesions (benign or malignant) using elastography,https://ClinicalTrials.gov/show/NCT02724059
791,NCT02724033,Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery,Recruiting,No Results Available,"Anesthesia, Pediatrics, Surgery",Procedure: regional nerve block|Drug: Antiemetic,Indiana University,Both,Child|Adult,Phase 4,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject),Inner Ear PONV_Nouri,"April 21, 2015",May-14,Dec-17,"March 24, 2016",Mar-16,No Study Results Posted,null,Dec-16,Evidence of Post Operative Nausea and Vomiting,https://ClinicalTrials.gov/show/NCT02724033
792,NCT02723942,CAR-T Cell Immunotherapy for HCC Targeting GPC3,Recruiting,No Results Available,GPC3 Positive Hepatocellular Carcinoma|CAR-T Cell Immunotherapy,Biological: CAR-T cell immunotherapy,"Fuda Cancer Hospital, Guangzhou",Both,Adult|Senior,Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CAR-T for GPC3+ HCC,"March 20, 2016",Jun-15,Jun-19,"March 24, 2016",Mar-16,No Study Results Posted,null,Jun-16,Radiological assessment|The safety of CAR-T cell immunotherapy (adverse events)|Peripheral blood tumor markers|CAR-T cell testing,https://ClinicalTrials.gov/show/NCT02723942
793,NCT02723916,Parent Training in Pediatric Care: A Self Directed Tablet-Based Approach,Recruiting,No Results Available,Parent Training|Primary Care,Behavioral: ezParent Program|Behavioral: Health-e Kids Control App,Rush University Medical Center,Both,Adult|Senior,,312,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,ORA# 15012705,"January 21, 2016",Sep-15,Aug-19,"March 24, 2016",Mar-16,No Study Results Posted,null,May-19,Change in Parenting Behaviors|Change in Parent Behaviors|Evaluate the cost of delivering the ezParent Program in Primary Care|REAIM model to evaluate implementation of ezParent in primary care|Change in child behavior problems|Change in child externalizing behavior problems|Change in Parenting Stress|Change in Parenting Self-efficacy,https://ClinicalTrials.gov/show/NCT02723916
794,NCT02723903,Hierarchical Treatment Based on Somatization Symptom Checklist,Recruiting,No Results Available,Syndrome X,Drug: Deanxit|Drug: Prozac|Procedure: coronary artery disease treatment,RenJi Hospital,Both,Adult|Senior,Phase 1|Phase 2,200,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,81470391,"February 15, 2016",Dec-15,Dec-17,"March 24, 2016",Mar-16,No Study Results Posted,null,Dec-16,The efficacy of somatization symptom score|scale chest discomfort|The efficacy of Patient Health Questionnaire|The efficacy of Generalized Anxiety Disorder 7-items,https://ClinicalTrials.gov/show/NCT02723903
795,NCT02723864,"Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors",Recruiting,No Results Available,Neoplasms,Drug: Veliparib + VX-970 + Cisplatin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,Adult|Senior,Phase 1,60,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,160087|16-C-0087,"March 30, 2016",Mar-16,Dec-17,"April 21, 2016",Jan-16,No Study Results Posted,null,Jun-17,"To establish the safety, tolerability, and MTD of the combination of VX 970 and veliparib in combination with cisplatin in patients with advanced refractory solid tumors|To assess the effect of the combination of VX-970, veliparib, and cisplatin on markers of DNA damage and apoptosis",https://ClinicalTrials.gov/show/NCT02723864
796,NCT02723773,"A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults",Recruiting,No Results Available,Herpes Zoster,Biological: Herpes Zoster Vaccine GSK1437173A,GlaxoSmithKline,Both,Adult|Senior,Phase 3,12500,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Prevention|Masking: Open Label,201190,"March 10, 2016",Apr-16,Apr-23,"April 21, 2016",Apr-16,No Study Results Posted,null,Apr-23,"Number of subjects with confirmed herpes zoster (HZ).|Number of subjects with confirmed post herpetic neuralgia (PHN).|Antigen-glicoprotein E (gE) humoral immunogenicity.|Cell mediated immunity (CMI) in terms of frequencies of antigen-specific CD4+ T cells.|Solicited local and general symptoms in subjects administered with 1 or 2 additional doses of HZ/su vaccine.|Unsolicited Adverse Events (AEs) in subjects administered with 1 or 2 additional doses of HZ/su vaccine.|Occurrence and relationship to vaccination of all Serious Adverse Events (SAEs).|Occurrence of SAEs related to investigational vaccine, related to study participation or to GSK concomitant medication/vaccine.|Occurrence of AEs of specific interest: Potential immune mediated diseases (pIMDs).",https://ClinicalTrials.gov/show/NCT02723773
797,NCT02723760,99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients,Recruiting,No Results Available,Rheumatoid Arthritis,Drug: 99mTc-3PRGD2,First Affiliated Hospital of Fujian Medical University,Both,Adult|Senior,Phase 0,40,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,FAHFMUNM001,"March 10, 2016",Nov-15,May-20,"March 24, 2016",Mar-16,No Study Results Posted,TRGDRA,Dec-19,99mTc-3PRGD2 SPECT/CT scan|X-ray radiography and/or CT(computed tomograph) and/or MRI(magnetic resonance imaging)|99mTc-MDP bone scan|18F-FDG PET/CT|Serum rheumatoid factor (RF)|Serum antinuclear antibodies (ANAs)|Erythrocyte sedimentation rate (ESR)|Adverse events collection,https://ClinicalTrials.gov/show/NCT02723760
798,NCT02723747,Quantitative Myocardial Perfusion Reserve by Cardiovascular Magnetic Resonance,Recruiting,No Results Available,Myocardial Ischemia,Other: myocardial perfusion with magnetic resonance imaging,Karolinska Institutet,Both,Adult|Senior,,80,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,QUACK,"March 16, 2016",Mar-16,null,"March 29, 2016",Mar-16,No Study Results Posted,null,Dec-16,Accuracy of global myocardial first pass perfusion in mL/min/g measured in automatic post-processed color maps compared with myocardial blood volume measured in the coronary sinus (mL/min) divided by the total left ventricle mass (g),https://ClinicalTrials.gov/show/NCT02723747
799,NCT02723695,Perception and Equilibrium After Cochlear Implantation,Recruiting,No Results Available,Deafness,Other: Evaluation of postural performances,"Central Hospital, Nancy, France|University of Lorraine",Both,Adult,,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label,2013-A01086-39,"March 24, 2016",Mar-14,Mar-19,"March 24, 2016",Mar-16,No Study Results Posted,ORIENTIMPLANT,Mar-18,Change from baseline in postural perception of the gravitational vertical|Change from baseline in visual perception of the gravitational vertical|Change from baseline in dynamic balance control|Change from baseline in quiet standing within a specific sound environment|Change from baseline in vestibular function|Change from baseline in speech recognition|Change from baseline in quality of life|Change from baseline in dizziness,https://ClinicalTrials.gov/show/NCT02723695
800,NCT02723656,Proactive Care Coordination for Cancer Survivors Who Smoke,Recruiting,No Results Available,Cancer,Behavioral: Online Referral NYS Quitline|Behavioral: Tobacco cessation counseling and coordination of cessation medications,New York University School of Medicine,Both,Adult|Senior,,600,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,15-01069,"March 24, 2016",Mar-16,Mar-17,"March 24, 2016",Mar-16,No Study Results Posted,null,Mar-17,Proportion of patients in the study's original proactive outreach cohort of N=600 who complete at least one call with the Quitline|biochemically validated 7-day abstinence,https://ClinicalTrials.gov/show/NCT02723656
801,NCT02723643,Potential Associated Factors of Uncontrolled Hypertension,Recruiting,No Results Available,"Hypertension,Essential",,Guangdong General Hospital,Both,Adult|Senior,,2000,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,GDREC 2015373H,"March 18, 2016",Jan-16,null,"March 29, 2016",Mar-16,No Study Results Posted,null,Dec-18,Hypertension controlled rate in participants after potential associated factors are corrected,https://ClinicalTrials.gov/show/NCT02723643
802,NCT02723604,Low-Level Laser Therapy for Prevention of Oral Mucositis,Recruiting,No Results Available,Mucositis,Device: Low Level Laser Therapy,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Both,Adult|Senior,Phase 2,25,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,2015-170|NCI-2016-00406|P30CA022453,"March 21, 2016",Mar-16,Mar-18,"March 24, 2016",Mar-16,No Study Results Posted,null,Mar-17,Incidence of severe (Common Terminology Criteria for Adverse Events version 4.0 [CTCAE v. 4.0] grade 3-5 or World Health Organization [WHO] grade 3-4) oral mucositis in patients treated to a cumulative radiation dose of at least 5000 cGy|Change in OM-related QOL assessed using FACT-H&N questionnaire|Duration of oral mucositis|Incidence of any grade oral mucositis in patients treated to a cumulative radiation dose of at least 5000 cGy|Incidence of dysgeusia assessed by CTCAE v. 4.0|Incidence of dysphagia assessed by CTCAE v. 4.0 and diet assessment|Incidence of pain as assessed by the Visual Analogue Scale (VAS)|Incidence of radiodermatitis assessed by CTCAE v. 4.0|Incidence of trismus assessed by measurement of interincisal distance|Incidence of xerostomia assessed by CTCAE v. 4.0|Mean cumulative radiation dose at time of onset of severe (CTCAE v. 4.0 grade 3-4) oral mucositis|Time to onset of severe (CTCAE v. 4.0 grade 3-4) oral mucositis following the initiation of radiotherapy,https://ClinicalTrials.gov/show/NCT02723604
803,NCT02723578,Pemetrexed and Erlotinib for Metastatic Colorectal Cancer,Recruiting,No Results Available,Metastatic Colorectal Cancer,Drug: Pemetrexed|Drug: Erlotinib,Yonsei University,Both,Adult|Senior,Phase 2,50,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,4-2015-0617,"March 9, 2016",Dec-15,Jul-17,"March 29, 2016",Mar-16,No Study Results Posted,null,Jul-16,Overall response rate|Progression-free survival|Overall survival|Disease control rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,https://ClinicalTrials.gov/show/NCT02723578
804,NCT02723526,Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Other: Blood drawing,Fudan University,Male,Adult|Senior,,100,Other,Observational,Time Perspective: Prospective,CTC-mHSPC,"March 26, 2016",Mar-16,Mar-19,"March 30, 2016",Mar-16,No Study Results Posted,null,Mar-19,time to castration-resistant prostate cancer|time to radiographic progression|time to prostate specific antigen (PSA) progression|time to prostate specific antigen (PSA) nadir|complete serologic response rate at 6 month and 12 month,https://ClinicalTrials.gov/show/NCT02723526
805,NCT02723500,129 Xenon MRI in Chronic Lung Disease,Recruiting,No Results Available,Lung Disease,Device: Hyperpolarized Xenon MRI,"Western University, Canada",Both,Adult|Senior,,100,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,ROB0031,"June 24, 2015",Aug-11,Aug-16,"March 23, 2016",Mar-16,No Study Results Posted,null,Aug-16,Ventilation Defect Percent (VDP) of the lung|Apparent Diffusion Coefficients (ADC) of the lung,https://ClinicalTrials.gov/show/NCT02723500
806,NCT02723474,A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease,Recruiting,No Results Available,Lung Disease,Device: MRI at baseline and over time,"Western University, Canada",Both,Adult|Senior,,100,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,ROB0010,"December 7, 2015",Nov-07,Oct-17,"March 29, 2016",Mar-16,No Study Results Posted,null,Oct-17,Lung function as measured using inhaled gas MRI ventilation defect percent (VDP)|Lung microstructure as measured using inhaled gas MRI Apparent Diffusion Coefficients (ADC),https://ClinicalTrials.gov/show/NCT02723474
807,NCT02723461,Continuous Oxytocin Infusion Versus Pulsatile Intravenous Oxytocin for Augmentation of First Stage of Labor,Recruiting,No Results Available,Failed Induction (of Labor) by Oxytocin,Drug: Pulsatile Oxytocin|Drug: Continuous Oxytocin,Ain Shams Maternity Hospital,Female,Child|Adult,Phase 4,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),pulsatile oxytocin,"March 26, 2016",Mar-16,Aug-16,"March 26, 2016",Mar-16,No Study Results Posted,null,Jun-16,duration of active phase of first stage of labor,https://ClinicalTrials.gov/show/NCT02723461
808,NCT02723409,Trial of Techniques for Umbilical Reconstruction,Recruiting,No Results Available,Umbilicoplasty,"Procedure: Round Procedure Umbilicoplasty|Procedure: Scarless"" round procedure|Procedure: ""Inverted U"" Procedure|Procedure: ""Inverted V""Procedure|Procedure: ""Y deepithelialized"" Procedure",New York University School of Medicine,Female,Adult,,175,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,15-00480,"March 8, 2016",Jan-16,Dec-16,"March 23, 2016",Mar-16,No Study Results Posted,null,Dec-16,"Change in measurement of patient assessment post-operative and pre-operative, using a VAS survey results with a positive result indicating a favorable outcome|Assessment of inter-rater reliability among physicians in the assessment of the aesthetic outcomes of umbilical reconstruction.|Comparison of aesthetic outcomes of umbilical reconstruction using five accepted techniques for umbilicoplasty following abdominoplasty or abdominally-based free tissue transfer (TRAM/DIEP flaps).",https://ClinicalTrials.gov/show/NCT02723409
809,NCT02723396,"Sleep, Awake & Move - Part I",Recruiting,No Results Available,Idiopathic Parkinson Disease,,"Neurocenter of Southern Switzerland|Parkinson Schweiz|Ente Ospedaliero Cantonale, Bellinzona|Penn State University",Both,Adult|Senior,,80,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,EOC.NSI.LS.15.3.I,"March 12, 2016",Mar-16,Dec-18,"March 23, 2016",Mar-16,No Study Results Posted,SA&M-I,Aug-18,Objective prospective and repeated assessment of motor function|Subjective prospective and repeated assessment of motor function|Objective prospective assessment of sleep and wakefulness|Subjective prospective assessment of sleep and wakefulness|Subjective prospective assessment of sleepiness,https://ClinicalTrials.gov/show/NCT02723396
810,NCT02723357,The Impact of Family Financial Support on Parental Mental Health,Recruiting,No Results Available,Financial Coaching|Mental Health|Social Determinants|Medical-Financial Partnership|Toxic Stress,Behavioral: Financial Coaching|Behavioral: Access to Social Service Referrals,"University of California, Los Angeles",Both,Child|Adult|Senior,,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label,UCLASchickedanzFCMH,"March 24, 2016",Mar-16,Jul-17,"March 24, 2016",Mar-16,No Study Results Posted,null,Jul-17,Mental Health,https://ClinicalTrials.gov/show/NCT02723357
811,NCT02723318,The Impact of Family Financial Support on Cognition,Recruiting,No Results Available,Cognition,Behavioral: Financial Coaching|Behavioral: Access to Referrals to Social Services,"University of California, Los Angeles",Both,Child|Adult|Senior,,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label,UCLASchickedanzFCCog,"March 25, 2016",Mar-16,Jul-17,"March 25, 2016",Mar-16,No Study Results Posted,null,Jul-17,Cognition,https://ClinicalTrials.gov/show/NCT02723318
812,NCT02723240,NUC-3373 in Advanced Solid Tumours,Recruiting,No Results Available,Cancer,Drug: NUC-3373,University of Oxford,Both,Adult|Senior,Phase 1,68,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,OCTO_074|2015-002250-13,"December 8, 2015",Jan-16,Jul-17,"March 23, 2016",Mar-16,No Study Results Posted,NuTide:301,Jul-17,"To establish the recommended Phase 2 Dose (RP2D) of NUC-3373 that will optimise the risk/benefit reward for the participants, administered weekly (Part 1) and when administered fortnightly (Part 2), as a single I.V. infusion.|Dose Limiting Toxicities (DLT) to assess the tolerability of NUC-3373|Dose Limiting Toxicities (DLT) and SAEs/AEs to assess the safety of NUC-3373|Analysis of NUC-3373 metabolites in plasma to determine Area under the curve (AUC)|Analysis of NUC-3373 metabolites in plasma to determine Peak Plasma Concentration (Cmax)|Analysis of NUC-3373 metabolites in plasma to determine Clearance|Analysis of NUC-3373 metabolites in plasma to determine plasma half T1/2|Analysis of NUC-3373 metabolites in PBMC to determine Peak Plasma Concentration (Cmax)|Analysis of NUC-3373 metabolites in PBMC to determine Area under the curve (AUC)|Analysis of NUC-3373 metabolites in PBMC determine plasma half T1/2|Analysis of NUC-3373 metabolites in PBMC to determine Clearance|Measuring the ratio between the intracellular dTMP and dUMP concentrations.|Response Evaluation Criteria in Solid Tumours (RECIST) to explore the anti-tumour activity of NUC-3373",https://ClinicalTrials.gov/show/NCT02723240
813,NCT02723227,The Impact of Family Financial Support on Parental Stress,Recruiting,No Results Available,Stress,Behavioral: Financial Coaching|Behavioral: Referral to Social Services,"University of California, Los Angeles",Both,Child|Adult|Senior,,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label,UCLASchickedanzFCS,"March 25, 2016",Mar-16,Jul-17,"March 25, 2016",Mar-16,No Study Results Posted,null,Jul-17,Family Economic Strain|Parenting Stress,https://ClinicalTrials.gov/show/NCT02723227
814,NCT02723175,The Effects of CBT and (tDCS) on Fibromyalgia Patients,Recruiting,No Results Available,Fibromyalgia|Chronic Pain,Device: Transcranial Direct Current Stimulation,Medical University of South Carolina|National Institutes of Health (NIH)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Both,Adult|Senior,,72,Other|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",Pro00039603|1R21AR066428-01,"December 14, 2015",Nov-14,Dec-16,"March 23, 2016",Nov-15,No Study Results Posted,null,Nov-16,Quantitative Sensory Testing|The Beck Depression Inventory|The Beck Anxiety Inventory|The Brief Pain Inventory|Daily pain diaries|The Mcgill Pain Questionnaire|The Short-Form 12 Healthy Survey|The Fibromyalgia Impact Questionnaire,https://ClinicalTrials.gov/show/NCT02723175
815,NCT02723149,Marijuana Approach Bias Retraining and Neural Response in Youth,Recruiting,No Results Available,Alcohol Approach/Avoidance Task|Sham Approach/Avoidance Task,Behavioral: Marijuana Approach Avoidance Training,Medical University of South Carolina,Both,Child|Adult,,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Double Blind (Subject, Investigator)",44583,"March 14, 2016",Nov-15,Sep-17,"March 23, 2016",Feb-16,No Study Results Posted,MJ-AAT,Sep-16,Change in marijuana use from baseline through end of intervention|Change in neural reactivity (as measured by BOLD: Blood Oxygen Level-Dependent response) in reward regions during marijuana-cue reactivity task|Change in marijuana approach tendencies (via Approach Avoidance Assessment Task) as measured by reaction times.|Change in short-term marijuana use from baseline to 1 month post-intervention|Change in long-term marijuana use from baseline to 1 year post-treatment,https://ClinicalTrials.gov/show/NCT02723149
816,NCT02723136,Implementation of a Smartphone Application in Medical Education,Recruiting,No Results Available,"Education, Medical",Device: Smartphone Application,Universidad de Valparaiso|Laboratorio de IngenierÌ_a y TecnologÌ_a (LABITEC),Both,Adult|Senior,,75,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)",CEC098-16,"March 27, 2016",Apr-16,Jun-16,"April 8, 2016",Apr-16,No Study Results Posted,iSTART,Jun-16,Academic Performance|Time to complete tests,https://ClinicalTrials.gov/show/NCT02723136
817,NCT02723110,"Defining the Physiological Mechanisms of Risk Genes for Hyperglycaemia, Insulin Resistance and Type 2 Diabetes",Recruiting,No Results Available,Type 2 Diabetes,Other: 4 Hour Frequently Sampled Oral Glucose Tolerance Test|Other: Isoglycaemic Clamp,University of Oxford|University of Exeter|Medical Research Council,Both,Adult,,40,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,15/SC/0072,"February 12, 2016",Jun-15,May-16,"April 1, 2016",Apr-16,No Study Results Posted,DIVA - PAM,May-16,Calculated Incretin Effect|Insulin concentration|Glucose concentrations|GLP-1 (glucagon-like peptide-1) amidated and unamidated concentration|PAM enzyme activity assay,https://ClinicalTrials.gov/show/NCT02723110
818,NCT02723032,Validation of a Miniature SpO2 Sensor in Healthy Subjects and Patients With Long-term Oxygen Therapy.,Recruiting,No Results Available,Pulse Oximeter Validation|Long Term Oxygen Therapy,Device: OxyFrame,"University Hospital Inselspital, Berne",Both,Adult|Senior,,45,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,OxyFrame,"March 23, 2016",Mar-16,null,"March 23, 2016",Mar-16,No Study Results Posted,OxyFrame,Jun-16,Assessment of accuracy in patients|Assessment of accuracy in healthy volunteers,https://ClinicalTrials.gov/show/NCT02723032
819,NCT02722993,Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders,Recruiting,No Results Available,Antibiotic-associated Diarrhea,Dietary Supplement: Probiotics|Dietary Supplement: Placebo,Probi AB,Both,Child,Phase 2,100,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",ProGastro Kids 16,"March 16, 2016",Feb-16,null,"March 23, 2016",Mar-16,No Study Results Posted,null,Mar-17,Number of loose/watery stools,https://ClinicalTrials.gov/show/NCT02722993
820,NCT02722967,Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System,Recruiting,No Results Available,Schizophrenia|Major Depressive Disorder|Bipolar I Disorder,Drug: Aripiprazole + IEM (Ingestible Event Marker),"Otsuka Pharmaceutical Development & Commercialization, Inc.",Both,Adult,Phase 2,50,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,316-13-215,"March 13, 2016",Mar-16,Jun-16,"March 24, 2016",Mar-16,No Study Results Posted,null,Jun-16,Number of Inbound and Outbound Calls by help type,https://ClinicalTrials.gov/show/NCT02722967
821,NCT02722954,A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors,Recruiting,No Results Available,Locally Advanced or Metastatic Solid Tumors,Drug: Demcizumab|Drug: Pembrolizumab,"OncoMed Pharmaceuticals, Inc.|Celgene Corporation",Both,Adult|Senior,Phase 1,42,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,M18-008,"March 7, 2016",Jan-16,Jan-19,"April 19, 2016",Mar-16,No Study Results Posted,null,Jan-18,Dose limiting toxicities (DLT) of demcizumab given in combination with pembrolizumab|Pharmacokinetics (PK) of demcizumab and pembrolizumab,https://ClinicalTrials.gov/show/NCT02722954
822,NCT02722928,Ventilation With High Oxygen Content and Postoperative Pneumocephalus,Recruiting,No Results Available,Pneumocephalus,Other: Controlled Ventilation with 100% oxygen,Ohio State University,Both,Adult|Senior,,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor),2015H0032,"March 21, 2016",Aug-15,Dec-16,"March 24, 2016",Mar-16,No Study Results Posted,null,Dec-16,Volume of postoperative pneumocephalus|Occurrence of postoperative pneumocephalus|Incidence of postoperative pneumocephalus among subgroups|Volume of postoperative pneumocephalus among subgroups,https://ClinicalTrials.gov/show/NCT02722928
823,NCT02722889,The Age-related Elongation of the Proximal Aorta,Recruiting,No Results Available,Thoracic Aorta,,Maastricht University Medical Center,Both,Adult|Senior,,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,16-4-027,"March 7, 2016",Mar-16,Sep-17,"March 31, 2016",Mar-16,No Study Results Posted,null,Sep-16,Length of the ascending aorta,https://ClinicalTrials.gov/show/NCT02722889
824,NCT02722863,Samsca Post Marketing Surveillance Study,Recruiting,No Results Available,Hypervolemic and Euvolemic Hyponatremia,,"Korea Otsuka Pharmaceutical Co.,Ltd.",Both,Child|Adult|Senior,,3000,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,156-KOA-1201n,"March 18, 2016",Nov-13,Aug-17,"March 23, 2016",Mar-16,No Study Results Posted,Samsca PMS,Aug-17,"The numbers of subjects presenting at least one adverse event/adverse drug reaction, at least one serious adverse event/adverse drug reaction, or at least one unexpected adverse event/adverse drug reaction.|The percentage of subjects presenting at least one adverse event/adverse drug|The incidence rate of subjects presenting at least one adverse event/adverse drug|The number of subjects who discontinued Samscaå¨ (inc.due to an adverse event)|The percentage of subjects who discontinued Samscaå¨ (inc.due to an adverse event)|Change of the serum sodium level at the first visit and Day 4 after the first visit",https://ClinicalTrials.gov/show/NCT02722863
825,NCT02722824,Efficacy of a Non-invasive Device for Alleviation of Parkinson's Disease Symptoms,Recruiting,No Results Available,Parkinson's Disease,Device: Electro-stimulation|Other: Placebo,KoÌ¤ University|Istanbul University,Both,Adult|Senior,,32,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",Par-01,"March 6, 2016",Nov-15,Jun-16,"March 23, 2016",Mar-16,No Study Results Posted,null,Jun-16,Change in the UPDRS Motor Score (Part III)|Change in the gait and balance parameters (cadence)|Change in the gait and balance parameters (Stride length)|Change in the gait and balance parameters (Stride velocity)|Change in the gait and balance parameters,https://ClinicalTrials.gov/show/NCT02722824
826,NCT02722811,Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis,Recruiting,No Results Available,Osteoarthritis Of Knee,"Drug: Etanercept|Other: Health education, exercise and diet guidance","First Affiliated Hospital of Harbin Medical University|Shanghai Baiying Medical Technology Co., Ltd.",Both,Child|Adult|Senior,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,SI-ETN-KOA-201614,"March 24, 2016",Feb-16,Aug-17,"April 20, 2016",Feb-16,No Study Results Posted,ESIETNKOA,Jul-17,Pain VAS score(Pain Visual Analogue Scale/Score)|KOOS score(The Knee injury and Osteoarthritis Score)|30s-CST score(30 seconds Sit/chair Test)|40m FPWT score(40 meters fast walking test)|Assessment score under ultrasound|Assessment score under MRI|TNF-ë± (pg/ml) level in serum|IL1-ë± (pg/ml) level in serum|IL1-ë_ (pg/ml) level in serum|MMP1 (ng/ml) level in serum|MMP13 (ng/ml) level in serum|SF-12 score(MOS 12-item Short Form Health Survey),https://ClinicalTrials.gov/show/NCT02722811
827,NCT02722772,Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis,Recruiting,No Results Available,Osteoarthritis of Knee,"Drug: Etanercept|Other: Health education, exercise and diet guidance","First Affiliated Hospital of Harbin Medical University|Shanghai baiying pharmaceutical technology Co., Ltd.",Both,Child|Adult|Senior,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IAI-ETN-KOA-201613,"March 24, 2016",Feb-16,Aug-17,"April 7, 2016",Feb-16,No Study Results Posted,EIAIETNKOA,Jul-17,Pain VAS score(Pain Visual Analogue Scale/Score)|KOOS score(The Knee injury and Osteoarthritis Score)|30s-CST score(30 seconds Sit/chair Test)|40m FPWT score(40 meters fast walking test)|Assessment score under ultrasound|Assessment score under MRI|TNF-ë± (pg/ml) level in serum|IL1-ë± (pg/ml) level in serum|IL1-ë_ (pg/ml) level in serum|MMP1 (ng/ml) level in serum|MMP13 (ng/ml) level in serum|SF-12 score(MOS 12-item Short Form Health Survey),https://ClinicalTrials.gov/show/NCT02722772
828,NCT02722733,Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma,Recruiting,No Results Available,Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma,Drug: G-CSF (filgrastim)|Drug: Cytosine arabinoside with G-CSF (filgrastim),"Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology",Both,Adult,Phase 3,90,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,HL/NHLMobil-COI-01,"March 11, 2016",Mar-16,Apr-17,"March 24, 2016",Mar-16,No Study Results Posted,null,Mar-17,‰Û¢ The proportion of patients with stem cell yield at least 2 ÌÑ 10^6 CD34+ cells/kg in each treatment arm.|Peak level of CD34+ cells in peripheral blood (cells/ë_l).|Total number of harvested CD34+cells/kg.|Number of leukaphereses needed to harvest target amount of stem cells.|The proportion of hematologic and non-hematologic complications.|Duration of neutropenia < 0.5 x10^9/L.|Number of blood transfusions needed.|Duration of hospital stay.|Time of neutrophil and platelet engraftment after autologous stem cel transplantation.|Duration of thrombocytopenia <50 x 10 ^9/L.|Number of days of antibiotics therapy.,https://ClinicalTrials.gov/show/NCT02722733
829,NCT02722720,Carotid Arteries Stenting Complications: Transradial Approach Versus Transfemoral,Recruiting,No Results Available,Carotid Atherosclerosis|Carotid Stenosis|Ischemic Attack|Stroke|Bleeding,Procedure: Transradial carotid artery stenting|Procedure: Transfemoral carotid artery stenting,Meshalkin Research Institute of Pathology of Circulation,Both,Adult|Senior,,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CASTE-1.0,"March 13, 2016",Sep-15,null,"March 24, 2016",Mar-16,No Study Results Posted,null,Dec-16,Cerebral embolism|MACCE|Neurocognitive disorders|Device success|Lesion success|In-hospital procedure success|Operative access complications|Fluoroscopic time,https://ClinicalTrials.gov/show/NCT02722720
830,NCT02722707,"Clinical Use of an Artificial Rectal Sphincter Device, Trade Name Fenix",Recruiting,No Results Available,Fecal Incontinence,Device: Artificial rectal sphincter for fecal incontinence,Mayo Clinic,Female,Adult|Senior,Phase 4,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,16-000150,"February 26, 2016",Mar-16,Jan-18,"March 24, 2016",Mar-16,No Study Results Posted,null,Jan-18,Change in Pelvic Floor Distress Index Score|Postoperative Adverse Events,https://ClinicalTrials.gov/show/NCT02722707
831,NCT02722681,Developing a Biomarker for Monitoring Clinical Outcomes in Children With Spinal Lipoma.,Recruiting,No Results Available,Lipoma of Spinal Cord,Procedure: Blood and urine sampling|Procedure: Cerebrospinal fluid sampling,Institute of Child Health|Great Ormond Street Hospital for Children NHS Foundation Trust,Both,Child,,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,13ND18,"March 16, 2016",Feb-16,Dec-18,"March 23, 2016",Mar-16,No Study Results Posted,null,Dec-18,Lipid signature within blood or urine samples of patients with symptomatic spinal lipomas,https://ClinicalTrials.gov/show/NCT02722681
832,NCT02722655,Cohort of Mexican Children With Diabetes Mellitus (CMC-DM),Recruiting,No Results Available,Diabetes Mellitus,,Hospital Regional de Alta Especialidad del Bajio,Both,Child,,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2015-018,"March 18, 2016",Mar-08,Dec-30,"March 29, 2016",Mar-16,No Study Results Posted,CMC-DM,Dec-20,Diabetic retinopathy|Peripheral diabetic neuropathy|Nerve damage|Microalbuminuria|Cardiac function|Cognitive evaluation|Intelligence quotient evaluation|Body composition|Glycemic control|Beta cell function|Pancreatic autoimmunity|Insulin resistance|Alpha cell function|Hyperlipidemia|Hypothyroidism|Hypertension,https://ClinicalTrials.gov/show/NCT02722655
833,NCT02722642,Autologous Bronchial Basal Cells Transplantation for Treatment of Bronchiectasis,Recruiting,No Results Available,Bronchiectasis,Biological: Bronchial basal cells,"Regend Therapeutics|Southwest Hospital, China|Tongji University",Both,Adult|Senior,Phase 1|Phase 2,20,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,201602301,"March 9, 2016",Mar-16,Jan-19,"March 29, 2016",Mar-16,No Study Results Posted,null,Jan-19,CT imaging of dilated bronchi|6-minute walk distance test|MRC chronic dyspnea scale|St. George's Respiratory Questionnaire (SGRQ) scale|inflammation indicators|fibrotic factor level|incidence of acute exacerbation|patients' self-evaluation|blood gas level•_öPH•_ä|blood gas level•_öHCO3•_ä|blood gas level•_öPaCO2•_ä|blood gas level•_öPaO2•_ä|pulmonary function test (DLco)|pulmonary function test (FEV1)|pulmonary function test (FVC)|pulmonary function test (MVV)|pulmonary function test (MMEF),https://ClinicalTrials.gov/show/NCT02722642
834,NCT02722616,Ultrasound Monitoring of Abdominal Soft Tissue,Recruiting,No Results Available,Pancreatic Cancer|Liver Cancer,Device: Ultrasound of the pancreas|Device: Ultrasound of the Liver|Drug: Reference ultrasound,Sidney Kimmel Comprehensive Cancer Center,Both,Adult|Senior,,65,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,J14176|IRB00053627,"April 15, 2015",May-15,null,"April 11, 2016",Mar-16,No Study Results Posted,null,May-18,Abdominal soft-tissue movement|Tissue change during radiation treatment|Change 4D ultrasound to traditional CBCT monitoring|Change in dosimetry measurements,https://ClinicalTrials.gov/show/NCT02722616
835,NCT02722525,Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer,Recruiting,No Results Available,Cardiovascular Injury|Prostate Carcinoma,Procedure: Magnetic Resonance Imaging|Behavioral: Exercise Intervention|Radiation: Gadopentetate Dimeglumine|Procedure: Perfusion Magnetic Resonance Imaging|Behavioral: Exercise Intervention|Procedure: Spectroscopy|Other: Laboratory Biomarker Analysis,Ohio State University Comprehensive Cancer Center|Pelontonia,Male,Child|Adult|Senior,,30,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,OSU-14186|NCI-2015-00029,"November 18, 2015",Oct-14,null,"March 23, 2016",Mar-16,No Study Results Posted,null,Feb-18,Heart rate (bpm)|Maximal rate of oxygen consumption|Cardiac muscle mass|Ventricular performance assessed by cardiac stress MRI|Myocardial perfusion reserve assessed by cardiac stress MRI|Skeletal muscle energetics assessed by PMRS,https://ClinicalTrials.gov/show/NCT02722525
836,NCT02722499,Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST),Recruiting,No Results Available,"Diabetes Mellitus|Type 2 Diabetes Mellitus|Adult-Onset Diabetes Mellitus|Non-Insulin-Dependent Diabetes Mellitus|Noninsulin Dependent Diabetes Mellitus, Type II",Behavioral: Financial Incentive Augmented Education and Skills Training,Medical University of South Carolina,Both,Adult|Senior,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),Pro00021791,"March 23, 2016",Mar-16,Mar-17,"March 23, 2016",Mar-16,No Study Results Posted,FITEST,Mar-17,HbA1c|Blood Pressure|Quality of Life|Resource Utilization and Cost,https://ClinicalTrials.gov/show/NCT02722499
837,NCT02722473,NSE Ancillary Study of The Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.,Recruiting,No Results Available,Cardiac Arrest|Hypothermia|Critical Care,"Biological: NSE dosage ""hypothermia arm""|Biological: NSE dosage ""normothermia arm""",Centre Hospitalier Departemental Vendee,Both,Adult|Senior,Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Single Blind (Outcomes Assessor),NSE-HYPERION,"March 24, 2016",Mar-16,Jul-17,"March 30, 2016",Mar-16,No Study Results Posted,NSE-HYPERION,Jan-17,NSE level between day 1 and day 3,https://ClinicalTrials.gov/show/NCT02722473
838,NCT02722460,Resuscitation Registry - Surrogate Markers of Outcome After Cardiac Arrest,Recruiting,No Results Available,Cardiac Arrest,,"University Hospital Inselspital, Berne",Both,Adult|Senior,,200,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,KEK BE 116/15,"March 2, 2016",Jan-16,Jun-19,"March 30, 2016",Mar-16,No Study Results Posted,CPR,Jan-19,"incidence of survival|incidence of unfavorable outcome after cardiac arrest according to Cerebral Performance Categories Scale|Number of Patient with a low voltage EEG, defined as amplitude below 20 microvolt more than 24 to 72 hours after resuscitation.|Number of patients with a Cut-off Value of Neuron specific enolase >/= 33 ug/l 72 hours after resuscitation|Number of patient with a burst suppression EEG more than 24 to 72 hours after resuscitation|Number of patients with an isoelectric EEG more than 24 to 72 hours after resuscitation",https://ClinicalTrials.gov/show/NCT02722460
839,NCT02722434,MC5-A Scrambler Therapy or TENS Therapy in Treating Patients With Chemotherapy-Induced Peripheral Neuropathy,Recruiting,No Results Available,Pain|Peripheral Neuropathy,Other: Laboratory Biomarker Analysis|Other: MC5-A Scrambler Therapy|Other: Questionnaire Administration|Other: Transcutaneous Electrical Nerve Stimulation,Mayo Clinic|National Cancer Institute (NCI),Both,Adult|Senior,,50,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,MC15C1|NCI-2016-00368|P30CA015083,"March 23, 2016",Apr-16,null,"April 18, 2016",Apr-16,No Study Results Posted,null,Aug-21,Changes in proportion of patients who achieve at least 50% reduction in pain or tingling|Change in functional MRI (fMRI)|Change in mRNA gene expression|Change in sensation|Change in use of pain medication for CIPN|Incidence of toxicity|Perceived treatment efficacy using Subjective Global Impression of Change instrument,https://ClinicalTrials.gov/show/NCT02722434
840,NCT02722343,Exploratory Pharmacodynamic Study of Tenofovir-Based Products,Recruiting,No Results Available,HIV,Drug: Tenofovir intravaginal ring|Drug: Truvada,"CONRAD|Eastern Virginia Medical School|University of North Carolina|Agility Clinical, Inc.",Female,Adult,Phase 1,20,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label,A15-140,"March 9, 2016",Apr-16,Nov-16,"April 18, 2016",Apr-16,No Study Results Posted,null,Nov-16,"p24 antigen production in cervico-vaginal tissues infected with HIV|Analysis of integrated DNA|Measure change in anti-HIV activity in cervicovaginal fluid (CVF)|Determine cervicovaginal tissue, fluid and plasma concentrations of tenofovir|Determine cervicovaginal tissue concentration of tenofovir diphosphate|Determine cervicovaginal tissue, fluid and plasma concentrations of emtricitabine|Determine cervicovaginal tissue concentration of emtricitabine triphosphate|Determine endogenous nucleotide concentrations in cervicovaginal tissue",https://ClinicalTrials.gov/show/NCT02722343
841,NCT02722304,Stage 1 Study of ARALAST NP and GLASSIA in A1PI,Recruiting,No Results Available,Chronic Obstructive Pulmonary Disease|Alpha1-antitrypsin Deficiency,Biological: ARALAST NP 60 mg/kg|Biological: ARALAST NP 120 mg/kg|Biological: GLASSIA 60 mg/kg|Biological: GLASSIA 120 mg/kg|Biological: Human Albumin 2%,Baxalta US Inc.,Both,Adult|Senior,Phase 4,138,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",460503,"March 23, 2016",Apr-16,Jul-21,"April 22, 2016",Apr-16,No Study Results Posted,null,Jul-21,Rate of change in lung density for (1) all ARALAST NP recipients versus placebo recipients; and (2) all GLASSIA recipients versus placebo recipients|Rate of change in lung density for each treatment group|Mean steady state trough concentration of antigenic and functional Alpha1-Proteinase Inhibitor (A1PI) for ARALAST NP and GLASSIA at each dose level|Number of related and unrelated serious and non-serious adverse events (AEs)|Rate of related and unrelated serious and non-serious adverse events (AEs)|Number of temporally related serious and non-serious adverse events (AEs)|Rate of temporally related serious and non-serious adverse events (AEs)|Number of suspected adverse reactions and adverse reactions (ARs)|Rate of suspected adverse reactions and adverse reactions (ARs)|Number of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped due to adverse events (AEs)|Rate of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped due to AEs|Number of participants who develop anti-A1PI antibodies following treatment with ARALAST NP or GLASSIA,https://ClinicalTrials.gov/show/NCT02722304
842,NCT02722291,Functional and Physiological Changes Induced by Pinhole Glasses in Presbyopia,Recruiting,No Results Available,Pinhole,"Device: Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)",Chung-Ang University Hospital,Both,Adult|Senior,,40,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,ChungAngUHophthalmology,"March 21, 2016",Mar-16,Mar-17,"March 30, 2016",Mar-16,No Study Results Posted,null,Dec-16,"Distant visual acuity (logMAR)|BUT|Near point of accommodation (NPA)|The fusional convergence|Stereopsis|Reading speed (letters per second)|Photopic pupil size (baseline, mm)|Pupil size with the one eye pinhole glasses (mm)",https://ClinicalTrials.gov/show/NCT02722291
843,NCT02722278,A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Recruiting,No Results Available,Hypogonadism,Drug: Oral Testosterone Undecanoate|Drug: Axiron Testosterone Topical Solution,"Clarus Therapeutics, Inc.|INC Research",Male,Adult,Phase 3,180,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label,CLAR-15012,"February 15, 2016",Mar-16,Jan-17,"April 5, 2016",Apr-16,No Study Results Posted,inTUne,Jan-17,"The proportion of oral TU treated subjects who have a total T Cavg in the eugonadal range of 300 to 1000 ng/dL at Visit 7|The proportion of oral TU treated subjects who have a total T Cmax ‰ä_ 1500 ng/dL, > 1800 ng/dL and ‰ä_ 2500 ng/dL, and > 2500 ng/dL",https://ClinicalTrials.gov/show/NCT02722278
844,NCT02722265,Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension,Recruiting,No Results Available,Essential Hypertension.,Drug: CS-3150,"Daiichi Sankyo Co., Ltd.|Daiichi Sankyo Inc.",Both,Adult|Senior,Phase 3,360,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,CS3150-A-J302,"March 23, 2016",Mar-16,Dec-17,"March 23, 2016",Mar-16,No Study Results Posted,null,Oct-17,change from baseline in sitting systolic and diastolic blood pressure|Change from baseline in 24-hr ambulatory blood pressure monitoring (ABPM)|number and severity of adverse events|number and severity of laboratory abnormalities,https://ClinicalTrials.gov/show/NCT02722265
845,NCT02722252,Comparative Study of Two Embryo Culture Systems,Recruiting,No Results Available,Infertility,Device: Embryoscope|Device: Embryo culture system without incorporated camera,Centre Hospitalier Universitaire Dijon,Both,Adult|Senior,,266,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,FAUQUE - INCUBATE,"March 18, 2016",Apr-16,null,"April 25, 2016",Mar-16,No Study Results Posted,INCUBATE,Dec-16,Implantation rate|Rate of miscarriages,https://ClinicalTrials.gov/show/NCT02722252
846,NCT02722239,"An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga‰ã¢, 10 mg and Two Glucophageå¨ Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions",Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Xigduo XR|Drug: Metformin ER (Glucophageå¨ long)|Drug: Dapagliflozin (Forxiga),AstraZeneca|Biocard,Both,Adult,Phase 1,40,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label,D1691C00012,"March 15, 2016",Mar-16,Apr-16,"April 12, 2016",Apr-16,No Study Results Posted,null,Apr-16,"Maximum concentration (Cmax).|Adverse events|Area under the ""concentration - time"" curve (AUC0-t)|Area under the ""concentration - time"" curve (AUC0-‰ö_)",https://ClinicalTrials.gov/show/NCT02722239
847,NCT02722187,The Role of Microsurgery in Surgical Treatment of Varicocele.,Recruiting,No Results Available,Varicocele|Infertility,Procedure: subinguinal microscopic varicocelectomy|Procedure: laparoscopic varicocelectomy,Medical University of Warsaw,Male,Adult|Senior,Phase 4,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,microvl/2015,"March 24, 2016",Apr-15,Jul-17,"March 24, 2016",Mar-16,No Study Results Posted,null,Jul-16,pregnancy rate after the intervention,https://ClinicalTrials.gov/show/NCT02722187
848,NCT02722096,Creation of Arteriovenous Ante-brachial Fistula Under Axillary Block Versus Local Anesthesia : Impact on Early Complications,Recruiting,No Results Available,"Kidney Failure, Chronic",Drug: Axillary block anesthesia with Ropivacaine and Lidocaine|Drug: Local anesthesia with Ropivacaine and Lidocaine,Hospices Civils de Lyon,Both,Adult|Senior,,220,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,2013.829,"March 23, 2016",Mar-14,Jun-17,"March 29, 2016",Mar-16,No Study Results Posted,FAV ss ALR,May-17,Rate of early complications related to arteriovenous fistula regardless of type|Rate of complications related to arteriovenous fistula regardless of type|Rate of stenosis of arteriovenous fistula|rate of thrombosis|incidence of abnormal arteriovenous fistula rate|incidence of clinical steal syndrome|incidence of arteriovenous fistula infection|incidence of arteriovenous fistula hemorrhage|necessity of radiologic ou surgical reintervention,https://ClinicalTrials.gov/show/NCT02722096
849,NCT02722044,Usability of an AI for M923 in Subjects With Moderate to Severe RA,Recruiting,No Results Available,Rheumatoid Arthritis,Biological: M923,Baxalta US Inc.,Both,Adult|Senior,Phase 3,32,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,911502,"March 23, 2016",Apr-16,May-17,"April 13, 2016",Apr-16,No Study Results Posted,null,Dec-16,Usability of the auto-injector (AI)|Observer assessment of usability of the autoinjector by the participants at baseline and week 4|Observer assessment of usability of the autoinjector by the participants at baseline and week 2|Clinically significant changes in vital signs|Clinically significant changes in clinical laboratory assessments|Clinically significant changes in Twelve-lead electrocardiogram (ECG)|Number of adverse events leading to premature study withdrawal|Immunogenicity of M923 assessed as proportion of participants with evidence of seroconversion as measured by titer of anti-drug antibody (ADA)|Immunogenicity of M923 assessed as proportion of participants with neutralizing anti-drug antibody (nADAs),https://ClinicalTrials.gov/show/NCT02722044
850,NCT02722031,"Severe Hypoxemia : Prevalence, Treatment and Outcome",Recruiting,No Results Available,Critically Ill Patients Admitted in ICU,,"French Society for Intensive Care|Clinical Research Committee, French Society for Intensive Care, France",Both,Adult|Senior,,2500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SPECTRUM,"March 23, 2016",Mar-16,Aug-16,"March 29, 2016",Mar-16,No Study Results Posted,null,Jun-16,Prevalence of hypoxemia defined by a ratio of the Partial Pressure of Oxygen in Arterial Blood (PaO2) / Fraction of inspired oxygen (FiO2) below 300 mm Hg|Prevalence of severe hypoxemia defined by a ratio PaO2/ FiO2 below 100 mm Hg|Prevalence of mild hypoxemia defined by a ratio PaO2/FiO2 below 200 mm Hg and above 100 mm Hg|Prevalence of moderate hypoxemia defined by a ratio PaO2/FiO2 below 300 mm Hg and above 200 mm Hg|Prevalence of Acute Respiratory Distress Syndrome (ARDS) according the Berlin definition|ICU mortality|Prevalence of the different modalities of oxygen therapy,https://ClinicalTrials.gov/show/NCT02722031
851,NCT02722018,Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810,Recruiting,No Results Available,Healthy Volunteer,Drug: GDC-0810 Phase II Tablet|Drug: GDC-0810 Phase III Prototype Tablet,"Genentech, Inc.",Female,Adult|Senior,Phase 1,48,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label,GP29826|2015-003730-27,"March 23, 2016",Dec-15,Mar-18,"April 2, 2016",Apr-16,No Study Results Posted,null,Mar-18,Maximum observed plasma concentration (Cmax) of GDC-0810|Time to reach maximum observed plasma concentration (Tmax) of GDC-0810|Area under the plasma concentration versus time curve from time zero to time of last quantifiable concentration [AUC(0-t)] of GDC-0810|Area under the plasma concentration versus time curve from time zero to extrapolated infinite time [AUC(0-inf)] of GDC-0810|Apparent terminal elimination rate constant (lambda Z) of GDC-0810|Apparent terminal elimination half-life (t1/2) of GDC-0810|Apparent oral clearance (CL/F) of GDC-0810|Apparent volume of distribution (Vz/F) of GDC-0810|Number of participants with adverse events (AEs),https://ClinicalTrials.gov/show/NCT02722018
852,NCT02722005,The Impact of Family Financial Support on Health Related Quality of Life,Recruiting,No Results Available,Health Related Quality of Life|Finances|Socioeconomic Status,Behavioral: Financial Coaching|Behavioral: Access to referral to social services,"University of California, Los Angeles",Both,Child|Adult|Senior,,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label,UCLASchickedanzFCHRQOL,"March 24, 2016",Mar-16,Jul-17,"March 24, 2016",Mar-16,No Study Results Posted,null,Jul-17,Health-Related Quality of Life,https://ClinicalTrials.gov/show/NCT02722005
853,NCT02721992,Graves' Orbitopathy and Hypercholesterolemia,Recruiting,No Results Available,Graves' Ophthalmopathy|Hypercholesterolemia,Other: No intervention,University of Pisa,Both,Adult|Senior,,66,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,GOCol,"March 17, 2016",Jan-16,Jun-16,"March 22, 2016",Mar-16,No Study Results Posted,GOCol,Jun-16,Proportion of patients with high total cholesterol levels|Proportion of patients with high LDL cholesterol levels|Proportion of patients with severely high total cholesterol levels|Proportion of patients with severely high LDL cholesterol levels|Proportion of patients with low HDL cholesterol levels|Total cholesterol levels|LDL cholesterol levels|HDL cholesterol levels|Proportion of patients with high triglyceride levels|Triglyceride levels|Graves' Orbitopathy degree and activity according to lipid profile,https://ClinicalTrials.gov/show/NCT02721992
854,NCT02721953,The Effects of Butyrate on Children With Obesity,Recruiting,No Results Available,Insulin Resistance|Obesity,Dietary Supplement: Butyrate|Other: Placebo,Federico II University,Both,Child,Phase 2|Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",29/14,"March 23, 2016",Mar-16,Mar-18,"March 29, 2016",Mar-16,No Study Results Posted,null,Jan-18,Reduction of insulin resistance|Reduction of body weight,https://ClinicalTrials.gov/show/NCT02721953
855,NCT02721914,The Effectiveness of the Massage and the Hypopressive Abdominal Gymnastics on Low Back Pain (MAS-GAH),Recruiting,No Results Available,Low-back Pain,Procedure: GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|Procedure: GROUP RECEIVING MASSOTHERAPY|Procedure: GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC,University of Seville,Both,Adult,,70,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)",USeville-MSalas,"March 18, 2016",Apr-16,Jul-16,"April 5, 2016",Apr-16,No Study Results Posted,MAS-GAH,Jun-16,Change from Self-reported lumbar pain intensity at 3 weeks.|Change from Self-reported lumbar pain intensity at 5 weeks.|Change from Disability at 3 weeks.|Change from Disability at 5 weeks.|Change from Lumbar joint mobility at 3 weeks.|Change from Lumbar joint mobility at 5 weeks.|Change from Quality of life at 3 weeks.|Change from Quality of life at 5 weeks.,https://ClinicalTrials.gov/show/NCT02721914
856,NCT02721901,Integrated Eating Aversion Treatment Manual-Parent Version,Recruiting,No Results Available,Feeding and Eating Disorders of Childhood,Behavioral: iEAT Manual Intervention|Behavioral: Control group,Emory University,Both,Child,,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IRB00086399,"March 23, 2016",Mar-16,Jan-18,"March 23, 2016",Mar-16,No Study Results Posted,iEAT,Jan-18,Change in acceptance of food during a 10-minute meal|Change in disruptions during a 10-minute meal|Change in grams of food consumed during a 10-minute meal|Change in Clinical Global Impression - Improvement scale (CGI-I) score|Change in Parenting Stress Index-Short Form (PSI) score,https://ClinicalTrials.gov/show/NCT02721901
857,NCT02721888,Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism,Recruiting,No Results Available,Type 2 Diabetes,Drug: Liraglutide|Drug: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|Biological: Blood sample|Other: Kinetic substudy (10 patients),Centre Hospitalier Universitaire Dijon,Both,Adult|Senior,Phase 4,120,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,VERGES NOVO 2012,"February 29, 2016",Jul-12,null,"March 23, 2016",Feb-16,No Study Results Posted,LIRA-NAFLD/LIP,Mar-16,"Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes|Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) production rate|Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) production rate|Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) production rate|Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) production rate|Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) production rate|Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) fractional catabolic rate|Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) fractional catabolic rate|Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) fractional catabolic rate|Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) fractional catabolic rate|Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) fractional catabolic rate|Modification of body weight|Modification of subcutaneous fat by Magnetic Resonance Imaging (MRI)|Modification of visceral fat by Magnetic Resonance Imaging (MRI)",https://ClinicalTrials.gov/show/NCT02721888
858,NCT02721862,Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy,Recruiting,No Results Available,Cholelithiasis,Drug: Ursodeoxycholic Acid|Drug: Placebo|Radiation: Gallbladder Ultrasound,American University of Beirut Medical Center|Makassed General Hospital,Both,Child|Adult|Senior,Phase 3,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",SUR.RA.01,"March 18, 2016",Mar-16,Mar-19,"March 23, 2016",Mar-16,No Study Results Posted,null,Sep-18,Incidence of gallstone formation after laparoscopic sleeve gastrectomy,https://ClinicalTrials.gov/show/NCT02721862
859,NCT02721836,Yoga for Patients With Irritable Bowel Syndrome,Recruiting,No Results Available,Irritable Bowel Syndrome,Behavioral: Yoga|Behavioral: Nutrition Counselling,UniversitÌ_t Duisburg-Essen,Both,Adult|Senior,,58,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)",15-6653-BO,"March 17, 2016",Apr-16,Mar-17,"April 4, 2016",Apr-16,No Study Results Posted,null,Dec-16,Irritable Bowel Syndrome Symptoms|disease specific quality of life|Generic Health-related Quality of life|Emotional distress|Subjective Stress|Subjective improvement of symptoms|Gut microbiome|Adverse Event,https://ClinicalTrials.gov/show/NCT02721836
860,NCT02721771,Acid-Base and Point of Care Ultrasound in Severe Preeclampsia,Recruiting,No Results Available,Pre-Eclampsia,Procedure: Ultrasound examination,University of Cape Town|Medical University of Vienna|University of Washington,Female,Adult|Senior,,84,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,UCapeTown,"March 10, 2016",Mar-16,Oct-16,"March 22, 2016",Mar-16,No Study Results Posted,null,Oct-16,Association BE(alb) and with delivery outcome|Correlation BE(alb) with comet score and optic nerve sheath diameter (ONSD)|Association B-pattern on lung ultrasound and delivery outcome|Association increased intracranial pressure (ICP) based on ONSD and delivery outcome,https://ClinicalTrials.gov/show/NCT02721771
861,NCT02721706,Cost-effectiveness Study of the New Nutrition Screening Tool CIPA at Hospital Admission,Recruiting,No Results Available,Malnutrition,Other: CIPA nutritional screening tool,University Hospital of the Nuestra SeÌ±ora de Candelaria|Instituto de Salud Carlos III,Both,Adult|Senior,,752,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Screening|Masking: Open Label,PI14/01226,"March 1, 2016",Jan-15,Dec-17,"March 22, 2016",Mar-16,No Study Results Posted,null,Sep-16,Cost-effectiveness measured by incremental Cost-effectiveness ratio (ICER)|incidence of mortality|Quality of life measured by quality-adjusted life years (QALYs)|mean length of stay (days)|incidence of readmissions,https://ClinicalTrials.gov/show/NCT02721706
862,NCT02721628,Epi-keratoplasty Versus Collagen Cross-Linking in Progressive Keratoconus,Recruiting,No Results Available,Progressive Keratoconus,Procedure: Epi-keratoplasty|Procedure: Collagen Cross-Linking|Device: Femtosecond laser,Sun Yat-sen University,Both,Adult|Senior,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,zoc-ekccl2015,"March 6, 2016",Sep-15,Mar-18,"March 22, 2016",Mar-16,No Study Results Posted,null,Dec-17,Changes of Spherical equivalent|maximum keratometry (K-max) derived from computerized video keratography|minimum keratometry|Visual acuity,https://ClinicalTrials.gov/show/NCT02721628
863,NCT02721615,Injured Spinal Cord Pressure Evaluation,Recruiting,No Results Available,Spinal Cord Injuries,Procedure: Insertion of intra spinal sub dural pressure monitor|Procedure: Insertion of sub dural microdialysis probe,"St George's, University of London",Both,Adult|Senior,,100,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label,09.0151|10/H0807/23,"March 17, 2016",Sep-10,Aug-19,"March 22, 2016",Mar-16,No Study Results Posted,ISCoPE,Feb-19,Intra spinal pressure|Spinal metabolites,https://ClinicalTrials.gov/show/NCT02721615
864,NCT02721602,Families Preventing Diabetes Together,Recruiting,No Results Available,Type 2 Diabetes|Pediatric Obesity,Behavioral: Families Preventing Diabetes Together,University of Minnesota - Clinical and Translational Science Institute,Both,Child|Adult,,192,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,23085,"February 16, 2016",Feb-16,Sep-16,"March 28, 2016",Mar-16,No Study Results Posted,null,Jun-16,Feasibility of the study measured via the ability to successfully recruit 30-40 families for the study.|Feasibility of the study measured via the ability to successfully measure 100% of the adults and 80% of the children in enrolled families at baseline measurements.|Feasibility of the study measured via the ability to successfully retain 85% of the enrolled families over the course of the study measured by their participate in post-intervention measurements.|Acceptability of the intervention measured via family participation rates (families attend at least 70% of the sessions).|Acceptability of the intervention measured via family feedback indicating at least 90% approve of the sessions on post-intervention surveys.|Child BMIz|Blood glucose control in parent with Type 2 diabetes,https://ClinicalTrials.gov/show/NCT02721602
865,NCT02721589,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects,Recruiting,No Results Available,Lung Cancer,Drug: SHR-1210,"Jiangsu HengRui Medicine Co., Ltd.",Both,Adult|Senior,Phase 1,45,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,SHR-1210-101,"March 23, 2016",Apr-16,Apr-17,"April 19, 2016",Mar-16,No Study Results Posted,null,Dec-16,Dose limited toxicity,https://ClinicalTrials.gov/show/NCT02721589
866,NCT02721576,A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC,Recruiting,No Results Available,Esophageal Neoplasms,Drug: Sodium Glycididazole,Shandong Cancer Hospital and Institute,Both,Adult|Senior,Phase 2,40,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,CMNAER3,"March 9, 2016",Sep-15,Dec-18,"March 22, 2016",Mar-16,No Study Results Posted,null,Dec-18,Objective response rate|Overall survival|Progression free survival,https://ClinicalTrials.gov/show/NCT02721576
867,NCT02721563,A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC,Recruiting,No Results Available,Esophageal Neoplasms,Drug: Sodium Glycididazole|Drug: Placebo,Shandong Cancer Hospital and Institute,Both,Adult|Senior,Phase 2,104,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),CMNAER2,"March 9, 2016",Sep-15,Dec-18,"March 22, 2016",Mar-16,No Study Results Posted,null,Dec-18,Objective response rate|Overall survival|Progression free survival,https://ClinicalTrials.gov/show/NCT02721563
868,NCT02721550,A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC,Recruiting,No Results Available,Esophageal Neoplasms,Drug: Sodium Glycididazole,Shandong Cancer Hospital and Institute,Both,Adult|Senior,Phase 2,40,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,CMNAER1,"March 9, 2016",Sep-15,Dec-18,"March 22, 2016",Mar-16,No Study Results Posted,null,Dec-18,pathologic Complete Response|Overall Survival|Disease-Free Survival,https://ClinicalTrials.gov/show/NCT02721550
869,NCT02721524,Ring Versus Suture Annuloplasty For Functional Tricuspid Regurgitation In Rheumatic Mitral Valve Diseases,Recruiting,No Results Available,Functional Tricuspid Regurgitation,Procedure: Tricuspid Annuloplasty,Shahid Gangalal National Heart Centre,Both,Child|Adult|Senior,,86,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,TRICUSPID STUDY-RCT,"March 16, 2016",Nov-15,Sep-16,"March 22, 2016",Mar-16,No Study Results Posted,null,Sep-16,Improvement in severity of FTR|Mortality,https://ClinicalTrials.gov/show/NCT02721524
870,NCT02721381,Comparative Efficacy of Self-directed & Therapist-assisted Telehealth Parent Training Intervention for Children With ASD,Recruiting,No Results Available,Autism Spectrum Disorder,Behavioral: ImPACT Online,Michigan State University,Both,Child,,90,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),R40MC27704,"March 14, 2016",Mar-15,Jul-18,"March 22, 2016",Mar-16,No Study Results Posted,null,Mar-18,ImPACT Online Fidelity Change Scale|Parent Sense of Competence Change Scale|Mullen Scales of Early Learning Change Score|MacArthur-Bates Child Developmental Inventory Change Score|Parent-child Interaction Change|ImPACT Online electronic tracking system|Intervention Log Change|Vineland Adaptive Behavior Scales Change Score,https://ClinicalTrials.gov/show/NCT02721381
871,NCT02721355,Effect of Chicken Egg Antibody (IgY) on Patients With Chronic Gastritis,Recruiting,No Results Available,Chronic Gastritis Caused by Helicobacter Pylori,Dietary Supplement: GastimunHP,Immunology Research Institute in Gifu|Dong Do Pharmaceutical Co.,Both,Child|Adult|Senior,,80,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,BV108-15,"March 3, 2016",Jun-13,null,"March 22, 2016",Mar-16,No Study Results Posted,null,May-16,Effect of IgY in combination with EAC on Helicobacter pylori eradication in patients with chronic gastritis|Effect of IgY in combination with EAC on severity of abdominal pain.|Effect of IgY in combination with EAC on nausea and vomiting|Effect of IgY in combination with EAC on bloating,https://ClinicalTrials.gov/show/NCT02721355
872,NCT02721342,Remission Clinic in Proteinuric Chronic Nephropathies,Recruiting,No Results Available,Chronic Kidney Disease.,"Drug: Ramipril, Irbesartan and Atorvastin",Mario Negri Institute for Pharmacological Research,Both,Adult|Senior,,1500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Remission Clinic,"March 14, 2016",Jun-09,Mar-19,"March 22, 2016",Mar-16,No Study Results Posted,null,Dec-18,Glomerular Filtration Rate (GFR) estimated|24 hour proteinuria|Number of participants with fatal and non-fatal cardiovascular events,https://ClinicalTrials.gov/show/NCT02721342
873,NCT02721290,Comparison of the Sensitive Cutaneous Block Distribution Following Femoral Nerve Block Using Two Femoral Block Techniques,Recruiting,No Results Available,Regional Anesthesia|Femoral Nerve Block,Procedure: Femoral nerve block using Ultrasound and neurostimulator|Procedure: Femoral nerve block using Ultrasound|Drug: Ropivacaine 0.5%,Maisonneuve-Rosemont Hospital,Both,Adult|Senior,,80,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),20160112,"March 15, 2016",Jan-16,Oct-16,"March 29, 2016",Mar-16,No Study Results Posted,null,May-16,Sensitive cutaneous block distribution area for the two techniques|Time of block completion|Ease of ultrasound visualization of the femoral nerve|Ease of ultrasound visualization of the femoral artery|Numbers of needle redirection|Vascular puncture|Paresthesia|Patient Satisfaction,https://ClinicalTrials.gov/show/NCT02721290
874,NCT02721264,Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.,Recruiting,No Results Available,Non Alcoholic Steatohepatitis,Biological: Fecal Microbiota Transplant|Other: Standard Medical Treatment,"Institute of Liver and Biliary Sciences, India",Both,Adult|Senior,,112,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,ILBS-NASH-03,"March 1, 2016",Mar-16,Sep-17,"April 1, 2016",Mar-16,No Study Results Posted,null,Sep-17,"Reduction in Hepatic Venous Pressure Gradient in the two groups from baseline.|Improvement in liver function test as compared to baseline.|Improvement in Liver Stiffness Measurement as compared to baseline.|Assess improvement in insulin resistance (Fasting plasma and insulin levels, HOMA-IR)|Incidence of new onset upper gastrointestinal bleed in both groups|development of new onset of ascites in both groups.|Number of Spontaneous Bacterial peritonitis cases in both groups.|ACLF (Acute on Chronic Liver failure) cases in both groups.|Reduction in hepatic and systemic inflammatory markers like TNF-ë± in both groups|Reduction in hepatic and systemic inflammatory markers like C Reactive Protein in both groups|Reduction in hepatic and systemic inflammatory markers like serum endotoxins in both groups.|Histological and permeability changes in the duodenal biopsy in both groups.",https://ClinicalTrials.gov/show/NCT02721264
875,NCT02721238,Comparison of Colloid (20% Albumin) Versus Crystalloid (Plasmalyte) for Fluid Resuscitation in Cirrhotics With Sepsis Induced Hypotension.,Recruiting,No Results Available,Cirrhosis With Sepsis,Biological: 20% Albumin|Other: Plasmalyte,"Institute of Liver and Biliary Sciences, India",Both,Adult|Senior,,90,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,ILBS-Cirrhosis-03,"March 1, 2016",Mar-16,Mar-17,"April 1, 2016",Mar-16,No Study Results Posted,null,Mar-17,Reversal of hypotension in both groups|Mortality in both groups|Survival time during the first 28 days|Proportion of patients with new organ failures.|Duration of mechanical ventilation.|Requirement of renal-replacement therapy.|The duration of the Intensive Care Unit stay.,https://ClinicalTrials.gov/show/NCT02721238
876,NCT02721225,Prebiotic in Preventing Low Birth Weight,Recruiting,No Results Available,Birth Weight <2500gm|Genitourinary Tract Infection,Dietary Supplement: Fructooligosaccharide|Dietary Supplement: Pocari-Sweat,"International Centre for Diarrhoeal Disease Research, Bangladesh|Karolinska Institutet|Swedish International Development Cooperation Agency (SIDA)",Female,Adult,Phase 1,210,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",PR-14038,"March 14, 2016",Jun-15,Jun-17,"April 4, 2016",Feb-16,No Study Results Posted,null,Jun-17,1. Infant birth weight|Gestational age|Vaginal colonization of Lactobacillus (LAB)|Intestinal Colonization of LAB|Rate of Genito-urinary (GU) infection|Gain in Z-score of infant from birth|Incidence of Acute respiratory infection and diarrhoea,https://ClinicalTrials.gov/show/NCT02721225
877,NCT02721199,EMG in COPD - Factor Analysis,Recruiting,No Results Available,COPD,Other: Neural Respiratory Drive Automated EMGpara assessment,Guy's and St Thomas' NHS Foundation Trust|Philips Healthcare,Both,Adult|Senior,,10,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,178765,"January 27, 2016",Jan-16,Dec-16,"March 22, 2016",Jan-16,No Study Results Posted,EMGCOPD,Sep-16,"During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), the physiological factors that can change EMG parasternal readings. Collecting Medication Intake|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), the physiological factors that can change EMG parasternal readings. Collecting oxygen therapy.|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), the physiological factors that can change EMG parasternal readings. Collecting use of non invasive ventilation.|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), the physiological factors that can change EMG parasternal readings. Collecting intubation details.|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), the physiological factors that can change EMG parasternal readings. Collecting information if participant is transferred to critical care.|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), the physiological factors that can change EMG parasternal readings. Collecting information if participant takes part in a respiratory physiotherapy session.|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), physiological factors that change EMG parasternal readings. If participant goes into clinical respiratory deterioration by the need for treatment/care escalation.|During the course of an exacerbation of COPD, the physiological factors that can change EMG parasternal readings. If participant goes into clinical respiratory deterioration National Early Warning Score (NEWS) CREWS|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), the physiological factors that can change EMG parasternal readings. Collecting information if participant partakes in physical activity|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), physiological factors that change EMG parasternal readings. Collecting information when participant sleeps|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), the physiological factors that can change EMG parasternal readings. Collecting information if there is any postural change|During the course of an exacerbation of Chronic Obstructive Pulmonary Disease (COPD), the physiological factors that can change EMG parasternal readings. Collecting information if participant takes part in a rehabilitation physiotherapy session.|Is it possible to perform Continuous EMGpara acquisition in a clinical setting|Continuous EMGpara acquisition in clinical setting, is it applicable.|Continuous EMGpara acquisition in clinical setting, preliminary insights on device requirements for this environment.|EMGpara trends as it relates to standardly used metrics, e.g. vital signs, patient-reported symptoms.|Rhe automated neural respiratory drive (NRD) calculation algorithm during continuous measurements will be optimised to increase the robustness of the algorithm against artefacts.|Standardise the measurement set-up and measurement protocol in routine AECOPD management.",https://ClinicalTrials.gov/show/NCT02721199
878,NCT02721147,Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer,Recruiting,No Results Available,Breast Cancer,"Behavioral: Intimacy Enhancing Intervention|Behavioral: Educational Control|Behavioral: Partner-Assisted Coping Skills Training|Behavioral: Behavioral, Psychological or Informational Intervention",Fox Chase Cancer Center,Female,Adult|Senior,,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label,15-8007,"March 14, 2016",Jan-16,Mar-17,"March 28, 2016",Mar-16,No Study Results Posted,null,Mar-17,Feasibility of the treatment as measured through study accrual|Feasibility of the treatment as measured through study attrition|Feasibility of the treatment as measured through session completion by participant|Participant treatment satisfaction measured using study questionnaires|Acceptability measured using the Client Satisfaction Questionnaire (CSQ-8)|Change in sexual function measured using the International Index of Erectile Function|Change in sexual satisfaction measured using the Patient-Reported-Outcomes Measurement Information System (PROMIS) Sexual Satisfaction Items|Change in sexual distress measured using the Female Sexual Distress Scale-Revised|Change in sexual intimacy measured using the PAIR Sexual Intimacy Subscale|Change in beliefs (self-efficacy)|Change in frequency of sexual activity/use of aids measured using the Intimate Activities and Use of Sexual Aids PROMIS|Change in emotional intimacy measured using the PAIR Emotional Intimacy Scale|Change in sexual communication measured using the Dyadic Sexual Communication Scale|Change in relationship quality measured using the Dyadic Adjustment Scale-7 item|Change in body image distress measured using the Body Image Scale|Change in depression measured using the Patient Health Questionnaire-9 item|Change in anxiety measured using the Generalized Anxiety Disorder 7-item|Study participation barriers as measured by study accrual|Change in sexual function measured using the Female Sexual Function Index,https://ClinicalTrials.gov/show/NCT02721147
879,NCT02721134,Diagnostic Performance of a New Bio-marker During Bacterial Sepsis,Recruiting,No Results Available,Sepsis,Other: additional blood tubes,Centre Hospitalier Universitaire de Nice|Bio-Rad Laboratories,Both,Adult|Senior,,400,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,14-PP-18,"March 7, 2016",Mar-16,Jun-18,"April 22, 2016",Mar-16,No Study Results Posted,BACTIDIAG,Mar-18,determine the AUC,https://ClinicalTrials.gov/show/NCT02721134
880,NCT02721121,Comparison of Circumferential Pulmonary Vein Isolation Alone Versus Linear Ablation in Addition to Circumferential Pulmonary Vein Isolation for Catheter Ablation in Persistent Atrial Fibrillation: Prospective Randomized Controlled Trial,Recruiting,No Results Available,Atrial Fibrillation,Procedure: circumferential pulmonary vein isolation|Procedure: Linear ablation in addiction to circumferential pulmonary vein isolation,Yonsei University,Both,Adult|Senior,,220,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,4-2016-0029,"March 22, 2016",Mar-16,Mar-21,"March 25, 2016",Mar-16,No Study Results Posted,null,Mar-21,Recurrence of atrial fibrillation after catheter ablation|procedure time|procedure related complication rate|rate of hospitalization,https://ClinicalTrials.gov/show/NCT02721121
881,NCT02721095,Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl,Recruiting,No Results Available,Hypokalemia,Other: KCl plus 0.9%NaCl|Other: KCl plus 0.45%NaCl,Phramongkutklao College of Medicine and Hospital,Both,Adult|Senior,Phase 4,84,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,PMK1981,"May 25, 2015",Aug-14,Sep-16,"March 22, 2016",Mar-16,No Study Results Posted,null,Jul-16,Number of participants with normal serum K as assessed by serum electrolyte,https://ClinicalTrials.gov/show/NCT02721095
882,NCT02721069,Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects,Recruiting,No Results Available,Acute Repetitive Seizures|Breakthrough Seizures,Drug: NRL-1,"Neurelis, Inc.",Both,Child|Adult,Phase 3,80,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,DIAZ.001.05,"March 17, 2016",Mar-16,Sep-17,"March 30, 2016",Mar-16,No Study Results Posted,null,Jul-17,Safety Assessment by collection of adverse events data|Tolerability Assessment by smell test|Tolerability Assessment by examination of nasal mucosa|Caregiver Assessment|Quality of Life,https://ClinicalTrials.gov/show/NCT02721069
883,NCT02721056,NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers,Recruiting,No Results Available,Hepatocellular Carcinoma|Liver Cancer,"Radiation: NBTXR3, IL or IA injection + SBRT","Nanobiotix|Quintiles, Inc.",Both,Adult|Senior,Phase 1|Phase 2,200,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,NBTXR3-103,"December 24, 2015",Nov-15,Dec-18,"March 31, 2016",Mar-16,No Study Results Posted,null,Jun-17,Determination of the Recommended Doses Toxicities (DLT)|Determination of the early Dose Limiting|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0|Response Rate|Local Progression Free Survival,https://ClinicalTrials.gov/show/NCT02721056
884,NCT02721030,Mbarara Acute Heart Failure Registry,Recruiting,No Results Available,Heartfailure,,Mbarara University of Science and Technology|University of Virginia,Both,Child|Adult|Senior,,250,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,26/11/2014,"March 16, 2016",Mar-16,Jun-18,"March 25, 2016",Mar-16,No Study Results Posted,MAFHER,May-18,All-cause mortality|Length of hospitalization|Quality of life using the SF-36 questionnaire|Functional status using the Kansas city cardiomyopathy questionnaire,https://ClinicalTrials.gov/show/NCT02721030
885,NCT02721017,Cryoanalgesia vs. Epidural in the Nuss Procedure,Recruiting,No Results Available,Pectus Excavatum|Funnel Chest,"Device: Cryoanalgesia|Drug: Thoracic epidural (ropivicaine, fentanyl)","Michael Harrison|University of California, San Francisco",Both,Child|Adult|Senior,Phase 4,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,15-18202,"March 22, 2016",Mar-16,Sep-17,"March 25, 2016",Mar-16,No Study Results Posted,null,Aug-17,length of hospitalization|Narcotic usage|side effects|cost analysis,https://ClinicalTrials.gov/show/NCT02721017
886,NCT02720952,Treatment of Adrenal Insufficiency in Children,Recruiting,No Results Available,Adrenal Insufficiency,Drug: Infacortå¨,Diurnal Limited|TAIN (Treatment of Adrenal Insufficiency in Neonates) consortium,Both,Child,Phase 3,24,Industry|Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,Infacort-003,"March 16, 2016",Mar-15,Jun-16,"March 25, 2016",Mar-16,No Study Results Posted,null,Jun-16,Serum cortisol concentration up to 240 minutes|Serum cortisol concentration up to 6 hours|Subject assessment of taste of the product|Incidence of serious adverse events (SAEs) and adverse events (AE),https://ClinicalTrials.gov/show/NCT02720952
887,NCT02720939,ASD-specific Induced Pluripotent Stem Cells for Disease Modeling,Recruiting,No Results Available,Autism Spectrum Disorder,,National Taiwan University Hospital,Both,Child|Adult|Senior,,20,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,201507086RINA,"March 22, 2016",Jan-16,null,"March 25, 2016",Mar-16,No Study Results Posted,null,Dec-16,iPSC derivation and characterization,https://ClinicalTrials.gov/show/NCT02720939
888,NCT02720900,Prebiotic Intervention for Autism Spectrum Disorders,Recruiting,No Results Available,Autism,Dietary Supplement: B-GOS|Dietary Supplement: Maltodextrin,Clasado Limited|University of Reading,Both,Child,Phase 1,42,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",ASD2015,"November 10, 2015",Dec-15,Apr-17,"March 25, 2016",Mar-16,No Study Results Posted,null,Dec-16,effect on faecal microbiota composition using pyrosequencing|effect on faecal microbiota activity using nuclear magnetic resonance spectroscopy|questionnaire as a measure of bowel function|questionnaire as a measure of mood|questionnaire as a measure of behaviour,https://ClinicalTrials.gov/show/NCT02720900
889,NCT02720861,Prevalence of Genetic Polymporphism on RNF213 rs112735431 Gene in Non-cardioemboli Ischemic Cerebrovascular Disease,Recruiting,No Results Available,Ischemic Stroke,Genetic: DNA sequencing,Chulalongkorn University,Both,Adult|Senior,,200,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,COA No.282/2015,"March 15, 2016",Mar-15,Jun-16,"March 25, 2016",Mar-16,No Study Results Posted,null,Mar-16,Number of Participants With RNF213 rs112735431 Gene polymorphism,https://ClinicalTrials.gov/show/NCT02720861
890,NCT02720835,"Efficacy and Safety of PIPAC/PITAC in Gastric,Ovarian, Colorectal Cancer and Mesothelioma With Pleural Carcinomatosis.",Recruiting,No Results Available,Colorectal Cancer|Ovarian Cancer|Gastric Cancer|Mesothelioma,Procedure: pressurized intraperitoneal/intrathoracal aerosol chemoTx,"Othmar Schoeb|Klinik Hirslanden, Zurich",Both,Adult|Senior,,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Visz-001-2016,"March 22, 2016",Feb-16,Feb-18,"March 22, 2016",Mar-16,No Study Results Posted,PIPAC/PITAC,Feb-18,Clinical Benefit Rate (CBR) according to RECIST criteria after three cycles of PIPAC/PITAC|Peritoneal carcinomatosis index (PCI)|Histological tumor regression/progression|Time until tumor progression|Ascites/pleural affusion volume|Degree of tumor cell apoptosis|Overall survival,https://ClinicalTrials.gov/show/NCT02720835
891,NCT02720796,Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma,Recruiting,No Results Available,Sarcoma,Other: PDX drug sensitivity testing,"Champions Oncology|Mount Sinai Hospital, Canada",Both,Child|Adult|Senior,,226,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,CO-001,"November 5, 2015",Nov-15,Nov-18,"March 22, 2016",Mar-16,No Study Results Posted,null,Nov-18,Number of patients' whose personalized PDX model accurately predicts clinical response to therapy with same drug treatment.|Number of patients' whose personalized PDX model accurately predicts clinical response to therapy over subsequent lines of therapy.|Factors that impact on engraftment success.|Factors that impact time to drug sensitivity testing.,https://ClinicalTrials.gov/show/NCT02720796
892,NCT02720783,Tolerability and Pharmacokinetic Study of Econazole Nitrate Plus Benzydamine HCl Vaginal Pessary,Recruiting,No Results Available,Healthy Women,Drug: Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary|Drug: Placebo plus Econazole nitrate 150 mg vaginal pessary|Drug: Placebo plus Benzydamine HCl 6 mg vaginal pessary|Drug: Placebo vaginal pessary,Aziende Chimiche Riunite Angelini Francesco S.p.A|Cross Research S.A.,Female,Adult,Phase 1,60,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",030(4C)HO15323|CRO-PK-15-302,"March 22, 2016",Mar-16,null,"March 29, 2016",Mar-16,No Study Results Posted,null,Jun-16,"Local Adverse Drug Reactions (ADRs)|Econazole (free base), benzydamine (free base) and benzydamine N-oxide (free base) plasma concentrations|Area under the plasma concentration versus time curve [AUC(0-t)] of econazole (free base), benzydamine (free base) and benzydamine N-oxide (free base)|Overall local tolerability assessment scale|Occurrence of all AEs and ADRs|Change from screening in laboratory parameters|Questionnaire for the comfort of use",https://ClinicalTrials.gov/show/NCT02720783
893,NCT02720705,Oral Dexmedetomidine for the Prevention of Emergence Agitation After Sevoflurane Anaesthesia in Pre-school Children,Recruiting,No Results Available,Agitation,Drug: Dexmedetomidine|Drug: saline,Assiut University,Both,Child,Phase 2|Phase 3,120,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",AssuitU,"March 17, 2016",Feb-16,Sep-16,"March 25, 2016",Mar-16,No Study Results Posted,null,Aug-16,The agitation score up to 1hour postoperative.|Pain score assessed using the objective pain scale.,https://ClinicalTrials.gov/show/NCT02720705
894,NCT02720692,Evaluation of N1539 Following Major Surgery,Recruiting,No Results Available,"Pain, Post-operative",Drug: N1539|Drug: Intravenous Placebo,"Recro Pharma, Inc.",Both,Adult|Senior,Phase 3,700,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",REC-15-017,"March 22, 2016",Mar-16,Feb-17,"March 22, 2016",Mar-16,No Study Results Posted,null,Feb-17,Number of subjects with adverse events,https://ClinicalTrials.gov/show/NCT02720692
895,NCT02720679,Investigation of the Genetics of Hematologic Diseases,Recruiting,No Results Available,Bone Marrow Failure Syndromes|Erythrocyte Disorder|Leukocyte Disorder|Hemostasis|Blood Coagulation Disorder|Sickle Cell Disease|Dyskeratosis Congenita|Diamond-Blackfan Anemia|Congenital Thrombocytopenia|Severe Congenital Neutropenia|Fanconi Anemia,,St. Jude Children's Research Hospital|Children's Hospital Boston,Both,Child|Adult|Senior,,1716,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,INSIGHT-HD,"March 16, 2016",Mar-16,Aug-26,"March 25, 2016",Mar-16,No Study Results Posted,null,Aug-26,Percent of participants who agree to participate|Number by type of inherited genetic aberrations associated with hematologic disorders|Number by type of modifier genes|Number by type of genetic variants,https://ClinicalTrials.gov/show/NCT02720679
896,NCT02720666,K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability,Recruiting,No Results Available,Pancreatic Cancer,Drug: K-001,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",Both,Adult|Senior,Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CPOG001_01,"February 13, 2016",Jan-16,Oct-16,"March 22, 2016",Mar-16,No Study Results Posted,null,Aug-16,The maximum-tolerated dose (MTD) of K-001|Change of life quality assessed using EORTC QLQ-C30 V 3.0|Change from Baseline of the Treg cell count|Evaluation of suffered pains assessed using Numerical Rating Scale (NRS)|Change from Baseline of the C-reactive protein (CRP)|Clinical efficacy of K-001 assessed by disease control rate (DCR) according to RECIST V 1.0 criteria,https://ClinicalTrials.gov/show/NCT02720666
897,NCT02720640,Safety and Efficacy of the Alpha AMS Subretinal Implant for Partial Restoration of Vision in Visually Impaired Participants With Degenerative Retinal Disease,Recruiting,No Results Available,Retinitis Pigmentosa,Device: Subretinal electronic retinal implant,University of Oxford,Both,Adult|Senior,,6,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,E/2015/0119,"December 4, 2015",May-15,Aug-17,"March 21, 2016",Mar-16,No Study Results Posted,OX-RI,Jul-16,Efficacy of the Alpha AMS retinal implant system used for activities of daily living tasks.|Efficacy of the Alpha AMS retinal implant system used for recognition tasks.|Efficacy of the Alpha AMS retinal implant system used for mobility.|Efficacy of the Alpha AMS retinal implant system used for activities of daily living and mobility.|Efficacy of the Alpha AMS retinal implant system used for partial restoration of visual acuity.|Safety of the Alpha AMS retinal implant.,https://ClinicalTrials.gov/show/NCT02720640
898,NCT02720588,Investigating Neuroimaging Endophenotypes for Autism Spectrum Disorder,Recruiting,No Results Available,Autism Spectrum Disorder,,National Taiwan University Hospital,Both,Adult,,90,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,201505142RINC,"March 22, 2016",Jan-16,null,"March 25, 2016",Mar-16,No Study Results Posted,null,Dec-16,Psychiatric Interview,https://ClinicalTrials.gov/show/NCT02720588
899,NCT02720549,The Effect of Remote Ischemic Postconditioning on Postoperative Renal Dysfunction in Patients Undergoing Valvular Heart Surgery,Recruiting,No Results Available,Valvular Heart Disease Patients,Procedure: remote ischemic postconditioning|Procedure: valvular surgery with bypass,Yonsei University,Both,Adult|Senior,,252,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)",4-2015-1198,"March 22, 2016",Feb-16,Feb-18,"March 26, 2016",Mar-16,No Study Results Posted,null,Jan-18,incidence of postoperative renal dysfunction using AKIN(acute kidney injury network) criteria,https://ClinicalTrials.gov/show/NCT02720549
900,NCT02720523,"A Phase 2b/3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Japanese Subjects With Rheumatoid Arthritis",Recruiting,No Results Available,Rheumatoid Arthritis,Drug: ABT-494|Drug: Placebo,AbbVie,Both,Adult|Senior,Phase 2,192,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",M14-663,"March 22, 2016",Mar-16,Aug-17,"March 22, 2016",Mar-16,No Study Results Posted,null,Aug-17,Proportion of subjects achieving American College of Rheumatology (ACR) 20 response at Week 12|Change from baseline (week 0) in Disease Activity Score (DAS)28 C-Reactive Protein (CRP)|Change from baseline (week 0) in Health Assessment Questionnaire Disability Index (HAQ-DI)|ACR 50 Response Rate|ACR 70 Response Rate|Change from baseline (week 0) in Short-Form 36 (SF-36) Physical Component Score (PCS)|Proportion of subjects achieving Low Disease Activity (LDA) based on DAS28 (CRP)|Proportion of subjects achieving Clinical Remission (CR) based on DAS28 (CRP)|Change from baseline (week 0) in Functional Assessment of Chronic Illness Therapy (FACIT-F)|Change from baseline (week 0) in Rheumatoid Arthritis Work Instability Scale (RA-WIS)|Change from baseline (week 0) in morning stiffness (severity),https://ClinicalTrials.gov/show/NCT02720523
901,NCT02720484,Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer,Recruiting,No Results Available,Metastatic Carcinoma in the Adrenal Cortex|Recurrent Adrenal Cortex Carcinoma|Stage III Adrenal Cortex Carcinoma|Stage IV Adrenal Cortex Carcinoma,Other: Laboratory Biomarker Analysis|Drug: Nivolumab,Northwestern University|National Cancer Institute (NCI),Both,Adult|Senior,Phase 2,33,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,NU 15E01|STU00202153|P30CA060553|NCI-2016-00194,"March 16, 2016",Mar-16,null,"March 29, 2016",Mar-16,No Study Results Posted,null,Feb-19,Overall Response Rate|Progression-free survival (PFS)|Overall survival (OS)|Incidence of adverse events,https://ClinicalTrials.gov/show/NCT02720484
902,NCT02720471,Local Analgesia Versus Local Peroperative Infiltration After Total Hip Replacement,Recruiting,No Results Available,Total Hip Replacement,Drug: Locoregional anesthesia|Drug: peroperative infiltration of local anesthetics,Hospices Civils de Lyon,Both,Adult|Senior,Phase 3,84,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),69HCL15_0189,"December 15, 2015",Sep-15,Mar-17,"March 21, 2016",Nov-15,No Study Results Posted,ALRIAL,Mar-17,Quantity of morphine consumed|Pain at rest|Pain while moving|Time between intervention and first support by the upright posture in bipedal station.|Time between intervention and resumption of the walk,https://ClinicalTrials.gov/show/NCT02720471
903,NCT02720406,Topical Ketamine Analgesia in Children Undergoing Tonsillectomy: a Clinical and Serum Level Assays Study.,Recruiting,No Results Available,Postoperative Pain,Drug: Intravenous ketamine0.5mg/kg|Drug: Nebulized Ketamine 0.5mg/kg|Drug: Nebulized Ketamine 1mg/kg,Assiut University,Both,Child,Phase 2|Phase 3,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",AssuitUniversity,"March 22, 2016",Feb-16,Sep-16,"March 24, 2016",Mar-16,No Study Results Posted,null,Aug-16,postoperative analgesic consumption|time to first analgesic request and pain scores|Ketamine serum levels to exclude systemic absorption of topical ketamine.,https://ClinicalTrials.gov/show/NCT02720406
904,NCT02720380,Buteyko Method for Children With Asthma,Recruiting,No Results Available,Asthma|Child|Breathing Exercises,Other: Buteyko|Other: Asthma education,Universidade Federal do Rio Grande do Norte,Both,Child,,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),562.554,"March 7, 2016",Jul-15,null,"March 21, 2016",Mar-16,No Study Results Posted,null,May-16,Change in Quality of life (questionnaire)|Change in pulmonary function (spirometry)|Change in the Six-minute walk test distance|Numbers of visits to the emergency room|Numbers of Days off-school|Number of exacerbations|Number of times using Beta2-agonists,https://ClinicalTrials.gov/show/NCT02720380
905,NCT02720341,"VIT-ARMin Virtual, Intensified and Patient-tailored Robotic Arm Therapy With the Exoskeleton Robot ARMin",Recruiting,No Results Available,Stroke|Spinal Cord Injury|Healthy,Device: ARMin,Prof. Robert Riener|Swiss Federal Institute of Technology,Both,Adult|Senior,Phase 0,420,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,VIT-ARMin,"February 11, 2016",Apr-15,Jan-18,"March 29, 2016",Mar-16,No Study Results Posted,VIT-ARMin,Jan-18,"Intrinsic Motivation Inventory (IMI) questionaire|performance tests (kinematic and kinetic data) in virtual reality on the ARMin robot (time in msec)|performance tests (kinematic and kinetic data) in virtual reality on the ARMin robot (position in cm)|performance tests (kinematic and kinetic data) in virtual reality on the ARMin robot ( force in Nm)|muscle strength in Nm|questionaire on interaction, time and effort|EMG for muscle activity (time and electric potential)|EMG for muscle activity (time in sec)|EMG for muscle activity (electric potential in V)|detection thresholds (time)|detection thresholds (position in cm)",https://ClinicalTrials.gov/show/NCT02720341
906,NCT02720302,Treatment of Overweight in Children on Distance,Recruiting,No Results Available,Overweight,Behavioral: SOFT|Behavioral: TeleSOFT,SkÌ´ne University Hospital|Lund University,Both,Child,,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2015/141,"November 23, 2015",Mar-16,Jun-21,"March 21, 2016",Mar-16,No Study Results Posted,TeleSOFT,Jun-17,Body mass index standard deviation score (BMI Z-score) during treatment of overweight|Change in fat percent measured by TANITA|Change in fat distribution measured by abdominal height (F-indicator)|Change in fat distribution measured by waist circumference|Change in KIDSCREEN-index|Change in physical activity measured by Moves application to smartphone|Change child's metabolic health (Blood pressure)|Change child's metabolic health (LDL-cholesterol)|Change child's metabolic health (HDL-cholesterol)|Change child's metabolic health (triglycerides)|Change child's metabolic health (HbA1c)|Change child's metabolic health (F-blood glucose)|Change child's metabolic health (f-insulin)|Change child's metabolic health (ccK-18)|Change child's metabolic health (ALAT)|Change in dietary habits|Change in Outcome Rating Scale and Session Rating Scale|Change in Session Rating Scale,https://ClinicalTrials.gov/show/NCT02720302
907,NCT02720250,Omega-3 Fatty Acids Enriched Food and Microvascular Reactivity,Recruiting,No Results Available,Omega-3 Polyunsaturated Fatty Acids,Dietary Supplement: Omega-3 chicken eggs|Dietary Supplement: Regular chicken eggs,Josip Juraj Strossmayer University of Osijek,Both,Adult,,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)",2.15861E+12,"March 22, 2016",Mar-16,Dec-18,"March 29, 2016",Mar-16,No Study Results Posted,null,Dec-17,microvascular reactivity|lipid profile,https://ClinicalTrials.gov/show/NCT02720250
908,NCT02720237,Reducing Hazardous Alcohol Use & Human Immunodeficiency Virus (HIV) Viral Load,Recruiting,No Results Available,Alcohol Drinking|HIV,Behavioral: Brief Intervention|Behavioral: Motivational Enhancement Therapy (MET) Intervention|Behavioral: Cognitive Behavioral Therapy (CBT) Intervention,"University of North Carolina, Chapel Hill|National Institute on Drug Abuse (NIDA)|Thai Nguyen Center for Preventive Medicine|Johns Hopkins University",Both,Adult|Senior,,441,Other|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)",14-0225b|1R01DA037440-01,"March 15, 2016",Mar-16,Apr-18,"March 31, 2016",Mar-16,No Study Results Posted,REDART,Apr-18,Alcohol use|HIV viral load|Number of participants who report a high level of readiness to change for alcohol use reduction|Number of participants who report a high level of coping skills for alcohol abstinence,https://ClinicalTrials.gov/show/NCT02720237
909,NCT02720224,"Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol",Recruiting,No Results Available,Contraception|Menopause,Drug: Estetrol,Estetra|Quotient Clinical,Female,Adult,Phase 1,6,Industry|Other,Interventional,Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label,MIT -Es0001-C105|2014-000622-38,"January 8, 2016",Feb-16,Jun-16,"March 21, 2016",Jan-16,No Study Results Posted,null,Mar-16,Mass Balance of total radioactivity in urine:|Mass Balance of total radioactivity in faeces:|The elapsed time (Tlag) of total radioactivity in plasma|Maximum concentration (Cmax) of total radioactivity in plasma|Time to maximum concentration (Tmax) of total radioactivity in plasma|Area under the plasma concentration-time curve (AUC (o-t)) of total radioactivity in plasma|Area under the plasma concentration-time curve (AUC (o-infinity) of total radioactivity in plasma|The terminal elimination rate constant (lambda-z) of total radioactivity in plasma|Half-life (t1/2) of total radioactivity in plasma|The mean residence time (MRT) of total radioactivity in plasma|The elapsed time (Tlag) of total radioactivity in whole blood|Maximum concentration (Cmax) of total radioactivity in whole blood|Area under the plasma concentration-time curve (AUC (o-t)) of total radioactivity in whole blood|Area under the plasma concentration-time curve (AUC (o-infinity) of total radioactivity in whole blood|The terminal elimination rate constant (lambda-z) of total radioactivity in whole blood|Half-life (t1/2) of total radioactivity in whole blood|The mean residence time (MRT) of total radioactivity in whole blood|The elapsed time (Tlag) of estetrol in plasma|Maximum concentration (Cmax) of estetrol in plasma|Area under the plasma concentration-time curve (AUC (o-t)) of estetrol in plasma|Area under the plasma concentration-time curve (AUC (o-infinity)) of estetrol in plasma|The terminal elimination rate constant (lambda-z) of estetrol in plasma|Half-life (t1/2) of estetrol in plasma|The mean residence time (MRT) of estetrol in plasma|Urine pharmacokinetic parameters for estetrol:|Renal clearance (CLr) for estetrol|Renal clearance (CLr) for total radioactivity|Proportion of unchanged estetrol and metabolites in plasma|Proportion of metabolites in urine|Proportion of metabolites in faeces|Number of subjects with adverse events as a measure of safety and tolerability,https://ClinicalTrials.gov/show/NCT02720224
910,NCT02720172,Early Postoperative Home Exercise Program After Cervical Spine Surgery,Recruiting,No Results Available,Spinal Fusion|Cervical Spine Degenerative Disease,Behavioral: Early Home Exercise Program|Other: Usual Care,Vanderbilt University,Both,Adult|Senior,Phase 1|Phase 2,96,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor),150912,"March 21, 2016",Mar-16,Dec-18,"March 21, 2016",Mar-16,No Study Results Posted,null,Dec-18,Neck Disability Index (NDI)|Numeric Rating Scale (NRS)|12-Item Short Form Health Survey (SF-12)|Movement Accelerometry,https://ClinicalTrials.gov/show/NCT02720172
911,NCT02720159,Early Feasibility Study of the Percutaneous Osseointegrated Prosthesis (POP),Recruiting,No Results Available,Traumatic Amputee,Device: Percutaneous Osseintegrated Prosthesis,"Encore Medical, L.P.|VA Salt Lake City Health Care System",Both,Adult|Senior,,10,Industry|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,POP,"March 8, 2016",Dec-15,null,"March 21, 2016",Mar-16,No Study Results Posted,POP,Dec-17,"Assess AP & Lateral x-rays for osteolysis, radioulucencies indicative of component moevent and orientation and stress shielding or bone remodeling around the implant|Changes in Bone Mineral Density as collected using DEXA scan|Changes in implant exit site using Modified Holgers Skin Metric|Analyze measurable changes in the stoma punch|Analyze changes of walking and standing|Analyze changes in metabolic efficiency|Analyze changes in 6 minute walk test|Assess changes in Donning and Doffing prosthetic time|Assess changes in Comprehensive High-Level Activity Mobility Predictor (CHAMP) test|Changes in psychosocial adjustment with the Trinity Amputation and Prosthesis Experience Scales - Revised (TAPES-R) Part I, 37 questions|Changes in depressive symptomatology using the Center for Epidemiologic Studies Depression Scale Revisited (CES-D)|Changes in consequences of pain on relevant aspects of persons' lives using PROMIS: Pain Interference questions|Changes in ability to carry out activities that require physical actions using PROMIS: Physical Function|Changes in overall quality of life using QOL Visual Analog Scale, no numerical weighting|Changes in at-home prosthetic usage using StepWatch activity monitor",https://ClinicalTrials.gov/show/NCT02720159
912,NCT02720055,Rehabilitation Workbook After Wrist Fracture.,Recruiting,No Results Available,"Fractures, Bone",Other: Psychological workbook|Other: Basic information workbook,NHS Lothian,Both,Adult|Senior,,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",2016/0037,"March 21, 2016",Mar-16,null,"March 29, 2016",Mar-16,No Study Results Posted,null,Jul-17,Disability of Arm Shoulder and Hand|Objective wrist function|Patient satisfaction|Illness Perception Questionnaire - revised|Complications,https://ClinicalTrials.gov/show/NCT02720055
913,NCT02720042,Study of Phasix‰ã¢ Mesh for VHWG Grade 3 Midline Hernia Repair,Recruiting,No Results Available,"Hernia|Hernia, Abdominal|Hernia, Incisional",Device: Phasix‰ã¢ Mesh,C. R. Bard,Both,Adult|Senior,,85,Industry,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,DVL-HE-016,"February 11, 2016",Feb-16,Sep-19,"April 7, 2016",Apr-16,No Study Results Posted,null,Apr-18,Surgical Site Occurrence|Hernia Recurrence|Surgical Site Infections|Change in Pain|Incidence Device-related Adverse Events|Rate of Reoperation due to Index Hernia Repair|Carolinas Comfort Scale|EuroQol-5D|Surgical procedure time as measured from incision to closure|Time Until Return to Work|Length of Hospital Stay|Cost of Care,https://ClinicalTrials.gov/show/NCT02720042
914,NCT02720003,A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries,Recruiting,No Results Available,Femoral Artery Stenosis|Femoral Artery Occlusion|Stenosis of Popliteal Arteries|Occlusion of Popliteal Arteries,Device: LTX DCB,C. R. Bard,Both,Adult|Senior,,147,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,BC1401PV,"February 26, 2016",Mar-16,Jun-19,"March 31, 2016",Mar-16,No Study Results Posted,null,Jun-18,"Primary Efficacy - Percentage of Subjects With Primary Patency of the Target Lesion at One Year|Primary Safety - Percentage of Subjects With Composite of Freedom From All-cause Peri-operative Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-limb-related Death|Device Success|Technical Success|Acute Technical Success|Procedural Success|Percentage of Subjects with Primary Patency of the Target Lesion|Target Lesion Revascularization|Change in Rutherford Classification|Change in Ankle Brachial Index|Percentage of subjects who died from any cause|Amputation-free Survival|Percentage of subjects with Target Vessel Revascularization",https://ClinicalTrials.gov/show/NCT02720003
915,NCT02719990,Open-label Extension Study to Evaluate the Safety of Long-term Monthly Administration of Somavaratan in Adults With GHD,Recruiting,No Results Available,Adult Growth Hormone Deficiency (AGHD),Drug: somavaratan,Versartis Inc.|Premier Research Group plc,Both,Adult|Senior,Phase 2,250,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,15VR8,"March 16, 2016",Jan-16,Dec-19,"March 24, 2016",Mar-16,No Study Results Posted,null,Dec-19,"Safety as measured by the number of subjects with adverse events, concomitant medications, safety labs, vital signs and physical exams|Immunogenicity of VRS-317 by measurement of serum anti-drug antibody (ADA) titers|Immunogenicity of VRS-317 by detection of neutralizing antibodies (NAbs)|Pharmacodynamics of VRS-317 by measurement of serum Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)",https://ClinicalTrials.gov/show/NCT02719990
916,NCT02719938,Triggered Palliative Care for Advanced Dementia,Recruiting,No Results Available,Alzheimer Disease|Dementia,Behavioral: Specialty Palliative Care,"University of North Carolina, Chapel Hill|Icahn School of Medicine at Mount Sinai",Both,Adult|Senior,,120,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Outcomes Assessor),15-1708,"March 21, 2016",Mar-16,Jul-17,"March 30, 2016",Mar-16,No Study Results Posted,null,Jul-17,Hospital transfers|Comfort|Caregiver Strain|Access to hospice or palliative care|POLST (Physician Orders for Life Sustaining Treatment)|Palliative Care Domains|Burdensome treatment,https://ClinicalTrials.gov/show/NCT02719938
917,NCT02719899,Effect of Fasting and Refeeding on T-cell Fate,Recruiting,No Results Available,Asthma|Inflammation,,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",Both,Adult,,30,NIH,Observational,Time Perspective: Prospective,160085|16-H-0085,"March 24, 2016",Mar-16,Feb-17,"April 6, 2016",Mar-16,No Study Results Posted,null,Feb-17,To explore the effect of fasting and refeeding on NLRP3 inflammasome and it's ability to orchestrate differentiation of na(SqrRoot) ve T cells into TH2 cell.|To identify if nutrient-load regulates T-Cell differentiation capacity and to test whether this pathway could be investigated as atherapeutic target to blunt/negate the inflammation associated with nutrient-excess associated diseases includin...|Evaluate whether these effects are associated with activation of the Sirt3 and its canonical mitochondrial adaptive programs.,https://ClinicalTrials.gov/show/NCT02719899
918,NCT02719847,Additive Value of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation Therapy,Recruiting,No Results Available,Lung Cancer,Procedure: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA),M.D. Anderson Cancer Center,Both,Adult|Senior,,150,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,2015-0615,"March 21, 2016",Mar-16,null,"March 21, 2016",Mar-16,No Study Results Posted,null,Mar-20,Lymphnode Staging Accuracy,https://ClinicalTrials.gov/show/NCT02719847
919,NCT02719808,Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection,Recruiting,No Results Available,"Hepatitis B, Chronic",Drug: Tenofovir1|Drug: Tenofovir2|Drug: Tenofovir3|Drug: Tenofovir4,First Affiliated Hospital Xi'an Jiaotong University,Female,Child|Adult|Senior,,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,XJTU1AHCR2014-018,"March 6, 2016",Mar-15,Feb-18,"March 24, 2016",Feb-16,No Study Results Posted,null,Dec-17,deoxyribonucleic acid of Hepatitis B Virus (HBV-DNA) in serum|the concentration of Interleukin 2 (IL-2)|interferon-ë_ (IFN-ë_)|Interleukin 4 (IL-4)|Interleukin 6 (IL-6)|T cell ratio|HBV-DNA of babies|hepatitis B e-antigen (HBeAg)|HBV-DNA in placenta tissue,https://ClinicalTrials.gov/show/NCT02719808
920,NCT02719795,Pectoral Nerves Blocks for Chronic Pain,Recruiting,No Results Available,Breast Neoplasms,Drug: Ropivacaine|Drug: Normal saline,First Affiliated Hospital Xi'an Jiaotong University,Female,Adult|Senior,Phase 0,140,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",XJTU1AF-CRS-2016-003,"March 15, 2016",Apr-16,May-17,"April 13, 2016",Apr-16,No Study Results Posted,PNBCP,Dec-16,The incidence of chronic postoperative pain for 3 months after modified radical mastectomy surgery|Postoperative Numerical Rating scale (NRS) score for pain,https://ClinicalTrials.gov/show/NCT02719795
921,NCT02719782,TCR-Redirected T Cell Infusions to Treat Recurrent Hepatocellular Carcinoma Post Liver Transplantation,Recruiting,No Results Available,Recurrent Hepatocellular Carcinoma,Other: Biological: HBV antigen specific TCR redirected T cell,"Lion TCR Pte. Ltd.|Agency for Science, Technology and Research|Third Affiliated Hospital, Sun Yat-Sen University",Both,Adult,Phase 1|Phase 2,10,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,LTCR-HCC-I-2,"March 21, 2016",Dec-15,Nov-20,"March 21, 2016",Mar-16,No Study Results Posted,null,Nov-17,Safety of the TCR treatment (according to CTCAE 4.0)|Efficacy of induction of tumor specific T cell responses as measured by the persistence of HBV specific T cells in peripheral blood samples at several time points following adoptive transfer|Systemic release of inflammatory cytokines after administration of transduced T cells compared to baseline,https://ClinicalTrials.gov/show/NCT02719782
922,NCT02719665,THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease,Recruiting,No Results Available,Critical Limb Ischemia|Peripheral Artery Disease,"Dietary Supplement: SPM Emulsion, Dose-modality|Dietary Supplement: SPM Emulsion|Other: Placebo","University of California, San Francisco",Both,Child|Adult|Senior,Phase 1,50,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)",15-17371,"March 21, 2016",Mar-16,null,"March 28, 2016",Mar-16,No Study Results Posted,null,Mar-20,Optimal Phase 1b Dose|Change in the Resolution Index,https://ClinicalTrials.gov/show/NCT02719665
923,NCT02719652,Vessel Wall and Perfusion Imaging in Intracranial Atherosclerosis,Recruiting,No Results Available,Intracranial Atherosclerosis,,Xiuhai Guo|Capital Medical University,Both,Adult|Senior,,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ICAD-001,"March 16, 2016",Nov-15,Sep-17,"March 27, 2016",Mar-16,No Study Results Posted,null,Jun-16,"Stroke recurrence|Death|Any stroke, severe transient ischemic attack (TIA) outside the territory of symptomatic MCA|Stroke of asymptomatic participants",https://ClinicalTrials.gov/show/NCT02719652
924,NCT02719574,Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation,Recruiting,No Results Available,Acute Myeloid Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome,Drug: FT-2102|Drug: Azacitidine,"Forma Therapeutics, Inc.",Both,Adult|Senior,Phase 1,76,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,2102-HEM-101,"March 21, 2016",Apr-16,Jul-18,"April 21, 2016",Apr-16,No Study Results Posted,null,Mar-18,Maximum Tolerated Doses (MTDs)|Dose LImiting Toxicities (DLTs)|Doses recommended for future studies|Area under the plasma concentration versus time curve (AUC)|Peak Plasma Concentration (Cmax)|Time of peak plasma concentration (TMax)|Time for half of the drug to be absent in blood stream following dose (T 1/2)|Rate at which drug is removed from blood stream (CL/F)|Rate of drug distribution within the blood stream (Vd/F)|Observe patients for any evidence of anti-leukemic or anti-myelodysplastic activity of FT-2102 as single agent or in combination with azacitidine,https://ClinicalTrials.gov/show/NCT02719574
925,NCT02719535,Corneal Biomechanics and Corneal Reshaping Therapy,Recruiting,No Results Available,Myopia,Other: Corneal reshaping therapy,The Hong Kong Polytechnic University,Both,Adult,,60,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,B-Q46G,"January 18, 2016",Jan-16,Dec-17,"March 21, 2016",Jan-16,No Study Results Posted,null,Dec-17,Change of corneal stiffness from baseline at 6 months|Change of tangent modulus from baseline at 6 months,https://ClinicalTrials.gov/show/NCT02719535
926,NCT02719509,Emergency Department Cardiac Ultrasound,Recruiting,No Results Available,Chest Pain|Dyspnea,Procedure: Cardiac Ultrasound,Minneapolis Medical Research Foundation,Both,Adult|Senior,,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HSR # 15-4092,"February 4, 2016",Feb-16,Jul-16,"March 21, 2016",Mar-16,No Study Results Posted,null,Jul-16,Incidence of management changes,https://ClinicalTrials.gov/show/NCT02719509
927,NCT02719418,Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses,Recruiting,No Results Available,"Renal Insufficiency, Chronic|Deep Venous Thrombosis, Protection Against",Drug: Tinzaparin,Maisonneuve-Rosemont Hospital,Both,Adult|Senior,,25,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,STRIP-001,"March 14, 2016",Feb-16,Oct-16,"March 21, 2016",Mar-16,No Study Results Posted,STRIP,Oct-16,Peak anti-Xa levels in patients with eGFR ‰ä_ 30 mL/min/1.73 m2 receiving repeated daily doses of tinzaparin for VTE prophylaxis|Peak anti-Xa levels in patients with eGFR ‰ä_ 20 mL/min/1.73 m2 receiving repeated daily doses of tinzaparin for VTE prophylaxis|Anti-Xa trough level,https://ClinicalTrials.gov/show/NCT02719418
928,NCT02719405,Impact of Infant Formula on Resolution of Cow's Milk Allergy,Recruiting,No Results Available,Milk Allergy,Dietary Supplement: Lactobacillus GG|Dietary Supplement: Extensively Hydrolyzed Casein Formula|Dietary Supplement: Amino Acid Formula,Massachusetts General Hospital|Mead Johnson Nutrition,Both,Child,Phase 2,231,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator)",2015P000962,"October 30, 2015",Feb-16,Feb-19,"March 21, 2016",Mar-16,No Study Results Posted,null,Feb-19,"The percentage of subjects who develop tolerance to cow's milk protein by 12 months post randomization to study formula.|Safety as assessed by adverse events graded using the NCI-CTCAE scale by treatment group.|Tolerance as assessed by the transcriptional profile of milk-specific T cells by clinical outcome.|Tolerance as assessed by weight for age Z-scores.|Tolerance as assessed by length for age Z-scores.|Tolerance as assessed by weight for length Z-scores.|Tolerance as assessed by stool consistency using the Bristol Stool Chart.|Tolerance as assessed by stool frequency.|Tolerance as assessed by changes in the stool microbiome.|Tolerance as assessed by the estimated frequency of milk-specific T cells by clinical outcome.|Tolerance as assessed by the TCR diversity of milk-specific T cells by clinical outcome.|Tolerance as assessed by the milk allergen component-specific IgE, IgG4 and IgA by clinical outcome.",https://ClinicalTrials.gov/show/NCT02719405
929,NCT02719314,Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis,Recruiting,No Results Available,Osteoporosis,Drug: Glucocorticoid treatment,"Prof Dr Frank Buttgereit|Charite University, Berlin, Germany",Both,Adult|Senior,,10000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EA1/367/14,"March 21, 2016",Dec-15,Jul-29,"March 21, 2016",Mar-16,No Study Results Posted,Rh-GIOP,Nov-25,Bone mineral density|glucocorticoid dosage,https://ClinicalTrials.gov/show/NCT02719314
930,NCT02719288,Peroneal and Achilles Tendon Repair Indications With CLARIXå¨ CORD 1K,Recruiting,No Results Available,Peroneal and Achilles Tendon Tears,Biological: CLARIXå¨ CORD 1K graft,"Amniox Medical, Inc.",Both,Adult|Senior,,40,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),CR-2010,"March 17, 2016",Feb-16,Dec-17,"March 21, 2016",Mar-16,No Study Results Posted,PATRICC,Dec-17,Change from baseline in patient questionnaire describing function limitation (American Orthopaedic Foot and Ankle Society ankle hindfoot score).,https://ClinicalTrials.gov/show/NCT02719288
931,NCT02719262,Reduced of Ambient Melamine Exposure by Melamine Workplace Intervention,Recruiting,No Results Available,Environmental Exposure,Device: installing ventilation in the workplace,Kaohsiung Medical University Chung-Ho Memorial Hospital,Both,Adult,,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label,KMU-F105002,"March 16, 2016",Jan-16,Dec-17,"March 21, 2016",Mar-16,No Study Results Posted,null,Dec-17,Urinary melamine concentration measured by liquid chromatograph/tandem mass spectrometry|oxidative stress markers 8-hydoxy-2-deoxyguanosine (8-OHdG)|oxidative stress markers malondialdehyde (MDA)|renal injury markers N-acetyl ë_-D-glucosaminidase (NAG)|renal injury markers microalbumin|renal injury markers ë_2-microglobulin (ë_2-MG),https://ClinicalTrials.gov/show/NCT02719262
932,NCT02719236,Direct Anterior Approach Versus Direct Lateral Approach in Total Hip Arthroplasty,Recruiting,No Results Available,Coxarthrosis,Procedure: direct anterior approach|Procedure: direct lateral approach,Iuliu Hatieganu University of Medicine and Pharmacy|Emergency County Hospital Cluj-Napoca,Both,Adult|Senior,Phase 4,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)",517/17.12.2015,"February 12, 2016",Dec-15,Jun-18,"March 21, 2016",Mar-16,No Study Results Posted,DAAvsDLA,Dec-17,Muscle damage assay using Myoglobin biomarker|Muscle damage assay using Troponin T biomarker|Functional outcome using Harris Hip Score|Functional outcome using the Oxford Hip Score Survey|Functional outcome using the 36-Item Short Form Health Survey (SF-36)|Functional outcome using the 20-meters-timed-walk(66 feet) test|Functional outcome using the Stair Climbing Test (SCT)|Post Operative Pain Medication Usage|Pain assessment using the Visual Numeric Scale|Muscle damage - Creatine kinase (CK)|Muscle damage - Lactate dehydrogenase (LDH or LD)|Muscle damage assay using Aspartate aminotransferase (AST)|radiological assessment of cup positioning in the replaced hip|radiological assessment of stem positioning in the replaced hip|radiological assessment of cup and stem osteointegration in the replaced hip|Length of Hospital Stay,https://ClinicalTrials.gov/show/NCT02719236
933,NCT02719210,High Volume Plasma Exchange in Children With Acute Liver Failure,Recruiting,No Results Available,Acute Liver Failure,Biological: High Volume Plasma Exchange|Drug: Hypertonic 3% saline|Drug: Mannitol|Device: Elective positive pressure ventilation,"Institute of Liver and Biliary Sciences, India",Both,Child|Adult,,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,ILBS-ALF-02,"February 17, 2016",Jan-16,Dec-17,"March 21, 2016",Feb-16,No Study Results Posted,null,Dec-17,"Transplant free Survival.|Transplant free survival|Survival after liver transplant with or without High Volume Plasma Exchange.|Incidence of organ dysfunction (other than liver and Central Nervous System).|Number of organs (other than liver and CNS) affected in children with organ dysfunction.|Incidence of High Volume Plasma Exchange related complications- Major/Minor.|Change in hemodynamic parameters and Hepatic Encephalopathy (HE) before and after in the High Volume Plasma Exchange group group.|Change in hemodynamic parameters and Hepatic Encephalopathy (HE) before and after in the High Volume Plasma Exchange group.|Change in Laboratory parameters - Bilirubin, INR and Ammonia in control group.|Change in Laboratory parameters - Bilirubin, INR and Ammonia- in control group.|Change in the levels of IL-6 and TNF alpha (Tumor Necrosis Factor) in HVPE arm from baseline till within 24-hours of the last session of High Volume Plasma Exchange.|Change in the levels of IL-6 and TNF alpha (Tumor Necrosis Factor) in control arm from baseline till 5 days.",https://ClinicalTrials.gov/show/NCT02719210
934,NCT02719197,First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders,Recruiting,No Results Available,Healthy Subjects,Drug: AC-083|Drug: Placebo,Actelion,Male,Adult,Phase 1,48,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)",AC-083-101|2015-005012-15,"March 14, 2016",Feb-16,Jul-16,"March 21, 2016",Mar-16,No Study Results Posted,null,Jun-16,Number of participants with adverse events (AEs)|Changes from baseline in supine blood pressure|Changes from baseline in electrocardiogram (ECG) variables|Changes from baseline in pulse rate|Maximum plasma concentration (Cmax) following single oral ascending doses|Time to reach Cmax (tmax) following single oral ascending doses|Terminal half-life [t(1/2)] following single oral ascending doses|Area under the plasma concentration-time curve (AUC) following single oral ascending doses,https://ClinicalTrials.gov/show/NCT02719197
935,NCT02719184,Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease),Recruiting,No Results Available,"Pulmonary Disease, Chronic Obstructive|Pulmonary Emphysema",,Boehringer Ingelheim,Both,Adult,,540,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,352.2069,"March 18, 2016",Apr-16,Jan-19,"April 18, 2016",Apr-16,No Study Results Posted,null,Jan-19,Duration of exacerbations|Severity of exacerbations|Lung function decline|Number of exacerbations|Change of lung density assessed by computed tomography scan,https://ClinicalTrials.gov/show/NCT02719184
936,NCT02719171,BI 655066 Compared to Placebo in Patients With Active Psoriatic Arthritis,Recruiting,No Results Available,"Arthritis, Psoriatic",Drug: Placebo|Drug: BI 655066 high dose|Drug: BI 655066 medium high dose|Drug: BI 655066 medium dose|Drug: BI 655066 low dose,Boehringer Ingelheim,Both,Adult|Senior,Phase 2,180,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind,1311.5|2015-003625-34,"March 18, 2016",Apr-16,Sep-17,"April 18, 2016",Apr-16,No Study Results Posted,null,May-17,American College of Rheumatology (ACR) 20 response at Week 16|Change in Tender Joint Count at Week 16 as compared to baseline|Change in Swollen Joint Count at Week 16 as compared to baseline|Change in Dactylitis Count at Week 16 as compared to baseline (in patients with dactylitis at baseline)|American College of Rheumatology (ACR) 50 response at Week 16|American College of Rheumatology (ACR) 70 response at Week 16|Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16 as compared to baseline|Change in Short Form-36 Health Survey (SF-36) at Week 16 as compared to baseline|Change in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index at Week 16 as compared to baseline (in patients with enthesitis at baseline)|Change in modified Nail Psoriasis Severity Index (mNAPSI) at Week 16 as compared to baseline (in patients with nail psoriasis)|Psoriasis Area and Severity Index (PASI) 90 response at Week 16 assessed in patients with a >/= 3% baseline psoriasis Body Surface Area (BSA),https://ClinicalTrials.gov/show/NCT02719171
937,NCT02719158,Dose Ranging Study of OTO-201 in AOMT,Recruiting,No Results Available,Acute Otitis Media|AOMT,Drug: 6 mg ciprofloxacin|Drug: 12 mg ciprofloxacin|Other: Sham,"Otonomy, Inc.",Both,Child,Phase 2,125,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Caregiver),201-201508,"March 21, 2016",Feb-16,Jul-16,"March 21, 2016",Mar-16,No Study Results Posted,null,Jun-16,Safety as assessed by adverse events|Safety as assessed by otoscopic exams|Comparative clinical activity as assessed by the absence of otorrhea,https://ClinicalTrials.gov/show/NCT02719158
938,NCT02719145,Circulating Micro RNAs Expression in Egyptian Bronchial Asthma and COPD Patients,Recruiting,No Results Available,Asthma|COPD,,Tanta University,Both,Adult|Senior,,30,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,TFMEC1015,"March 19, 2016",Oct-15,Jun-16,"March 24, 2016",Mar-16,No Study Results Posted,null,Apr-16,"miR-7, miR-20a, miR-21, miR-22, miR-145 and miR-155 in serum samples from control, asthma and COPD Egyptian subjects.",https://ClinicalTrials.gov/show/NCT02719145
939,NCT02719119,Trial of Monthly Versus Bi-weekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding,Recruiting,No Results Available,Esophageal and Gastric Varices,Procedure: monthly Endoscopic Variceal Ligation (EVL)|Procedure: bi-weekly Endoscopic Variceal Ligation (EVL),West China Hospital,Both,Adult|Senior,,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,monthly versus bi-weekly EVL,"March 19, 2016",Mar-16,Feb-17,"March 27, 2016",Mar-16,No Study Results Posted,null,Feb-17,variceal rebleeding rate|gastrointestinal rebleeding rate|variceal obliteration rate|number of sessions required to abstain variceal obliteration|adverse events|mortality,https://ClinicalTrials.gov/show/NCT02719119
940,NCT02719067,A Longitudinal Follow-up Imaging Study on Children and Adolescents With Autism Spectrum Disorder,Recruiting,No Results Available,Autism Spectrum Disorder,,National Taiwan University Hospital,Both,Child|Adult,,140,Other,Observational,Observational Model: Case Control|Time Perspective: Cross-Sectional,201602058RIN,"March 10, 2016",Jan-16,null,"March 20, 2016",Mar-16,No Study Results Posted,null,Dec-16,Structural neuroimaging|Neuropsychological functions,https://ClinicalTrials.gov/show/NCT02719067
941,NCT02718963,Treatment of Dysphagia by Using a Synchronized Electrical Stimulation Device,Recruiting,No Results Available,Deglutition Disorders,Device: Synchronized Electrical Stimulation Device,Seoul National University Hospital,Both,Adult|Senior,,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,B-1507/306-002,"March 20, 2016",Aug-15,Aug-16,"March 23, 2016",Mar-16,No Study Results Posted,null,Aug-16,pressure change,https://ClinicalTrials.gov/show/NCT02718963
942,NCT02718937,"Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study",Recruiting,No Results Available,Respiratory Syncytial Virus (RSV) Infection,Drug: BTA-C585 oral capsule|Drug: Matching placebo capsules,"Biota Pharmaceuticals, Inc.|Aviragen Therapeutics",Both,Adult,Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",BTA585-003,"March 21, 2016",Mar-16,null,"April 12, 2016",Apr-16,No Study Results Posted,null,Nov-16,Area under the curve (AUC) viral load of RSV-A Memphis 37b|Area under the curve (AUC) of total RSV symptom scores|Number of adverse events,https://ClinicalTrials.gov/show/NCT02718937
943,NCT02718924,Detecting Hypercoagulability in Morbidly Obese and Non Obese Parturients Following Cesarean Section Delivery,Recruiting,No Results Available,Pregnancy|Obesity|Hypercoagulability,,Corniche Hospital,Female,Adult,,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ch23031401,"January 17, 2016",Nov-15,Jul-16,"March 23, 2016",Jan-16,No Study Results Posted,null,May-16,Calculated clot strength using EXTEM Maximum Clot Firmness (G value for EXTEM)|EXTEM clotting time and clot formation time in seconds.|EXTEM maximum clot firmness in millimeters|INTEM clotting time and clot formation time in seconds.|INTEM maximum clot firmness in millimeters|FIBTEM maximum clot firmness in millimeters,https://ClinicalTrials.gov/show/NCT02718924
944,NCT02718859,Study of the Combined Therapy for Pancreatic Cancer,Recruiting,No Results Available,Pancreatic Cancer,Biological: NK cells|Procedure: irreversible electroporation (IRE ),"Fuda Cancer Hospital, Guangzhou",Both,Adult|Senior,Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,pancreatic cancer NK cells,"March 9, 2016",Mar-16,Mar-17,"March 19, 2016",Mar-16,No Study Results Posted,null,Mar-17,Relief degree|Progress free survival•_öPFS•_ä|Overall survival•_öOS•_ä,https://ClinicalTrials.gov/show/NCT02718859
945,NCT02718820,Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer,Recruiting,No Results Available,Head and Neck Carcinoma,Drug: Docetaxel|Drug: Pembrolizumab,Medical University of Vienna,Both,Adult|Senior,Phase 1|Phase 2,22,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,PemDoc II,"March 15, 2016",Mar-16,Aug-18,"March 23, 2016",Mar-16,No Study Results Posted,null,Jan-18,"Overall response rate|Best overall response categories i.e. complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) given in percentages of the total study population|Individual duration of response over time|To report changes in the in health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) C-30 scoring manual|To report changes in the in health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) H&N35 scoring manual|Median Overall Survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Median Progression Free Survival (PFS)",https://ClinicalTrials.gov/show/NCT02718820
946,NCT02718794,Simulation-based and Problem-based Learning for Difficult Airway Management,Recruiting,No Results Available,Education,Procedure: Simulation training|Procedure: Problem-based learning,Siriraj Hospital,Both,Adult,,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Health Services Research|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",233/2558(EC4),"March 16, 2016",Aug-15,Jun-16,"March 23, 2016",Mar-16,No Study Results Posted,null,May-16,Learning achievement,https://ClinicalTrials.gov/show/NCT02718794
947,NCT02718781,Community Health Campaign: Fitter Families Project,Recruiting,No Results Available,Health Behavior,Behavioral: Health talk|Behavioral: Regular contact with community leaders|Device: Handgrip,The University of Hong Kong,Both,Child|Adult|Senior,,900,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label,UW15-401,"March 10, 2016",Sep-15,Jun-17,"March 20, 2016",Mar-16,No Study Results Posted,null,Dec-16,Changes in family harmony from baseline to 3 months after intervention|Changes in family happiness from baseline to 3 months after intervention|Changes in family health from baseline to 3 months after intervention|Changes in knowledge on zero-time exercise from baseline to 3 months after intervention|Changes in attitude towards performing zero-time exercise from baseline to 3 months after intervention|Changes in intention at performing zero-time exercise from baseline to 3 months after intervention|Changes in the frequency and amount on performing exercise from baseline to 3 months after intervention|Changes in neighborhood cohesion from baseline to 3 months after intervention|Changes in utilization of community resources from baseline to 3 months after intervention|Changes in grip strength (kg) from baseline to 3 months after intervention|Changes in chair stand (times) from baseline to 3 months after intervention|Changes in single leg stand (s) from baseline to 3 months after intervention|Changes in seat and reach (cm) from baseline to 3 months after intervention|Changes in body fat (%) from baseline to 3 months after intervention|Changes in body weight (kg) from baseline to 3 months after intervention|Satisfaction towards the program,https://ClinicalTrials.gov/show/NCT02718781
948,NCT02718729,Anastomotic Leakage Following Laparoscopic Resection for Rectal Cancer,Recruiting,No Results Available,Anastomotic Leakage,Procedure: Laparoscopic resection for rectal cancer,Mansoura University|University of Rome Tor Vergata,Both,Child|Adult|Senior,,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,MD 84,"March 12, 2016",Jan-14,Jan-17,"March 31, 2016",Mar-16,No Study Results Posted,null,May-16,Incidence of anastomotic leakage|Role of diversion in prevention of anastomotic leakage.|Management of anastomotic leakage|Oncological outcomes of anastomotic leakage|30 days postoperative morbidity and mortality,https://ClinicalTrials.gov/show/NCT02718729
949,NCT02718716,"Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia",Recruiting,No Results Available,Thrombocytopenia,Drug: UCB7665,UCB Biopharma S.P.R.L.|Parexel|UCB Pharma,Both,Adult|Senior,Phase 2,30,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,TP0001,"March 11, 2016",Mar-16,Jun-17,"April 25, 2016",Apr-16,No Study Results Posted,null,Jun-17,Subjects experiencing at least one Treatment Emergent Event (TEAE) during the study,https://ClinicalTrials.gov/show/NCT02718716
950,NCT02718664,Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity,Recruiting,No Results Available,Drug Safety Biomarkers,Other: Test meal (breakfast),The Netherlands Cancer Institute,Both,Adult|Senior,,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label,N16URA,"February 24, 2016",Apr-16,Dec-16,"April 4, 2016",Apr-16,No Study Results Posted,null,Dec-16,"Uracil levels (ng/ml) and dihydrouracil levels (ng/ml), compared in fed and fasting condition|dihydropyrimidine dehydrogenase enzyme activity (nmol/mg*h)",https://ClinicalTrials.gov/show/NCT02718664
951,NCT02718651,Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",,University of Aarhus|Aarhus University Hospital|Aalborg Universitetshospital|Odense University Hospital|Herning Hospital,Both,Adult|Senior,,70,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2015-1881-2|1-10-72-266-15|1-16-02-56-16,"March 18, 2016",Mar-16,Dec-18,"March 18, 2016",Mar-16,No Study Results Posted,null,Dec-18,Progression-free survival,https://ClinicalTrials.gov/show/NCT02718651
952,NCT02718599,Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery,Recruiting,No Results Available,"Hemodynamics, Liver, Terlipressin",Drug: terlipressin|Drug: normal saline,Assiut University,Both,Adult|Senior,Phase 2,50,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",ABC-123-DE,"March 19, 2016",Dec-15,Dec-17,"March 25, 2016",Mar-16,No Study Results Posted,null,Dec-17,portal pressure changes|Effect on systemic vascular resistance|Renal impairment|Blood units transfused,https://ClinicalTrials.gov/show/NCT02718599
953,NCT02718560,Handwriting Rehabilitation in Parkinson Disease,Recruiting,No Results Available,Parkinson Disease|Neurorehabilitation|Handwriting,Behavioral: Writing,Ospedale Generale Di Zona Moriggia-Pelascini,Both,Adult|Senior,,180,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)",Handwriting rehab in PD,"March 15, 2016",Sep-15,Sep-16,"March 29, 2016",Mar-16,No Study Results Posted,HRPD,Jul-16,"letters size|writing speed (time spent to write every single letter and word, measured in milliseconds)|centimeters away from a straight line during writing",https://ClinicalTrials.gov/show/NCT02718560
954,NCT02718508,An e-Parenting Skills Intervention to Decrease Injured Adolescents' Alcohol Use,Recruiting,No Results Available,Parenting|Alcohol Drinking,Behavioral: eParenting,"Michael J. Mello, MD, MPH|Connecticut Children's Medical Center|Children's Hospital of Pittsburgh|Rhode Island Hospital",Both,Child,,75,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,1R21AA024185-01,"March 2, 2016",Sep-15,Aug-17,"March 23, 2016",Mar-16,No Study Results Posted,e-Parenting,Mar-17,Feasibility of an e-Parenting Skills Intervention as assessed by Parenting Wisely usage data.|Acceptability of an e-Parenting Skills Intervention as assessed by Systems Usability Scale (SUS).|Acceptability of an e-Parenting Skills Intervention as assessed Consumer Satisfaction Questionnaire (CSQ).|Effects on Alcohol Use as assessed by Adolescent Drug Questionnaire (ADQ).|Effects on Drug use as assessed by Drug Use Questionnaire (DUQ).|Effects on Alcohol and Drug Related Problems as assessed by Add Health measures.,https://ClinicalTrials.gov/show/NCT02718508
955,NCT02718495,"Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis",Recruiting,No Results Available,Cystic Fibrosis,Drug: PTI-428|Drug: Placebo,"Proteostasis Therapeutics, Inc.",Both,Adult,Phase 1,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",PTI-428-01,"March 10, 2016",Mar-16,Mar-17,"March 29, 2016",Mar-16,No Study Results Posted,null,Dec-16,"SAD: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs.|MAD: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in pulmonary function tests, safety labs, ECGs, physical examinations, and vital signs.|SAD: Apparent terminal half-life (t1/2) of single oral dose|SAD: Time to reach maximum plasma concentration (Tmax) of single oral dose|SAD: Maximum plasma concentration (Cmax) of single oral dose|SAD: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) of single oral dose|MAD: Apparent terminal half-life (t1/2) of multiple oral doses|MAD: Time to reach maximum plasma concentration (Tmax) of multiple oral doses|MAD: Maximum plasma concentration (Cmax) of multiple oral doses|MAD: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) of multiple oral doses|MAD: Area under the concentration-time curve from time 0 to infinity (AUC0-‰ö_) of multiple oral doses",https://ClinicalTrials.gov/show/NCT02718495
956,NCT02718469,Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults,Recruiting,No Results Available,Ebola Virus Disease,Biological: Ebola Vaccine - low dose|Biological: Ebola Vaccine - mid dose|Biological: Ebola Vaccine - high dose|Biological: Placebo,"Profectus BioSciences, Inc.|Accelovance|United States Department of Defense",Both,Adult,Phase 1,39,Industry|U.S. Fed,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)",rVSV-EBOV-01,"March 9, 2016",Jan-16,Nov-16,"March 18, 2016",Mar-16,No Study Results Posted,null,Nov-16,Incidence of Treatment Emergent Adverse Events (Safety and Tolerability),https://ClinicalTrials.gov/show/NCT02718469
957,NCT02718456,Overcoming Barriers to HIV/AIDS Care and ART Initiation,Recruiting,No Results Available,Engagement in HIV Care,Behavioral: Expedited CD4 testing|Behavioral: Supplemental peer counseling,University of Washington,Both,Adult|Senior,,450,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label,41427-EJ,"March 11, 2016",Aug-13,Oct-17,"March 23, 2016",Mar-16,No Study Results Posted,LINC,Oct-17,Number of days from study enrollment until first visit to a comprehensive care center for HIV care.|Number of days from study enrollment until initiation of antiretroviral therapy.|Interviewer-administered questionnaire to determine the number of visits made to a comprehensive care center for HIV care.|Measurement of CD4+ T-cell count.,https://ClinicalTrials.gov/show/NCT02718456
958,NCT02718430,VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis,Recruiting,No Results Available,Colorectal Cancer,Drug: VXM01,Vaximm GmbH,Both,Adult|Senior,Phase 1,24,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,VXM01-03-DE,"March 16, 2016",Feb-16,Mar-18,"March 18, 2016",Mar-16,No Study Results Posted,null,Mar-18,Safety and tolerability taking into account treatment-limiting toxicities (TLTs)|Immune Response by Enzme Linked Immuno Spot (ELISpot)|Immune biomarker by tumor tissue immunohistochemistry staining|Tumor vasculature by tumor tissue immunohistochemistry staining|Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA)|Clinical Response including tumor staging according to the response criteria in solid tumors (RECIST)|Biodistribution and shedding of VXM01,https://ClinicalTrials.gov/show/NCT02718430
959,NCT02718404,3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound in the Treatment of Pain From Bone Metastases of Solid Tumors,Recruiting,No Results Available,Solid Tumors,Procedure: MR-HIFU Treatment|Drug: MR contrast media and medications|Procedure: MR images,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,Both,Adult|Senior,,41,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,IRST198.01,"January 21, 2016",Jul-15,Jul-18,"April 7, 2016",Apr-16,No Study Results Posted,HIFU-Bone,Jul-18,Pain response|Time to pain palliation|Time to pain progression|Duration of pain palliation|Recording of pain medication|Quality of Life|Local Tumor Control|Side effects|reduction/increase of tumor markers|identification of the brain regions involved in oncological pain,https://ClinicalTrials.gov/show/NCT02718404
960,NCT02718391,Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.,Recruiting,No Results Available,Malignant Melanoma|Adjuvant Drug Therapy|Vaccin Therapy,Biological: Autologous Dendritic Cell vaccine,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,Both,Adult|Senior,Phase 2,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,IRST172.04|2014-005123-27,"January 21, 2016",Aug-15,Aug-18,"April 7, 2016",Apr-16,No Study Results Posted,ACDC,Aug-18,Relapse-free survival (RFS)|Overall survival (OS)|Immunologic efficacy will be measured by best delayed-type hypersensitivity score (reactivity to lysate or KLH) obtained after at least 4 vaccine doses,https://ClinicalTrials.gov/show/NCT02718391
961,NCT02718378,Evaluation of Safety and Efficacy of Estetrol in Healthy Men,Recruiting,No Results Available,Prostatic Neoplasms,Drug: estetrol|Drug: placebo,Pantarhei Oncology B.V.,Male,Adult|Senior,Phase 1,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",PR3107,"February 18, 2016",Mar-16,null,"March 18, 2016",Mar-16,No Study Results Posted,null,Jul-16,Number of participants with Adverse Events (AEs)|Change from baseline in hormone levels|Change from baseline in haemostasis parameters|Change from baseline in lipid parameters|Change from baseline in glucose levels|Change from baseline in bone turnover markers|Change from baseline in sex-hormone binding globulin (SHBG) levels|Pharmacokinetic effect of estetrol,https://ClinicalTrials.gov/show/NCT02718378
962,NCT02718261,Sup-Icu RENal (SIREN),Recruiting,No Results Available,Critical Illness|Acute Kidney Injury|End-stage Renal Disease,Drug: Pantoprazole|Drug: Saline 0.9% (matching placebo),"University Hospital Inselspital, Berne|SUP-ICU Principle investigator: Dr. M. Krag, Rigshospitalet, Copenhagen, Denmark|SUP-ICU Sponsor: Dr. M.H. Moller, Rigshospitalet, Copenhagen, Denmark",Both,Adult|Senior,Phase 4,3350,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)",SIREN,"March 14, 2016",Feb-16,Dec-17,"March 22, 2016",Mar-16,No Study Results Posted,SIREN,Dec-17,"Total number of patients with clinically important gastrointestinal (GI)-bleeding episodes undergoing RRT therapy within the first 3 days following ICU admission (""RRT group"") vs. in patients without need for RRT during ICU stay (""control group"").|Total number of ICU patients with clinically important GI-bleeding episodes in ""ESRD"" vs. ""RRT group"" vs. RRT at any time during ICU stay vs. ""control group"" incl. analysis of verum/ placebo subgroups.|Number of patients receiving interventions to stop GI-bleeding in ""RRT group"", ""ESRD group"", ""RRT at any time on the ICU group"", and ""control group"": incl. analysis of verum/ placebo subgroups.|Number of GI bleeding events in ""RRT group"", ""ESRD group"", ""RRT at any time on the ICU group"", and ""control group"": incl. analysis of verum/ placebo subgroups.|Number of units of red blood cells (RBC) transfused on ICU in ""RRT group"", ""ESRD group"", ""RRT at any time on the ICU"" and ""control group"" incl. assessment of verum/ placebo subgroups.|Number of units of RBC transfused per day on ICU in ""RRT group"", ""ESRD group"", ""RRT at any time on the ICU"" and ""control group"" incl. assessment of verum/ placebo subgroups.|Number of onset of pneumonia during ICU stay in ""RRT group"" vs. ""ESRD group"" vs. ""RRT at any time on the ICU"" vs. ""control group"" incl. analysis of verum/ placebo subgroups|Days on treatment of Clostridium difficile enteritis in ""RRT group"" vs. ""ESRD group"" vs. ""RRT at any time on the ICU"" vs. ""control group"" incl. analysis of verum/ placebo subgroups|ICU length of stay in ""RRT group"" vs. ""ESRD group"" vs. ""RRT at any time on the ICU"" vs. ""control group"" incl. analysis of verum/placebo subgroups|90-day/360-day/ ICU mortality rate in ""RRT group"" vs. ""ESRD group"" vs. ""RRT at any time on the ICU"" vs. ""control group"" incl. analysis of verum/ placebo subgroups.",https://ClinicalTrials.gov/show/NCT02718261
963,NCT02718222,Impact and Performance of Institutionalizing Immediate Post-partum IUD Services,Recruiting,No Results Available,Contraception,Device: Post-partum IUD,Harvard School of Public Health|International Federation of Gynaecology and Obstetrics,Female,Child|Adult|Senior,,64800,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Health Services Research|Masking: Open Label,6904190-01,"March 11, 2016",Sep-15,Sep-18,"March 29, 2016",Mar-16,No Study Results Posted,null,Jun-18,Percentage uptake of PPIUD|Percentage of women receiving PPIUD counseling|Percentage of PPIUD acceptors who have expulsions at 4-6 weeks postpartum|Percentage of women using modern contraception at 9 months postpartum|Percentage of women using modern contraception at 18 months postpartum|Percentage of women pregnant at 18 months postpartum,https://ClinicalTrials.gov/show/NCT02718222
964,NCT02718079,High-Volume Plasma Exchange Versus Fractional Plasma Separation and Adsorption (Prometheus) in Patients With Acute Liver Failure,Recruiting,No Results Available,Acute Liver Failure,Biological: High Volume Plasma Exchange|Drug: Prometheus|Other: Management of cerebral edema/intracranial hypertension:|Other: Transfer to Intensive Care Unit|Drug: Prophylactic Antibiotics|Other: Intubation of trachea|Other: Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|Other: Volume Replacement|Other: Pressor Support|Drug: N-acetyl-L-cysteine|Other: Correction of metabolic parameters|Dietary Supplement: Correction of nutrition,"Institute of Liver and Biliary Sciences, India",Both,Child|Adult|Senior,,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,ILBS-ALF-03,"February 29, 2016",Mar-16,Feb-18,"April 1, 2016",Feb-16,No Study Results Posted,null,Feb-18,Survival in both groups|To compare the improvement in serum ammonia.|To compare the improvement in serum bilirubin.|To compare the improvement in INR.|To compare the improvement in bile acids.|To compare the improvement in lactate.|To compare the improvement in blood urea.|To compare the improvement in serum creatinine.|Adverse events of High Volume Plasma and Prometheus therapy in both groups|Duration of Mechanical ventilation in both groups.|Duration of Intensive Care Unit stay in both groups.|Improvement in SIRS (Systemic Inflammatory Response Syndrome) score.|Improvement in SOFA (Sequential Organ Failure Assessment) score.|Improvement in APACHE II (Acute Physiology and Chronic Health Evaluation) score.|Effect on systemic haemodynamics in both groups|Cost of treatments in both groups|Pro inflammatory cytokines profile in both groups|Serum Endotoxin levels in both groups.,https://ClinicalTrials.gov/show/NCT02718079
965,NCT02718053,Reliability of Spasticity Measurement With Lokomat,Recruiting,No Results Available,"Spasticity, Lokomat",Other: L-stiff|Other: Ashworth,Ospedale Generale Di Zona Moriggia-Pelascini,Both,Adult|Senior,,20,Other,Observational,Time Perspective: Prospective,spasticity01,"March 11, 2016",Jul-15,null,"March 19, 2016",Mar-16,No Study Results Posted,null,Apr-16,correlation of spasticity measurement obtained with L-Stiff (Lokomat) and Ashworth scale,https://ClinicalTrials.gov/show/NCT02718053
966,NCT02718027,Biomarker for Patient With Alport Disease or Highly Suspected for Alport Disease,Recruiting,No Results Available,"Nephritis, Hereditary|Alport Syndrome|Alport Syndrome, Autosomal Dominant|Alport Syndrome, Autosomal Recessive|Hematuria-Nephropathy-Deafness Syndrome",,University of Rostock|Centogene AG Rostock,Both,Child|Adult|Senior,,50,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,BAP 07-2015,"November 10, 2015",Nov-15,Nov-17,"March 18, 2016",Mar-16,No Study Results Posted,BioAlport,Oct-17,Development of a new MS-based biomarker for the early diagnosis of Alport disease from plasma|Number of correctly identified patients with Alport disease,https://ClinicalTrials.gov/show/NCT02718027
967,NCT02718001,Edwards Lifesciences CardiAQ‰ã¢ Transcatheter Mitral Valve Replacement (TMVR) Early Feasibility Study,Recruiting,No Results Available,Mitral Valve Regurgitation (Degenerative or Functional),Device: Transcatheter Mitral Valve Replacement (TMVR),Edwards Lifesciences,Both,Adult|Senior,Phase 1,28,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,2013-05C,"March 1, 2016",Feb-15,Dec-21,"March 18, 2016",Mar-16,No Study Results Posted,null,Dec-16,Safety assessed by freedom from device or procedure-related adverse events|NYHA functional class|Six minute walk test|Reduction in MR grade,https://ClinicalTrials.gov/show/NCT02718001
968,NCT02717988,"Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers",Recruiting,No Results Available,Rheumatoid Arthritis,Drug: SKI-O-703 capsule|Drug: Placebo capsule,Oscotec Inc.|PPD,Both,Adult,Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)",Oscotec,"March 4, 2016",Sep-15,Mar-16,"March 18, 2016",Mar-16,No Study Results Posted,null,Mar-16,"Number of participants (Healthy Volunteers) with reported adverse events receiving single dose of SKI-O-703 as assessment of safety and tolerability.|area under the concentration versus time curve from time 0 to the last quantifiable concentration for estimating the pharmacokinetic parameters of SKI-O-592 (the free base of SKI-O-703) and its metabolites.|area under the concentration versus time curve from time 0 extrapolated to infinity|maximum observed plasma concentration|time to reach the maximum observed plasma concentration|apparent terminal elimination half-life|apparent volume of distribution (SKI-O-592, free base of SKI-O-703)|amount of drug excreted in urine over the collection intervals of 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, 12 to 24 hours, 24 to 48 hours, and 48 to 72 hours post dose.|renal clearance (SKI-O-592, free base of SKI-O-703 only)",https://ClinicalTrials.gov/show/NCT02717988
969,NCT02717975,The Effect of Catheter Valve Vs. Standard Catheter Removal in Outpatients,Recruiting,No Results Available,Urinary Retention,Procedure: Use of catheter valve before 'trial removal of catheter'|Procedure: Trial removal of catheter in patients with urinary retention,Medway NHS Foundation Trust,Male,Adult|Senior,Phase 2|Phase 3,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,191435,"January 20, 2016",Mar-16,May-17,"March 25, 2016",Mar-16,No Study Results Posted,null,Mar-17,Time to spontaneous void after catheter removal|Complications associated with valve|Reduction in clinic waiting time (hours)|Reduction in the cost of running the clinic,https://ClinicalTrials.gov/show/NCT02717975
970,NCT02717949,Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study,Recruiting,No Results Available,Liver Disease,Drug: sofosbuvir/ledipasvir|Drug: sofosbuvir|Drug: Ribavirin,University of Texas Southwestern Medical Center|Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University,Both,Adult|Senior,Phase 4,21,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,042015-086,"November 10, 2015",Feb-16,Aug-18,"April 1, 2016",Apr-16,No Study Results Posted,Optimal,Feb-18,Number subjects who experience adverse events on HCV treatment as assessed by Division of AIDS (DAIDS) Adverse Event (AE) grading table version 2.0.|Number of subjects who have a change in lymph node size from baseline after HCV treatment as defined by international lymphoma grading scale.,https://ClinicalTrials.gov/show/NCT02717949
971,NCT02717936,Investigation of Desmoplastic Squamous Cell Carcinoma,Recruiting,No Results Available,Squamous Cell Carcinoma of the Skin,Procedure: Immunohistochemistry using Pancytokeratin Staining,University Hospital Tuebingen,Both,Adult|Senior,,73,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,DESMOPEK1,"January 27, 2016",Jan-16,Jan-20,"March 24, 2016",Jan-16,No Study Results Posted,DesmoPEK,Jan-18,Recurrence free survival of patients with desmoplastic squamous cell carcinoma (SCC) diagnosed with immunohistochemistry .|Reduction of local recurrence with immunohistochemistry|Histological pattern of tumour growth (continuous versus discontinuous)|Dimension of the tumor spreading according to histological work-up (measured in mm)|Presence of perineurial and perivascular tumor invasion according to histological work-up,https://ClinicalTrials.gov/show/NCT02717936
972,NCT02717923,"A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer",Recruiting,No Results Available,Colorectal Neoplasms,Other: maintenance treatment with capecitabine plus cetuximab,Huazhong University of Science and Technology,Both,Child|Adult|Senior,Phase 2,50,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,TJCC005,"March 18, 2016",Jan-14,null,"April 3, 2016",Apr-16,No Study Results Posted,null,Jan-19,Progression-Free Survival of maintaining treatment•_ömPFS•_ä,https://ClinicalTrials.gov/show/NCT02717923
973,NCT02717910,Digital Health Game as an Intervention Supporting Tobacco-related Health Literacy in Early Adolescents,Recruiting,No Results Available,Smoking Prevention,Behavioral: Health game|Behavioral: Web page,University of Turku,Both,Child,,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject),NTSF2016,"March 14, 2016",Mar-16,Jun-16,"March 25, 2016",Mar-16,No Study Results Posted,null,Jun-16,Change in anti-smoking self-efficacy|Change in smoking outcome expectations|Change in attitudes towards tobacco use questionnaire scores|Change in tobacco use-related motives questionnaire scores|Actual use of the intervention|Self-assessed interest towards the intervention,https://ClinicalTrials.gov/show/NCT02717910
974,NCT02717884,Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP),Recruiting,No Results Available,Acute Myeloid Leukemia|Myelodysplastic Syndrome,Drug: tranylcypromine|Drug: all-trans retinoic acid|Drug: cytarabine,Ulrike Kohlweyer|University Hospital Freiburg,Both,Adult|Senior,Phase 1|Phase 2,60,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,00806 UKF,"February 4, 2016",May-15,May-18,"March 18, 2016",Mar-16,No Study Results Posted,TRANSATRA,May-17,"MTD determination of TCP in combination with fixed-dose of ATRA and with fixed-dose Cytarabine;|objective best response (CR complete remission, CRi complete remission with incomplete blood count recovery, PR partial remission)|Overall survival (OS)",https://ClinicalTrials.gov/show/NCT02717884
975,NCT02717871,Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis,Recruiting,No Results Available,Keratitis; Infectious Disease (Manifestation),Device: PACK-CXL|Drug: Cefazolin in combination with either tobramycin or gentamicin|Drug: Cycloplegic agents (cyclopentolate 1% eye drops)|Drug: Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Drug: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops),"University Hospital, Geneva",Both,Adult|Senior,Phase 3,252,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,CER 11-198,"March 9, 2016",Mar-16,Aug-17,"March 23, 2016",Mar-16,No Study Results Posted,null,Mar-17,Time to re-epithelialization of the corneal surface|Time from treatment to discharge of the patient,https://ClinicalTrials.gov/show/NCT02717871
976,NCT02717858,A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects,Recruiting,No Results Available,Obesity,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Both,Adult,Phase 1,48,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)",NN8022-4192|2014-004772-38|U1111-1163-4641,"March 15, 2016",Mar-16,Mar-17,"April 4, 2016",Mar-16,No Study Results Posted,null,Mar-17,Maximum postprandial gallbladder ejection fraction (GBEFmax)|GBEFmax (maximum gallbladder ejection fraction) after first treatment dose|Gallbladder volume|Area under gallbladder EF-time (ejection fraction) curve|Area under gallbladder EF-time curve|Area under the paracetamol concentration-time curve|Incremental area under the plasma glucose concentration-time curve,https://ClinicalTrials.gov/show/NCT02717858
977,NCT02717845,CT Imaging Study for Knee Osteotomy (CISKO),Recruiting,No Results Available,Bone Malalignment,Device: Ellipse|Device: Tomofix,North Cumbria University Hospitals NHS Trust|NuVasive,Male,Adult|Senior,,10,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label,PR0251|16/NW/0038,"March 15, 2016",Mar-16,Feb-17,"April 7, 2016",Apr-16,No Study Results Posted,CISKO,Jan-17,Healing score|Patient satisfaction score|Change in KOOS score,https://ClinicalTrials.gov/show/NCT02717845
978,NCT02717819,The Importance of Additional Protein to Benefit More From Training During and After Hospitalization,Recruiting,No Results Available,Sarcopenia,Dietary Supplement: Protein|Dietary Supplement: Placebo|Other: Resistance training,"Copenhagen University Hospital at Herlev|University of Copenhagen|Mejeribrugets Research Foundation|Arla Foods|Glostrup University Hospital, Copenhagen|University Hospital, Gentofte, Copenhagen",Both,Senior,,120,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)",EFFECT.PEPOP.2016|H-16018240,"March 9, 2016",Apr-16,Jun-19,"April 23, 2016",Apr-16,No Study Results Posted,PEPOP,Jun-18,Change in 30-s chair stand performance|Total lean body mass|Appendicular lean body mass|Trunk lean body mass|Change in hand grip strength|Change in 4 m gait speed|Change in Activities of daily living (ADL)|Change in mobility|Change in cognitive functioning|Use of home care|Residence|Use of gait aid|Length of hospital stay (LOS)|Readmission to hospital|Length of total hospital stay for readmissions|Mortality|Change in health related Quality of life|Change in Body weight|Energy intake|Protein intake|Study population acceptance of product,https://ClinicalTrials.gov/show/NCT02717819
979,NCT02717780,Short Life Agents in Balanced Anesthesia on Obstructive Sleep Apnea Syndrome,Recruiting,No Results Available,"Sleep Apnea Syndromes|Sleep Apnea, Obstructive",Drug: Fentanyl and sevoflurane|Drug: Remifentanil and desflurane,Centre Hospitalier Universitaire Vaudois,Both,Adult|Senior,Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",CER 192/15,"March 15, 2016",Feb-16,Jun-18,"March 18, 2016",Mar-16,No Study Results Posted,DESAT,Dec-17,"Number of apnea and hypopnea events per hour of sleep (Apnea-Hypopnea index) in supine position|Number of obstructive apnea events|Percentage of time with saturation < 90%|Mean oxygen saturation|Total sleep duration|Percentage of time in supine position|Mean amplitude of desaturation (AD%)|Percentage of time in obstructive apnea|Percentage of time in central apnea|Percentage of time in mixt apnea|Sleep Apnea screening questionnaire (STOP BANG questionnaire)|Sleep Apnea screening questionnaire (Berlin questionnaire)|Sleep Apnea screening questionnaire (Epworth questionnaire)|Sleep Apnea screening questionnaire (NOSAS questionnaire)|Pain scores (numeric rating scale, 0-10)|Postoperative nausea and vomiting (yes/no)|Pruritus (yes/no)|Opiate consumption (mg morphine)|Level of satisfaction (visual analog scale)",https://ClinicalTrials.gov/show/NCT02717780
980,NCT02717741,A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor,Recruiting,No Results Available,Neoplasms,Drug: tafetinib,"Nanjing Yoko Biomedical Co., Ltd.",Both,Adult,Phase 1,30,Industry,Interventional,Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label,NanjingYoko,"March 3, 2016",May-15,Apr-17,"March 23, 2016",Mar-16,No Study Results Posted,null,Apr-17,Dose-limiting toxicity,https://ClinicalTrials.gov/show/NCT02717741
981,NCT02717715,SunRISe Study - Stroke Rehabilitation In Suriname,Recruiting,No Results Available,Stroke,Behavioral: Home base stroke rehabilitation,Katholieke Universiteit Leuven|Anton De Kom University|VU University of Amsterdam,Both,Child|Adult|Senior,,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,VG 023-15,"March 5, 2016",Mar-16,Dec-17,"March 18, 2016",Mar-16,No Study Results Posted,SunRISe,Dec-17,Change in peak oxygen uptake,https://ClinicalTrials.gov/show/NCT02717715
982,NCT02717689,A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma,Recruiting,No Results Available,Severe Persistent Asthma,Other: Biomarker based adjustment of corticosteroid dose,Belfast Health and Social Care Trust|Medical Research Council|Hoffmann-La Roche|Aerocrine AB,Both,Adult|Senior,,400,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),1,"March 16, 2016",Jan-16,Jun-18,"March 18, 2016",Mar-16,No Study Results Posted,null,Jun-18,Proportion of patients with any reduction in corticosteroid dose|Rate of protocol-defined severe exacerbations per patient per year|Time to first severe exacerbation from randomisation|Dose of inhaled steroid at end of study|Cumulative dose of inhaled corticosteroid during study|Proportion of patients on oral corticosteroids at the end of the study|Proportion of patients who decline to progress to oral corticosteroids despite composite biomarker score of 2|Frequency of hospital admission for asthma|Change in Asthma Control Questionnaire (ACQ-7)|Change in FEV1 (volume)|Change in exhaled breath nitric oxide level|Change in blood eosinophil count|Change in serum periostin levels|Change in Asthma Quality of Life Questionnaire (AQLQ),https://ClinicalTrials.gov/show/NCT02717689
983,NCT02717637,Oxycodone in Serum After Postoperative Oral Oxycodone in Caesarean Sections Under Spinal Anesthesia,Recruiting,No Results Available,Maternal Anaesthesia and Analgesia Affecting Fetus or Newborn,,"University Hospital, Akershus",Female,Adult,,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2014/1781,"March 15, 2016",Feb-16,Apr-17,"March 18, 2016",Mar-16,No Study Results Posted,null,Feb-17,level of oxycodone in serum|level of pain,https://ClinicalTrials.gov/show/NCT02717637
984,NCT02717624,A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma,Recruiting,No Results Available,Mantle Cell Lymphoma (MCL),Drug: ACP-196 in combination with BR,Acerta Pharma BV,Both,Adult|Senior,Phase 1,48,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label,ACE-LY-106,"February 24, 2016",Feb-16,null,"March 23, 2016",Mar-16,No Study Results Posted,null,Feb-21,Number of Participants with Treatment Emergent Adverse Events (AEs) as assessed by CTCAE v4.03,https://ClinicalTrials.gov/show/NCT02717624
985,NCT02717611,A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy,Recruiting,No Results Available,Chronic Lymphocytic Leukemia,Drug: ACP-196 (acalabrutinib),Acerta Pharma BV,Both,Adult|Senior,Phase 2,80,Industry,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label,ACE-CL-208,"March 11, 2016",Jan-16,Feb-20,"March 18, 2016",Mar-16,No Study Results Posted,null,Feb-20,The overall response rate (ORR) at 36 cycles of ACP-196 (acalabrutinib) in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy,https://ClinicalTrials.gov/show/NCT02717611
986,NCT02717598,Cold Snare Polypectomy Versus Hot Snare Polypectomy for Diminutive and Small Colorectal Polyps,Recruiting,No Results Available,Colonic Polyp|Intestinal Polyp,Procedure: cold snare polypectomy|Procedure: hot snare polypectomy,Wulumuqi General Hospital of Lanzhou Military Command|Fourth Military Medical University,Both,Adult|Senior,,330,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",2016LL001,"March 17, 2016",Feb-16,Dec-16,"April 24, 2016",Apr-16,No Study Results Posted,CSPVHSP,Dec-16,complete polyp resection rate|rate of postpolypectomy adverse events,https://ClinicalTrials.gov/show/NCT02717598
987,NCT02717585,Effect of CPAP on Symptoms of Patients With Fibromyalgia and Obstructive Sleep Apnea,Recruiting,No Results Available,Fibromyalgia|Obstructive Sleep Apnea,Device: Continuous Positive Airway Pressure Therapy (CPAP),"Women's College Hospital|University Health Network, Toronto",Both,Adult|Senior,,54,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator),2015-0112-B,"March 17, 2016",Mar-16,Mar-18,"April 13, 2016",Apr-16,No Study Results Posted,FM-OSA,Jan-18,Pain Score|Sleep quality|Sleepiness|Quality of Life (QoL)|Inflammatory Marker,https://ClinicalTrials.gov/show/NCT02717585
988,NCT02717572,18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR,Recruiting,No Results Available,Solid Tumor,Radiation: Fludeoxyglucose F 18|Device: Positron Emission Tomography|Device: Computerized Tomography|Device: Magnetic Resonance Imaging,Washington University School of Medicine,Both,Adult|Senior,Phase 0,30,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label,201508093,"March 17, 2016",Mar-16,Mar-18,"March 17, 2016",Mar-16,No Study Results Posted,null,Mar-18,Variability of repeated quantitative measures of FDG uptake as measured by SUVmax|Variability of repeated quantitative measures of FDG uptake as measured by SUVpeak|Repeatability of diffusion-weighted imaging on PET/MR as measured by difference in mean ADC|Repeatability of diffusion-weighted imaging on PET/MR as measured by differences in minimum ADC|Evaluation of the ratio of SUVmax and ADCmin,https://ClinicalTrials.gov/show/NCT02717572
989,NCT02717546,Zimmerå¨ MotionLocå¨ in Distal Tibia Fractures,Recruiting,No Results Available,Distal Tibia Fractures,Device: Zimmer MotionLoc Screw,"Zimmer, Inc.",Both,Adult|Senior,Phase 3,40,Industry,Observational,Time Perspective: Prospective,CSE2014-08T,"February 22, 2016",Feb-16,Feb-19,"March 22, 2016",Feb-16,No Study Results Posted,null,Feb-18,Radiographic Fracture Healing of the Tibia|Clinical Fracture Healing of the Tibia|Complications|Callus size & distribution,https://ClinicalTrials.gov/show/NCT02717546
990,NCT02717520,Long Term Clinical Evaluation of a Posterior Glass Hybrid System vs. Composite Resin,Recruiting,No Results Available,Dental Caries,Device: EQUIA Forte|Device: Tetric EvoCeram,University of Zagreb|University of Milan|University of Belgrade|Ege University,Both,Adult|Senior,,88,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)",05-PA-26-7/2015,"March 8, 2016",Sep-15,Jun-22,"March 27, 2016",Mar-16,No Study Results Posted,null,Jun-17,Evaluating surface and marginal staining of the materials|Evaluating fracture and retention of the materials|Evaluating marginal adaptation and discoloration of the materials|Evaluating wear of the materials|Evaluating suitability of direct impression scanning vs. replica model scanning for wear assessment,https://ClinicalTrials.gov/show/NCT02717520
991,NCT02717507,Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors,Recruiting,No Results Available,Cancer Survivor|Heart Failure,Drug: Carvedilol|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo|Other: Quality-of-Life Assessment|Other: Questionnaire Administration,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult|Senior,Phase 2,250,Other|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)",ALTE1621|NCI-2016-00232|COG-ALTE1621|R01CA196854|UG1CA189955,"March 9, 2016",Apr-16,null,"April 12, 2016",Apr-16,No Study Results Posted,null,Apr-22,"LV thickness-dimension ratio (LVT-D) derived from echocardiogram, reported in terms of LV posterior wall dimension in systole and LV dimension based on the internal diameter in diastole|blood natriuretic peptide (BNP),|cardiac troponins (cTnT and cTnI), and galectin-3|galectin-3|diastolic measurements|systolic measurements|afterload|bilirubin|AST|ALT|Grade 2-4 adverse events, assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Patient reported symptoms|Treatment adherence as measured by pill counts",https://ClinicalTrials.gov/show/NCT02717507
992,NCT02717494,Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women,Recruiting,No Results Available,PNC Vaccine|HIV-infected Pregnant Women,Biological: PPV-23|Biological: PCV-10|Other: NaCl,Westat|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Female,Child|Adult|Senior,Phase 2,345,Other|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",NICHD P1091,"March 18, 2016",Mar-16,May-19,"March 22, 2016",Mar-16,No Study Results Posted,null,May-19,Safety of PCV10 and PPV23 administered in pregnancy|Maternal Immunogenicity of PPV23 and PCV10|Persistence of Transplacentally Transmited Maternal Antibodies to PNC Vaccine Serotypes in the Infant|Ratio of Infant/Mother PNC Antibody Levels|Maternal and Infant Immunogenicity to PNC Vaccines,https://ClinicalTrials.gov/show/NCT02717494
993,NCT02717468,Comparative Noninvasive Continuous Cardiac Output by the Clearsight With Invasive Monitoring by Pulsioflex in Abdominal Surgery,Recruiting,No Results Available,Cardiac Output Measurement,Device: Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSightå¨)|Device: Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflexå¨).,Poitiers University Hospital,Both,Adult|Senior,,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,2015-A01895-44,"February 18, 2016",Feb-16,Feb-17,"March 17, 2016",Feb-16,No Study Results Posted,CLEARSIGHT,Dec-16,Stroke Ejection Volume (SEV) measure by ClearSightå¨|Stroke Ejection Volume (SEV) measure by Pulsioflexå¨|Cardiac Output (CO) measure by ClearSightå¨|Cardiac Output (CO) measure by Pulsioflexå¨|Stroke Ejection Volume Variations (SVV) measure by ClearSightå¨|Stroke Ejection Volume Variations (SVV) measure by Pulsioflexå¨,https://ClinicalTrials.gov/show/NCT02717468
994,NCT02717442,Study of OTO-104 in Subjects With Unilateral Meniere's Disease,Recruiting,No Results Available,Meniere's Disease,Drug: OTO-104|Drug: Placebo,"Otonomy, Inc.",Both,Adult|Senior,Phase 3,160,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)",104-201508,"March 10, 2016",Mar-16,Oct-17,"March 17, 2016",Mar-16,No Study Results Posted,AVERTS-2,Jul-17,Reduction in number of definitive vertigo days compared to placebo as assessed by a daily diary|Change in hearing from baseline as assessed by audiometry|Change in the condition of the ear from baseline as assessed by otoscopic examinations|Evaluation of adverse events as a measure of safety and tolerability|Impact of vertigo experience on daily activities,https://ClinicalTrials.gov/show/NCT02717442
995,NCT02717429,Cognitive and Emotion Regulation Training in MS,Recruiting,No Results Available,Multiple Sclerosis,Behavioral: Mindfulness Meditation|Behavioral: Computerized Cognitive Training,Ohio State University,Both,Adult,,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),2014H0212,"October 21, 2015",Oct-15,Aug-17,"March 17, 2016",Mar-16,No Study Results Posted,CERT-MS,Aug-16,Change in Reported Engagement After Worry and Rumination Inductions|Cognitive Performance on Brief Repeatable Battery (BRB)|Heart Rate Variability (HRV)|Daily Emotion Regulation Diary|Improvements on a Self-Report Measure of Emotion Dysregulation|Improvements on a Self-Report Measure of Depression|Improvements on a Self-Report Measures of Anxiety|Improvements on a Self-Report Measure of Perceived Stress|Improvements on a Self-Report Measure of Quality of Life,https://ClinicalTrials.gov/show/NCT02717429
996,NCT02717403,Effects of Social Networking on Chronic Disease Management in Arthritis,Recruiting,No Results Available,Chronic Disease Management|Rheumatoid Arthritis,Behavioral: Questionnaires|Behavioral: Facebook|Behavioral: Educational Website|Behavioral: Phone Interview,M.D. Anderson Cancer Center|Rheumatology Research Foundation,Both,Adult|Senior,Phase 2|Phase 3,240,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label,2015-0349|14038089,"March 18, 2016",Apr-16,null,"April 7, 2016",Apr-16,No Study Results Posted,null,Apr-17,Participant Knowledge of Rheumatoid Arthritis assessed with the Patient Knowledge Questionnaire (PKQ-RA)|Control in Health Care Decisions assessed with the Control Preferences Scale (CPS-RA),https://ClinicalTrials.gov/show/NCT02717403
997,NCT02717364,"Yervoyå¨ Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma",Recruiting,No Results Available,Melanoma,Drug: Yervoy,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Both,Child|Adult|Senior,,400,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CA184-438,"February 16, 2016",Aug-15,Aug-18,"March 18, 2016",Mar-16,No Study Results Posted,null,Aug-18,The incidence of adverse events (AEs) by types among the analysis population|The Overall Survival (OS) Rate|The factors that potentially affect safety or effectiveness,https://ClinicalTrials.gov/show/NCT02717364
998,NCT02717312,"Prevalence, Risk Factors and Consequences Related to Cesarean Scar Defect (Defect in Cesarean Scar)",Recruiting,No Results Available,Cesarean Scar Defect,,Tampere University Hospital,Female,Adult,,400,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,R15104,"March 9, 2016",Jan-16,Apr-27,"March 17, 2016",Mar-16,No Study Results Posted,DICE,Apr-18,Association between cesarean scar defect and post menstrual spotting|Quality of life related to cesarean scar defect|Association between cesarean scar and adverse pregnancy outcome|Prevalence of cesarean scar defect measured by sonography|Impact of cervical opening at the time of cesarean section on the prevalence of cesarean scar defect.,https://ClinicalTrials.gov/show/NCT02717312
999,NCT02717299,Making Sense Out of Total Knee Sensor Assisted Technology: A Randomized Control Trial,Recruiting,No Results Available,"Arthroplasty, Replacement, Knee",Device: Verasense,"TriHealth Inc.|Orthosensor, Inc.",Both,Adult|Senior,,100,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject),15-053,"March 15, 2016",Nov-15,Dec-19,"March 22, 2016",Mar-16,No Study Results Posted,null,Dec-18,Patient Satisfaction,https://ClinicalTrials.gov/show/NCT02717299
1000,NCT02717260,Inhibition Transcranial Random Noise Stimulation,Recruiting,No Results Available,Impulsive Behavior|Inhibition,Device: transcranial random noise stimulation (tRNS) (Starstim),HÌ«pital le Vinatier,Both,Adult,Phase 2,36,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)",2015-A01554-45,"January 28, 2016",Feb-16,Jun-16,"March 17, 2016",Mar-16,No Study Results Posted,inhibistim,May-16,Change in go no go test|Change in Stroop test|Change in Hayling test|Change in BIS 10|Change in STAXI|Change in STAI|Change in EEG|occurrence of adverse effects,https://ClinicalTrials.gov/show/NCT02717260